PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32798057-12 2020 Glargine co-administered with regular insulin showed superiority for clinical outcomes compared with regular insulin: consuming less time (MD, -3.1 h; 95% CrI, -7.9 to 1.8), amount of insulin required (MD, -32 U; 95% CrI, 83.0 to 18.0), and the length of hospitalization (MD, -0.82 day; 95% CrI, -2.7 to 1.0) to normalize DKA. Insulin Glargine 0-8 insulin Homo sapiens 38-45 34643020-5 2022 A total of 149 patients were randomised 1:1 to basal-bolus therapy with insulin degludec and insulin aspart or insulin glargine U100 and insulin aspart. Insulin Glargine 119-127 insulin Homo sapiens 111-118 34643020-11 2022 CONCLUSIONS/INTERPRETATION: Patients with T1D prone to nocturnal severe hypoglycaemia have lower rates of nocturnal symptomatic hypoglycaemia and all-day severe hypoglycaemia with insulin degludec as compared with insulin glargine U100. Insulin Glargine 222-230 insulin Homo sapiens 214-221 34514696-0 2022 Switching the Basal Insulin to Insulin Glargine 300 U/mL in People with Type 2 Diabetes under Basal Insulin Supported Oral Therapy - Observational Trial on Effectiveness and Safety. Insulin Glargine 39-47 insulin Homo sapiens 31-38 34530162-4 2022 Specifically, by introducing a FRL-triggered optogenetic device into human mesenchymal stem cells (hMSCs), which we encapsulated in poly-(L-lysine)-alginate and implanted subcutaneously under the dorsum of type 1 diabetic (T1D) model mice, we achieved FRL-illumination-inducible secretion of insulin that yielded improvements in glucose tolerance and sustained blood glucose control over traditional insulin glargine treatment. Insulin Glargine 408-416 insulin Homo sapiens 292-299 34917687-0 2021 Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice. Insulin Glargine 97-105 insulin Homo sapiens 47-54 34784005-0 2022 Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Insulin Glargine 62-70 insulin Homo sapiens 54-61 34971335-4 2021 Insulin glargine-yfgn 100 units/mL is the first biosimilar insulin to attain interchangeable status with the reference insulin glargine. Insulin Glargine 8-16 insulin Homo sapiens 0-7 34971335-4 2021 Insulin glargine-yfgn 100 units/mL is the first biosimilar insulin to attain interchangeable status with the reference insulin glargine. Insulin Glargine 8-16 insulin Homo sapiens 59-66 34971335-4 2021 Insulin glargine-yfgn 100 units/mL is the first biosimilar insulin to attain interchangeable status with the reference insulin glargine. Insulin Glargine 127-135 insulin Homo sapiens 119-126 34971335-6 2021 Insulin glargine-yfgn may be substituted at the pharmacy counter without consultation with the prescriber, in accordance with state laws. Insulin Glargine 8-16 insulin Homo sapiens 0-7 34971335-7 2021 In suit with other biosimilars, insulin glargine-yfgn"s list price is significantly lower than other insulin glargine products. Insulin Glargine 40-48 insulin Homo sapiens 32-39 34971335-7 2021 In suit with other biosimilars, insulin glargine-yfgn"s list price is significantly lower than other insulin glargine products. Insulin Glargine 109-117 insulin Homo sapiens 101-108 34971335-8 2021 This increases market competition leading to decreases in costs of other insulin glargine products. Insulin Glargine 81-89 insulin Homo sapiens 73-80 34917687-8 2021 The results showed that glargine was able to upregulate the expression of PI3K and activate serine phosphorylation of AKT through the upregulation of Cav-1 expression in paraepididymal adipose tissue of the insulin group. Insulin Glargine 24-32 insulin Homo sapiens 207-214 34917687-10 2021 These results suggest that Cav-1 is essential for the activation of AKT and improving insulin sensitivity in type 2 diabetic mice during glargine treatment. Insulin Glargine 137-145 insulin Homo sapiens 86-93 34925042-3 2021 Participants were subcutaneously injected with long-acting insulin glargine (0.4 IU/kg). Insulin Glargine 67-75 insulin Homo sapiens 59-66 34866291-5 2022 Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine, as well as for treatment with dulaglutide when added to insulin glargine compared with insulin glargine alone. Insulin Glargine 231-239 insulin Homo sapiens 223-230 34866291-5 2022 Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine, as well as for treatment with dulaglutide when added to insulin glargine compared with insulin glargine alone. Insulin Glargine 305-313 insulin Homo sapiens 297-304 34866291-5 2022 Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine, as well as for treatment with dulaglutide when added to insulin glargine compared with insulin glargine alone. Insulin Glargine 336-344 insulin Homo sapiens 328-335 34410042-0 2021 A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects. Insulin Glargine 98-106 insulin Homo sapiens 90-97 34410042-1 2021 Insulin glargine (IGlar) and LY2963016 (LY IGlar) are long-acting insulin analogs with identical primary amino acid sequences. Insulin Glargine 8-16 insulin Homo sapiens 0-7 34852652-0 2021 Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars. Insulin Glargine 62-70 insulin Homo sapiens 54-61 34472693-0 2021 Benefit of Insulin Glargine/Lixisenatide for Reducing Residual Hyperglycaemia in Japan: Post-Hoc Analysis of the LixiLan JP-O2 Trial. Insulin Glargine 19-27 insulin Homo sapiens 11-18 34472693-1 2021 AIMS: To compare the benefits of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi), over insulin glargine (iGlar) for reducing residual hyperglycaemia (defined as glycated haemoglobin (HbA1c) >=7% despite fasting plasma glucose (FPG) <130 mg/dL) in Japanese people with type 2 diabetes (T2D) inadequately controlled on oral antidiabetic drugs. Insulin Glargine 142-150 insulin Homo sapiens 134-141 34852652-2 2021 Only a few reports of thorough evaluation of the quality of insulin glargine biosimilars are available in literature. Insulin Glargine 68-76 insulin Homo sapiens 60-67 34852652-3 2021 Here, we examine the structural and functional similarity of biosimilars of insulin glargine, the first basal long-acting insulin analogue with respect to its innovator product (Lantus from Sanofi Aventis). Insulin Glargine 84-92 insulin Homo sapiens 76-83 34852652-3 2021 Here, we examine the structural and functional similarity of biosimilars of insulin glargine, the first basal long-acting insulin analogue with respect to its innovator product (Lantus from Sanofi Aventis). Insulin Glargine 84-92 insulin Homo sapiens 122-129 34852652-10 2021 CONCLUSIONS: While an overall structural and functional similarity was observed across insulin glargine biosimilars with respect to the innovator product, low amounts of product-related variants were seen in some biosimilars and these impact product stability. Insulin Glargine 95-103 insulin Homo sapiens 87-94 34917025-10 2021 Conclusion: In patients with well-controlled T2DM who were treated with insulin glargine, Lantus group showed lower MBG, GV, and lower PT (BG > 10.0 mmol/L, BG > 13.9 mmol/L) than Basalin group. Insulin Glargine 80-88 insulin Homo sapiens 72-79 34917025-10 2021 Conclusion: In patients with well-controlled T2DM who were treated with insulin glargine, Lantus group showed lower MBG, GV, and lower PT (BG > 10.0 mmol/L, BG > 13.9 mmol/L) than Basalin group. Insulin Glargine 90-96 insulin Homo sapiens 72-79 34322967-1 2021 AIMS: To compare time in range (TIR) with insulin degludec U100 (degludec) versus insulin glargine U100 (glargine U100), in people with type 2 diabetes. Insulin Glargine 105-113 insulin Homo sapiens 82-89 34815261-11 2021 Finally, an expanded nonmedical substitution policy including insulin glargine would affect 115 895 patients and save $288.7 million (not including adalimumab). Insulin Glargine 70-78 insulin Homo sapiens 62-69 34672967-1 2021 BACKGROUND: We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications. Insulin Glargine 175-183 insulin Homo sapiens 167-174 34672968-0 2021 Surpassing insulin glargine in type 2 diabetes with tirzepatide. Insulin Glargine 19-27 insulin Homo sapiens 11-18 34322967-1 2021 AIMS: To compare time in range (TIR) with insulin degludec U100 (degludec) versus insulin glargine U100 (glargine U100), in people with type 2 diabetes. Insulin Glargine 90-98 insulin Homo sapiens 82-89 34956518-0 2021 Clinical effects of insulin glargine combined with repaglinide in the treatment of type 2 diabetes. Insulin Glargine 28-36 insulin Homo sapiens 20-27 34956518-1 2021 OBJECTIVE: To analyze the clinical effects of insulin glargine combined with repaglinide on the treatment of type 2 diabetes (T2D). Insulin Glargine 54-62 insulin Homo sapiens 46-53 34956518-2 2021 METHODS: One hundred and twelve T2D patients were divided into two groups based on the treatment strategy, the control group (N=56) receiving insulin glargine and the experimental group (N=56) receiving insulin glargine combined with repaglinide. Insulin Glargine 211-219 insulin Homo sapiens 203-210 34956518-8 2021 CONCLUSION: Insulin glargine combined with repaglinide is an effective and safe regimen in clinical practice, which can effectively control the blood glucose level, lower insulin dosage, and reduce adverse effects of T2D. Insulin Glargine 20-28 insulin Homo sapiens 12-19 34599749-0 2021 Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study. Insulin Glargine 36-44 insulin Homo sapiens 28-35 34121308-1 2021 OBJECTIVE: Compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) with the reference product (Lantus ) insulin glargine (IGlar) in Chinese patients with type 1 diabetes mellitus (T1DM). Insulin Glargine 46-55 insulin Homo sapiens 56-63 34467826-7 2021 The newer analogs insulin glargine U300 and insulin degludec provide non-inferior efficacy, although insulin glargine U300 is less potent unit-to-unit. Insulin Glargine 109-117 insulin Homo sapiens 101-108 34467826-8 2021 Insulin degludec reduces hypoglycemia risk compared to insulin glargine U100. Insulin Glargine 63-71 insulin Homo sapiens 55-62 34676266-13 2021 However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. Insulin Glargine 94-102 insulin Homo sapiens 86-93 34676266-16 2021 Conclusions: There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. Insulin Glargine 73-81 insulin Homo sapiens 65-72 34121308-1 2021 OBJECTIVE: Compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) with the reference product (Lantus ) insulin glargine (IGlar) in Chinese patients with type 1 diabetes mellitus (T1DM). Insulin Glargine 64-72 insulin Homo sapiens 56-63 34121308-1 2021 OBJECTIVE: Compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) with the reference product (Lantus ) insulin glargine (IGlar) in Chinese patients with type 1 diabetes mellitus (T1DM). Insulin Glargine 129-137 insulin Homo sapiens 121-128 34180955-0 2021 Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market. Insulin Glargine 65-73 insulin Homo sapiens 57-64 34345540-5 2021 Results We included four RCTs with 534 participants (349 in the insulin degludec group and 185 in the insulin glargine group) with type 2 diabetes mellitus (T2DM). Insulin Glargine 110-118 insulin Homo sapiens 102-109 34594103-2 2021 The insulin analog glargine differs from insulin in three residues (GlyA21, ArgB31, ArgB32), and it is converted to metabolite M1 (lacks residues ArgB31 and ArgB32) by in vivo processing. Insulin Glargine 19-27 insulin Homo sapiens 4-11 34551215-0 2022 Comparisons of efficacy and safety in insulin glargine and lixisenatide (iGlarLixi) plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes. Insulin Glargine 46-54 insulin Homo sapiens 38-45 34580638-3 2021 Methods: In this single-blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n = 19), insulin glargine group (n = 10), and placebo (n = 17). Insulin Glargine 192-200 insulin Homo sapiens 184-191 34580638-7 2021 In the dulaglutide group, only the BMD of the femoral neck decreased (P = 0.027), but the magnitude of decrease was less than that in the placebo group; the BMD of L1-L4, femoral neck, and total hip decreased significantly (P < 0.05) in the placebo group, while in the insulin glargine group, the BMD of L2, L4, and L1-4 increased (P < 0.05). Insulin Glargine 277-285 insulin Homo sapiens 269-276 34580638-8 2021 Compared with the placebo group, the BMD of the femoral neck and total hip in the exenatide group and the insulin glargine group were increased significantly (P < 0.05); compared with the exenatide group, the BMD of L4 in the insulin glargine group was also increased (P = 0.001). Insulin Glargine 114-122 insulin Homo sapiens 106-113 34580638-8 2021 Compared with the placebo group, the BMD of the femoral neck and total hip in the exenatide group and the insulin glargine group were increased significantly (P < 0.05); compared with the exenatide group, the BMD of L4 in the insulin glargine group was also increased (P = 0.001). Insulin Glargine 234-242 insulin Homo sapiens 226-233 34393250-4 2021 He presented with type 2 diabetes for more than 3 years, with oral administration of metformin enteric coated tablets and subcutaneous injection of insulin glargine to control blood glucose, and satisfied with blood glucose control. Insulin Glargine 156-164 insulin Homo sapiens 148-155 34337072-0 2021 Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial. Insulin Glargine 101-109 insulin Homo sapiens 93-100 34337072-1 2021 To observe whether different insulin glargine titration algorithms based on fasting blood glucose (FBG) levels lead to different glycaemic variations (GVs) in type 2 diabetes (T2D) patients, a prospective, randomized, single-centre, comparative, three-arm parallel-group, open-label, treat-to-target, 24-week study was performed. Insulin Glargine 37-45 insulin Homo sapiens 29-36 34337072-3 2021 The initiated insulin glargine dose was recommended at 0.2 U/kg/day and was then titrated following the FBG target. Insulin Glargine 22-30 insulin Homo sapiens 14-21 34337072-8 2021 Moreover, our data indicated that an FBG of 6.1 mmol/L could possibly be an insulin glargine titration target in T2D patients. Insulin Glargine 84-92 insulin Homo sapiens 76-83 34305809-3 2021 We recruited adults with type 2 diabetes who expressed an intention to fast during Ramadan and were adherent to one of four regimens-namely: metformin and glimepiride; metformin and vildagliptin; metformin and insulin glargine U100; or, metformin, insulin glargine U100, and human regular insulin. Insulin Glargine 218-226 insulin Homo sapiens 210-217 34904015-1 2021 The aim of this study was to compare the insulin glargine and detemir effects on hormons affecting appetite and metabolic control of patients with type 1 diabetes. Insulin Glargine 49-57 insulin Homo sapiens 41-48 34636912-10 2021 Insulin glargine was the most frequently used insulin from 2016 to 2020, accounting for approximately half of treatment visits (eg, 2020: 2.6 of 4.9 million visits; 95% CI, 2.1-3.1 million). Insulin Glargine 8-16 insulin Homo sapiens 0-7 34636912-10 2021 Insulin glargine was the most frequently used insulin from 2016 to 2020, accounting for approximately half of treatment visits (eg, 2020: 2.6 of 4.9 million visits; 95% CI, 2.1-3.1 million). Insulin Glargine 8-16 insulin Homo sapiens 46-53 34481498-0 2021 Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Insulin Glargine 174-182 insulin Homo sapiens 166-173 34357560-2 2021 This study aimed to assess the effectiveness of the insulin glargine + lixisenatide (iGlarLixi) FRC on glycaemic control and hypoglycaemia in real-life settings. Insulin Glargine 60-68 insulin Homo sapiens 52-59 34299526-8 2021 The 2D 1H-13C HSQC spectral comparison of insulin glargine DPs provided similarity metrics for chemical shift difference (Deltadelta) and methyl peak profile, i.e., 4 ppb for 1H, 15 ppb for 13C and 98% peaks with equivalent peak height. Insulin Glargine 50-58 insulin Homo sapiens 42-49 34160790-0 2021 Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study. Insulin Glargine 28-36 insulin Homo sapiens 20-27 34345540-6 2021 Results show that both insulin glargine and degludec are equally efficacious in reducing fasting blood glucose (mean difference is -4.45, confidence interval -13.32- 4.43, I2=67%) and HbA1c (glycosylated hemoglobin) (mean difference is 0.12, confidence interval -0.12-0.35, I2=0%). Insulin Glargine 31-39 insulin Homo sapiens 23-30 34345540-7 2021 However, insulin glargine was associated with lower risks of hypoglycemia (risk ratio = 0.9684, confidence interval- 0.8003- 1.1717, I2=30%). Insulin Glargine 17-25 insulin Homo sapiens 9-16 34345540-8 2021 Conclusion Insulin glargine and degludec are comparable in achieving glycemic control with fewer hypoglycemic episodes in the insulin glargine-treated group. Insulin Glargine 19-27 insulin Homo sapiens 11-18 34345540-8 2021 Conclusion Insulin glargine and degludec are comparable in achieving glycemic control with fewer hypoglycemic episodes in the insulin glargine-treated group. Insulin Glargine 134-142 insulin Homo sapiens 126-133 34249838-7 2021 These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. Insulin Glargine 120-128 insulin Homo sapiens 112-119 34174848-0 2021 Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies. Insulin Glargine 96-104 insulin Homo sapiens 88-95 34174848-1 2021 BACKGROUND: MYL-1501D is a proposed biosimilar to insulin glargine. Insulin Glargine 58-66 insulin Homo sapiens 50-57 34174848-11 2021 A similar proportion of patients had anti-HCP antibodies in both treatment groups in INSTRIDE 1 at week 52 (MYL-1501D, 93.9 %; reference insulin glargine, 89.6 %; P = 0.213) and in INSTRIDE 2 at week 24 (MYL-1501D, 87.3 %; reference insulin glargine, 86.9 %; P > 0.999). Insulin Glargine 145-153 insulin Homo sapiens 137-144 34174848-12 2021 CONCLUSIONS: In INSTRIDE 1 and INSTRIDE 2, similar immunogenicity profiles were observed for MYL-1501D and reference insulin glargine in patients with type 1 diabetes and type 2 diabetes, respectively. Insulin Glargine 125-133 insulin Homo sapiens 117-124 34249838-19 2021 Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. Insulin Glargine 73-81 insulin Homo sapiens 65-72 35187770-0 2022 Immunogenicity of LY2963016 insulin glargine and Lantus insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus. Insulin Glargine 65-73 insulin Homo sapiens 57-64 34133466-0 2021 Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine. Insulin Glargine 95-103 insulin Homo sapiens 87-94 34133466-1 2021 Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years. Insulin Glargine 8-16 insulin Homo sapiens 0-7 34133466-1 2021 Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years. Insulin Glargine 8-16 insulin Homo sapiens 52-59 34133466-2 2021 Insulin glargine has a relatively constant concentration-time profile that mimics basal levels of insulin and allows for once-daily administration. Insulin Glargine 8-16 insulin Homo sapiens 0-7 34133466-3 2021 MYL-1501D is a biosimilar insulin glargine designed to offer greater access of insulin glargine to patients, with comparable efficacy and safety to the marketed reference product. Insulin Glargine 34-42 insulin Homo sapiens 26-33 34133466-3 2021 MYL-1501D is a biosimilar insulin glargine designed to offer greater access of insulin glargine to patients, with comparable efficacy and safety to the marketed reference product. Insulin Glargine 34-42 insulin Homo sapiens 79-86 34133466-3 2021 MYL-1501D is a biosimilar insulin glargine designed to offer greater access of insulin glargine to patients, with comparable efficacy and safety to the marketed reference product. Insulin Glargine 87-95 insulin Homo sapiens 79-86 34133466-4 2021 We conducted a comprehensive panel of studies based on a formal analysis of critical quality attributes to characterize the structural and functional properties of MYL-1501D and reference insulin glargine products available in the United States and European Union. Insulin Glargine 196-204 insulin Homo sapiens 188-195 34133466-9 2021 Rabbit bioassay studies showed MYL-1501D and EU-approved insulin glargine are highly similar to US-licensed insulin glargine. Insulin Glargine 65-73 insulin Homo sapiens 57-64 34133466-9 2021 Rabbit bioassay studies showed MYL-1501D and EU-approved insulin glargine are highly similar to US-licensed insulin glargine. Insulin Glargine 116-124 insulin Homo sapiens 108-115 34133466-10 2021 These product quality studies show high similarity between MYL-1501D and licensed or approved insulin glargine products and suggest the potential of MYL-1501D as an alternative cost-effective treatment option for patients and clinicians. Insulin Glargine 102-110 insulin Homo sapiens 94-101 34075142-0 2021 A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care. Insulin Glargine 69-77 insulin Homo sapiens 61-68 34075142-1 2021 This pilot, randomized, open-label controlled study compared the basal-bolus regimens of insulin glargine (IG) and neutral protamine Hagedorn (NPH) insulin in stroke patients with hyperglycemia receiving intensive care. Insulin Glargine 97-105 insulin Homo sapiens 89-96 34211933-0 2021 Comparison of the effect of insulin glargine and regular insulin on perioperative glycemic control in patients with type 2 diabetes mellitus under insulin treatment during vitrectomy surgery under general anesthesia: A randomized clinical trial study. Insulin Glargine 36-44 insulin Homo sapiens 28-35 34211933-3 2021 Given the importance of the issue and the limited studies on glucose control using insulin glargine during surgery, we aimed to investigate the effects of glargine on glucose control in patients with diabetes mellitus during vitrectomy surgery. Insulin Glargine 91-99 insulin Homo sapiens 83-90 34211933-3 2021 Given the importance of the issue and the limited studies on glucose control using insulin glargine during surgery, we aimed to investigate the effects of glargine on glucose control in patients with diabetes mellitus during vitrectomy surgery. Insulin Glargine 155-163 insulin Homo sapiens 83-90 34211933-5 2021 In the control group, the patients received regular insulin based on the blood glucose and the sliding scale, and in the intervention group, they received insulin glargine (0.3 unit/kg) before surgery. Insulin Glargine 163-171 insulin Homo sapiens 155-162 34211933-12 2021 Results: Use of insulin glargine was associated with significantly lower blood glucose levels compared to regular insulin at 90-minutes (p=0.004), 135 minutes (p=0.001), and 6 hours after the operation (p=0.005). Insulin Glargine 24-32 insulin Homo sapiens 16-23 34763587-1 2021 OBJECTIVES: The present cost-consequence analysis compared estimated hospitalization costs in a Canadian setting with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk. Insulin Glargine 161-169 insulin Homo sapiens 153-160 34763587-1 2021 OBJECTIVES: The present cost-consequence analysis compared estimated hospitalization costs in a Canadian setting with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk. Insulin Glargine 184-192 insulin Homo sapiens 153-160 35532858-0 2022 Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naive People with Type 2 Diabetes: the ATOS Study. Insulin Glargine 47-55 insulin Homo sapiens 39-46 34130445-0 2022 Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial. Insulin Glargine 60-68 insulin Homo sapiens 52-59 34130445-1 2022 Background: To compare the efficacy and safety of two insulin self-titration algorithms, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment (INSIGHT) and EDITION, for insulin glargine 300 units/mL (Gla-300) in Korean individuals with uncontrolled type 2 diabetes mellitus (T2DM). Insulin Glargine 130-138 insulin Homo sapiens 54-61 34130445-1 2022 Background: To compare the efficacy and safety of two insulin self-titration algorithms, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment (INSIGHT) and EDITION, for insulin glargine 300 units/mL (Gla-300) in Korean individuals with uncontrolled type 2 diabetes mellitus (T2DM). Insulin Glargine 130-138 insulin Homo sapiens 122-129 34130445-1 2022 Background: To compare the efficacy and safety of two insulin self-titration algorithms, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment (INSIGHT) and EDITION, for insulin glargine 300 units/mL (Gla-300) in Korean individuals with uncontrolled type 2 diabetes mellitus (T2DM). Insulin Glargine 202-210 insulin Homo sapiens 54-61 34078438-5 2021 CASE PRESENTATION: We report a case of a patient treated with insulin glargine at 13 years, due to glycemic intolerance, and with Lumacaftor/Ivacaftor at 15 years. Insulin Glargine 70-78 insulin Homo sapiens 62-69 34078438-10 2021 CONCLUSIONS: our case highlights firstly that insulin glargine has contributed to preserve him from further clinical worsening due to prediabetes in the years before pandemic, secondly the negative impact of COVID-19 lockdown on the clinical course of a chronic disease as CF. Insulin Glargine 54-62 insulin Homo sapiens 46-53 35471721-0 2022 Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus ): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial. Insulin Glargine 41-49 insulin Homo sapiens 33-40 35600866-0 2022 Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Insulin Glargine 88-96 insulin Homo sapiens 80-87 35579011-1 2022 OBJECTIVES: : Performing an updated meta-analysis to compare the safety and efficacy of insulin glargine and insulin detemir in adults with type 1 and type 2 diabetes. Insulin Glargine 96-104 insulin Homo sapiens 88-95 35579011-4 2022 RESULTS: : Nine studies compared insulin detemir and insulin glargine in type 2 diabetes and three studies in patients with type 1 diabetes. Insulin Glargine 61-69 insulin Homo sapiens 33-40 35579011-4 2022 RESULTS: : Nine studies compared insulin detemir and insulin glargine in type 2 diabetes and three studies in patients with type 1 diabetes. Insulin Glargine 61-69 insulin Homo sapiens 53-60 35600866-9 2022 Then, we provide an example that illustrates the use of this database by describing the uptake of insulin glargine-yfgn, a new exchangeable biosimilar for insulin glargine, in US nursing homes. Insulin Glargine 106-114 insulin Homo sapiens 98-105 35600866-9 2022 Then, we provide an example that illustrates the use of this database by describing the uptake of insulin glargine-yfgn, a new exchangeable biosimilar for insulin glargine, in US nursing homes. Insulin Glargine 106-114 insulin Homo sapiens 155-162 35600866-9 2022 Then, we provide an example that illustrates the use of this database by describing the uptake of insulin glargine-yfgn, a new exchangeable biosimilar for insulin glargine, in US nursing homes. Insulin Glargine 163-171 insulin Homo sapiens 98-105 35431280-0 2022 Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials. Insulin Glargine 74-82 insulin Homo sapiens 66-73 35014145-1 2022 AIM: To compare the efficacy of Triple Therapy (metformin/exenatide/pioglitazone) versus stepwise Conventional Therapy (metformin glipizide glargine insulin) on liver fat content and hepatic fibrosis in newly diagnosed, drug naive T2DM patients. Insulin Glargine 142-150 insulin Homo sapiens 151-158 35467938-0 2022 CGM-recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia. Insulin Glargine 59-67 insulin Homo sapiens 51-58 35467938-10 2022 CONCLUSION: In people with T1D, prone to nocturnal severe hypoglycemia, insulin degludec compared to insulin glargine U100 significantly reduces nocturnal CGM-recorded hypoglycemia. Insulin Glargine 109-117 insulin Homo sapiens 101-108 35141727-5 2022 Study Selection and Data Extraction: Included articles were those that followed adult patients with type 1 diabetes mellitus and/or type 2 diabetes mellitus and compared the following types of insulin: "NPH and glargine," "NPH and detemir," and "glargine and detemir" for at least 4 weeks, had documented basal insulin (BI) doses, and excluded pregnant patients. Insulin Glargine 211-219 insulin Homo sapiens 193-200 35410614-1 2022 BACKGROUND: Diabetes control without developing hypoglycemia is challenging in Type 1 diabetes (T1D) management with few studies evaluating the effect of insulin glargine timing on glucoregulation. Insulin Glargine 162-170 insulin Homo sapiens 154-161 35372263-2 2022 We previously showed that attaching two fluorophenylboronic acid (FPBA) residues to the C-terminal B chain of insulin glargine led to glucose-dependent solubility. Insulin Glargine 118-126 insulin Homo sapiens 110-117 35239165-0 2022 Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Who Fast During Ramadan in The Gulf Region: A Subgroup Analysis of the Real-World ORION Study. Insulin Glargine 36-44 insulin Homo sapiens 28-35 35171918-4 2022 In this prospective, open-label, randomized, parallel-group study, 63 patients with type 2 diabetes received metformin and insulin glargine U100 for 12 weeks. Insulin Glargine 131-139 insulin Homo sapiens 123-130 35141727-5 2022 Study Selection and Data Extraction: Included articles were those that followed adult patients with type 1 diabetes mellitus and/or type 2 diabetes mellitus and compared the following types of insulin: "NPH and glargine," "NPH and detemir," and "glargine and detemir" for at least 4 weeks, had documented basal insulin (BI) doses, and excluded pregnant patients. Insulin Glargine 246-254 insulin Homo sapiens 193-200 34716211-3 2022 RESEARCH DESIGN AND METHODS: This randomized crossover pilot study compared insulin degludec versus glargine U100 for adults with type 1 diabetes using MDI insulin during long-haul travel to and from Hawaii to New York. Insulin Glargine 100-108 insulin Homo sapiens 156-163 34728531-0 2022 Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. Insulin Glargine 88-96 insulin Homo sapiens 80-87 35463857-1 2022 A 72-year-old man with type 2 diabetes mellitus with good glucose control for 20 years and maintained on oral hypoglycaemic agents was diagnosed with Hodgkin"s Lymphoma (HL) and started on insulin glargine for glycaemic control. Insulin Glargine 197-205 insulin Homo sapiens 189-196 34052987-0 2021 Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naive Patients with Type 2 Diabetes Mellitus: DosInGlar Study. Insulin Glargine 26-34 insulin Homo sapiens 18-25 34052987-0 2021 Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naive Patients with Type 2 Diabetes Mellitus: DosInGlar Study. Insulin Glargine 26-34 insulin Homo sapiens 52-59 34052987-1 2021 INTRODUCTION: In the EDITION clinical trial programme, patients with type 2 diabetes mellitus (T2DM) receiving insulin glargine (IGlar) U300 required 10-15% more insulin than those receiving IGlar U100. Insulin Glargine 119-127 insulin Homo sapiens 111-118 34003539-0 2021 Clinical Research of Insulin Glargine U300 basal-bolus therapy and Insulin Degludec/Aspart Co-Formulation in Type 2 Diabetes Mellitus: A Real World Experience (CRIGDA Study). Insulin Glargine 29-37 insulin Homo sapiens 21-28 34047960-2 2021 METHODS: The study population comprised 376 insulin-naive patients who were started on basal insulin (glargine U100, glargine U300, or degludec) for the management of T2D and followed the treatment regimen for at least 6 months in 13 institutions in Japan. Insulin Glargine 102-110 insulin Homo sapiens 93-100 33501891-4 2021 Obesity prone and resistant rats were fed a low-fat diet for 5 weeks and treated with insulin (Lantus, 3 units/rat s.c.) 16 h before vagally induced bronchoconstriction was measured. Insulin Glargine 95-101 insulin Homo sapiens 86-93 34002663-0 2021 Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes. Insulin Glargine 34-42 insulin Homo sapiens 26-33 34002663-13 2021 CONCLUSION: Insulin detemir exhibited less GV than insulin glargine, although the small difference is unlikely to be clinically significant. Insulin Glargine 59-67 insulin Homo sapiens 51-58 33938149-1 2021 AIMS/INTRODUCTION: To evaluate and compare the efficacy of insulin degludec (IDeg) and insulin glargine 300 U/mL (Gla300) 6 months after switching from other basal insulins by assessing the changes in glycated hemoglobin (HbA1c), body mass index (BMI), and insulin doses in patients with type 1 and type 2 diabetes in a real-world clinical setting. Insulin Glargine 95-103 insulin Homo sapiens 87-94 33721211-3 2021 The aim of the present real-word study was to investigate differences in mortality among insulin-naive people with T2D who initiated insulin detemir (detemir) and insulin glargine (glargine). Insulin Glargine 181-189 insulin Homo sapiens 89-96 33721211-14 2021 CONCLUSION: In this real-world observational study, there was an association between all-cause mortality and basal insulin choice in insulin-naive people with T2D; the mortality risk was lower with detemir versus glargine after adjustment for potential confounders. Insulin Glargine 213-221 insulin Homo sapiens 115-122 33738774-0 2021 Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naive Chinese Type 2 Diabetes Patients. Insulin Glargine 83-91 insulin Homo sapiens 75-82 33738774-1 2021 INTRODUCTION: To compare glycemic variability (GV) and time in range (TIR) in Chinese patients with type 2 diabetes (T2D) initiated on once-daily bedtime insulin glargine 300U/ml (Gla-300) versus neutral protamine Hagedorn (NPH) insulin using continuous glucose monitoring (CGM). Insulin Glargine 162-170 insulin Homo sapiens 154-161 33926446-0 2021 The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naive patients suffering from type two diabetes mellitus - outcomes from cross-over open-label randomized trial. Insulin Glargine 32-40 insulin Homo sapiens 24-31 33845056-5 2021 Binding of short-acting insulin and long-acting insulin glargine to nanoparticles resulted in extended hypoglycemic activities in rat models of diabetes. Insulin Glargine 56-64 insulin Homo sapiens 48-55 33845056-6 2021 Following subcutaneous injection in diabetic rats, insulin- and insulin glargine-loaded nanoparticles of diverse morphologies had demonstrated up to 2.6-fold and 1.7-fold increase in pharmacological availability, in comparison to free insulin and insulin glargine, respectively. Insulin Glargine 72-80 insulin Homo sapiens 64-71 33845056-6 2021 Following subcutaneous injection in diabetic rats, insulin- and insulin glargine-loaded nanoparticles of diverse morphologies had demonstrated up to 2.6-fold and 1.7-fold increase in pharmacological availability, in comparison to free insulin and insulin glargine, respectively. Insulin Glargine 72-80 insulin Homo sapiens 64-71 33843291-11 2021 A number of gaps were identified and interventions were undertaken to reduce insulin pen waste, which resulted in a significant decrease in both aspart (p = 0.0002) and glargine (p = 0.0005) pens/patient over time. Insulin Glargine 169-177 insulin Homo sapiens 77-84 33675117-10 2021 Body weight loss was seen with dulaglutide whereas weight gain was seen with insulin glargine. Insulin Glargine 85-93 insulin Homo sapiens 77-84 33721211-0 2021 All-Cause and Cardiovascular Mortality Among Insulin-Naive People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK. Insulin Glargine 119-127 insulin Homo sapiens 45-52 33931817-1 2021 Glargine is a long-acting insulin analog with less hypoglycemia risk. Insulin Glargine 0-8 insulin Homo sapiens 26-33 33931817-2 2021 Like human insulin, glargine is a globular protein composed of two polypeptide chains linked by two disulfide bonds. Insulin Glargine 20-28 insulin Homo sapiens 11-18 33931817-3 2021 Pichia pastoris KM71 Muts strains were engineered to produce and secrete insulin glargine through the cleavage of two Kex2 sites. Insulin Glargine 81-89 insulin Homo sapiens 73-80 33931817-4 2021 Nevertheless, the recombinant product was the single-chain insulin glargine (glargine precursor) instead of the expected double-chain glargine. Insulin Glargine 67-75 insulin Homo sapiens 59-66 33931817-4 2021 Nevertheless, the recombinant product was the single-chain insulin glargine (glargine precursor) instead of the expected double-chain glargine. Insulin Glargine 77-85 insulin Homo sapiens 59-66 33931817-4 2021 Nevertheless, the recombinant product was the single-chain insulin glargine (glargine precursor) instead of the expected double-chain glargine. Insulin Glargine 77-85 insulin Homo sapiens 59-66 33953588-0 2021 Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus. Insulin Glargine 23-31 insulin Homo sapiens 15-22 33953588-1 2021 Purpose: To assess the association of type 2 diabetes mellitus (T2DM) and insulin glargine treatment with bone mineral density (BMD) in Chinese people. Insulin Glargine 82-90 insulin Homo sapiens 74-81 33953588-7 2021 BMD and serum calcium levels were associated with the application of insulin glargine. Insulin Glargine 77-85 insulin Homo sapiens 69-76 33953588-8 2021 Conclusion: These results suggest that insulin glargine may affect bone metabolism in patients diagnosed with T2DM. Insulin Glargine 47-55 insulin Homo sapiens 39-46 33734004-10 2021 This has been helped by growing prescribing and dispensing of biosimilar insulin glargine at lower costs that the originator, with this trend likely to continue with envisaged growth in the number of patients. Insulin Glargine 81-89 insulin Homo sapiens 73-80 33881797-0 2021 Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: a review of the DELIVER programme. Insulin Glargine 8-16 insulin Homo sapiens 0-7 33881797-1 2021 Evidence from randomised controlled trials (RCTs) has shown that second-generation basal insulin (BI) analogues, insulin glargine 300 U/mL (Gla-300) and insulin degludec (IDeg), provide similar glycaemic control with lower risk of hypoglycaemia compared with the first-generation BI analogue insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes (T2D). Insulin Glargine 121-129 insulin Homo sapiens 89-96 34027219-1 2021 Introduction: We aimed to see whether insulin glargine U300 can provide better blood glucose control while reducing hypoglycaemia in a more homogeneous population compared to previous studies. Insulin Glargine 46-54 insulin Homo sapiens 38-45 34027219-9 2021 Hypoglycaemic events occurred in all patients (100%) before using insulin glargine U300, while the incidence of hypoglycaemic events gradually decreased to 74.3%, 68.6%, and 68.6% between months 1-3, 3-6, and 6-9, respectively. Insulin Glargine 74-82 insulin Homo sapiens 66-73 34027219-11 2021 Conclusions: Over 9-16 months of follow-up, insulin glargine U300 led to a significant reduction not only of HbA1c levels but also of the frequency of hypoglycaemia, and also yielded high satisfaction rates. Insulin Glargine 52-60 insulin Homo sapiens 44-51 33845056-6 2021 Following subcutaneous injection in diabetic rats, insulin- and insulin glargine-loaded nanoparticles of diverse morphologies had demonstrated up to 2.6-fold and 1.7-fold increase in pharmacological availability, in comparison to free insulin and insulin glargine, respectively. Insulin Glargine 72-80 insulin Homo sapiens 64-71 33845056-6 2021 Following subcutaneous injection in diabetic rats, insulin- and insulin glargine-loaded nanoparticles of diverse morphologies had demonstrated up to 2.6-fold and 1.7-fold increase in pharmacological availability, in comparison to free insulin and insulin glargine, respectively. Insulin Glargine 255-263 insulin Homo sapiens 51-58 33845056-6 2021 Following subcutaneous injection in diabetic rats, insulin- and insulin glargine-loaded nanoparticles of diverse morphologies had demonstrated up to 2.6-fold and 1.7-fold increase in pharmacological availability, in comparison to free insulin and insulin glargine, respectively. Insulin Glargine 255-263 insulin Homo sapiens 64-71 33845056-6 2021 Following subcutaneous injection in diabetic rats, insulin- and insulin glargine-loaded nanoparticles of diverse morphologies had demonstrated up to 2.6-fold and 1.7-fold increase in pharmacological availability, in comparison to free insulin and insulin glargine, respectively. Insulin Glargine 255-263 insulin Homo sapiens 64-71 33845056-6 2021 Following subcutaneous injection in diabetic rats, insulin- and insulin glargine-loaded nanoparticles of diverse morphologies had demonstrated up to 2.6-fold and 1.7-fold increase in pharmacological availability, in comparison to free insulin and insulin glargine, respectively. Insulin Glargine 255-263 insulin Homo sapiens 64-71 33307335-1 2021 Insulin glargine (IGla) is a synthetic human-recombinant insulin analog that is used routinely in people as a q24h basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 33307335-1 2021 Insulin glargine (IGla) is a synthetic human-recombinant insulin analog that is used routinely in people as a q24h basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 57-64 33307335-1 2021 Insulin glargine (IGla) is a synthetic human-recombinant insulin analog that is used routinely in people as a q24h basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 121-128 33751403-0 2021 Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis. Insulin Glargine 31-39 insulin Homo sapiens 23-30 31280640-0 2021 Impact of Dosing Conversion From Basal Insulin to Follow-On Insulin Glargine. Insulin Glargine 68-76 insulin Homo sapiens 60-67 31280640-1 2021 BACKGROUND: Several basal insulins have recently come to market including follow-on insulin glargine (Basaglar ). Insulin Glargine 92-100 insulin Homo sapiens 26-33 33592769-5 2021 This study describes the first validated quantitative method for analysis human insulin and its six analogues (lispro, aspart, glulisine, glargine, detemir and degludec) in plasma and post-mortem sera. Insulin Glargine 138-146 insulin Homo sapiens 80-87 33790599-9 2021 Conclusion: Decision supporting of basal insulin glargine self-titration assisted by Diabetes Specialty Nurses is effective and safe in patients with T2DM. Insulin Glargine 49-57 insulin Homo sapiens 41-48 33662147-31 2021 Severe hypoglycaemia was observed in 122/1191 participants (10.2%) in the insulin glargine group compared with 145/1159 participants (12.5%) in the NPH insulin group (RR 0.84, 95% CI 0.67 to 1.04; 9 studies, 2350 participants; moderate-certainty evidence). Insulin Glargine 82-90 insulin Homo sapiens 74-81 33662147-40 2021 Both insulin detemir and insulin glargine compared with NPH insulin did not show benefits or harms for severe nocturnal hypoglycaemia. Insulin Glargine 33-41 insulin Homo sapiens 25-32 33662147-40 2021 Both insulin detemir and insulin glargine compared with NPH insulin did not show benefits or harms for severe nocturnal hypoglycaemia. Insulin Glargine 33-41 insulin Homo sapiens 25-32 33655870-0 2021 Evaluation of Early Administration of Insulin Glargine in the Acute Management of Diabetic Ketoacidosis. Insulin Glargine 46-54 insulin Homo sapiens 38-45 33655870-2 2021 Early insulin glargine use in DKA was safe and associated with a trend towards faster DKA resolution. Insulin Glargine 14-22 insulin Homo sapiens 6-13 33655870-3 2021 OBJECTIVES: To evaluate the efficacy and safety of early insulin glargine administration for acute management of DKA in critically ill patients. Insulin Glargine 65-73 insulin Homo sapiens 57-64 33655870-10 2021 CONCLUSION: Early administration of insulin glargine is potentially safe and may be associated with a reduction in time to DKA resolution and shorter duration of insulin infusion. Insulin Glargine 44-52 insulin Homo sapiens 36-43 33655870-10 2021 CONCLUSION: Early administration of insulin glargine is potentially safe and may be associated with a reduction in time to DKA resolution and shorter duration of insulin infusion. Insulin Glargine 44-52 insulin Homo sapiens 162-169 33604804-0 2021 Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study. Insulin Glargine 47-55 insulin Homo sapiens 39-46 33604804-1 2021 INTRODUCTION: The aim of this study is to demonstrate the real-life effectiveness and safety of insulin glargine 300 U/mL (Gla-300) in patients with type 2 diabetes (T2D) previously uncontrolled on NPH +- prandial insulin or premixed insulins in routine clinical practice in Bulgaria. Insulin Glargine 104-112 insulin Homo sapiens 96-103 33354715-1 2021 PURPOSE: In comparative randomized studies, use of insulin detemir has been consistently demonstrated to be associated with less weight gain than the industry standard, insulin glargine. Insulin Glargine 177-185 insulin Homo sapiens 51-58 33354715-1 2021 PURPOSE: In comparative randomized studies, use of insulin detemir has been consistently demonstrated to be associated with less weight gain than the industry standard, insulin glargine. Insulin Glargine 177-185 insulin Homo sapiens 169-176 33354715-2 2021 However, the magnitude of the relative reduction in weight gain with use of insulin determir vs insulin glargine in regulatory studies (reported values ranged from 0.77 kg to 3.6 kg) may not be generalizable to patients in real-world practice conditions. Insulin Glargine 104-112 insulin Homo sapiens 96-103 33354715-4 2021 METHODS: A retrospective longitudinal cohort study design was applied in reviewing electronic medical records to identify insulin-naive, overweight patients with type 2 diabetes who received insulin detemir or insulin glargine therapy continued for up to 1 year. Insulin Glargine 218-226 insulin Homo sapiens 122-129 33512347-0 2021 In Brief: Semglee - a new insulin glargine for diabetes. Insulin Glargine 34-42 insulin Homo sapiens 26-33 33317342-0 2021 Needle-free jet injection of insulin glargine improves glycaemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system. Insulin Glargine 37-45 insulin Homo sapiens 29-36 33317342-3 2021 RESEARCH DESIGN AND METHODS: In this randomized, controlled, cross-sectional study, 66 patients with T2DM who received insulin glargine (12-18 IU/day) injection were enrolled. Insulin Glargine 127-135 insulin Homo sapiens 119-126 33317342-10 2021 CONCLUSIONS: Needle-free jet injection of insulin glargine was more effective than use of an insulin pen for good glycemic control in patients with T2DM. Insulin Glargine 50-58 insulin Homo sapiens 42-49 33131992-0 2021 Glargine insulin loaded lipid nanoparticles: Oral delivery of liquid and solid oral dosage forms. Insulin Glargine 0-8 insulin Homo sapiens 9-16 33131992-2 2021 Preliminary evidence for peptide uptake by the gut has recently been obtained, by our research group, following the administration of nanostructured lipid-carrier suspensions loaded with glargine insulin in healthy animal models. Insulin Glargine 187-195 insulin Homo sapiens 196-203 33131992-3 2021 METHODS AND RESULTS: In this experimental study, glargine insulin-loaded nanostructured lipid carriers have been converted into solid oral dosage forms (tablets, capsules), that are more suitable for administration in humans and have prolonged shelf-life. Insulin Glargine 49-57 insulin Homo sapiens 58-65 33131992-5 2021 A suitable composition gave redispersible solid oral dosage forms from glargine insulin-loaded carriers, using both spray-drying and freeze-drying. Insulin Glargine 71-79 insulin Homo sapiens 80-87 33315628-4 2021 The newest basal insulin analogues, insulin glargine U300 and degludec, have proven to be efficient in reducing hypoglycaemic events due to a more stable action profile. Insulin Glargine 44-52 insulin Homo sapiens 17-24 33315628-4 2021 The newest basal insulin analogues, insulin glargine U300 and degludec, have proven to be efficient in reducing hypoglycaemic events due to a more stable action profile. Insulin Glargine 44-52 insulin Homo sapiens 36-43 33469328-0 2021 Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Insulin Glargine 39-47 insulin Homo sapiens 31-38 33469328-15 2021 Conclusion: Overall, insulin glargine biosimilar EZL and originator insulin glargine LAN have shown a similar immunogenicity profile, as well as efficacy in providing glucose control and safety findings in T2D populations. Insulin Glargine 29-37 insulin Homo sapiens 21-28 33201346-0 2021 Correction to: Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus ) and Lantus in healthy subjects: a double-blind, randomized clamp study. Insulin Glargine 90-98 insulin Homo sapiens 82-89 33030354-0 2020 Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study. Insulin Glargine 72-80 insulin Homo sapiens 64-71 33569407-2 2021 The aim of our study was to assess on a large cohort of insulin-naive T2DM subjects the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) in a real-life setting. Insulin Glargine 124-132 insulin Homo sapiens 56-63 33540243-0 2021 Use of insulin glargine during pregnancy: A review. Insulin Glargine 15-23 insulin Homo sapiens 7-14 33540243-3 2021 Insulin glargine, in spite of widespread use in non-pregnant adults, lacks randomized controlled trial evidence as safe basal insulin during pregnancy. Insulin Glargine 8-16 insulin Homo sapiens 0-7 33540243-4 2021 Aim of this review is to discuss major available evidences and recommendations on the use of insulin glargine during pregnancy. Insulin Glargine 101-109 insulin Homo sapiens 93-100 33540243-5 2021 METHODS: Evidences related to use of insulin glargine during pregnancy, including animal studies, placental transfer studies, case reports as well as observational studies were retrieved using PUBMED & Google scholar. Insulin Glargine 45-53 insulin Homo sapiens 37-44 33540243-6 2021 Recommendations regarding use of insulin glargine during pregnancy by international and Indian organizations were reviewed. Insulin Glargine 41-49 insulin Homo sapiens 33-40 33540243-7 2021 RESULTS: Trans-placental transfer studies show that insulin glargine does not cross placenta when used at therapeutic concentrations. Insulin Glargine 60-68 insulin Homo sapiens 52-59 33540243-10 2021 CONCLUSIONS: Insulin glargine can be continued safely during pregnancy in women who are already taking it prior to pregnancy and have achieved good glycemic control with it. Insulin Glargine 21-29 insulin Homo sapiens 13-20 32991041-0 2021 Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus GLP-1 RAs in people with type 2 diabetes mellitus: a network meta-analysis. Insulin Glargine 45-53 insulin Homo sapiens 37-44 33030354-1 2020 Objective: To evaluate insulin treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice for Japanese patients with type 2 diabetes mellitus (T2DM) who switched from originator insulin glargine (100 U/mL) or insulin degludec treatment to GLY treatment.Methods: The Insulin Treatment Satisfaction Questionnaire (ITSQ) was used to assess treatment satisfaction in a subgroup analysis of a post-marketing safety study. Insulin Glargine 103-111 insulin Homo sapiens 95-102 33030354-1 2020 Objective: To evaluate insulin treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice for Japanese patients with type 2 diabetes mellitus (T2DM) who switched from originator insulin glargine (100 U/mL) or insulin degludec treatment to GLY treatment.Methods: The Insulin Treatment Satisfaction Questionnaire (ITSQ) was used to assess treatment satisfaction in a subgroup analysis of a post-marketing safety study. Insulin Glargine 103-111 insulin Homo sapiens 95-102 33030354-1 2020 Objective: To evaluate insulin treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice for Japanese patients with type 2 diabetes mellitus (T2DM) who switched from originator insulin glargine (100 U/mL) or insulin degludec treatment to GLY treatment.Methods: The Insulin Treatment Satisfaction Questionnaire (ITSQ) was used to assess treatment satisfaction in a subgroup analysis of a post-marketing safety study. Insulin Glargine 103-111 insulin Homo sapiens 95-102 33247658-4 2020 After several attempts at prolonging insulin action using phenol and structural modifications of the insulin hexamer, insulin glargine was developed in 1988. Insulin Glargine 126-134 insulin Homo sapiens 37-44 33035599-0 2020 Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Insulin Glargine 23-31 insulin Homo sapiens 15-22 33035599-9 2020 After 26 weeks of treatment, compared to the placebo group, in the liraglutide and insulin glargine groups, IHCL significantly decreased from baseline to week 26 (liraglutide 26.4 % +- 3.2% to 20.6% +- 3.9%, P < 0.05; insulin glargine 25.0 % +- 4.3% to 22.6% +- 5.8%, P > 0.05). Insulin Glargine 91-99 insulin Homo sapiens 83-90 33035599-9 2020 After 26 weeks of treatment, compared to the placebo group, in the liraglutide and insulin glargine groups, IHCL significantly decreased from baseline to week 26 (liraglutide 26.4 % +- 3.2% to 20.6% +- 3.9%, P < 0.05; insulin glargine 25.0 % +- 4.3% to 22.6% +- 5.8%, P > 0.05). Insulin Glargine 226-234 insulin Homo sapiens 83-90 33035599-10 2020 SAT and VAT decreased significantly in the liraglutide group and in the insulin glargine group (P < 0.05). Insulin Glargine 80-88 insulin Homo sapiens 72-79 33035599-11 2020 DeltaSAT and DeltaVAT were greater with liraglutide than insulin glargine, they were significantly different between the two groups (DeltaSAT, -36 vs.-24.5, P < 0.05; and DeltaVAT, -47 vs.-16.6, P > 0.05). Insulin Glargine 65-73 insulin Homo sapiens 57-64 33247659-3 2020 The advent of the first truly long-acting basal insulin, i.e. insulin glargine 100 U/mL (Gla-100) brought to the table a remarkably long duration of action and a very minimal risk of hypoglycemia by due to less pronounced peaks in their action profile. Insulin Glargine 70-78 insulin Homo sapiens 48-55 33247660-2 2020 However, the advent of insulin glargine 100 U/mL (Gla-100) opened up a new dimension in insulin therapy landscape in India. Insulin Glargine 31-39 insulin Homo sapiens 23-30 33247661-3 2020 Insulin glargine 100 U/mL (Gla-100) has been extensively studied under various scenarios as the initial insulin administered early in T2DM disease course, registering significant glycemic and vascular benefits over the standard of care. Insulin Glargine 8-16 insulin Homo sapiens 104-111 33247662-4 2020 In this context, insulin glargine 100 U/mL (Gla-100) appears to be the ideal insulin to overcome titration inertia, owing to its low risk of hypoglycemia and effective glycemic control. Insulin Glargine 25-33 insulin Homo sapiens 17-24 33247666-5 2020 It also throws light on how insulin glargine 100 U/mL has emerged as a preferred choice of insulin therapy in most of these situations, on the strength of its inherently low hypoglycemia and weight gain potential, which has found traction even in the recent diabetes guidelines. Insulin Glargine 36-44 insulin Homo sapiens 28-35 33251697-2 2021 METHODS: Participants were randomly assigned to groups for therapy with insulin glulisine (IGlu) or insulin glargine (IGla). Insulin Glargine 108-116 insulin Homo sapiens 100-107 33299890-0 2020 Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs. Insulin Glargine 95-103 insulin Homo sapiens 87-94 33299890-11 2020 Conclusion: Dapagliflozin may reduce blood glucose levels, ameliorate glycemic variability, and improve pancreatic beta-cell function in patients with T2D under insulin glargine combined with other oral hypoglycemic drugs, especially in those with poor glucose control and abdominal obesity. Insulin Glargine 169-177 insulin Homo sapiens 161-168 33247658-4 2020 After several attempts at prolonging insulin action using phenol and structural modifications of the insulin hexamer, insulin glargine was developed in 1988. Insulin Glargine 126-134 insulin Homo sapiens 101-108 33247658-4 2020 After several attempts at prolonging insulin action using phenol and structural modifications of the insulin hexamer, insulin glargine was developed in 1988. Insulin Glargine 126-134 insulin Homo sapiens 101-108 33247658-5 2020 The superior and unique pharmacological properties, longer duration of action, and significantly lowered risk of hypoglycemia enabled insulin glargine to be distinguished from NPH as a better basal insulin, providing holistic glycemic control. Insulin Glargine 142-150 insulin Homo sapiens 134-141 33247658-5 2020 The superior and unique pharmacological properties, longer duration of action, and significantly lowered risk of hypoglycemia enabled insulin glargine to be distinguished from NPH as a better basal insulin, providing holistic glycemic control. Insulin Glargine 142-150 insulin Homo sapiens 198-205 33166419-22 2020 Insulin glargine compared to NPH insulin had a risk ratio (RR) for severe hypoglycaemia of 0.68 (95% confidence interval (CI) 0.46 to 1.01; P = 0.06; absolute risk reduction (ARR) -1.2%, 95% CI -2.0 to 0; 14 trials, 6164 participants; very low-certainty evidence). Insulin Glargine 8-16 insulin Homo sapiens 0-7 33166419-24 2020 Treatment with insulin glargine reduced the incidence of confirmed hypoglycaemia and confirmed nocturnal hypoglycaemia. Insulin Glargine 23-31 insulin Homo sapiens 15-22 33166419-33 2020 AUTHORS" CONCLUSIONS: While the effects on HbA1c were comparable, treatment with insulin glargine and insulin detemir resulted in fewer participants experiencing hypoglycaemia when compared with NPH insulin. Insulin Glargine 89-97 insulin Homo sapiens 81-88 32700442-0 2020 Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared to premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. Insulin Glargine 8-16 insulin Homo sapiens 0-7 32700442-2 2020 A fixed-ratio combination of insulin glargine 100U/mL and lixisenatide, iGlarLixi, is a marketed treatment option. Insulin Glargine 37-45 insulin Homo sapiens 29-36 32729217-0 2020 A pragmatic randomized clinical trial of insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 6-month outcomes of ACHIEVE Control. Insulin Glargine 49-57 insulin Homo sapiens 41-48 32975710-3 2020 Second-generation basal insulin analogues (insulin glargine 300 U/mL and degludec) have demonstrated reductions in hypoglycemia compared with insulin glargine 100 U/mL although evidence of this benefit across specific populations is less clear. Insulin Glargine 51-59 insulin Homo sapiens 24-31 32813262-0 2020 Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study. Insulin Glargine 42-50 insulin Homo sapiens 34-41 32963612-5 2020 In the present study, the HCC4006 cell line, which harbors EGFR mutations, was co-treated with gefitinib and long-acting insulin glargine. Insulin Glargine 129-137 insulin Homo sapiens 121-128 32694215-4 2020 In the albiglutide + glargine group, 218 participants (54%) replaced all prandial insulin without reintroducing lispro up to week 26. Insulin Glargine 21-29 insulin Homo sapiens 82-89 32694215-5 2020 Total daily prandial insulin dose was similar at baseline but was lower by 62 units/day (95% CI -65.9 to -57.8; P < 0.0001) at week 26 in the albiglutide + glargine group, and the total number of weekly injections was also reduced from 29 to 13 per week. Insulin Glargine 156-164 insulin Homo sapiens 21-28 33133703-5 2020 In this case report, we present a case of refractory hypoglycemia following an overdose of 900 units of long-acting insulin glargine that failed to respond to usual modes of therapy mentioned above. Insulin Glargine 124-132 insulin Homo sapiens 116-123 32515543-0 2020 Lower Risk for Severe Hypoglycaemia with Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Participants with Type 1 Diabetes: a Meta-Analysis of 6-Month Phase 3 Clinical Trials. Insulin Glargine 49-57 insulin Homo sapiens 41-48 32984519-7 2020 Following the diagnosis of autoimmune diabetes, 5 units of glargine insulin was commenced which maintained euglycemia and resolved her symptoms of hyperglycemia. Insulin Glargine 59-67 insulin Homo sapiens 68-75 32681460-0 2020 Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. Insulin Glargine 85-93 insulin Homo sapiens 77-84 32037850-0 2020 Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar). Insulin Glargine 67-75 insulin Homo sapiens 59-66 32037850-0 2020 Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar). Insulin Glargine 77-83 insulin Homo sapiens 59-66 32037850-0 2020 Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar). Insulin Glargine 96-104 insulin Homo sapiens 88-95 32037850-1 2020 Background: Basaglar, insulin glargine (BGlar; Eli Lilly, Indianapolis, IN), a follow-on biologic, was developed after the patent for Lantus, insulin glargine (LGlar; Sanofi-Aventis, Paris, France) expired. Insulin Glargine 30-38 insulin Homo sapiens 22-29 32118347-3 2020 The Italian Titration Approach Study (ITAS) compared the efficacy and safety of insulin glargine 300 U/mL (Gla-300) initiation and titration using patient- (nurse-supported) or physician-management in insulin-naive patients with uncontrolled T2DM. Insulin Glargine 88-96 insulin Homo sapiens 80-87 32220551-5 2020 RESULTS: The probability of reaching the FSG target without hypoglycemia was higher with dulaglutide than with insulin glargine at weeks 4 (OR 1.78; 95% confidence interval [CI] 1.22-2.60) and 8 (OR 1.69; 95% CI 1.15-2.48). Insulin Glargine 119-127 insulin Homo sapiens 111-118 32291880-1 2020 AIMS: To assess efficacy and safety of 26-week treatment with insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with insulin glargine U100 (iGlar) in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs). Insulin Glargine 70-78 insulin Homo sapiens 62-69 32314521-0 2020 Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naive people with type 2 diabetes: a post hoc analysis of the EDITION 3 trial. Insulin Glargine 32-40 insulin Homo sapiens 24-31 31288531-0 2020 In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects. Insulin Glargine 67-73 insulin Homo sapiens 51-58 32399816-0 2020 Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus. Insulin Glargine 32-40 insulin Homo sapiens 24-31 32399816-1 2020 The article MYL1501D Insulin Glargine: A Review in Diabetes Mellitus, written by Sheridan M. Insulin Glargine 29-37 insulin Homo sapiens 21-28 32527798-0 2020 Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018). Insulin Glargine 52-60 insulin Homo sapiens 44-51 32527798-1 2020 BACKGROUND: Lantus, the reference insulin glargine used for the treatment of diabetes, lost its patent protection in 2014, opening the market to biosimilar competitors. Insulin Glargine 12-18 insulin Homo sapiens 34-41 32527798-1 2020 BACKGROUND: Lantus, the reference insulin glargine used for the treatment of diabetes, lost its patent protection in 2014, opening the market to biosimilar competitors. Insulin Glargine 42-50 insulin Homo sapiens 34-41 32527798-2 2020 OBJECTIVE: First, to analyze the adoption rates of insulin glargine biosimilars in primary care in England and estimate the savings realized and missed, since an insulin glargine biosimilar was first used, and second, to assess potential variations in adoption rates across Clinical Commissioning Groups (CCGs). Insulin Glargine 59-67 insulin Homo sapiens 51-58 32527798-2 2020 OBJECTIVE: First, to analyze the adoption rates of insulin glargine biosimilars in primary care in England and estimate the savings realized and missed, since an insulin glargine biosimilar was first used, and second, to assess potential variations in adoption rates across Clinical Commissioning Groups (CCGs). Insulin Glargine 170-178 insulin Homo sapiens 162-169 32527798-8 2020 RESULTS: Insulin glargine biosimilars generated savings of $900,000 between October 2015 (time of first prescription) and December 2018. Insulin Glargine 17-25 insulin Homo sapiens 9-16 32527798-10 2020 The analyses demonstrated a large level of variation in the uptake of insulin glargine biosimilars across CCGs, with market shares ranging from 0 to 53.3% (December 2018). Insulin Glargine 78-86 insulin Homo sapiens 70-77 32651837-1 2020 INTRODUCTION: A second-generation basal insulin analogue insulin glargine 300 U/mL (Gla-300) has been marketed in France since June 2016. Insulin Glargine 65-73 insulin Homo sapiens 40-47 32403130-0 2020 Remission of type 2 diabetes following a short-term intervention with insulin glargine, metformin and dapagliflozin. Insulin Glargine 78-86 insulin Homo sapiens 70-77 31955491-1 2020 BACKGROUND: The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Insulin Glargine 91-99 insulin Homo sapiens 83-90 31955491-6 2020 In comparison, only LFC (DeltaLFC, -10.49 +- 11.38%; P < .05), and not VAT, SAT, or FIB-4 index (all P > .05), was reduced after insulin glargine treatment. Insulin Glargine 137-145 insulin Homo sapiens 129-136 31955491-10 2020 CONCLUSION: Both exenatide and insulin glargine reduced LFC in patients with drug-naive T2DM and NAFLD; however, exenatide showed greater reductions in body weight, visceral fat area, liver enzymes, FIB-4, postprandial plasma glucose, and LDL-C. Insulin Glargine 39-47 insulin Homo sapiens 31-38 33786271-12 2021 Conclusion: Our results suggest that basal insulin with either degludec or glargine decreases the incidence of post-breakfast hyperglycemia accompanied by decreasing the post-breakfast PI/CPR ratio and fasting FFA levels in patients with type 2 diabetes. Insulin Glargine 75-83 insulin Homo sapiens 43-50 32360709-0 2020 Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. Insulin Glargine 47-55 insulin Homo sapiens 39-46 32643130-1 2020 INTRODUCTION: MAGE was a Multicenter, single-Arm, observational 6-month (plus 6-month extension) study that aimed to assess treatment satisfaction, efficacy, and safety of insulin Glargine 300 U/mL (Gla-300) in people with type 2 diabetes (T2DM) receiving basal-bolus insulin in a rEal-world setting. Insulin Glargine 180-188 insulin Homo sapiens 172-179 32412055-8 2020 Adalimumab was the top drug in US expenditures in 2019, followed by apixaban and insulin glargine. Insulin Glargine 89-97 insulin Homo sapiens 81-88 32388224-0 2020 Development of a robust functional cell-based assay for replacing the rabbit blood sugar bioidentity test of insulin glargine drug substance. Insulin Glargine 117-125 insulin Homo sapiens 109-116 32753920-0 2020 Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland. Insulin Glargine 36-44 insulin Homo sapiens 28-35 32753920-1 2020 Introduction: Insulin glargine 300 U/mL (Gla-300; Toujeo ) is a second-generation once-daily basal insulin. Insulin Glargine 22-30 insulin Homo sapiens 99-106 32753920-1 2020 Introduction: Insulin glargine 300 U/mL (Gla-300; Toujeo ) is a second-generation once-daily basal insulin. Insulin Glargine 50-56 insulin Homo sapiens 99-106 32220551-7 2020 CONCLUSIONS: Dulaglutide"s balanced efficacy-to-safety profile compares favorably with that of insulin glargine and is apparent soon after treatment initiation and after 6 months of therapy. Insulin Glargine 103-111 insulin Homo sapiens 95-102 32210600-1 2020 Objective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU). Insulin Glargine 77-85 insulin Homo sapiens 69-76 32606850-10 2020 The total additional QALY gained from insulin Glargine was 0.1317 and from insulin Detemir was 0.8376. Insulin Glargine 46-54 insulin Homo sapiens 38-45 32595277-0 2020 Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. Insulin Glargine 81-89 insulin Homo sapiens 73-80 32160049-7 2020 Conclusion: The presence of T2DM with end-organ damage complications, longer TPN duration, belonging to the glargine insulin group, and greater GV are factors associated with the risk of hypoglycemia in diabetic noncritically ill inpatients with parenteral nutrition. Insulin Glargine 108-116 insulin Homo sapiens 117-124 32295808-1 2020 OBJECTIVE: To assess the efficacy and safety of a 1:1 fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) versus lixisenatide (Lixi) in insulin-naive Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs). Insulin Glargine 89-97 insulin Homo sapiens 81-88 32315508-3 2020 The second-generation basal insulin analogues glargine 300 U/mL (Gla-300) and degludec (IDeg) provide pharmacokinetic and pharmacodynamic improvements that may allow them to be more effective in appropriately managing diabetes compared with first-generation basal insulin analogues. Insulin Glargine 46-54 insulin Homo sapiens 28-35 32315508-3 2020 The second-generation basal insulin analogues glargine 300 U/mL (Gla-300) and degludec (IDeg) provide pharmacokinetic and pharmacodynamic improvements that may allow them to be more effective in appropriately managing diabetes compared with first-generation basal insulin analogues. Insulin Glargine 46-54 insulin Homo sapiens 264-271 32313609-3 2020 Recently introduced second-generation basal insulin analogues [for e.g., insulin glargine 300 U/mL (Gla-300) and insulin degludec] are designed to have improved pharmacokinetic profiles with an intention to deliver steady insulin levels over a longer period. Insulin Glargine 81-89 insulin Homo sapiens 44-51 32313609-3 2020 Recently introduced second-generation basal insulin analogues [for e.g., insulin glargine 300 U/mL (Gla-300) and insulin degludec] are designed to have improved pharmacokinetic profiles with an intention to deliver steady insulin levels over a longer period. Insulin Glargine 81-89 insulin Homo sapiens 73-80 32313609-3 2020 Recently introduced second-generation basal insulin analogues [for e.g., insulin glargine 300 U/mL (Gla-300) and insulin degludec] are designed to have improved pharmacokinetic profiles with an intention to deliver steady insulin levels over a longer period. Insulin Glargine 81-89 insulin Homo sapiens 73-80 32308446-7 2020 The model aims to estimate total direct costs related to the above-reported treatments and find out the real gap in costs between dulaglutide, the apparently cheaper gliclazide and basal insulin glargine (IGlargine) based on the Italian National Healthcare System (INHS). Insulin Glargine 195-203 insulin Homo sapiens 187-194 32308446-7 2020 The model aims to estimate total direct costs related to the above-reported treatments and find out the real gap in costs between dulaglutide, the apparently cheaper gliclazide and basal insulin glargine (IGlargine) based on the Italian National Healthcare System (INHS). Insulin Glargine 205-214 insulin Homo sapiens 187-194 32337298-3 2020 One potential option to improve diabetes control in these patients may be the use of new insulin formulations including second-generation basal insulin analogues such as insulin glargine 300 U/mL (Gla-300). Insulin Glargine 178-186 insulin Homo sapiens 89-96 32337298-3 2020 One potential option to improve diabetes control in these patients may be the use of new insulin formulations including second-generation basal insulin analogues such as insulin glargine 300 U/mL (Gla-300). Insulin Glargine 178-186 insulin Homo sapiens 144-151 32130661-9 2020 DISCUSSION: Given the current lack of clinical data, this study will provide evidence supporting safe and effective glycemic control using basal insulin glargine-based therapy plus OADs compared with twice-daily premixed insulin in Chinese patients with T2DM after short-term IIT. Insulin Glargine 153-161 insulin Homo sapiens 145-152 32595277-15 2020 Despite the higher annual direct total cost, the additional cost per quality-adjusted life year (QALY) gained, compared with gliclazide, has been $11 517, and $4639, when compared with insulin glargine in the base-case scenario, and the robustness of the results has been shown in the sensitivity analysis. Insulin Glargine 193-201 insulin Homo sapiens 185-192 32271092-0 2020 Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study. Insulin Glargine 57-65 insulin Homo sapiens 49-56 32271092-1 2020 Objective: To evaluate the long-term safety and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice.Methods: This prospective, non-interventional, multicenter, observational, post-marketing safety study (PMSS) enrolled Japanese patients with type 1 or 2 diabetes mellitus (T1DM or T2DM) starting GLY therapy, and was required by Japanese Pharmaceutical Affairs Law mandating post-marketing safety surveillance to acquire safety and effectiveness data of biosimilar products. Insulin Glargine 84-92 insulin Homo sapiens 76-83 32397452-13 2020 This could also be the case for the equal and under-reimbursement of insulin glargine and metformin (targeting diabetes), respectively, although this has to be considered with caution. Insulin Glargine 77-85 insulin Homo sapiens 69-76 32984521-7 2020 He was ultimately diagnosed with autoimmune diabetes that was treated with insulin glargine and insulin aspart with improvement in his glycemic control. Insulin Glargine 83-91 insulin Homo sapiens 75-82 32277401-4 2020 Mean daily dose of glimepiride and insulin glargine was 2.51 mg and 21.0 IU, respectively. Insulin Glargine 43-51 insulin Homo sapiens 35-42 32350009-3 2020 Insulin glargine 300 units/mL (Gla-300) is a second-generation basal insulin analogue with preserved glucose-lowering efficacy but reduced risk of hypoglycaemia. Insulin Glargine 8-16 insulin Homo sapiens 69-76 32342025-0 2020 Case Report: High-concentration Insulin Glargine Overdose Complicated by Hepatic Steatosis. Insulin Glargine 40-48 insulin Homo sapiens 32-39 32342025-3 2020 A patient with type 1 diabetes mellitus self-administered 4050 units of high-concentration (300 units/mL) insulin glargine, in addition to coingestants. Insulin Glargine 114-122 insulin Homo sapiens 106-113 32342025-6 2020 Owing to the altered pharmacology of high-concentration insulin glargine when administered at large doses in cases of intentional overdose, patients are likely to require a much longer period of supplemental dextrose support than may otherwise be expected when these agents are used at therapeutic doses. Insulin Glargine 64-72 insulin Homo sapiens 56-63 32215829-0 2020 MYL1501D Insulin Glargine: A Review in Diabetes Mellitus. Insulin Glargine 17-25 insulin Homo sapiens 9-16 32215829-1 2020 Subcutaneous MYL1501D insulin glargine 100 U/mL (hereafter referred to as MYL1501D insulin glargine) [Semglee ] is a long-acting human insulin analogue approved as a biosimilar of insulin glargine 100 U/mL (hereafter referred to as reference insulin glargine 100 U/mL) [Lantus ] in various countries, including those of the EU for the treatment of diabetes mellitus in patients aged >= 2 years, as well as Japan for diabetes where insulin therapy is indicated. Insulin Glargine 30-38 insulin Homo sapiens 22-29 32215829-1 2020 Subcutaneous MYL1501D insulin glargine 100 U/mL (hereafter referred to as MYL1501D insulin glargine) [Semglee ] is a long-acting human insulin analogue approved as a biosimilar of insulin glargine 100 U/mL (hereafter referred to as reference insulin glargine 100 U/mL) [Lantus ] in various countries, including those of the EU for the treatment of diabetes mellitus in patients aged >= 2 years, as well as Japan for diabetes where insulin therapy is indicated. Insulin Glargine 91-99 insulin Homo sapiens 22-29 32215829-1 2020 Subcutaneous MYL1501D insulin glargine 100 U/mL (hereafter referred to as MYL1501D insulin glargine) [Semglee ] is a long-acting human insulin analogue approved as a biosimilar of insulin glargine 100 U/mL (hereafter referred to as reference insulin glargine 100 U/mL) [Lantus ] in various countries, including those of the EU for the treatment of diabetes mellitus in patients aged >= 2 years, as well as Japan for diabetes where insulin therapy is indicated. Insulin Glargine 91-99 insulin Homo sapiens 22-29 32215829-1 2020 Subcutaneous MYL1501D insulin glargine 100 U/mL (hereafter referred to as MYL1501D insulin glargine) [Semglee ] is a long-acting human insulin analogue approved as a biosimilar of insulin glargine 100 U/mL (hereafter referred to as reference insulin glargine 100 U/mL) [Lantus ] in various countries, including those of the EU for the treatment of diabetes mellitus in patients aged >= 2 years, as well as Japan for diabetes where insulin therapy is indicated. Insulin Glargine 91-99 insulin Homo sapiens 22-29 32215829-2 2020 MYL1501D insulin glargine has similar physicochemical characteristics and biological properties to those of EU- and US-sourced reference insulin glargine 100 U/mL, with the bioequivalence of pharmacodynamic and pharmacokinetic parameters between these agents shown in adults with type 1 diabetes. Insulin Glargine 17-25 insulin Homo sapiens 9-16 32215829-3 2020 Once-daily MYL1501D insulin glargine demonstrated noninferior glycaemic efficacy to that of once-daily reference insulin glargine 100 U/mL in adults with type 1 or 2 diabetes, with its glycated haemoglobin-lowering benefits maintained over the longer-term (52 weeks) and unaffected by previous insulin exposure. Insulin Glargine 28-36 insulin Homo sapiens 20-27 32215829-5 2020 MYL1501D insulin glargine was well tolerated, demonstrating a safety and immunogenicity profile similar to that of reference insulin glargine 100 U/mL in patients with type 1 and 2 diabetes, and in those with type 1 diabetes switching between the two agents. Insulin Glargine 17-25 insulin Homo sapiens 9-16 32215829-7 2020 Thus, MYL1501D insulin glargine provides an effective biosimilar alternative for patients requiring insulin glargine therapy. Insulin Glargine 23-31 insulin Homo sapiens 15-22 32215829-7 2020 Thus, MYL1501D insulin glargine provides an effective biosimilar alternative for patients requiring insulin glargine therapy. Insulin Glargine 108-116 insulin Homo sapiens 15-22 32215829-7 2020 Thus, MYL1501D insulin glargine provides an effective biosimilar alternative for patients requiring insulin glargine therapy. Insulin Glargine 108-116 insulin Homo sapiens 100-107 32318639-0 2020 Insulin/carbohydrates ratio during the first 6-month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. Insulin Glargine 163-171 insulin Homo sapiens 0-7 32318639-3 2020 Objective: To assess changes in insulin/carbohydrate ratio (I:CHO) after the first 6 months of degludec therapy in a paediatric population with type 1 diabetes previously treated with glargine U100. Insulin Glargine 184-192 insulin Homo sapiens 32-39 32210600-9 2020 Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. Insulin Glargine 32-40 insulin Homo sapiens 24-31 32210600-9 2020 Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. Insulin Glargine 32-40 insulin Homo sapiens 164-171 31608548-0 2020 Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Insulin Glargine 124-132 insulin Homo sapiens 8-17 31608548-0 2020 Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Insulin Glargine 124-132 insulin Homo sapiens 57-64 31608548-1 2020 AIM: To examine the relationship between baseline fasting C-peptide (FCP) and outcomes in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL (Gla-100). Insulin Glargine 157-165 insulin Homo sapiens 58-67 31608548-1 2020 AIM: To examine the relationship between baseline fasting C-peptide (FCP) and outcomes in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL (Gla-100). Insulin Glargine 157-165 insulin Homo sapiens 90-97 31995840-0 2020 Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing. Insulin Glargine 8-16 insulin Homo sapiens 0-7 32419872-5 2020 A good glycemic control was achieved with insulin glargine and metformin. Insulin Glargine 50-58 insulin Homo sapiens 42-49 31995840-1 2020 OBJECTIVE: Twice/day dosing of insulin glargine has been used to treat hyperglycemia in clinical practice; however, data supporting its use in the critically ill population are lacking. Insulin Glargine 39-47 insulin Homo sapiens 31-38 31995840-2 2020 This study was designed to evaluate the safety and efficacy of twice/day insulin glargine in critically ill patients. Insulin Glargine 81-89 insulin Homo sapiens 73-80 31995840-3 2020 METHODS: A retrospective study was conducted in adult patients admitted to the intensive care units between February 2013 and June 2017 who received insulin glargine twice/day or 40 units or more once/day for 48 hours or longer. Insulin Glargine 157-165 insulin Homo sapiens 149-156 31995840-13 2020 CONCLUSIONS: This is the first study demonstrating that twice/day insulin glargine reduced the rate of predose hyperglycemia without increasing the risk of hypoglycemia in critically ill patients. Insulin Glargine 74-82 insulin Homo sapiens 66-73 32520154-13 2020 The most frequently used basal insulin was glargine in 401 (70%) patients. Insulin Glargine 43-51 insulin Homo sapiens 31-38 32011961-0 2020 Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer. Insulin Glargine 129-137 insulin Homo sapiens 121-128 31150327-0 2020 Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes. Insulin Glargine 56-64 insulin Homo sapiens 48-55 31150327-2 2020 Among these, insulin glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) are formulations indicated for once daily sc administration in MDI therapy of T1D. Insulin Glargine 21-29 insulin Homo sapiens 13-20 31150327-3 2020 A few semi-mechanistic models of sc absorption of insulin glargine have been proposed in the literature, but were not quantitatively assessed on a large dataset. Insulin Glargine 58-66 insulin Homo sapiens 50-57 31150327-4 2020 The aim of this work is to propose a model of sc absorption of insulin glargine able to describe the data and provide precise model parameters estimates with a clear physiological interpretation. Insulin Glargine 71-79 insulin Homo sapiens 63-70 31365765-0 2020 Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. Insulin Glargine 80-88 insulin Homo sapiens 72-79 31365765-9 2020 CONCLUSION: Insulin glargine and lixisenatide as a fixed-ratio combination resulted in more participants reaching both FPG and PPG targets, leading to better HbA1c target attainment. Insulin Glargine 20-28 insulin Homo sapiens 12-19 32011961-4 2020 We calculated the market share of the biosimilar insulin glargine and generic glatiramer among the corresponding drugs. Insulin Glargine 57-65 insulin Homo sapiens 49-56 32966971-13 2020 CONCLUSION: Exenatide plus insulin glargine treatment for 24 weeks resulted in a reduction of albuminuria in T2DM patients with DKD. Insulin Glargine 35-43 insulin Homo sapiens 27-34 31342163-2 2020 We aimed to explore the factors and outcomes associated with titration of glargine 100 U/mL (Gla-100) in patients uncontrolled on oral antidiabetic drugs (OAD) and initiating insulin therapy. Insulin Glargine 74-82 insulin Homo sapiens 175-182 31407113-7 2019 Insulin and insulin analog-glargine insulin-were entrapped in the lipid matrix through hydrophobic ion pairing. Insulin Glargine 27-35 insulin Homo sapiens 12-19 32543316-1 2020 A rapid-acting insulin lispro and long-acting insulin glargine are commonly used for the treatment of diabetes. Insulin Glargine 54-62 insulin Homo sapiens 46-53 31976334-1 2019 Background: This study is aimed at estimating the proportion of type 2 diabetes mellitus (T2DM) patients treated with basal insulin (insulin glargine U100) and at evaluating daily insulin dose, treatment pattern, and adherence to treatment of these patients. Insulin Glargine 141-149 insulin Homo sapiens 124-131 31976334-3 2019 All patients with a diagnosis of T2DM between 01/01/2012 and 31/12/2012 were considered, and those with at least a prescription of insulin glargine between 01/01/2013 and 31/12/2014 were included and followed up for one year. Insulin Glargine 139-147 insulin Homo sapiens 131-138 31976334-8 2019 Median daily dose of insulin among insulin glargine only patients was higher than in other groups (35 IU vs. 20 IU, p < 0.05), and a higher percentage of them achieved a target HbA1c value of less than 7.0% (53.8% vs. 30%, p < 0.001). Insulin Glargine 43-51 insulin Homo sapiens 21-28 31976334-8 2019 Median daily dose of insulin among insulin glargine only patients was higher than in other groups (35 IU vs. 20 IU, p < 0.05), and a higher percentage of them achieved a target HbA1c value of less than 7.0% (53.8% vs. 30%, p < 0.001). Insulin Glargine 43-51 insulin Homo sapiens 35-42 31976334-9 2019 Adherence to insulin treatment was lowest (41%) in the insulin glargine only group compared to other groups (ranging from 58.4% to 64.4%), p < 0.001. Insulin Glargine 63-71 insulin Homo sapiens 13-20 31976334-9 2019 Adherence to insulin treatment was lowest (41%) in the insulin glargine only group compared to other groups (ranging from 58.4% to 64.4%), p < 0.001. Insulin Glargine 63-71 insulin Homo sapiens 55-62 31411498-0 2020 Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus. Insulin Glargine 73-81 insulin Homo sapiens 65-72 31976334-0 2019 Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study. Insulin Glargine 8-16 insulin Homo sapiens 0-7 31407113-7 2019 Insulin and insulin analog-glargine insulin-were entrapped in the lipid matrix through hydrophobic ion pairing. Insulin Glargine 27-35 insulin Homo sapiens 36-43 31407113-10 2019 Gut tied up experiments showed the superiority of glargine insulin-loaded nanostructured lipid carriers, which demonstrated significantly higher permeation (till 30% dose/mL) compared to free peptide. Insulin Glargine 50-58 insulin Homo sapiens 59-66 31407113-13 2019 CONCLUSIONS: Given the optimized ex vivo and in vivo intestinal uptake of glargine insulin from nanostructured lipid carriers, further studies will be carried out on healthy and diabetic rat models in order to establish a glargine insulin dose-glucose response relation. Insulin Glargine 74-82 insulin Homo sapiens 83-90 31385425-3 2019 MATERIALS AND METHODS: DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart <=4 times/day) (N = 254). Insulin Glargine 153-161 insulin Homo sapiens 145-152 31335198-0 2019 Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS). Insulin Glargine 82-90 insulin Homo sapiens 74-81 32735306-9 2019 They go on to discuss iGlarLixi and iDegLira (fixed-ratio combinations of insulin glargine/ lixisenatide and insulin degludec/liraglutide, respectively), which have been shown to be effective in patients with A1C >=9%. Insulin Glargine 82-90 insulin Homo sapiens 74-81 31243228-1 2019 Objective We compared the pain accompanying the injection of high-concentration (300 units/mL) insulin glargine (U300G) with that accompanying the injection of conventional (100 units/mL) insulin glargine (U100G). Insulin Glargine 103-111 insulin Homo sapiens 95-102 31243228-11 2019 Conclusion There is possibility that switching from U100G to U300G might be associated with better QOL for patients who require insulin glargine injections. Insulin Glargine 136-144 insulin Homo sapiens 128-135 31376619-0 2019 The quaternary structure of insulin glargine and glulisine under formulation conditions. Insulin Glargine 36-44 insulin Homo sapiens 28-35 31376619-1 2019 The quaternary structures of insulin glargine and glulisine under formulation conditions and upon dilution using placebo or water were investigated using synchrotron small-angle X-ray scattering. Insulin Glargine 37-45 insulin Homo sapiens 29-36 31376619-4 2019 Insulin glargine in Lantus and Toujeo is present in a stable hexamer/dimer equilibrium, which is hardly affected by dilution with water down to 1 mg/ml insulin concentration. Insulin Glargine 8-16 insulin Homo sapiens 0-7 31376619-4 2019 Insulin glargine in Lantus and Toujeo is present in a stable hexamer/dimer equilibrium, which is hardly affected by dilution with water down to 1 mg/ml insulin concentration. Insulin Glargine 8-16 insulin Homo sapiens 154-161 31376619-4 2019 Insulin glargine in Lantus and Toujeo is present in a stable hexamer/dimer equilibrium, which is hardly affected by dilution with water down to 1 mg/ml insulin concentration. Insulin Glargine 20-26 insulin Homo sapiens 0-7 30735983-0 2019 Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies. Insulin Glargine 34-42 insulin Homo sapiens 26-33 30735983-1 2019 OBJECTIVE: Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) are long-acting insulin analogs providing basal insulin supply in multiple daily injection (MDI) therapy of type 1 diabetes (T1D). Insulin Glargine 11-19 insulin Homo sapiens 78-85 30735983-1 2019 OBJECTIVE: Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) are long-acting insulin analogs providing basal insulin supply in multiple daily injection (MDI) therapy of type 1 diabetes (T1D). Insulin Glargine 11-19 insulin Homo sapiens 110-117 30693980-3 2019 This study aimed to compare regular insulin added to PN (RI-in-PN) with subcutaneous insulin glargine for the management of hyperglycemia in patients receiving PN. Insulin Glargine 93-101 insulin Homo sapiens 85-92 30693980-9 2019 Among patients with diabetes mellitus (DM), however, the insulin glargine group had a significantly higher percentage of admissions with at least 1 hypoglycemic event (45.5% vs 20%, P = 0.035). Insulin Glargine 65-73 insulin Homo sapiens 57-64 31124388-7 2019 These results suggest hAmy-PEG5k and the insulin analogs glargine and detemir are physicochemically compatible and are candidate ready-to-use fixed-dose combinations. Insulin Glargine 57-65 insulin Homo sapiens 41-48 31264764-2 2019 Data were from two clinical trials in which patients were able to improve glycaemic control by self-titration of insulin glargine using a simple algorithm. Insulin Glargine 121-129 insulin Homo sapiens 113-120 31067999-0 2019 Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. Insulin Glargine 56-64 insulin Homo sapiens 48-55 31067999-5 2019 RESULTS: Cooling the skin around the glargine injection site reduced insulin concentrations by >40% ( P < .01 versus the warming study, P = .21 versus the control study), accompanied by a 55 mg/dL increase in serum glucose ( P < .01 versus the control study). Insulin Glargine 37-45 insulin Homo sapiens 69-76 31067999-7 2019 CONCLUSIONS: This proof of concept study has shown that cooling and warming the skin around the injection site provides a means to decrease and increase the rate of absorption and action of insulin glargine from its subcutaneous depot. Insulin Glargine 198-206 insulin Homo sapiens 190-197 31376619-4 2019 Insulin glargine in Lantus and Toujeo is present in a stable hexamer/dimer equilibrium, which is hardly affected by dilution with water down to 1 mg/ml insulin concentration. Insulin Glargine 32-38 insulin Homo sapiens 154-161 31335198-2 2019 This analysis of Indian subset of Asian Treat to Target Lantus Study (ATLAS) compared effectiveness of patient-led with physician-led titration of once-daily insulin glargine 100 U/mL (Glargine-U-100) in patients with type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetes drug (OAD). Insulin Glargine 166-174 insulin Homo sapiens 158-165 31335198-2 2019 This analysis of Indian subset of Asian Treat to Target Lantus Study (ATLAS) compared effectiveness of patient-led with physician-led titration of once-daily insulin glargine 100 U/mL (Glargine-U-100) in patients with type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetes drug (OAD). Insulin Glargine 185-193 insulin Homo sapiens 158-165 31393288-4 2019 Both insulin glargine U-300 and insulin degludec have been compared with insulin glargine U-100 and have demonstrated longer durations of action, as well as lower rates of hypoglycemia. Insulin Glargine 13-21 insulin Homo sapiens 5-12 31359368-0 2019 Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Insulin Glargine 111-119 insulin Homo sapiens 103-110 31359368-0 2019 Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Insulin Glargine 168-176 insulin Homo sapiens 160-167 31144445-0 2019 Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naive D real-world study. Insulin Glargine 103-111 insulin Homo sapiens 95-102 31359813-3 2019 All patients received subcutaneous insulin glargine administered by a needle-free injector or a glargine pen for 7 ~ 14 days, and were then crossed over after wash out. Insulin Glargine 43-51 insulin Homo sapiens 35-42 30993855-0 2019 Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring. Insulin Glargine 54-62 insulin Homo sapiens 46-53 31119716-0 2019 Lilly Insulin Glargine Versus Lantus in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study. Insulin Glargine 14-22 insulin Homo sapiens 6-13 31119716-1 2019 BACKGROUND AND OBJECTIVES: Lilly insulin glargine (LY IGlar; Basaglar ) and the reference insulin glargine product (IGlar; Lantus ) are basal insulin glargine analogs with identical amino acid sequence and similar pharmacological profiles. Insulin Glargine 41-49 insulin Homo sapiens 33-40 31050109-1 2019 This report describes novel clinical data assessing the pharmacodynamics of insulin glargine/lixisenatide (iGlarLixi) compared with placebo and insulin glargine alone, to determine pharmacokinetics of lixisenatide, and to assess safety of iGlarLixi in Japanese people with type 2 diabetes mellitus (T2DM). Insulin Glargine 84-92 insulin Homo sapiens 76-83 31050109-5 2019 iGlarLixi 5 U/5 mug and 10 U/10 mug reduced mean PPG dose-dependently compared with placebo and insulin glargine 5 U. Insulin Glargine 104-112 insulin Homo sapiens 96-103 31050109-10 2019 iGlarLixi was safe and well tolerated, and would be expected to provide the 24-hour plasma glucose-lowering effects of insulin glargine and the postprandial antihyperglycaemic effects of lixisenatide. Insulin Glargine 127-135 insulin Homo sapiens 119-126 31228089-0 2019 Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec. Insulin Glargine 104-112 insulin Homo sapiens 96-103 31237133-12 2019 CONCLUSION: The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia despite the use of OADs. Insulin Glargine 54-62 insulin Homo sapiens 46-53 31329878-0 2019 A Case of Surreptitious Glargine Overdose Confirmed by Insulin Pharmacokinetic Time Curves. Insulin Glargine 24-32 insulin Homo sapiens 55-62 30270723-6 2019 Provider awareness of the availability and dosing of insulin glargine/lixisenatide and insulin degludec/liraglutide is essential to reduce errors in the medication reconciliation process. Insulin Glargine 61-69 insulin Homo sapiens 53-60 31329878-3 2019 Comparing the pharmacokinetic time curves of serum insulin levels on two insulin immunoassays with different insulin analog cross-reactivity allowed the likely diagnosis of surreptitious glargine overdose to be made rapidly. Insulin Glargine 187-195 insulin Homo sapiens 51-58 31329878-3 2019 Comparing the pharmacokinetic time curves of serum insulin levels on two insulin immunoassays with different insulin analog cross-reactivity allowed the likely diagnosis of surreptitious glargine overdose to be made rapidly. Insulin Glargine 187-195 insulin Homo sapiens 73-80 31329878-3 2019 Comparing the pharmacokinetic time curves of serum insulin levels on two insulin immunoassays with different insulin analog cross-reactivity allowed the likely diagnosis of surreptitious glargine overdose to be made rapidly. Insulin Glargine 187-195 insulin Homo sapiens 73-80 31337371-7 2019 Patients are randomised (1:1) to basal therapy with insulin degludec or insulin glargine. Insulin Glargine 80-88 insulin Homo sapiens 72-79 31303866-0 2019 Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. Insulin Glargine 8-16 insulin Homo sapiens 0-7 31303866-4 2019 Objectives: The objective of this study was to assess the cost-effectiveness of insulin glargine U100 compared to NPH insulin in patients with type-2 diabetes uncontrolled with non-insulin anti-diabetic agents alone in Hong Kong. Insulin Glargine 88-96 insulin Homo sapiens 80-87 31303866-9 2019 Results: Insulin glargine U100 resulted in an ICER of HKD 98,663 per Quality Adjusted Life Year (QALY) gained. Insulin Glargine 17-25 insulin Homo sapiens 9-16 31303866-12 2019 Conclusion: Insulin glargine U100 is a cost-effective treatment for patients with type 2 diabetes compared to NPH insulin in setting in Hong Kong. Insulin Glargine 20-28 insulin Homo sapiens 12-19 30850995-1 2019 AIMS: The aim of this study was to describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or older. Insulin Glargine 153-161 insulin Homo sapiens 145-152 31001865-6 2019 At 6 months in the Type 1 diabetes group, switching to insulin degludec from insulin glargine 100 units/ml resulted in significantly lower hypoglycaemia rates across all hypoglycaemia categories; for the insulin detemir group, this significance was also observed for severe and nocturnal non-severe hypoglycaemia, while the low number of people in the neutral protamine Hagedorn group resulted in nonsignificant reductions in hypoglycaemia rates. Insulin Glargine 85-93 insulin Homo sapiens 55-62 30828929-1 2019 Because of its physico-chemical properties, insulin glargine is usually not mixable with rapid insulins. Insulin Glargine 52-60 insulin Homo sapiens 44-51 30828929-2 2019 BioChaperone BC147 is a polyanionic amphiphilic polymer, solubilizing insulin glargine at neutral pH, and thus enabling stable glargine formulation with fast-acting insulin lispro (BioChaperone glargine lispro co-formulation [BC Combo]). Insulin Glargine 78-86 insulin Homo sapiens 70-77 31001865-6 2019 At 6 months in the Type 1 diabetes group, switching to insulin degludec from insulin glargine 100 units/ml resulted in significantly lower hypoglycaemia rates across all hypoglycaemia categories; for the insulin detemir group, this significance was also observed for severe and nocturnal non-severe hypoglycaemia, while the low number of people in the neutral protamine Hagedorn group resulted in nonsignificant reductions in hypoglycaemia rates. Insulin Glargine 85-93 insulin Homo sapiens 77-84 31001865-6 2019 At 6 months in the Type 1 diabetes group, switching to insulin degludec from insulin glargine 100 units/ml resulted in significantly lower hypoglycaemia rates across all hypoglycaemia categories; for the insulin detemir group, this significance was also observed for severe and nocturnal non-severe hypoglycaemia, while the low number of people in the neutral protamine Hagedorn group resulted in nonsignificant reductions in hypoglycaemia rates. Insulin Glargine 85-93 insulin Homo sapiens 77-84 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 149-157 insulin Homo sapiens 124-131 31102482-0 2019 Insulin Glargine Dose and Weight Changes in Underweight, Normal Weight, and Overweight Children Newly Diagnosed with Type 1 Diabetes Mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 31294087-0 2019 Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. Insulin Glargine 113-121 insulin Homo sapiens 43-50 31294087-0 2019 Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. Insulin Glargine 113-121 insulin Homo sapiens 105-112 31294087-0 2019 Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. Insulin Glargine 113-121 insulin Homo sapiens 105-112 31294087-3 2019 This study aims to evaluate treatment persistence and hypoglycaemia in adult patients with T2D on prior basal insulin who were switched to insulin glargine 300 units/mL (Gla-300) or other basal insulins in a real-world setting. Insulin Glargine 147-155 insulin Homo sapiens 139-146 30724009-0 2019 When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control. Insulin Glargine 79-87 insulin Homo sapiens 71-78 31020539-8 2019 CONCLUSIONS: Insulin degludec and insulin glargine provide similar glycemic control, but insulin degludec also lowers the risk of hypoglycemia. Insulin Glargine 42-50 insulin Homo sapiens 34-41 31020539-9 2019 Consequently, insulin degludec may be an alternative treatment for the management of patients with type 2 diabetes who are prone to hypoglycemia with insulin glargine. Insulin Glargine 158-166 insulin Homo sapiens 14-21 31020539-9 2019 Consequently, insulin degludec may be an alternative treatment for the management of patients with type 2 diabetes who are prone to hypoglycemia with insulin glargine. Insulin Glargine 158-166 insulin Homo sapiens 150-157 30341767-0 2019 Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Insulin Glargine 38-46 insulin Homo sapiens 30-37 30341767-8 2019 Changes from baseline in MRI-PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin. Insulin Glargine 113-121 insulin Homo sapiens 105-112 30900200-4 2019 A total of 476 patients diagnosed with T2DM, hospitalized, and treated with subcutaneous insulin glargine were included. Insulin Glargine 97-105 insulin Homo sapiens 89-96 30900200-7 2019 RESULTS: Compared to patients who received Basalin, patients who received Lantus achieved more reduction in FBG during insulin treatment (- 1.24 mmol/L vs. - 2.20 mmol/L; p = 0.04) and had a lower mean FBG at the end of treatment (8.20 mmol/L vs. 7.26 mmol/L; p = 0.12). Insulin Glargine 74-80 insulin Homo sapiens 119-126 30900200-8 2019 Patients in Basalin and Lantus groups had a comparable mean daily dose of basal insulin at initiation (0.19 vs. 0.18 IU/kg; p = 0.30) and end of treatment (0.21 vs. 0.21 IU/kg; p = 0.99), and a similar duration of basal insulin treatment (16.4 vs. 15.3 days; p = 0.74). Insulin Glargine 24-30 insulin Homo sapiens 80-87 30762290-6 2019 BW decreased with dulaglutide 1.5 and 0.75 mg and increased with insulin glargine ([LSM change (SE)], -2.66 [0.47] kg and -1.71 [0.45] vs 1.57 [0.43] kg; P < 0.001). Insulin Glargine 73-81 insulin Homo sapiens 65-72 30785660-5 2019 During a 6.2-year follow-up period, allocation to insulin glargine vs standard care had a neutral effect on the composite of PAD incidence (HR, 0.99; 95% CI, 0.86-1.15) and progression (HR, 0.88; 95% CI, 0.63-1.22). Insulin Glargine 58-66 insulin Homo sapiens 50-57 31020539-0 2019 Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis. Insulin Glargine 73-81 insulin Homo sapiens 0-7 31020539-1 2019 INTRODUCTION: The purpose of this study was to compare insulin degludec with insulin glargine in terms of efficacy and safety in patients with type 2 diabetes. Insulin Glargine 85-93 insulin Homo sapiens 77-84 30036160-0 2019 Effect of Telephone-Delivered Interventions on Glycemic Control in Type 2 Diabetes Treated with Glargine Insulin. Insulin Glargine 96-104 insulin Homo sapiens 105-112 30036160-2 2019 "eStar program" is a telephone support platform for type 2 diabetes on glargine insulin treatment. Insulin Glargine 72-80 insulin Homo sapiens 81-88 30036160-5 2019 This study aimed to evaluate if eStar program was effective in helping patients reach their optimal insulin glargine dose within 6 months. Insulin Glargine 108-116 insulin Homo sapiens 100-107 30036160-6 2019 Materials and Methods: An observational prospective study was conducted with type 2 diabetes patients who were initiating insulin glargine or requiring dose titration and were eligible to be included in the eStar program. Insulin Glargine 130-138 insulin Homo sapiens 122-129 30036160-8 2019 The primary outcome was to evaluate if this program was effective in helping patients reach their optimal insulin glargine dose within 6 months. Insulin Glargine 114-122 insulin Homo sapiens 106-113 30036160-14 2019 Conclusions: The eStar program is an effective way to help patients reach their optimal insulin glargine dose, besides improving their glycemic control. Insulin Glargine 96-104 insulin Homo sapiens 88-95 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 387-395 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 387-395 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 387-395 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 387-395 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 387-395 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 149-157 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 149-157 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 149-157 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 149-157 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 149-157 insulin Homo sapiens 141-148 30929185-4 2019 Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir. Insulin Glargine 387-395 insulin Homo sapiens 124-131 30729549-5 2019 So we designed this 26-week comparative trial, aiming to evaluate the efficacy and safety of liraglutide, sitagliptin, and insulin glargine as an add-on treatment to metformin in patients with T2DM and NAFLD. Insulin Glargine 131-139 insulin Homo sapiens 123-130 30370783-9 2019 CONCLUSIONS: The efficacy and safety of titratable fixed-ratio co-formulations have been demonstrated for insulin degludec/liraglutide and insulin glargine/lixisenatide in the DUAL and LixiLan trials, respectively, in both insulin-naive and -experienced patients. Insulin Glargine 147-155 insulin Homo sapiens 139-146 30520564-0 2019 Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment. Insulin Glargine 71-79 insulin Homo sapiens 6-13 30520564-0 2019 Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment. Insulin Glargine 71-79 insulin Homo sapiens 63-70 30520252-0 2019 Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study. Insulin Glargine 103-111 insulin Homo sapiens 95-102 30520252-1 2019 This post-hoc analysis of the DURATION-3 study aimed to identify factors associated with sustained glycaemic response with exenatide once weekly (QW) or insulin glargine (IG) among patients with type 2 diabetes. Insulin Glargine 161-169 insulin Homo sapiens 153-160 30393950-10 2019 CONCLUSION: When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycaemia. Insulin Glargine 36-44 insulin Homo sapiens 28-35 30995433-0 2019 EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS. Insulin Glargine 22-30 insulin Homo sapiens 14-21 30641166-3 2019 Patients self-titrated insulin glargine according to physicians" guidance. Insulin Glargine 31-39 insulin Homo sapiens 23-30 30641166-9 2019 CONCLUSIONS: Continuous titration of insulin glargine U100 is a safe and efficient option for T2DM management, regardless of the titration algorithm applied. Insulin Glargine 45-53 insulin Homo sapiens 37-44 31114694-0 2019 Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world. Insulin Glargine 49-57 insulin Homo sapiens 41-48 30160324-0 2019 Differences in UK healthcare professionals" knowledge, attitude and practice towards infliximab and insulin glargine biosimilars. Insulin Glargine 108-116 insulin Homo sapiens 100-107 30160324-1 2019 OBJECTIVES: To investigate knowledge and attitudes of different healthcare professionals in UK towards infliximab and insulin glargine biosimilars METHODS: UK medical consultants/registrars, nurses and pharmacists participated in anonymised, self-administered web-based survey distributed by professional associations. Insulin Glargine 126-134 insulin Homo sapiens 118-125 30789066-1 2019 INTRODUCTION: Although premixed fixed ratio NPH insulin products are commonly used in type 2 diabetes patients, the advent of Glargine insulin which cannot be formulated together with a rapid-acting insulin (basal-bolus) has largely eliminated premixed insulin from use in type 1 diabetes. Insulin Glargine 126-134 insulin Homo sapiens 135-142 30789066-1 2019 INTRODUCTION: Although premixed fixed ratio NPH insulin products are commonly used in type 2 diabetes patients, the advent of Glargine insulin which cannot be formulated together with a rapid-acting insulin (basal-bolus) has largely eliminated premixed insulin from use in type 1 diabetes. Insulin Glargine 126-134 insulin Homo sapiens 135-142 30997973-4 2019 For a similar glucose control (reduction in glycated haemoglobin), less hypoglycaemic episodes were recorded, including severe hypoglycaemia, during the nocturnal period, with insulin degludec than with insulin glargine U100. Insulin Glargine 211-219 insulin Homo sapiens 203-210 30421545-0 2019 Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia. Insulin Glargine 8-16 insulin Homo sapiens 0-7 30328252-1 2019 AIMS: To investigate efficacy, safety and usability of the GlucoTab system for glycaemic management using insulin glargine U300 in non-critically ill hospitalized patients with type 2 diabetes (T2D). Insulin Glargine 114-122 insulin Homo sapiens 106-113 29947060-0 2019 Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles. Insulin Glargine 31-39 insulin Homo sapiens 23-30 30328252-10 2019 CONCLUSIONS: Treatment with GlucoTab using insulin glargine U300 in hospitalized patients with T2D is effective and safe. Insulin Glargine 51-59 insulin Homo sapiens 43-50 29987755-0 2019 Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study. Insulin Glargine 48-56 insulin Homo sapiens 14-21 29987755-2 2019 The aim is the definition of the change in insulin needs in patients switching from detemir/glargine to degludec in real-life conditions. Insulin Glargine 92-100 insulin Homo sapiens 43-50 29987755-3 2019 METHODS: In this retrospective cohort observational study, all outpatients with either type 1 or type 2 diabetes, starting therapy with degludec insulin-after a prior treatment with either detemir or glargine insulin for at least 6 months-were included. Insulin Glargine 200-208 insulin Homo sapiens 209-216 29987755-5 2019 The equations describing the relationship between baseline and follow-up doses of basal insulin (6 months) were Y = 3.39 + 0.78X and Y = 0.44 + 0.69X, in patients receiving detemir/glargine either once or twice daily, respectively (Y = degludec dose at 6 months and X = basal insulin dose at switch). Insulin Glargine 181-189 insulin Homo sapiens 88-95 29987755-9 2019 CONCLUSIONS: The present results provide a suggestion for a simple method for the adjustment of basal and prandial insulin doses in type 1 diabetic patients, switching from glargine or detemir to degludec. Insulin Glargine 173-181 insulin Homo sapiens 115-122 29989335-1 2019 AIMS/INTRODUCTION: We compared the efficacy and safety of insulin glargine 300 U/mL (Gla300) and insulin degludec U100 (Deg) using a flash glucose monitoring system. Insulin Glargine 66-74 insulin Homo sapiens 58-65 30443804-2 2019 Current long-acting insulin analogues that have been approved by the National Institute for Health and Care Excellence in the UK for use in pregnancy include glargine and detemir. Insulin Glargine 158-166 insulin Homo sapiens 20-27 30604091-0 2019 Lilly Insulin Glargine Versus Lantus in Insulin-Naive and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5). Insulin Glargine 14-22 insulin Homo sapiens 6-13 30122087-4 2019 DATA SYNTHESIS: Follow-on insulin glargine and insulin lispro products have been recently approved as the first lower-cost alternatives to innovator insulin products. Insulin Glargine 34-42 insulin Homo sapiens 26-33 30539523-0 2019 A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide. Insulin Glargine 91-99 insulin Homo sapiens 83-90 30641690-5 2019 RESULTS: The dose of insulin glargine was reduced from 42.51 +- 22.16 at the baseline to 40.11 +- 18.51-units during Ramadan (p = 0.002) in the intervention group while it remained the same in the control group before Ramadan and during Ramadan (38.51 +- 18.63 and 38.14 +- 18.46, P = 0.428, respectively). Insulin Glargine 29-37 insulin Homo sapiens 21-28 30623349-3 2019 Large-scale multicentre randomised clinical trial programmes (BEGIN for degludec U100 and U200 and EDITION for glargine U300) evaluating these insulin therapies against glargine U100 have demonstrated that they are either non-inferior or superior for glycaemic efficacy and safety, but less likely to result in severe or nocturnal hypoglycaemia than glargine U100. Insulin Glargine 169-177 insulin Homo sapiens 143-150 30623349-3 2019 Large-scale multicentre randomised clinical trial programmes (BEGIN for degludec U100 and U200 and EDITION for glargine U300) evaluating these insulin therapies against glargine U100 have demonstrated that they are either non-inferior or superior for glycaemic efficacy and safety, but less likely to result in severe or nocturnal hypoglycaemia than glargine U100. Insulin Glargine 111-119 insulin Homo sapiens 143-150 30623349-3 2019 Large-scale multicentre randomised clinical trial programmes (BEGIN for degludec U100 and U200 and EDITION for glargine U300) evaluating these insulin therapies against glargine U100 have demonstrated that they are either non-inferior or superior for glycaemic efficacy and safety, but less likely to result in severe or nocturnal hypoglycaemia than glargine U100. Insulin Glargine 169-177 insulin Homo sapiens 143-150 30793566-0 2019 [Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua )]. Insulin Glargine 15-23 insulin Homo sapiens 7-14 30793566-2 2019 Both molecules exert complementary antihyperglycaemic effects : insulin glargine mainly targets fasting glycaemia while lixisenatide mainly targets postprandial hyperglycaemia. Insulin Glargine 72-80 insulin Homo sapiens 64-71 30793566-5 2019 It has a good tolerance profile, with a more favourable effect on body weight compared with insulin glargine alone and less gastrointestinal adverse effects when compared with lixisenatide alone, because of a more progressive titration of the GLP-1 receptor agonist component. Insulin Glargine 100-108 insulin Homo sapiens 92-99 29861115-1 2019 OBJECTIVES: To examine the effects of specific interventions on biosimilar glargine insulin (BGI) prescribing in general practices and to analyse the influence of prescriber and economic impact. Insulin Glargine 75-83 insulin Homo sapiens 84-91 30112792-8 2019 CONCLUSIONS: Demonstration of non-inferiority between MYL-1501D and reference insulin glargine for reduction of HbA1c during 24 weeks of treatment was achieved. Insulin Glargine 86-94 insulin Homo sapiens 78-85 31258562-0 2019 Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 30653163-8 2019 The patient received continuous subcutaneous insulin infusion (CSII) during hospitalization, and then changed to insulin glargine preparation during the follow-up period. Insulin Glargine 121-129 insulin Homo sapiens 113-120 30369394-0 2019 Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL : . Insulin Glargine 78-86 insulin Homo sapiens 0-7 30369394-0 2019 Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL : . Insulin Glargine 78-86 insulin Homo sapiens 70-77 30369394-2 2019 MATERIALS AND METHODS: The formation and redissolution of subcutaneous depots of insulin glargine 100 U/mL (Gla-100) and insulin glargine 300 U/mL (Gla-300) are modeled. Insulin Glargine 89-97 insulin Homo sapiens 81-88 30369394-2 2019 MATERIALS AND METHODS: The formation and redissolution of subcutaneous depots of insulin glargine 100 U/mL (Gla-100) and insulin glargine 300 U/mL (Gla-300) are modeled. Insulin Glargine 129-137 insulin Homo sapiens 121-128 30369394-7 2019 Simulating a switch from one insulin glargine product to the other results in temporary alteration of previous steady state, but this is regained within ~ 3 days. Insulin Glargine 37-45 insulin Homo sapiens 29-36 30369394-9 2019 The model employed also allowed estimation of insulin glargine concentrations when varying the time interval between injections as well as when switching from one insulin glargine product to the other. Insulin Glargine 54-62 insulin Homo sapiens 46-53 31487242-8 2019 Gla-300 is a new formulation of insulin glargine which has a more stable and prolonged pharmacokinetic and pharmacodynamic profile. Insulin Glargine 40-48 insulin Homo sapiens 32-39 31258562-1 2019 Objective: To investigate the clinical efficacy of insulin glargine combined with acarbose in the treatment of elderly patients with diabetes. Insulin Glargine 59-67 insulin Homo sapiens 51-58 31258562-3 2019 The control group was treated with insulin glargine, while the observation group was treated with insulin glargine combined with acarbose. Insulin Glargine 106-114 insulin Homo sapiens 98-105 31258562-9 2019 Conclusion: The combination of insulin Glargine and Acarbose can significantly control the blood glucose level of elderly patients with diabetes, improve the biochemical indicators, and enhance the quality of life. Insulin Glargine 39-47 insulin Homo sapiens 31-38 30302721-0 2018 Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo ) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland. Insulin Glargine 39-47 insulin Homo sapiens 31-38 30622720-2 2018 The COACH Program was launched in 2015 with the goal of supporting patients with diabetes who are prescribed insulin glargine 300 U/mL (Gla-300). Insulin Glargine 117-125 insulin Homo sapiens 109-116 30619716-0 2019 Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. Insulin Glargine 20-28 insulin Homo sapiens 12-19 30302721-7 2018 Here we report the results for the Swiss patient cohort after 12 months of treatment with insulin glargine 300 U/mL. Insulin Glargine 98-106 insulin Homo sapiens 90-97 30455389-1 2018 OBJECTIVE: To investigate UK healthcare professionals" perceptions and perspectives towards biosimilar infliximab, etanercept and insulin glargine and the potential barriers and facilitators to their prescribing. Insulin Glargine 138-146 insulin Homo sapiens 130-137 30455389-6 2018 OUTCOMES: Participants" opinion and attitudes about biosimilars and the barriers and facilitators to the prescribing of infliximab, etanercept and insulin glargine biosimilars in gastroenterology, rheumatology and diabetology specialties. Insulin Glargine 155-163 insulin Homo sapiens 147-154 29923298-0 2018 Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Insulin Glargine 101-109 insulin Homo sapiens 93-100 29943493-0 2018 Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus. Insulin Glargine 66-74 insulin Homo sapiens 58-65 29943493-0 2018 Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus. Insulin Glargine 66-74 insulin Homo sapiens 98-105 30545262-4 2018 AIM: The aims of the study were to investigate the effectiveness of insulin glargine + insulin glulisine basal-bolus regimen from the payer"s perspective and to investigate the ability to maintain the achieved glycaemic control in previously uncontrolled T2DM patients (HbA1c >9.0%). Insulin Glargine 76-84 insulin Homo sapiens 68-75 30545262-12 2018 CONCLUSIONS: More than half of the patients with T2DM who were newly switched to insulin glargine + glulisine basal-bolus treatment could achieve the reimbursement rule criteria requiring for prescription of the analogue insulins with no co-payment beyond 1 year of treatment in Hungary. Insulin Glargine 89-97 insulin Homo sapiens 81-88 28828553-0 2018 [Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE]. Insulin Glargine 63-71 insulin Homo sapiens 46-53 30302721-0 2018 Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo ) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland. Insulin Glargine 58-64 insulin Homo sapiens 31-38 30302721-1 2018 INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo ) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). Insulin Glargine 22-30 insulin Homo sapiens 14-21 30302721-1 2018 INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo ) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). Insulin Glargine 22-30 insulin Homo sapiens 94-101 30302721-1 2018 INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo ) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). Insulin Glargine 22-30 insulin Homo sapiens 198-205 30302721-1 2018 INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo ) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). Insulin Glargine 50-56 insulin Homo sapiens 14-21 30302721-1 2018 INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo ) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). Insulin Glargine 50-56 insulin Homo sapiens 94-101 30302721-1 2018 INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo ) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). Insulin Glargine 50-56 insulin Homo sapiens 198-205 30302721-1 2018 INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo ) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). Insulin Glargine 206-214 insulin Homo sapiens 14-21 30206903-1 2018 INTRODUCTION: We comprehensively evaluated the effects of combination therapy with insulin glargine and the incretin-based drugs lixisenatide or vildagliptin in Japanese patients with type 2 diabetes. Insulin Glargine 91-99 insulin Homo sapiens 83-90 30206903-3 2018 The dose of insulin glargine was titrated after the switch to maintain fasting blood glucose at approximately 110 mg/dL. Insulin Glargine 20-28 insulin Homo sapiens 12-19 30218432-0 2018 Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program. Insulin Glargine 80-88 insulin Homo sapiens 72-79 30203238-0 2018 Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. Insulin Glargine 83-91 insulin Homo sapiens 75-82 30218432-4 2018 METHODS: The study population included 1724 patients with diabetes who filled a first prescription for insulin glargine 300 U/mL (Gla-300) between April and December 2015 and received a welcome call from a Guide, and 1724 matched control patients from the Symphony Health Integrated Dataverse prescription claims database. Insulin Glargine 111-119 insulin Homo sapiens 103-110 30262205-0 2018 [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. Insulin Glargine 1-10 insulin Homo sapiens 11-18 30302121-10 2018 Conclusions: For overweight and obese patients whose T2DM was inadequately controlled with metformin, exenatide and glargine achieved similar improvements in glycemic control, insulin sensitivity, and beta-cell function.However, exenatide produced better weight and fat mass reduction, which were beneficial for blood glucose control. Insulin Glargine 116-124 insulin Homo sapiens 176-183 30262205-0 2018 [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. Insulin Glargine 1-10 insulin Homo sapiens 50-57 30262205-0 2018 [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. Insulin Glargine 19-27 insulin Homo sapiens 11-18 30262205-0 2018 [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. Insulin Glargine 19-27 insulin Homo sapiens 50-57 30262205-6 2018 Phase III studies, ELEMENT 1 in patients with type 1 diabetes mellitus and ELEMENT 2 in patients with type 2 diabetes mellitus, showed LY2963016 insulin glargine to have similar efficacy and a comparable safety profile to the insulin glargine Lantus . Insulin Glargine 135-144 insulin Homo sapiens 145-152 30158268-6 2018 He was given nothing per mouth in preparation for a left heart catheterisation but received his reported insulin glargine dosage at bedtime. Insulin Glargine 113-121 insulin Homo sapiens 105-112 29756388-8 2018 Both doses demonstrated superior glycaemic efficacy compared to other antidiabetic agents, including sitagliptin, exenatide, liraglutide, dulaglutide and insulin glargine. Insulin Glargine 162-170 insulin Homo sapiens 154-161 29761615-0 2018 Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. Insulin Glargine 23-30 insulin Homo sapiens 31-38 30116911-8 2018 Recent data on the use of new insulins in pregnancy (e.g. insulin degludec and glargine (U 300)) is limited to case reports. Insulin Glargine 79-87 insulin Homo sapiens 30-37 30092829-10 2018 In both T1D and T2D, the magnitude of the association with the absolute dense volume was highest for long-term insulin therapy (>= 5 years) and the long-acting insulin analog glargine. Insulin Glargine 178-186 insulin Homo sapiens 163-170 30093131-8 2018 In contrast, 4.1% of insulin glargine-treated patients had an index eGFR <30 and >=15 mL/min/1.73 m2 and 1.2% had an index eGFR <15 mL/min/1.73 m2. Insulin Glargine 29-37 insulin Homo sapiens 21-28 30093131-10 2018 IMPLICATIONS: In clinical practice, the use of dulaglutide was relatively more limited in patients with a higher degree of renal impairment compared with use of insulin glargine. Insulin Glargine 169-177 insulin Homo sapiens 161-168 29807104-3 2018 RESULTS: The mean changes in HbA1c level were comparable as -0.97 +- 1.29% in dapagliflozin group and -0.95 +- 1.41% in insulin glargine group (p = 0.911). Insulin Glargine 128-136 insulin Homo sapiens 120-127 29600527-0 2018 In response to: Heise T, Norskov M, Nosek L, Kaplan K, Famulla S and Haahr H. L. (2017) Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Insulin Glargine 198-206 insulin Homo sapiens 88-95 29649539-0 2018 Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? Insulin Glargine 21-29 insulin Homo sapiens 13-20 29656504-1 2018 AIM: To test the safety and efficacy of MYL-1501D, a proposed insulin glargine biosimilar, in patients with type 1 diabetes mellitus (T1DM). Insulin Glargine 70-78 insulin Homo sapiens 62-69 29807104-4 2018 Also, the fasting plasma glucose or post-prandial 2 h glucose were comparably decreased in dapagliflozin or insulin glargine. Insulin Glargine 116-124 insulin Homo sapiens 108-115 29807104-5 2018 In terms of the body-weight, there was a significant decrease of -2.36 +- 0.51 kg following treatment of dapagliflozin, whereas the increment of 1.93 +- 0.49 kg was in insulin glargine (p < 0.001). Insulin Glargine 176-184 insulin Homo sapiens 168-175 29807104-6 2018 In terms of adverse events, hypoglycemic events were higher in insulin glargine rather than dapagliflozin (15.1% vs. 1.6%, p < 0.05). Insulin Glargine 71-79 insulin Homo sapiens 63-70 29915021-2 2018 In this secondary analysis, we included 34 overweight insulin glargine-treated type 2 diabetes mellitus patients (mean+-SD age, 62+-7 years; HbA1c, 8.0+-0.9%; systolic blood pressure [BP], 133.9+-16.1 mm Hg; diastolic BP, 75.4+-8.39 mm Hg) that were randomized to once-daily lixisenatide 20 mug or once-daily titrated insulin glulisine for 8 weeks. Insulin Glargine 62-70 insulin Homo sapiens 54-61 29971748-0 2018 Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries. Insulin Glargine 58-66 insulin Homo sapiens 50-57 29971748-1 2018 INTRODUCTION: Long-acting insulin analogs such as insulin glargine may offer improved glycemic control in patients with type 2 diabetes (T2D) compared to conventional insulin therapies. Insulin Glargine 58-66 insulin Homo sapiens 26-33 29971748-1 2018 INTRODUCTION: Long-acting insulin analogs such as insulin glargine may offer improved glycemic control in patients with type 2 diabetes (T2D) compared to conventional insulin therapies. Insulin Glargine 58-66 insulin Homo sapiens 50-57 29971748-1 2018 INTRODUCTION: Long-acting insulin analogs such as insulin glargine may offer improved glycemic control in patients with type 2 diabetes (T2D) compared to conventional insulin therapies. Insulin Glargine 58-66 insulin Homo sapiens 50-57 29971748-8 2018 Switching to insulin glargine decreased the incidence of hypoglycemia from 49.5% to 5.2% after six months of therapy; this decrease was associated with weight loss and was well perceived by the patients. Insulin Glargine 21-29 insulin Homo sapiens 13-20 29971748-9 2018 CONCLUSION: Insulin glargine-based regimens are beneficial and safe therapeutic alternatives for T2D patients inadequately controlled with pre-mixed insulin. Insulin Glargine 20-28 insulin Homo sapiens 12-19 29971748-9 2018 CONCLUSION: Insulin glargine-based regimens are beneficial and safe therapeutic alternatives for T2D patients inadequately controlled with pre-mixed insulin. Insulin Glargine 20-28 insulin Homo sapiens 149-156 30020738-10 2018 Patients receiving insulin glargine demonstrated higher adherence and persistence than patients on insulin detemir. Insulin Glargine 27-35 insulin Homo sapiens 19-26 29910024-15 2018 The differences in HbA1c concentration at 26 weeks between dulaglutide and insulin glargine treatments were LSM difference -0 05% (95% CI -0 26 to 0 15, p<0 0001) with dulaglutide 1 5 mg and 0 02% (-0 18 to -0 22, p=0 0001) with dulaglutide 0 75 mg. HbA1c-lowering effects persisted to 52 weeks (LSM -1 1% [SE 0 1] with dulaglutide 1 5 mg; -1 1% [0 1] with dulaglutide 0 75 mg; -1 0% [0 1] with insulin glargine). Insulin Glargine 83-91 insulin Homo sapiens 75-82 29910024-15 2018 The differences in HbA1c concentration at 26 weeks between dulaglutide and insulin glargine treatments were LSM difference -0 05% (95% CI -0 26 to 0 15, p<0 0001) with dulaglutide 1 5 mg and 0 02% (-0 18 to -0 22, p=0 0001) with dulaglutide 0 75 mg. HbA1c-lowering effects persisted to 52 weeks (LSM -1 1% [SE 0 1] with dulaglutide 1 5 mg; -1 1% [0 1] with dulaglutide 0 75 mg; -1 0% [0 1] with insulin glargine). Insulin Glargine 83-91 insulin Homo sapiens 398-405 29910024-20 2018 End-stage renal disease occurred in 38 participants: eight (4%) of 192 with dulaglutide 1 5 mg, 14 (7%) of 190 with dulaglutide 0 75 mg, and 16 (8%) of 194 with insulin glargine. Insulin Glargine 169-177 insulin Homo sapiens 161-168 30020738-11 2018 Economic models suggest that LAIAs are more cost-effective than NPH for T1D; for T2D, insulin glargine is more costly than NPH but less so than insulin detemir. Insulin Glargine 94-102 insulin Homo sapiens 86-93 29709796-1 2018 Insulin glargine 300 U/mL and insulin detemir are synthetic long-acting insulin analogs associated with minimal day-to-day variability or episodes of hypoglycemia in people. Insulin Glargine 8-16 insulin Homo sapiens 0-7 30441443-3 2018 The aim of this contribution is to reproduce multiple daily insulin injection (MDI) therapy, with insulin glargine 100 U/mL (Gla-100) as basal insulin, using the TID simulator. Insulin Glargine 106-114 insulin Homo sapiens 98-105 29979295-8 2018 Insulin glargine U300 and IDeg 200 are concentrated, allowing for administration of large doses by less volume, thereby theoretically improving absorption. Insulin Glargine 8-16 insulin Homo sapiens 0-7 30008232-9 2018 CONCLUSIONS: Switch to an insulin glargine-based basal-bolus regimen could achieve a significant improvement in the glycaemic control in patients who were inadequately controlled prior to the switch. Insulin Glargine 34-42 insulin Homo sapiens 26-33 30181850-0 2018 Effectiveness and safety of insulin glargine versus detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis. Insulin Glargine 36-44 insulin Homo sapiens 28-35 30008232-2 2018 AIM: To demonstrate that switching from a human basal-bolus insulin treatment to an insulin glargine-based basal-bolus regimen can achieve a better glycaemic control. Insulin Glargine 92-100 insulin Homo sapiens 84-91 30008232-3 2018 METHOD: This 3-month prospective, non-interventional study, including a 12-month retrospective data collection phase, enrolled patients who were switched to the insulin glargine- - 100 U/mL - based basal-bolus treatment at the time of enrolment if they were inadequately controlled and had at least one additional HbA1c result in the 12 months before the switch. Insulin Glargine 169-177 insulin Homo sapiens 161-168 30181850-12 2018 The meta-analysis of total insulin dose favored glargine (p = 0.006; I2 = 75). Insulin Glargine 48-56 insulin Homo sapiens 27-34 30181850-3 2018 Our study objective was to evaluate the effectiveness and safety of two long-acting insulins, insulin glargine and detemir, in treating patients with DM1. Insulin Glargine 102-110 insulin Homo sapiens 84-91 30181850-15 2018 These results can help in the current debate on the inclusion of long-acting analogs on the list of reimbursed medicines in Brazil, especially with the recent introduction of an insulin glargine biosimilar at a considerably lower price. Insulin Glargine 186-194 insulin Homo sapiens 178-185 29619751-1 2018 INTRODUCTION: Although reduction in the incidence of nocturnal hypoglycemia, as estimated by symptom or self-monitored plasma glucose, was shown to be more pronounced with 300 units/mL insulin glargine (Gla-300) than with 100 units/mL insulin glargine (Gla-100) in type 2 diabetes patients, the exact frequency of nocturnal hypoglycemia estimated with continuous glucose monitoring (CGM) has not been reported. Insulin Glargine 193-201 insulin Homo sapiens 185-192 29874257-0 2018 Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model. Insulin Glargine 104-112 insulin Homo sapiens 96-103 29874257-2 2018 Here, we sought to compare originator and non-originator copies of insulin glargine for innate immune activity and mechanisms leading to differences in these response profiles in an in vitro model of human immunity. Insulin Glargine 75-83 insulin Homo sapiens 67-74 29874257-3 2018 METHODS: An endothelial/dendritic cell-based innate immune model was used to study antigen-presenting cell activation, cytokine secretion, and insulin receptor signalling pathways induced by originator and non-originator insulin glargine products. Insulin Glargine 229-237 insulin Homo sapiens 143-150 29874257-5 2018 FINDINGS: All insulin glargine products elicited at least a minor innate immune response comparable to natural human insulin, but some lots of a non-originator copy product induced the elevated secretion of the cytokines, IL-8 and IL-6. Insulin Glargine 22-30 insulin Homo sapiens 14-21 29874257-6 2018 In studies aimed at addressing the mechanisms leading to differential cytokine production by these products, we found (1) the inflammatory response was not mediated by bacterial contaminants, (2) the innate response was driven by the native insulin receptor through the MAPK pathway, and (3) the removal of insulin glargine significantly reduced their capacity to induce innate activity. Insulin Glargine 315-323 insulin Homo sapiens 241-248 29874257-7 2018 No evidence of product aggregates was detected, though the presence of some high molecular weight proteins argues for the presence of insulin glargine dimers or others contaminants in these products. Insulin Glargine 142-150 insulin Homo sapiens 134-141 29874257-8 2018 CONCLUSION: The data presented here suggests some non-originator insulin glargine product lots drive heightened in vitro human innate activity and provides preliminary evidence that changes in the biochemical composition of non-originator insulin glargine products (dimers, impurities) might be responsible for their greater immunostimulatory potential. Insulin Glargine 73-81 insulin Homo sapiens 65-72 29874257-8 2018 CONCLUSION: The data presented here suggests some non-originator insulin glargine product lots drive heightened in vitro human innate activity and provides preliminary evidence that changes in the biochemical composition of non-originator insulin glargine products (dimers, impurities) might be responsible for their greater immunostimulatory potential. Insulin Glargine 247-255 insulin Homo sapiens 239-246 29300101-2 2018 The aim of this study is to demonstrate the effect of changing the basal insulin (glargine or detemir) to insulin degludec. Insulin Glargine 82-90 insulin Homo sapiens 73-80 29873004-0 2018 Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial. Insulin Glargine 70-78 insulin Homo sapiens 62-69 29654514-2 2018 Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). Insulin Glargine 14-22 insulin Homo sapiens 6-13 29654514-3 2018 With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. Insulin Glargine 142-150 insulin Homo sapiens 134-141 29619751-1 2018 INTRODUCTION: Although reduction in the incidence of nocturnal hypoglycemia, as estimated by symptom or self-monitored plasma glucose, was shown to be more pronounced with 300 units/mL insulin glargine (Gla-300) than with 100 units/mL insulin glargine (Gla-100) in type 2 diabetes patients, the exact frequency of nocturnal hypoglycemia estimated with continuous glucose monitoring (CGM) has not been reported. Insulin Glargine 193-201 insulin Homo sapiens 235-242 29619751-1 2018 INTRODUCTION: Although reduction in the incidence of nocturnal hypoglycemia, as estimated by symptom or self-monitored plasma glucose, was shown to be more pronounced with 300 units/mL insulin glargine (Gla-300) than with 100 units/mL insulin glargine (Gla-100) in type 2 diabetes patients, the exact frequency of nocturnal hypoglycemia estimated with continuous glucose monitoring (CGM) has not been reported. Insulin Glargine 243-251 insulin Homo sapiens 185-192 29569224-1 2018 In the original publication, values of the doses of insulin glargine, the most commonly used basal insulin analogue under the "Discussion" section was incorrectly published. Insulin Glargine 60-68 insulin Homo sapiens 52-59 29453671-0 2018 Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus ) and Lantus in healthy subjects: a double-blind, randomized clamp study. Insulin Glargine 75-83 insulin Homo sapiens 67-74 29453671-1 2018 AIMS: The objective of the study was to compare the pharmacokinetic (PK) and pharmacodynamic (PD) properties of an insulin glargine formulation, Glaritus (test) with the innovator"s formulation Lantus (reference) using the euglycemic clamp technique in a single-dose, double-blind, randomized, two sequences, four-period replicate crossover study in healthy volunteers (n = 40). Insulin Glargine 123-131 insulin Homo sapiens 115-122 29314667-7 2018 Per the multinomial logistic analysis, higher frequency of self-monitoring of blood glucose (SMBG) and use of glargine or detemir therapy were significantly inversely associated with risk of discordance between HbA1c and FPG, while dose of insulin was a risk factor for discordance at the end of follow-up (all P < .05). Insulin Glargine 110-118 insulin Homo sapiens 240-247 29314667-8 2018 CONCLUSIONS: Patients treated with insulin analogues (glargine or detemir), instead of neutral protamine Hagedorn, and with more frequent SMBG are more likely to exhibit concordance between HbA1c and FPG. Insulin Glargine 54-62 insulin Homo sapiens 35-42 29316143-0 2018 Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. Insulin Glargine 126-134 insulin Homo sapiens 118-125 29744819-0 2018 Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial. Insulin Glargine 94-102 insulin Homo sapiens 86-93 29744819-8 2018 Percentage of the time that the blood glucose value was > 7.8 mmol/L decreased after insulin glargine use (P < 0.05) but not with the exenatide intervention. Insulin Glargine 96-104 insulin Homo sapiens 88-95 29744819-11 2018 CONCLUSIONS: In overweight and obese patients with T2DM inadequately controlled by metformin, exenatide and insulin glargine have similar efficacies in terms of glycemic variability, HbA1c alleviation, and beta-cell function, but exenatide has a greater effect on body weight and BMI. Insulin Glargine 116-124 insulin Homo sapiens 108-115 29462782-3 2018 This study describes a qualitative method for detection of insulin analogues (lispro, aspart, glulisine, glargine, degludec, detemir) in human urine. Insulin Glargine 105-113 insulin Homo sapiens 59-66 29760944-0 2018 Characteristics of insulin-Naive people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials. Insulin Glargine 97-105 insulin Homo sapiens 19-26 29760944-0 2018 Characteristics of insulin-Naive people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials. Insulin Glargine 97-105 insulin Homo sapiens 89-96 29760944-1 2018 Background: To identify baseline/clinical characteristics associated with clinically meaningful responses to insulin glargine 100 U/mL (IGlar) in insulin-naive people with type 2 diabetes mellitus (T2DM). Insulin Glargine 117-125 insulin Homo sapiens 109-116 29760944-1 2018 Background: To identify baseline/clinical characteristics associated with clinically meaningful responses to insulin glargine 100 U/mL (IGlar) in insulin-naive people with type 2 diabetes mellitus (T2DM). Insulin Glargine 117-125 insulin Homo sapiens 146-153 29381818-13 2018 CONCLUSION: To our knowledge, this is the first described case of allergy to insulin glargine 300 units/ml and reiterates the potential use of omalizumab in insulin allergy. Insulin Glargine 85-93 insulin Homo sapiens 77-84 29741925-0 2018 Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice. Insulin Glargine 64-72 insulin Homo sapiens 56-63 28895030-3 2018 The results of these trials show that insulin glargine, three different dipeptidyl peptidase-4 (DPP-4) inhibitors (saxagliptin, alogliptin, and sitagliptin) and lixisenatide (a glucagon like peptide-1 receptor agonist) produce no significant difference in CVOT when compared with usual care or placebo. Insulin Glargine 46-54 insulin Homo sapiens 38-45 30034546-3 2018 The development of second-generation insulin analogues (insulin glargine 300 U/mL and insulin degludec) has provided physicians with agents that can provide comparable glycaemic control to first-generation insulin, but with a reduced risk of hypoglycaemia and modes of action suited to once-daily regimens. Insulin Glargine 64-72 insulin Homo sapiens 37-44 30034546-3 2018 The development of second-generation insulin analogues (insulin glargine 300 U/mL and insulin degludec) has provided physicians with agents that can provide comparable glycaemic control to first-generation insulin, but with a reduced risk of hypoglycaemia and modes of action suited to once-daily regimens. Insulin Glargine 64-72 insulin Homo sapiens 56-63 30034546-3 2018 The development of second-generation insulin analogues (insulin glargine 300 U/mL and insulin degludec) has provided physicians with agents that can provide comparable glycaemic control to first-generation insulin, but with a reduced risk of hypoglycaemia and modes of action suited to once-daily regimens. Insulin Glargine 64-72 insulin Homo sapiens 56-63 29034415-5 2018 The patient was treated by insulin glargine and insulin aspartate. Insulin Glargine 35-43 insulin Homo sapiens 27-34 29034415-6 2018 She regularly stopped insulin glargine injections seeking the asthenia sensation produced by hyperglycemia, keeping the insulin aspartate injections to treat the disabling symptom related to hyperketonemia. Insulin Glargine 30-38 insulin Homo sapiens 22-29 29357718-3 2018 METHODS: The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine. Insulin Glargine 146-154 insulin Homo sapiens 138-145 29609864-6 2018 Notably insulin glargine, the most studied long-acting analog, also has a higher affinity for the insulin-like growth factor (IGF)-1 receptor, a potent growth mediator. Insulin Glargine 16-24 insulin Homo sapiens 8-15 29796245-5 2018 Insulin glargine/lixisenatide 100/33 (IGlarLixi) can be dosed between 15 and 60 units once daily from a single pen-injector device. Insulin Glargine 8-16 insulin Homo sapiens 0-7 29862021-0 2018 Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review. Insulin Glargine 67-75 insulin Homo sapiens 59-66 29862021-13 2018 Conclusion: In this study population, switching from Basalin to Lantus was associated with further reductions in blood glucose, although the dose of insulin glargine did not increase. Insulin Glargine 157-165 insulin Homo sapiens 149-156 29652278-6 2018 Results: During surgery and in the postoperative period, random blood sugar and human insulin requirement are significantly higher in control group than glargine group. Insulin Glargine 153-161 insulin Homo sapiens 86-93 29686454-2 2018 The components of currently available co-formulations (insulin degludec/ liraglutide [IDegLira,] and insulin glargine U100/lixisenatide [iGlarLixi]) act synergistically to address multiple pathophysiologic defects while minimizing the side effects associated with either component when used alone. Insulin Glargine 109-117 insulin Homo sapiens 101-108 29686457-2 2018 Two FRCs-insulin degludec/liraglutide and insulin glargine/lixisenatide-have been approved for use in the United States. Insulin Glargine 50-58 insulin Homo sapiens 42-49 29569224-1 2018 In the original publication, values of the doses of insulin glargine, the most commonly used basal insulin analogue under the "Discussion" section was incorrectly published. Insulin Glargine 60-68 insulin Homo sapiens 99-106 29610159-2 2018 The use of long-acting insulin glargine has been described in the treatment of transient neonatal diabetes in the premature infant, but in these reports is a lack of regard to its use in the treatment of iatrogenic neonatal hyperglycemia. Insulin Glargine 31-39 insulin Homo sapiens 23-30 29610159-3 2018 We present the case of an ELBW infant with significant hyperglycemia that was refractory to usual treatment but demonstrated a favorable response to long-acting subcutaneous insulin glargine. Insulin Glargine 182-190 insulin Homo sapiens 174-181 29615978-4 2018 The present study was aimed at identifying the entire set of genes that are differentially activated by insulin glargine or detemir, in comparison to insulin and IGF1, in Type 1 and Type 2 endometrial cancer cell lines (ECC-1 and USPC-1, respectively). Insulin Glargine 112-120 insulin Homo sapiens 104-111 29615978-7 2018 Our data suggest that the activation of distinct sets of genes by glargine may lead to stimulation of specific pathways or, alternatively, may provide additive effects, different from those classically induced by insulin. Insulin Glargine 66-74 insulin Homo sapiens 213-220 29083520-0 2018 All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine. Insulin Glargine 129-137 insulin Homo sapiens 121-128 29721018-1 2018 Aims: Insulin degludec (IDeg) and insulin glargine (IGlar) are both proved to be effective in diabetes. Insulin Glargine 42-50 insulin Homo sapiens 34-41 29692348-1 2018 It is not fully clarified whether insulin glargine, an analogue with a high affinity for insulin-like growth factor-1 receptor (IGF-1R), increases the risk for cancers that abundantly express IGF-1R such as breast cancer or some types of breast cancer. Insulin Glargine 42-50 insulin Homo sapiens 34-41 28895655-1 2018 AIMS: In the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial (Clinicaltrials.gov: NCT000069784), titrated doses of basal insulin glargine targeting fasting normoglycaemia had a neutral effect on cardiovascular outcomes. Insulin Glargine 152-160 insulin Homo sapiens 144-151 29619381-0 2018 Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. Insulin Glargine 31-39 insulin Homo sapiens 23-30 29657375-0 2018 Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients. Insulin Glargine 112-120 insulin Homo sapiens 104-111 29657375-1 2018 Background and Aims: This study aimed to compare glycemic control between continuous intravenous regular insulin infusion and single-dose subcutaneous insulin glargine injection in medical critically ill patients. Insulin Glargine 159-167 insulin Homo sapiens 151-158 29657375-3 2018 The eligible patients were switched from the daily regular insulin requirement to single-dose subcutaneous insulin glargine injection by a 100% conversion dose. Insulin Glargine 115-123 insulin Homo sapiens 107-114 29657375-9 2018 Conclusions: Single-dose subcutaneous insulin glargine injection was feasibly applied for glycemic control in medical critically ill patients. Insulin Glargine 46-54 insulin Homo sapiens 38-45 29657375-10 2018 The glycemic control in the critically ill patients by a single dose of subcutaneous insulin glargine was comparable to standard intravenous regular insulin infusion. Insulin Glargine 93-101 insulin Homo sapiens 85-92 29413582-2 2018 Insulin glargine was used as the internal standard. Insulin Glargine 8-16 insulin Homo sapiens 0-7 29471700-0 2018 Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide. Insulin Glargine 98-106 insulin Homo sapiens 90-97 28766502-8 2018 The patient was initially started on a continuous intravenous insulin drip and subsequently placed on subcutaneous insulin (glargine, human isophane and regular insulin). Insulin Glargine 124-132 insulin Homo sapiens 115-122 28766502-8 2018 The patient was initially started on a continuous intravenous insulin drip and subsequently placed on subcutaneous insulin (glargine, human isophane and regular insulin). Insulin Glargine 124-132 insulin Homo sapiens 115-122 29541641-1 2018 Background: To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution. Insulin Glargine 111-119 insulin Homo sapiens 162-169 29541641-7 2018 The whole 12-month sequential treatment with exenatide and glargine added to metformin basically improved the insulin sensitivity and glucolipid control though VAT rebounded at the end, however without deteriorating the other parameters. Insulin Glargine 59-67 insulin Homo sapiens 110-117 29313285-0 2018 Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study. Insulin Glargine 130-138 insulin Homo sapiens 122-129 28817223-1 2018 AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Insulin Glargine 6-13 insulin Homo sapiens 20-27 28817223-1 2018 AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Insulin Glargine 6-13 insulin Homo sapiens 113-120 28817223-1 2018 AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Insulin Glargine 28-36 insulin Homo sapiens 20-27 28817223-1 2018 AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Insulin Glargine 28-36 insulin Homo sapiens 113-120 28817223-1 2018 AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Insulin Glargine 90-96 insulin Homo sapiens 20-27 28817223-1 2018 AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Insulin Glargine 90-96 insulin Homo sapiens 113-120 28817223-1 2018 AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Insulin Glargine 121-129 insulin Homo sapiens 20-27 28817223-1 2018 AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Insulin Glargine 121-129 insulin Homo sapiens 113-120 28817223-7 2018 Pharmacokinetic assessment was based on LC-MS/MS-based measurement of the major insulin glargine metabolite (M1) and PD was characterized using the euglycaemic clamp platform. Insulin Glargine 88-96 insulin Homo sapiens 80-87 28817248-1 2018 AIMS: To test the hypothesis that, as well as lowering weight and increasing plasma triglyceride (TG) levels and hepatic fat compared with insulin glargine (GL) in patients with type 1 diabetes, the attenuated peripheral effects of basal insulin peglispro (BIL) may include increased free fatty acid flux to the liver, causing increased very-low-density lipoprotein (VLDL)-TG secretion and lipid oxidation, and decreased TG adipose tissue deposition. Insulin Glargine 157-159 insulin Homo sapiens 139-146 28803366-3 2018 Secondary analyses of the Study of the Psychological Impact in Real care of Initiating insulin glargine Treatment (SPIRIT) aimed to investigate the relationship between hypoglycaemia and QoL when transitioning to insulin. Insulin Glargine 95-103 insulin Homo sapiens 87-94 29313285-1 2018 INTRODUCTION: Usage patterns and effectiveness of a longer-acting formulation of insulin glargine at a strength of 300 units per milliliter (Gla-300) have not been studied in real-world clinical practice. Insulin Glargine 89-97 insulin Homo sapiens 81-88 29313285-3 2018 METHODS: This was a retrospective observational study using medical record data obtained by physician survey for patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or Gla-300, or switching to treatment with Gla-300 from treatment with another basal insulin (BI). Insulin Glargine 154-162 insulin Homo sapiens 146-153 28452095-7 2017 RESULTS: Patients on exenatide twice daily + OAD had a lower predicted incidence of most cardiovascular and hypoglycaemic events and lower total costs compared with those on insulin glargine once daily + OAD. Insulin Glargine 182-190 insulin Homo sapiens 174-181 29155123-0 2018 Baseline factors associated with better response to insulin lispro low mixture or insulin glargine: A post hoc analysis of the DURABLE study. Insulin Glargine 90-98 insulin Homo sapiens 82-89 29155123-1 2018 AIMS: To identify baseline characteristics associated with better efficacy and safety responses to twice-daily insulin lispro low mixture (LM) or once-daily insulin glargine (IG) in insulin-naive patients with type 2 diabetes (T2D). Insulin Glargine 165-173 insulin Homo sapiens 157-164 29801995-0 2018 Prevalence of insulin glargine vial use beyond 28 days in a Medicaid population. Insulin Glargine 22-30 insulin Homo sapiens 14-21 29801995-1 2018 OBJECTIVES: Insulin glargine, one of the most commonly prescribed drugs for diabetes, has a 28-day limit on the use of a 10-mL (1000 units) multiple-dose vial once the bottle is punctured. Insulin Glargine 20-28 insulin Homo sapiens 12-19 29801995-2 2018 If patients who are using smaller doses or are not adherent continue to use insulin glargine beyond the 28-day window, it can result in questionable stability and sterility of the product. Insulin Glargine 84-92 insulin Homo sapiens 76-83 29801995-10 2018 CONCLUSION: A large proportion of Medicaid patients were found to use insulin glargine past the recommended 28-day limit. Insulin Glargine 78-86 insulin Homo sapiens 70-77 29275373-9 2017 CONCLUSIONS: Insulin glargine was associated with a significant 20.7% increase in NT-proBNP, a marker of myocardial stress, after 12 weeks of therapy. Insulin Glargine 21-29 insulin Homo sapiens 13-20 29276400-5 2017 Significant progress has been made with long-acting insulin analogs (insulin glargine 100 units/mL and insulin detemir), which provide longer coverage and less risk of hypoglycemia over intermediate-acting insulin (Neutral Protamine Hagedorn insulin). Insulin Glargine 77-85 insulin Homo sapiens 52-59 29276400-5 2017 Significant progress has been made with long-acting insulin analogs (insulin glargine 100 units/mL and insulin detemir), which provide longer coverage and less risk of hypoglycemia over intermediate-acting insulin (Neutral Protamine Hagedorn insulin). Insulin Glargine 77-85 insulin Homo sapiens 69-76 29276400-5 2017 Significant progress has been made with long-acting insulin analogs (insulin glargine 100 units/mL and insulin detemir), which provide longer coverage and less risk of hypoglycemia over intermediate-acting insulin (Neutral Protamine Hagedorn insulin). Insulin Glargine 77-85 insulin Homo sapiens 69-76 29276400-5 2017 Significant progress has been made with long-acting insulin analogs (insulin glargine 100 units/mL and insulin detemir), which provide longer coverage and less risk of hypoglycemia over intermediate-acting insulin (Neutral Protamine Hagedorn insulin). Insulin Glargine 77-85 insulin Homo sapiens 69-76 29276400-5 2017 Significant progress has been made with long-acting insulin analogs (insulin glargine 100 units/mL and insulin detemir), which provide longer coverage and less risk of hypoglycemia over intermediate-acting insulin (Neutral Protamine Hagedorn insulin). Insulin Glargine 77-85 insulin Homo sapiens 69-76 29276400-6 2017 Furthermore, recent clinical evidence suggests that newer long-acting insulin analogs, new insulin glargine 300 units/mL and insulin degludec, may address some of the unmet needs of current basal insulin options in terms of risk of hypoglycemia and dosing time inflexibility. Insulin Glargine 99-107 insulin Homo sapiens 91-98 29276400-6 2017 Furthermore, recent clinical evidence suggests that newer long-acting insulin analogs, new insulin glargine 300 units/mL and insulin degludec, may address some of the unmet needs of current basal insulin options in terms of risk of hypoglycemia and dosing time inflexibility. Insulin Glargine 99-107 insulin Homo sapiens 91-98 29094298-0 2017 Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations. Insulin Glargine 57-65 insulin Homo sapiens 49-56 28452095-8 2017 A greater number of quality-adjusted life years (QALYs; 1.94) at a cost saving of $117 706 gained was associated with exenatide twice daily vs insulin glargine once daily. Insulin Glargine 151-159 insulin Homo sapiens 143-150 29181962-6 2017 A registration trial for pediatric population (aged 6 to 17 years) is in progress for glargine U-300 insulin. Insulin Glargine 86-94 insulin Homo sapiens 101-108 29090600-0 2017 Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Insulin Glargine 70-78 insulin Homo sapiens 62-69 29179857-9 2017 CONCLUSIONS: In the transition from IV to SC insulin therapy, initial insulin glargine dose estimated as 50% of daily IV insulin requirements is adequate for patients on EN, but inadequate in those given TPN. Insulin Glargine 78-86 insulin Homo sapiens 45-52 29179857-9 2017 CONCLUSIONS: In the transition from IV to SC insulin therapy, initial insulin glargine dose estimated as 50% of daily IV insulin requirements is adequate for patients on EN, but inadequate in those given TPN. Insulin Glargine 78-86 insulin Homo sapiens 70-77 29179857-9 2017 CONCLUSIONS: In the transition from IV to SC insulin therapy, initial insulin glargine dose estimated as 50% of daily IV insulin requirements is adequate for patients on EN, but inadequate in those given TPN. Insulin Glargine 78-86 insulin Homo sapiens 70-77 28846865-0 2017 Insulin glargine and its two active metabolites: A sensitive (16pM) and robust simultaneous hybrid assay coupling immunoaffinity purification with LC-MS/MS to support biosimilar clinical studies. Insulin Glargine 8-16 insulin Homo sapiens 0-7 27807910-3 2017 We hypothesize that co-administration of glargine, a subcutaneous long-acting insulin analog, during insulin infusion may facilitate a flexible and safe transition from intravenous to subcutaneous therapy. Insulin Glargine 41-49 insulin Homo sapiens 78-85 27807910-3 2017 We hypothesize that co-administration of glargine, a subcutaneous long-acting insulin analog, during insulin infusion may facilitate a flexible and safe transition from intravenous to subcutaneous therapy. Insulin Glargine 41-49 insulin Homo sapiens 101-108 27807910-4 2017 OBJECTIVE: To determine if the practice of administering subcutaneous glargine during intravenous insulin is associated with an increased risk of hypoglycemia, hypokalemia, or other complications in children with DKA. Insulin Glargine 70-78 insulin Homo sapiens 98-105 28953430-10 2017 Conclusion Long-term use of insulin glargine is associated with an increased risk of breast cancer in women with type 2 diabetes. Insulin Glargine 36-44 insulin Homo sapiens 28-35 28407415-4 2017 First- and second-phase insulin secretion were not increased with glargine alone, but increased after addition of lixisenatide ( P < .001). Insulin Glargine 66-74 insulin Homo sapiens 24-31 28407415-6 2017 Addition of insulin glargine tended to further increase first-phase insulin secretion (P = .054), as well as insulin and C-peptide concentrations ( P < .05). Insulin Glargine 20-28 insulin Homo sapiens 12-19 28407415-6 2017 Addition of insulin glargine tended to further increase first-phase insulin secretion (P = .054), as well as insulin and C-peptide concentrations ( P < .05). Insulin Glargine 20-28 insulin Homo sapiens 68-75 28407415-6 2017 Addition of insulin glargine tended to further increase first-phase insulin secretion (P = .054), as well as insulin and C-peptide concentrations ( P < .05). Insulin Glargine 20-28 insulin Homo sapiens 68-75 28407415-9 2017 Thus, lixisenatide and, to a lesser extent, insulin glargine, increase glucose-stimulated insulin secretion in an additive manner. Insulin Glargine 52-60 insulin Homo sapiens 44-51 28407415-9 2017 Thus, lixisenatide and, to a lesser extent, insulin glargine, increase glucose-stimulated insulin secretion in an additive manner. Insulin Glargine 52-60 insulin Homo sapiens 90-97 29241887-9 2017 Insulin glargine (od) [iGlarg (od)] and iDet (od) were ranked as second and third, with NMBs of $180,893 and $180,423, respectively. Insulin Glargine 8-16 insulin Homo sapiens 0-7 29090977-8 2017 The general hypoglycemia rate was lowest with insulin glargine, whereas there was no significant difference in severe hypoglycemia among the three BI groups. Insulin Glargine 54-62 insulin Homo sapiens 46-53 27819164-7 2017 Long-acting insulin analogs (glargine and/or detemir) are used by 46% and 33.6% of respondents, respectively. Insulin Glargine 29-37 insulin Homo sapiens 12-19 29058131-11 2017 The ORIGIN trial suggests at least a neutral effect of the basal insulin glargine on cardiovascular outcomes. Insulin Glargine 73-81 insulin Homo sapiens 65-72 28803820-0 2017 TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL. Insulin Glargine 80-88 insulin Homo sapiens 72-79 28803820-1 2017 OBJECTIVE: It was uncertain whether an algorithm that involves increasing insulin dosages by 1 unit/day may cause more hypoglycemia with the longer-acting insulin glargine 300 units/mL (GLA-300). Insulin Glargine 163-171 insulin Homo sapiens 155-162 28608570-1 2017 Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar ), in 2014 expanded the treatment options available to people with diabetes. Insulin Glargine 63-72 insulin Homo sapiens 44-51 28608570-1 2017 Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar ), in 2014 expanded the treatment options available to people with diabetes. Insulin Glargine 63-72 insulin Homo sapiens 73-80 28608570-1 2017 Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar ), in 2014 expanded the treatment options available to people with diabetes. Insulin Glargine 81-89 insulin Homo sapiens 44-51 28608570-1 2017 Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar ), in 2014 expanded the treatment options available to people with diabetes. Insulin Glargine 81-89 insulin Homo sapiens 73-80 28608570-4 2017 This review explains the concept of biosimilar medicines and outlines regulatory requirements for registration of biosimilar insulins in Europe, which is illustrated by the successful development of LY2963016 insulin glargine and MK-1293 insulin glargine (Lusduna ). Insulin Glargine 199-208 insulin Homo sapiens 125-132 28608570-4 2017 This review explains the concept of biosimilar medicines and outlines regulatory requirements for registration of biosimilar insulins in Europe, which is illustrated by the successful development of LY2963016 insulin glargine and MK-1293 insulin glargine (Lusduna ). Insulin Glargine 199-208 insulin Homo sapiens 209-216 28608570-4 2017 This review explains the concept of biosimilar medicines and outlines regulatory requirements for registration of biosimilar insulins in Europe, which is illustrated by the successful development of LY2963016 insulin glargine and MK-1293 insulin glargine (Lusduna ). Insulin Glargine 217-225 insulin Homo sapiens 125-132 28608570-4 2017 This review explains the concept of biosimilar medicines and outlines regulatory requirements for registration of biosimilar insulins in Europe, which is illustrated by the successful development of LY2963016 insulin glargine and MK-1293 insulin glargine (Lusduna ). Insulin Glargine 217-225 insulin Homo sapiens 209-216 28608570-4 2017 This review explains the concept of biosimilar medicines and outlines regulatory requirements for registration of biosimilar insulins in Europe, which is illustrated by the successful development of LY2963016 insulin glargine and MK-1293 insulin glargine (Lusduna ). Insulin Glargine 246-254 insulin Homo sapiens 125-132 28608570-5 2017 Preclinical and clinical comparative studies of the biosimilar insulin glargine programmes include in vitro bioassays for insulin and insulin-like growth factor 1 receptor binding, assessment of in vitro biological activity, evaluation of pharmacokinetic/pharmacodynamic profiles in phase I studies and assessment of long-term safety and efficacy in phase III studies. Insulin Glargine 71-79 insulin Homo sapiens 63-70 28837885-5 2017 RESULTS: At follow-up, there was no difference in physical activity or TV viewing time between those taking insulin glargine and those receiving standard care, despite body weight increasing by 1.66 (7.56) kg in the insulin glargine group and reducing by -0.65 (7.90) kg in the standard care group (P<0.001). Insulin Glargine 224-232 insulin Homo sapiens 216-223 28837885-6 2017 The dose of insulin glargine was not associated with changes in physical activity. Insulin Glargine 20-28 insulin Homo sapiens 12-19 28864965-5 2017 The long-acting insulin analogues glargine and detemir appear safe with similar maternal/fetal outcomes compared to NPH. Insulin Glargine 34-42 insulin Homo sapiens 16-23 28846865-1 2017 MK-1293 is a newly approved follow-on/biosimilar insulin glargine for the treatment of Type 1 and Type 2 diabetics. Insulin Glargine 0-7 insulin Homo sapiens 49-56 28846865-1 2017 MK-1293 is a newly approved follow-on/biosimilar insulin glargine for the treatment of Type 1 and Type 2 diabetics. Insulin Glargine 57-65 insulin Homo sapiens 49-56 28683300-11 2017 Albiglutide was also associated with modest reductions in body weight vs pioglitazone, glimepiride, and insulin glargine, which were associated with weight gain. Insulin Glargine 112-120 insulin Homo sapiens 104-111 28960085-0 2017 The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications. Insulin Glargine 38-46 insulin Homo sapiens 30-37 28683239-1 2017 OBJECTIVE: Glargine and detemir insulin are the two most commonly prescribed basal insulin analogues for the ambulatory and inpatient management of diabetes. Insulin Glargine 11-19 insulin Homo sapiens 83-90 28960085-4 2017 MATERIALS & METHODS: Retrospective cohort study of Type I diabetes patients receiving insulin glargine in Brazil following NPH insulin who met the criteria. Insulin Glargine 98-106 insulin Homo sapiens 90-97 28526658-0 2017 Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR /ABASAGLAR ) approved in the European Union. Insulin Glargine 72-80 insulin Homo sapiens 64-71 28623551-12 2017 CONCLUSION: Younger patients with a shorter duration of diabetes and lower HbA1c, FPG, and premixed insulin dose following a switch in treatment to insulin glargine (100 U/ml) plus OADs from premixed insulin have greater potential to achieve HbA1c <7.0%. Insulin Glargine 156-164 insulin Homo sapiens 100-107 28623551-12 2017 CONCLUSION: Younger patients with a shorter duration of diabetes and lower HbA1c, FPG, and premixed insulin dose following a switch in treatment to insulin glargine (100 U/ml) plus OADs from premixed insulin have greater potential to achieve HbA1c <7.0%. Insulin Glargine 156-164 insulin Homo sapiens 148-155 28623551-12 2017 CONCLUSION: Younger patients with a shorter duration of diabetes and lower HbA1c, FPG, and premixed insulin dose following a switch in treatment to insulin glargine (100 U/ml) plus OADs from premixed insulin have greater potential to achieve HbA1c <7.0%. Insulin Glargine 156-164 insulin Homo sapiens 148-155 28667587-0 2017 Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 28667587-2 2017 Once-daily insulin glargine/lixisenatide, in combination with metformin, provided effective glycaemic control and was generally well tolerated in the 30-week, multinational, phase 3 LixiLan-O and LixiLan-L trials in insulin-naive and -experienced adult patients with inadequately controlled type 2 diabetes. Insulin Glargine 19-27 insulin Homo sapiens 11-18 28667587-2 2017 Once-daily insulin glargine/lixisenatide, in combination with metformin, provided effective glycaemic control and was generally well tolerated in the 30-week, multinational, phase 3 LixiLan-O and LixiLan-L trials in insulin-naive and -experienced adult patients with inadequately controlled type 2 diabetes. Insulin Glargine 19-27 insulin Homo sapiens 216-223 28589542-16 2017 Another study comparing T2D patients receiving oral agents given liraglutide with those given insulin glargine showed that those in the highest baseline HbA1c quartile (mean 10.6%) had an HbA1c reduction of 3.1% with either agent. Insulin Glargine 102-110 insulin Homo sapiens 94-101 28589542-18 2017 Similar superiority of the HbA1c-lowering effect of exenatide QW compared with that of insulin glargine was reported in a study with baseline HbA1c 8.5%. Insulin Glargine 95-103 insulin Homo sapiens 87-94 27091835-0 2017 Glargine Insulin Use Versus Continuous Regular Insulin in Diabetic Surgical Noncritically Ill Patients Receiving Parenteral Nutrition: Randomized Controlled Study. Insulin Glargine 0-8 insulin Homo sapiens 9-16 27091835-3 2017 The GLUCOSE-in-PN study aimed to compare the efficacy of glargine insulin versus continuously infused regular insulin in PN (RI-in-PN) to achieve glycemic control in noncritically ill surgical patients with diabetes who were receiving PN. Insulin Glargine 57-65 insulin Homo sapiens 66-73 27091835-11 2017 A significantly higher percentage of hyperglycemia was observed on day 5 for glargine insulin versus RI-in-PN (22.39% vs 5.97%, P = .0059). Insulin Glargine 77-85 insulin Homo sapiens 86-93 28817342-1 2017 BACKGROUND: Basal insulin peglispro (BIL) has a peripheral-to-hepatic distribution of action that resembles endogenous insulin and a prolonged duration of action with a flat pharmacokinetic/pharmacodynamic profile at steady state, characteristics that tend to reduce hypoglycemia risk compared to insulin glargine (GL). Insulin Glargine 305-313 insulin Homo sapiens 18-25 28817342-1 2017 BACKGROUND: Basal insulin peglispro (BIL) has a peripheral-to-hepatic distribution of action that resembles endogenous insulin and a prolonged duration of action with a flat pharmacokinetic/pharmacodynamic profile at steady state, characteristics that tend to reduce hypoglycemia risk compared to insulin glargine (GL). Insulin Glargine 315-317 insulin Homo sapiens 18-25 28526658-1 2017 Basaglar /Abasaglar (Lilly insulin glargine [LY IGlar]) is a long-acting human insulin analogue drug product granted marketing authorisation as a biosimilar to Lantus (Sanofi insulin glargine [SA IGlar]) by the European Medicines Agency. Insulin Glargine 36-44 insulin Homo sapiens 28-35 28672316-12 2017 A lower proportion of patients in the insulin degludec than in the insulin glargine U100 group experienced severe hypoglycemia during the maintenance period (10.3%, 95% CI, 7.3%-13.3% vs 17.1%, 95% CI, 13.4%-20.8%, respectively; McNemar P = .002; risk difference, -6.8%; 95% CI, -10.8% to -2.7%). Insulin Glargine 75-83 insulin Homo sapiens 67-74 28724420-10 2017 Insulin glargine was the most requested medication (6.3%), followed by insulin aspart (3.3%). Insulin Glargine 8-16 insulin Homo sapiens 0-7 27699623-9 2017 This article evaluates and summarizes the pharmacokinetics and pharmacodynamics of insulin glargine U-300, for patients with type 1 or 2 diabetes mellitus, and summarizes its application to clinical practice. Insulin Glargine 91-99 insulin Homo sapiens 83-90 28403644-2 2017 Their plasma levels are adversely affected in patients with dysglycaemia, and glucose normalization with insulin glargine might improve the levels of these factors. Insulin Glargine 113-121 insulin Homo sapiens 105-112 28042719-1 2017 INTRODUCTION: The longer acting basal insulin analogs glargine and detemir have shown a lower incidence of hypoglycemia compared to insulin NPH in clinical studies. Insulin Glargine 54-62 insulin Homo sapiens 38-45 28277867-4 2017 RESULTS: Although long-acting insulin analogs, such as insulin glargine 100 units/mL and insulin detemir, have come towards approximating physiologic basal insulin levels, limitations such as hypoglycemia and intra- and inter-individual variability are associated with their use resulting in glycemic fluctuations. Insulin Glargine 63-71 insulin Homo sapiens 30-37 28277867-4 2017 RESULTS: Although long-acting insulin analogs, such as insulin glargine 100 units/mL and insulin detemir, have come towards approximating physiologic basal insulin levels, limitations such as hypoglycemia and intra- and inter-individual variability are associated with their use resulting in glycemic fluctuations. Insulin Glargine 63-71 insulin Homo sapiens 55-62 28277867-4 2017 RESULTS: Although long-acting insulin analogs, such as insulin glargine 100 units/mL and insulin detemir, have come towards approximating physiologic basal insulin levels, limitations such as hypoglycemia and intra- and inter-individual variability are associated with their use resulting in glycemic fluctuations. Insulin Glargine 63-71 insulin Homo sapiens 55-62 28277867-7 2017 Long-acting insulin analogs, such as insulin glargine 300 units/mL and insulin degludec, have improved upon the shortcomings of the current basal insulin analogs. Insulin Glargine 45-53 insulin Homo sapiens 12-19 28277867-7 2017 Long-acting insulin analogs, such as insulin glargine 300 units/mL and insulin degludec, have improved upon the shortcomings of the current basal insulin analogs. Insulin Glargine 45-53 insulin Homo sapiens 37-44 28277867-7 2017 Long-acting insulin analogs, such as insulin glargine 300 units/mL and insulin degludec, have improved upon the shortcomings of the current basal insulin analogs. Insulin Glargine 45-53 insulin Homo sapiens 37-44 28357772-0 2017 Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients. Insulin Glargine 73-81 insulin Homo sapiens 65-72 28361463-0 2017 Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus Insulin Glargine. Insulin Glargine 119-128 insulin Homo sapiens 71-78 28361463-0 2017 Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus Insulin Glargine. Insulin Glargine 148-156 insulin Homo sapiens 71-78 28361463-0 2017 Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus Insulin Glargine. Insulin Glargine 148-156 insulin Homo sapiens 140-147 28368217-5 2017 During the first week of insulin therapy, she developed generalized immediate urticaria twice after long-acting insulin glargine first and then once after insulin degludec administration. Insulin Glargine 120-128 insulin Homo sapiens 25-32 28368217-5 2017 During the first week of insulin therapy, she developed generalized immediate urticaria twice after long-acting insulin glargine first and then once after insulin degludec administration. Insulin Glargine 120-128 insulin Homo sapiens 112-119 28368217-5 2017 During the first week of insulin therapy, she developed generalized immediate urticaria twice after long-acting insulin glargine first and then once after insulin degludec administration. Insulin Glargine 120-128 insulin Homo sapiens 112-119 28524340-8 2017 The most frequently prescribed medications were metformin (84.0%), glibenclamide (23.4%) and insulin glargine (20.7%). Insulin Glargine 101-109 insulin Homo sapiens 93-100 28394183-2 2017 We aimed to examine the changes in the serum IGF1 levels formed by insulin glargine and detemir in the insulin-naive type 2 diabetic patients. Insulin Glargine 75-83 insulin Homo sapiens 67-74 28394183-2 2017 We aimed to examine the changes in the serum IGF1 levels formed by insulin glargine and detemir in the insulin-naive type 2 diabetic patients. Insulin Glargine 75-83 insulin Homo sapiens 103-110 27699623-0 2017 Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. Insulin Glargine 58-66 insulin Homo sapiens 50-57 28892956-0 2017 Short Term Efficacy and Safety of Insulin Glargine in Type 2 Diabetes Inadequately Controlled with Single or Two Oral Agents: A Prospective, Open Label Study. Insulin Glargine 42-50 insulin Homo sapiens 34-41 28892956-3 2017 AIM: To assess the efficacy and safety of insulin glargine in patients with T2DM who have uncontrolled glycaemic levels despite single or two OAAs therapy. Insulin Glargine 50-58 insulin Homo sapiens 42-49 28892956-5 2017 Dosing of insulin glargine was adjusted as per Fasting Blood Glucose (FBG) and Post Prandial Blood Glucose (PPBG) levels. Insulin Glargine 18-26 insulin Homo sapiens 10-17 28892956-13 2017 CONCLUSION: Short term administration of insulin glargine is effective in reducing glycaemia and is safe with lower rates of severe hypoglycaemia. Insulin Glargine 49-57 insulin Homo sapiens 41-48 28652565-9 2017 After a few days, insulin glargine was initiated, given twice daily via subcutaneous route. Insulin Glargine 26-34 insulin Homo sapiens 18-25 28637743-0 2017 Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. Insulin Glargine 92-100 insulin Homo sapiens 84-91 28637743-1 2017 OBJECTIVE: To investigate healthcare professionals" knowledge and attitudes towards infliximab and insulin glargine biosimilars and the factors influencing their prescribing. Insulin Glargine 107-115 insulin Homo sapiens 99-106 28637743-6 2017 OUTCOMES: Participants" knowledge and awareness of biosimilars and factors influencing their use and corresponding usage of infliximab and insulin glargine biosimilars. Insulin Glargine 147-155 insulin Homo sapiens 139-146 28324049-7 2017 During the intensive intervention period, weight loss and normoglycemia were targeted using lifestyle approaches and treatment with metformin, acarbose, and insulin glargine. Insulin Glargine 165-173 insulin Homo sapiens 157-164 27995731-2 2017 Consequently, glargine-based basal-bolus insulin regimens may under treat daytime hyperglycaemia and cause nocturnal hypoglycaemia. Insulin Glargine 14-22 insulin Homo sapiens 41-48 27255431-0 2017 Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes. Insulin Glargine 68-76 insulin Homo sapiens 60-67 28344112-13 2017 Most discontinuations were due to adverse events-mostly gastrointestinal with semaglutide, and others such as skin and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine. Insulin Glargine 198-206 insulin Homo sapiens 190-197 28344112-16 2017 Severe or blood glucose-confirmed hypoglycaemia was reported by 16 (4%) participants with 0 5 mg semaglutide and 20 (6%) with 1 0 mg semaglutide versus 38 (11%) with insulin glargine (p=0 0021 and p=0 0202 for 0 5 mg and 1 0 mg semaglutide vs insulin glargine, respectively). Insulin Glargine 174-182 insulin Homo sapiens 166-173 28344112-17 2017 Severe hypoglycaemia was reported by two (<1%) participants with 0 5 mg semaglutide, five (1%) with 1 0 mg semaglutide, and five (1%) with insulin glargine. Insulin Glargine 150-158 insulin Homo sapiens 142-149 28344112-19 2017 The most frequently reported adverse events were nausea with semaglutide, reported in 77 (21%) patients with 0 5 mg and in 80 (22%) with 1 0 mg, and nasopharyngitis reported in 44 (12%) patients with insulin glargine. Insulin Glargine 208-216 insulin Homo sapiens 200-207 28314656-1 2017 OBJECTIVES: To assess the safety and efficacy of a basal-plus (BP) regimen with insulin glargine (as basal insulin) and insulin glulisine (as prandial insulin) with the main meal for elderly patients with type 2 diabetes mellitus (DM2) and high cardiovascular risk, following standard clinical practice. Insulin Glargine 88-96 insulin Homo sapiens 80-87 28132529-0 2017 Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 8-16 insulin Homo sapiens 0-7 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 8-16 insulin Homo sapiens 31-38 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 0-7 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 31-38 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 91-98 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 0-7 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 31-38 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 91-98 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 0-7 28197833-2 2017 The vascular benefit of insulin is evident from the Diabetes Control and Complication Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS), and the cardiovascular safety of insulin glargine has been demonstrated in individuals with newly diagnosed diabetes or prediabetes in the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention). Insulin Glargine 195-203 insulin Homo sapiens 187-194 27664062-0 2017 Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naive People With Type 2 Diabetes. Insulin Glargine 27-35 insulin Homo sapiens 19-26 28197833-3 2017 The top-line results of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events) have proven the cardiovascular safety of insulin degludec in persons with type 2 diabetes. Insulin Glargine 102-110 insulin Homo sapiens 94-101 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 31-38 28132529-1 2017 Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Insulin Glargine 39-47 insulin Homo sapiens 91-98 28264184-1 2017 In this issue, Pohlmeier et al report on a device assessment study in insulin-naive patients with type 2 diabetes, to investigate the ease of use/learning and patient preference of the new prefilled U300 insulin glargine injection pen. Insulin Glargine 212-220 insulin Homo sapiens 70-77 27705031-1 2017 BACKGROUND AND AIMS: Insulin degludec is an insulin analog with an ultra-long duration of action that exhibits less intra-patient variability in its glucose-lowering activity, and reduces nocturnal, overall, and severe hypoglycemia relative to insulin glargine. Insulin Glargine 252-260 insulin Homo sapiens 21-28 27705031-6 2017 RESULTS: Insulin degludec dominated insulin glargine (i.e. reduced costs while improving quality-adjusted life expectancy) in patients with T1D and patients with type 2 diabetes using a basal-only insulin regimen. Insulin Glargine 44-52 insulin Homo sapiens 36-43 28230445-12 2017 In general, for both existing and new basal insulin users, higher persistence rate and duration were associated with Medicare versus cash-pay patients, use of insulin pens versus vial/syringe, and use of insulin glargine versus NPH. Insulin Glargine 212-220 insulin Homo sapiens 44-51 27884723-3 2017 In the present study, we address the relationship between the induction of proliferation and genomic damage in vitro in cell lines with different expression of the insulin and the IGF-1 receptors after treating the cells with insulin and the insulin analog glargine. Insulin Glargine 257-265 insulin Homo sapiens 164-171 27884723-5 2017 Insulin as well as insulin glargine stimulated cell proliferation in IGF-receptor-dominated MCF-7 cells and not in insulin receptor-dominated BT-474 cells and PPP attenuated this effect. Insulin Glargine 27-35 insulin Homo sapiens 19-26 27884723-7 2017 Overall, we showed in this study that high levels of insulin and insulin glargine can enhance cell proliferation in cells which highly express IGF-1 receptor and induce DNA damage in cells with high and also in those with low IGF-1 receptor levels. Insulin Glargine 73-81 insulin Homo sapiens 65-72 28040350-0 2017 Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials. Insulin Glargine 86-94 insulin Homo sapiens 78-85 27664062-0 2017 Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naive People With Type 2 Diabetes. Insulin Glargine 27-35 insulin Homo sapiens 61-68 27664062-1 2017 BACKGROUND: Insulin glargine 300 U/mL (Gla-300) contains the same active ingredient as glargine 100 U/mL (Gla-100), and provides the same number of units in one-third of the volume. Insulin Glargine 20-28 insulin Homo sapiens 12-19 28069680-7 2017 Newly implemented initiatives to help ensure safe insulin use included involving frontline nursing staff in medication safety committee meetings and requiring that all insulin glargine doses be prepared in designated insulin syringes in the pharmacy for dispensing to patient care units. Insulin Glargine 176-184 insulin Homo sapiens 168-175 28238223-24 2017 One study comparing sitagliptin to insulin glargine showed an equivalent lowering of HbA1c (-0.6 +- 0.5% versus -0.6 +- 0.6%, P = NS) and fasting blood glucose (4.92 +- 1.42 versus 4.76 +- 1.09 mmol/L, P = NS) with sitagliptin. Insulin Glargine 43-51 insulin Homo sapiens 35-42 28024260-3 2017 The pharmacodynamic data were established and compared to insulin glargine characterized by the same profile of action in diabetics. Insulin Glargine 66-74 insulin Homo sapiens 58-65 28069680-7 2017 Newly implemented initiatives to help ensure safe insulin use included involving frontline nursing staff in medication safety committee meetings and requiring that all insulin glargine doses be prepared in designated insulin syringes in the pharmacy for dispensing to patient care units. Insulin Glargine 176-184 insulin Homo sapiens 168-175 28491437-0 2016 Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat. Insulin Glargine 55-63 insulin Homo sapiens 64-71 29017173-7 2017 In meta-analyses comparing regular insulin added to parenteral nutrition bag with glargine, MBG (MD 95% CI -3.78 mg/dL [-11.93 to 4.37]; I2 = 0%) or hypoglycemia frequency (RR 95% CI 1.37 [0.43-4.32]; I2 = 70.7%) did not differ. Insulin Glargine 82-90 insulin Homo sapiens 35-42 27578616-3 2017 METHODS: This was a prospective, observational, 24-week study in T2DM patients with BOT using insulin glargine and baseline glycated hemoglobin (HbA1c) between 7.0 and 8.5%. Insulin Glargine 102-110 insulin Homo sapiens 94-101 27578616-9 2017 During the study, insulin glargine dose was increased from 18.7 to 26.4U (plus 7.7U) in GLAR and from 24.9 to 27.3U (plus 2.4U) in GLARplus patients. Insulin Glargine 26-34 insulin Homo sapiens 18-25 27578616-15 2017 CONCLUSION: These findings provide evidence that treatment intensification in patients with type 2 diabetes not at glycemic target on BOT with insulin glargine is equally safe and effective using either long-acting insulin titration alone or the addition of a rapid-acting insulin analogue. Insulin Glargine 151-159 insulin Homo sapiens 143-150 27593206-7 2017 Newer basal insulin analogues have used up-concentration in addition to precipitation (insulin glargine U300), and multihexamer formation in addition to albumin binding (insulin degludec), to further increase duration of action and/or decrease the day-to-day variability of the glucose-lowering profile. Insulin Glargine 95-103 insulin Homo sapiens 12-19 27776251-9 2016 CONCLUSIONS: Both exenatide BID and prandial insulin lispro, each added to basal insulin glargine, were effective at reducing HbA1c in Latin American patients. Insulin Glargine 89-97 insulin Homo sapiens 81-88 27887605-1 2016 BACKGROUND: We aimed to describe the safety and efficacy of insulin glargine in Chinese paediatric patients with type 1 diabetes mellitus (T1DM). Insulin Glargine 68-76 insulin Homo sapiens 60-67 27887605-14 2016 CONCLUSIONS: Initiation of insulin glargine can aid Chinese paediatric patients with T1DM to safely reduce their HbA1c levels. Insulin Glargine 35-43 insulin Homo sapiens 27-34 28077204-0 2017 Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine. Insulin Glargine 90-98 insulin Homo sapiens 51-58 28077204-5 2017 When compared with the standard of care, long-acting insulin product insulin glargine U-100, insulin degludec, and insulin glargine U-300 had similar glucose-lowering effects, longer half-lives and durations of action, and a more even distribution over a 24-hour period. Insulin Glargine 77-85 insulin Homo sapiens 53-60 28077204-5 2017 When compared with the standard of care, long-acting insulin product insulin glargine U-100, insulin degludec, and insulin glargine U-300 had similar glucose-lowering effects, longer half-lives and durations of action, and a more even distribution over a 24-hour period. Insulin Glargine 77-85 insulin Homo sapiens 69-76 28077204-5 2017 When compared with the standard of care, long-acting insulin product insulin glargine U-100, insulin degludec, and insulin glargine U-300 had similar glucose-lowering effects, longer half-lives and durations of action, and a more even distribution over a 24-hour period. Insulin Glargine 77-85 insulin Homo sapiens 69-76 28077204-5 2017 When compared with the standard of care, long-acting insulin product insulin glargine U-100, insulin degludec, and insulin glargine U-300 had similar glucose-lowering effects, longer half-lives and durations of action, and a more even distribution over a 24-hour period. Insulin Glargine 77-85 insulin Homo sapiens 69-76 28491437-1 2016 CASE SUMMARY: A 14-year-old, domestic shorthair cat was treated for transient diabetes mellitus for 3 months with glargine insulin, which was discontinued when the diabetes mellitus resolved. Insulin Glargine 114-122 insulin Homo sapiens 123-130 28491437-2 2016 Approximately 36 months later the diabetes mellitus recurred and glargine insulin was restarted. Insulin Glargine 65-73 insulin Homo sapiens 74-81 28491437-6 2016 Six months later the cat re-presented for relapse of its diabetes mellitus and an intradermal skin challenge with 1:20 diluted insulin was performed confirming a hypersensitivity to glargine. Insulin Glargine 182-190 insulin Homo sapiens 127-134 28491437-9 2016 This is the first reported case of a hypersensitivity reaction secondary to glargine insulin in a cat. Insulin Glargine 76-84 insulin Homo sapiens 85-92 27169522-12 2016 The mean glucose infusion rate (GIR) normalized to insulin unit was lower for BIL than for glargine. Insulin Glargine 91-99 insulin Homo sapiens 51-58 27690710-0 2016 Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naive patients with type 2 diabetes. Insulin Glargine 55-63 insulin Homo sapiens 47-54 27690710-1 2016 OBJECTIVE: This study aims to compare the effectiveness of insulin glargine 300 U/mL (Gla-300) with its accompanying patient support program with that of other basal insulin and available patient support programs in patients with type 2 diabetes (T2D) in a real-world setting in terms of achieving HEDIS (Healthcare Effectiveness Data and Information Set) individualized glycemic targets without documented symptomatic hypoglycemia. Insulin Glargine 67-75 insulin Homo sapiens 59-66 27695620-11 2016 In 2013, insulin isophane and insulin glargine were the most common insulin analogues used. Insulin Glargine 38-46 insulin Homo sapiens 30-37 27363479-0 2016 Recombinant Glargine Insulin Production Process Using Escherichia coli. Insulin Glargine 12-20 insulin Homo sapiens 21-28 27363479-1 2016 Glargine insulin is a long-acting insulin analog that helps blood glucose maintenance in patients with diabetes. Insulin Glargine 0-8 insulin Homo sapiens 9-16 27363479-1 2016 Glargine insulin is a long-acting insulin analog that helps blood glucose maintenance in patients with diabetes. Insulin Glargine 0-8 insulin Homo sapiens 34-41 27363479-2 2016 We constructed the pPT-GI vector to express prepeptide glargine insulin when transformed into Escherichia coli JM109. Insulin Glargine 55-63 insulin Homo sapiens 64-71 27363479-5 2016 The prepeptide glargine insulin was 38.52% of the total protein. Insulin Glargine 15-23 insulin Homo sapiens 24-31 27363479-7 2016 To convert the prepeptide into glargine insulin, citraconylation and trypsin cleavage were performed. Insulin Glargine 31-39 insulin Homo sapiens 40-47 27363479-8 2016 Using citraconylation, the yield of enzymatic conversion for glargine insulin increased by 3.2-fold compared with that without citraconylation. Insulin Glargine 61-69 insulin Homo sapiens 70-77 27363479-9 2016 After the enzyme reaction, active glargine insulin was purified by two types of chromatography (ion-exchange chromatography and reverse-phase chromatography). Insulin Glargine 34-42 insulin Homo sapiens 43-50 27363479-10 2016 We obtained recombinant human glargine insulin at 98.11% purity and verified that it is equal to the standard of human glargine insulin, based on High-performance liquid chromatography analysis and Matrix-assisted laser desorption/ionization Time-of-Flight Mass Spectrometry. Insulin Glargine 30-38 insulin Homo sapiens 39-46 27363479-11 2016 We thus established a production process for high-purity recombinant human glargine insulin and a method to block Arg (B31)-insulin formation. Insulin Glargine 75-83 insulin Homo sapiens 84-91 27363479-12 2016 This established process for recombinant human glargine insulin may be a model process for the production of other human insulin analogs. Insulin Glargine 47-55 insulin Homo sapiens 56-63 27363479-12 2016 This established process for recombinant human glargine insulin may be a model process for the production of other human insulin analogs. Insulin Glargine 47-55 insulin Homo sapiens 121-128 27799746-0 2016 Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives. Insulin Glargine 8-16 insulin Homo sapiens 0-7 27799746-2 2016 Glargine-300 is a modified form of the long-acting insulin analog glargine in that it has been concentrated at 300 units/mL rather than the conventional 100 units/mL. Insulin Glargine 0-8 insulin Homo sapiens 51-58 27799746-2 2016 Glargine-300 is a modified form of the long-acting insulin analog glargine in that it has been concentrated at 300 units/mL rather than the conventional 100 units/mL. Insulin Glargine 66-74 insulin Homo sapiens 51-58 27799746-5 2016 Open-label studies in patients with diabetes have shown that treatment with glargine-300 achieves comparable glycemic control compared to treatment with glargine-100, albeit with consistently higher insulin requirements. Insulin Glargine 76-84 insulin Homo sapiens 199-206 27799746-6 2016 These studies also showed that treatment with glargine-300 was associated with lower risks of nocturnal hypoglycemia in patients with type 2 diabetes, particularly those already on insulin, whereas data are mixed in insulin-naive patients with type 2 diabetes or in patients with type 1 diabetes. Insulin Glargine 46-54 insulin Homo sapiens 181-188 27093968-6 2016 RESULTS: In the PSM cohort, a slightly greater reduction in FBG and HbA1c levels was seen in the insulin glargine group compared to the NPH group. Insulin Glargine 105-113 insulin Homo sapiens 97-104 27093968-7 2016 A weight loss, which was slightly more pronounced in insulin glargine patients despite receiving a lower insulin dose relative to the NPH group, was seen in both the groups. Insulin Glargine 61-69 insulin Homo sapiens 53-60 27093968-10 2016 A large proportion of patients changed from NPH therapy to insulin glargine therapy during the study, which was mainly attributable to insufficient glucose modulation. Insulin Glargine 67-75 insulin Homo sapiens 59-66 27093968-12 2016 CONCLUSIONS: This observational study provides evidence from a real-life setting that BOT with insulin glargine provides slightly greater reductions in weight, FBG and HbA1c levels, with a lower risk of hypoglycaemia than patients receiving NPH. Insulin Glargine 103-111 insulin Homo sapiens 95-102 27093968-13 2016 This conclusion indicates that insulin glargine may be preferable to NPH insulin for BOT. Insulin Glargine 39-47 insulin Homo sapiens 31-38 27098531-0 2016 Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis. Insulin Glargine 25-33 insulin Homo sapiens 111-118 27098531-3 2016 The aim was to summarize published data in Adriatic countries on effectiveness of insulin glargine based therapy in type 2 diabetic patients suboptimally controlled on premix insulin. Insulin Glargine 90-98 insulin Homo sapiens 82-89 27098531-3 2016 The aim was to summarize published data in Adriatic countries on effectiveness of insulin glargine based therapy in type 2 diabetic patients suboptimally controlled on premix insulin. Insulin Glargine 90-98 insulin Homo sapiens 175-182 27098531-5 2016 We searched observational studies with duration of at least 6 months, evaluating effectiveness and safety of insulin glargine (IGlar), in combination with OAD or bolus insulin in patients with T2 failing premixed insulin therapy. Insulin Glargine 117-125 insulin Homo sapiens 109-116 27098531-10 2016 CONCLUSION: Insulin glargine based therapy following premix failure is efficacious and safe option of type 2 diabetes treatment intensification. Insulin Glargine 20-28 insulin Homo sapiens 12-19 27846339-0 2016 An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Glargine U-300. Insulin Glargine 100-108 insulin Homo sapiens 37-44 27846339-0 2016 An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Glargine U-300. Insulin Glargine 100-108 insulin Homo sapiens 83-90 27846339-0 2016 An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Glargine U-300. Insulin Glargine 100-108 insulin Homo sapiens 83-90 27846339-1 2016 Rates of confirmed and severe, as well as nocturnal, hypoglycemia are generally lower with insulin glargine U-300 than insulin glargine U-100, thereby reducing an important concern of providers and patients regarding insulin therapy. Insulin Glargine 99-107 insulin Homo sapiens 91-98 27846339-2 2016 Although a higher dose of insulin glargine U-300 than U-100 is required in most patients, the observed increase in body weight is small and less than with insulin glargine U-100. Insulin Glargine 34-42 insulin Homo sapiens 26-33 27695620-11 2016 In 2013, insulin isophane and insulin glargine were the most common insulin analogues used. Insulin Glargine 38-46 insulin Homo sapiens 30-37 29652465-0 2016 The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes. Insulin Glargine 45-53 insulin Homo sapiens 85-92 27669747-0 2016 Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial. Insulin Glargine 63-71 insulin Homo sapiens 55-62 27669747-2 2016 The aim of this study is to identify the fasting plasma glucose (FPG) target that will provide the highest control rate of HbA1c <7 % in Chinese patients with T2DM treated with an insulin glargine-based regimen as an adjunct to an established OAD regimen. Insulin Glargine 191-199 insulin Homo sapiens 183-190 27669747-5 2016 They will be initiated on daily insulin glargine (Lantus ) in addition to their usual OAD regimen for 24 weeks. Insulin Glargine 50-56 insulin Homo sapiens 32-39 27182031-3 2016 It was carried out in 458 adult patients who were inadequately controlled on insulin glargine with or without oral antidiabetic drugs. Insulin Glargine 85-93 insulin Homo sapiens 77-84 29652465-7 2016 With the titrationof insulin glargine, target fasting glucose levels were not achieved. Insulin Glargine 29-37 insulin Homo sapiens 21-28 29652465-12 2016 Conclusion: Sitagliptin can improve diabetes control and induce modest weight loss in obese subjectspoorly controlled on insulin glargine and metformin. Insulin Glargine 129-137 insulin Homo sapiens 121-128 29652465-13 2016 Titration of insulin glargine to optimal fasting glucosevalues is a prerequisite of success of this combination therapy. Insulin Glargine 21-29 insulin Homo sapiens 13-20 27341040-0 2016 Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus. Insulin Glargine 34-42 insulin Homo sapiens 26-33 27565486-2 2016 In September 2014, insulin glargine (LY IGlar) was approved as a long-acting insulin analogue. Insulin Glargine 27-35 insulin Homo sapiens 19-26 27565486-2 2016 In September 2014, insulin glargine (LY IGlar) was approved as a long-acting insulin analogue. Insulin Glargine 27-35 insulin Homo sapiens 77-84 27540462-5 2016 Stratification by type of insulin showed the best renal status for treatment with insulins Glargine and Lispro. Insulin Glargine 91-99 insulin Homo sapiens 26-33 27540462-7 2016 CONCLUSIONS: Present results suggest that treatment of type 1 diabetic patients with normal and impaired renal function with insulin analogs, especially Glargine and Lispro, is associated with better kidney function, lower urinary albumin/creatinine ratio and lower hemoglobin concentration compared to therapy with human insulin. Insulin Glargine 153-161 insulin Homo sapiens 125-132 27540462-7 2016 CONCLUSIONS: Present results suggest that treatment of type 1 diabetic patients with normal and impaired renal function with insulin analogs, especially Glargine and Lispro, is associated with better kidney function, lower urinary albumin/creatinine ratio and lower hemoglobin concentration compared to therapy with human insulin. Insulin Glargine 153-161 insulin Homo sapiens 322-329 26509843-6 2016 Newer insulin products available include new insulin glargine 300 units/mL (United States and Europe) and the ultra-long-acting insulin degludec (Europe) with basal insulin peglispro currently in development. Insulin Glargine 53-61 insulin Homo sapiens 6-13 29652465-3 2016 Methods: A total of 23 obese subjects on metformin and insulin glargine participated in the study. Insulin Glargine 63-71 insulin Homo sapiens 55-62 27440852-7 2016 In November 2011, a further change to insulin glargine, metformin and sitagliptin was made. Insulin Glargine 46-54 insulin Homo sapiens 38-45 27440852-9 2016 In November 2014, liraglutide and insulin glargine were introduced and the HbA1c levels decreased dramatically to ~7.5% (58 mmol/mol IFCC) despite increasing insulin antibody titres (from 32.6 to >50.0 U/mL). Insulin Glargine 42-50 insulin Homo sapiens 34-41 27150973-0 2016 Insulin glargine use and breast cancer risk: Associations with cumulative exposure. Insulin Glargine 8-16 insulin Homo sapiens 0-7 27422524-0 2016 Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Insulin Glargine 44-52 insulin Homo sapiens 26-33 27422524-9 2016 In HL-1 cardiomyocytes, stimulation with insulin degludec resulted in a lower Akt(Ser(473)) and Akt(Thr(308)) phosphorylation compared to insulin, insulin glargine and its active metabolite M1 after 5- and 10-min incubation. Insulin Glargine 155-163 insulin Homo sapiens 41-48 27150973-1 2016 BACKGROUND: This study was aimed to assess the risk of breast cancer associated with exposure to insulin glargine in women with type 2 diabetes and evaluate whether the pattern of risk concurs with the hypothesized trend of an increase in risk with longer duration of use, taking into account previous cumulative exposure to other types of insulin. Insulin Glargine 105-113 insulin Homo sapiens 97-104 27150973-1 2016 BACKGROUND: This study was aimed to assess the risk of breast cancer associated with exposure to insulin glargine in women with type 2 diabetes and evaluate whether the pattern of risk concurs with the hypothesized trend of an increase in risk with longer duration of use, taking into account previous cumulative exposure to other types of insulin. Insulin Glargine 105-113 insulin Homo sapiens 340-347 26525806-8 2016 Insulin degludec/liraglutide phase III trials and a lixisenatide/insulin glargine phase II trial have shown robust HbA1c reductions, with weight loss and a low risk of hypoglycaemia. Insulin Glargine 73-81 insulin Homo sapiens 65-72 28485557-5 2016 After 6 weeks his blood glucose had not significantly improved, and an endocrinologist prescribed insulin glargine (Lantus) and insulin aspart (NovoLog). Insulin Glargine 106-114 insulin Homo sapiens 98-105 26822462-6 2016 Patients in insulin degludec group experienced significantly lesser patient reported hypoglycemic episodes (12 versus 40) and required significantly lesser dose (25.68Units versus 18.61Units per day; P=0.002) compared to insulin glargine. Insulin Glargine 229-237 insulin Homo sapiens 12-19 26822462-7 2016 41% of the patients reached HbA1C target of <=7% with insulin glargine compared to 69% with insulin degludec within the specified time period. Insulin Glargine 65-73 insulin Homo sapiens 57-64 26822462-8 2016 CONCLUSION: Results from this real world analysis suggest that among type 2 DM patients who were initiated on insulin degludec as compared to insulin glargine may be associated with significantly lesser patient reported hypoglycemic episodes and lesser dose of insulin while achieving similar glycemic control. Insulin Glargine 150-158 insulin Homo sapiens 110-117 26822462-8 2016 CONCLUSION: Results from this real world analysis suggest that among type 2 DM patients who were initiated on insulin degludec as compared to insulin glargine may be associated with significantly lesser patient reported hypoglycemic episodes and lesser dose of insulin while achieving similar glycemic control. Insulin Glargine 150-158 insulin Homo sapiens 142-149 26822462-8 2016 CONCLUSION: Results from this real world analysis suggest that among type 2 DM patients who were initiated on insulin degludec as compared to insulin glargine may be associated with significantly lesser patient reported hypoglycemic episodes and lesser dose of insulin while achieving similar glycemic control. Insulin Glargine 150-158 insulin Homo sapiens 142-149 27145344-9 2016 For insulin glargine use in pregnancy, most studies are small and retrospective. Insulin Glargine 12-20 insulin Homo sapiens 4-11 27540462-0 2016 Treatment with insulin analogs, especially Glargine and Lispro, associates with better renal function and higher hemoglobin levels in Type 1 diabetic patients with impaired kidney function. Insulin Glargine 43-51 insulin Homo sapiens 15-22 26239143-0 2016 Lower limbs edema by insulin glargine treatment: two other cases in pediatrics. Insulin Glargine 29-37 insulin Homo sapiens 21-28 27307429-0 2016 Basal insulin regime change from Lantus to Toujeo resulted in fewer hypoglycaemic episodes in a 28-year-old man with diabetes mellitus. Insulin Glargine 33-39 insulin Homo sapiens 6-13 27307429-0 2016 Basal insulin regime change from Lantus to Toujeo resulted in fewer hypoglycaemic episodes in a 28-year-old man with diabetes mellitus. Insulin Glargine 43-49 insulin Homo sapiens 6-13 27307429-1 2016 An active 28-year-old man with type 1 diabetes mellitus reported a reduced number of hypoglycaemic episodes following change in basal regime insulin glargine from U100 Lantus to U300 Toujeo. Insulin Glargine 149-157 insulin Homo sapiens 141-148 26961276-0 2016 Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand. Insulin Glargine 40-48 insulin Homo sapiens 32-39 26961276-1 2016 BACKGROUND: Even though Insulin glargine (IGlar) has been available and used in other countries for more than a decade, it has not been adopted into Thai national formulary. Insulin Glargine 32-40 insulin Homo sapiens 24-31 27098525-0 2016 A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naive Patients with Type 2 Diabetes Mellitus. Insulin Glargine 102-110 insulin Homo sapiens 94-101 26861811-0 2016 Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Insulin Glargine 35-43 insulin Homo sapiens 27-34 27210264-5 2016 Most studies with insulin glargine and newer glucose-lowering drugs (saxagliptin, alogliptin, sitagliptin, lixisenatide) demonstrated safety of newer glucose-lowering agents but did not show superiority in the CV outcomes compared with placebo. Insulin Glargine 26-34 insulin Homo sapiens 18-25 27048292-2 2016 The objective of this study was to evaluate the effectiveness and safety of analog insulin glargine compared to recombinant DNA (rDNA) insulin in patients with T1DM in observational studies, building on previous reviews of randomized controlled trials comparing neutral protamine Hagedorn insulin and insulin glargine. Insulin Glargine 91-99 insulin Homo sapiens 83-90 27048292-11 2016 CONCLUSION: Given the high heterogeneity of the studies, the discrete value presented by the estimated effect on effectiveness and safety, potential conflicts of interest of the studies, and the appreciable higher cost of insulin glargine, there is still no support for recommending first-line therapy with analogs. Insulin Glargine 230-238 insulin Homo sapiens 222-229 27098525-0 2016 A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naive Patients with Type 2 Diabetes Mellitus. Insulin Glargine 102-110 insulin Homo sapiens 94-101 27228041-1 2016 Two concentrated analog insulins, long-acting insulin glargine U-300 (Toujeo) and rapid-acting insulin lispro (Humalog U-200), were recently approved by the FDA. Insulin Glargine 70-76 insulin Homo sapiens 24-31 26324105-10 2016 In particular, patients with baseline depression and frequent or severe hypoglycemia have a higher likelihood for early discontinuation of basal insulin, whereas use of insulin glargine and diabetologist care are related to an increased chance of continuous insulin treatment. Insulin Glargine 177-185 insulin Homo sapiens 169-176 27092018-0 2016 Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes. Insulin Glargine 53-61 insulin Homo sapiens 12-19 27092018-0 2016 Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes. Insulin Glargine 53-61 insulin Homo sapiens 45-52 27092018-1 2016 In Brief New insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that has a more constant pharmacokinetic profile with a prolonged duration of action. Insulin Glargine 21-29 insulin Homo sapiens 13-20 27092018-1 2016 In Brief New insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that has a more constant pharmacokinetic profile with a prolonged duration of action. Insulin Glargine 21-29 insulin Homo sapiens 73-80 27092018-1 2016 In Brief New insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that has a more constant pharmacokinetic profile with a prolonged duration of action. Insulin Glargine 81-89 insulin Homo sapiens 13-20 27092018-1 2016 In Brief New insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that has a more constant pharmacokinetic profile with a prolonged duration of action. Insulin Glargine 81-89 insulin Homo sapiens 73-80 26749289-0 2016 Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Insulin Glargine 23-32 insulin Homo sapiens 33-40 26749289-0 2016 Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Insulin Glargine 23-32 insulin Homo sapiens 118-125 26749289-0 2016 Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Insulin Glargine 41-49 insulin Homo sapiens 33-40 26324105-8 2016 Diabetologist care (0.57; 0.36-0.89) and glargine treatment (vs. NPH: 0.78; 0.61-0.98) were related to a lower odds of having early insulin discontinuation. Insulin Glargine 41-49 insulin Homo sapiens 132-139 26953280-0 2016 Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 26953280-0 2016 Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 43-50 26953280-1 2016 PURPOSE: The pharmacokinetics, efficacy, and safety of U-300 insulin glargine for the management of diabetes are reviewed. Insulin Glargine 69-77 insulin Homo sapiens 61-68 26953280-2 2016 SUMMARY: U-300 (300 units/mL) insulin glargine is a long-acting basal insulin with low within-day variability, high day-to-day reproducibility, longer duration, and constant pharmacokinetic profile compared with U-100 (100 units/mL) insulin glargine. Insulin Glargine 38-46 insulin Homo sapiens 30-37 26953280-2 2016 SUMMARY: U-300 (300 units/mL) insulin glargine is a long-acting basal insulin with low within-day variability, high day-to-day reproducibility, longer duration, and constant pharmacokinetic profile compared with U-100 (100 units/mL) insulin glargine. Insulin Glargine 38-46 insulin Homo sapiens 70-77 26953280-2 2016 SUMMARY: U-300 (300 units/mL) insulin glargine is a long-acting basal insulin with low within-day variability, high day-to-day reproducibility, longer duration, and constant pharmacokinetic profile compared with U-100 (100 units/mL) insulin glargine. Insulin Glargine 38-46 insulin Homo sapiens 70-77 26953280-6 2016 For hypoglycemic episodes, U-300 insulin glargine was superior to U-100 insulin glargine when comparing the risk of hypoglycemia. Insulin Glargine 41-49 insulin Homo sapiens 33-40 26953280-7 2016 U-300 insulin glargine is supplied in a prefilled device (for safety purposes) and packaged in boxes of three or five pens. Insulin Glargine 14-22 insulin Homo sapiens 6-13 26953280-9 2016 When compared with U-100 insulin glargine, U-300 insulin glargine appeared to be associated with a lower risk of hypoglycemia and nocturnal hypoglycemia, most likely due to its pharmacokinetics. Insulin Glargine 57-65 insulin Homo sapiens 49-56 26953280-10 2016 The wholesale average cost of U-300 insulin glargine is $335.48 per box of three pens. Insulin Glargine 44-52 insulin Homo sapiens 36-43 26953280-11 2016 CONCLUSION: The efficacy outcomes of U-300 insulin glargine were similar to those of U-100 insulin glargine, but the constant pharmacokinetic profile and longer duration of action of U-300 insulin glargine may help certain patients with type 1 or type 2 diabetes achieve better glycemic control. Insulin Glargine 51-59 insulin Homo sapiens 43-50 27022271-4 2016 AREAS COVERED: This review highlights the published reports of the pharmacokinetic (PK) and glucodynamic properties of concentrated insulins: Humulin-R U500, insulin degludec U200, and insulin glargine U300, describes the clinical efficacy, risk of hypoglycemic, and metabolic changes observed, and finally, discusses observations about the complexity of introducing a new generation of concentrated insulins to the therapeutic market. Insulin Glargine 193-201 insulin Homo sapiens 132-139 27022271-6 2016 Insulin glargine U300 has differential PK/pharmacodynamic effects when compared with insulin glargine U100. Insulin Glargine 8-16 insulin Homo sapiens 0-7 26803355-11 2016 CONCLUSION: Supplementation of exenatide to glargine insulin compared to standard insulin was: (i) effective in inducing weight loss, (ii) non-inferior in lowering HbA1c and (iii) non-inferior in increasing circulating adiponectin. Insulin Glargine 44-52 insulin Homo sapiens 53-60 26283736-5 2016 RESULTS: After 12 weeks, the decrease in HbA1c was larger with liraglutide versus insulin glargine (Delta-0.7% vs. -0.2%, P < 0.001). Insulin Glargine 90-98 insulin Homo sapiens 82-89 26283736-6 2016 Body weight decreased during liraglutide versus insulin glargine (Delta-3.3 kg vs. 0.8 kg, P < 0.001). Insulin Glargine 56-64 insulin Homo sapiens 48-55 26725077-9 2016 CONCLUSIONS: Insulin-resistant patients with type 2 diabetes undergoing hemodialysis for end-stage renal disease on insulin detemir exhibit lower glycemic variability and pro-inflammatory profile than with insulin glargine. Insulin Glargine 214-222 insulin Homo sapiens 13-20 27799841-1 2016 PURPOSE: The purpose of this study was to evaluate the optimization of fasting blood glucose (FBG) levels in patients with type 2 diabetes mellitus newly initiated on insulin glargine who were enrolled in the Australian Diabetes CoStars Patient Support Program (PSP). Insulin Glargine 175-183 insulin Homo sapiens 167-174 27212224-7 2016 In our case, liraglutide, a glucagon-like peptide-1 receptor agonist, added to insulin glargine was effective for her glycemic control and showed no adverse effects, including gastrointestinal symptoms and hypoglycemia, during a 14-week observation. Insulin Glargine 87-95 insulin Homo sapiens 79-86 27212963-2 2016 The objective of this study was to assess the cost-effectiveness of pharmacists" prescribing of insulin glargine as an early intervention in uncontrolled patients with T2DM vs usual clinical practice. Insulin Glargine 104-112 insulin Homo sapiens 96-103 27212963-4 2016 The efficacy of insulin glargine, in terms of hemoglobin A1c reduction and hypoglycemia rates, was obtained from the RxING study. Insulin Glargine 24-32 insulin Homo sapiens 16-23 26681720-0 2016 Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Insulin Glargine 64-72 insulin Homo sapiens 56-63 26681720-1 2016 OBJECTIVE: The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutral effects of insulin glargine on cardiovascular outcomes and cancers and reduced incident diabetes in high-cardiovascular risk adults with dysglycemia after 6.2 years of active treatment. Insulin Glargine 46-54 insulin Homo sapiens 111-118 26681720-1 2016 OBJECTIVE: The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutral effects of insulin glargine on cardiovascular outcomes and cancers and reduced incident diabetes in high-cardiovascular risk adults with dysglycemia after 6.2 years of active treatment. Insulin Glargine 119-127 insulin Homo sapiens 111-118 26681720-9 2016 CONCLUSIONS: During >6 years of treatment followed by >2.5 years of observation, insulin glargine had neutral effects on health outcomes and salutary effects on metabolic control, whereas omega-3 fatty acid supplementation had no effect. Insulin Glargine 95-103 insulin Homo sapiens 87-94 26484727-0 2016 A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Insulin Glargine 103-111 insulin Homo sapiens 95-102 26484727-1 2016 AIMS: A prospective meta-analysis of phase 3 trials showed lower rates of nocturnal hypoglycaemia with insulin degludec vs. insulin glargine. Insulin Glargine 132-140 insulin Homo sapiens 124-131 26484727-7 2016 RESULTS: In Type 2 diabetesinsulin naive participants, risk of nocturnal hypoglycaemia was significantly lower with insulin degludec vs. insulin glargine for all hypoglycaemia definitions and trial periods. Insulin Glargine 145-153 insulin Homo sapiens 27-34 26484727-9 2016 For Type 2 diabetesBB , nocturnal hypoglycaemia rates were lower with insulin degludec vs. insulin glargine across all definitions, timescales and trial periods, with one exception. Insulin Glargine 99-107 insulin Homo sapiens 91-98 26740633-4 2016 We included cohort and case-control studies published in English on insulin glargine and detemir and any cancer incidence among patients with type 1 or 2 diabetes. Insulin Glargine 76-84 insulin Homo sapiens 68-75 26740633-10 2016 Four of 13 studies reported an increased risk of breast cancer with insulin glargine. Insulin Glargine 76-84 insulin Homo sapiens 68-75 26614892-3 2016 Insulin glargine amide was found to show a time/effect profile which is distinctly more flat and thus more advantageous than insulin glargine itself. Insulin Glargine 8-16 insulin Homo sapiens 0-7 26929655-9 2016 After a treatment duration >=2 years, insulin glargine showed a lower odds of having >=1 fracture compared to NPH users (OR: 0.78; 0.65-0.95) (detemir vs NPH insulin: OR: 1.03; 0.79-1.36). Insulin Glargine 49-57 insulin Homo sapiens 41-48 26929655-10 2016 CONCLUSION: Long-standing therapy with insulin glargine was associated with a lower odds of having any fractures compared to NPH insulin. Insulin Glargine 47-55 insulin Homo sapiens 39-46 26880669-0 2016 Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. Insulin Glargine 31-39 insulin Homo sapiens 23-30 26880669-1 2016 OBJECTIVE: To compare the efficacy and safety of a concentrated formulation of insulin glargine (Gla-300) with other basal insulin therapies in patients with type 2 diabetes mellitus (T2DM). Insulin Glargine 87-95 insulin Homo sapiens 79-86 26809253-0 2016 Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial. Insulin Glargine 69-77 insulin Homo sapiens 61-68 26809253-14 2016 However, in the second period, when insulin glargine was switched to insulin detemir, two, three and, one patients had hypoglycemia events on day 1, day 2 and day 3 of the second period, respectively. Insulin Glargine 44-52 insulin Homo sapiens 36-43 26725077-9 2016 CONCLUSIONS: Insulin-resistant patients with type 2 diabetes undergoing hemodialysis for end-stage renal disease on insulin detemir exhibit lower glycemic variability and pro-inflammatory profile than with insulin glargine. Insulin Glargine 214-222 insulin Homo sapiens 206-213 27141654-0 2016 [INSULIN GLARGINE 300 U/mL (TOUJEO )]. Insulin Glargine 9-17 insulin Homo sapiens 1-8 27141654-1 2016 This article presents a new formulation of insulin glargine concentrated at 300 U/mL (Gla-300). Insulin Glargine 51-59 insulin Homo sapiens 43-50 30603277-9 2016 Insulin glargine added to DPP-4i is a potential therapeutic approach. Insulin Glargine 8-16 insulin Homo sapiens 0-7 26324105-10 2016 In particular, patients with baseline depression and frequent or severe hypoglycemia have a higher likelihood for early discontinuation of basal insulin, whereas use of insulin glargine and diabetologist care are related to an increased chance of continuous insulin treatment. Insulin Glargine 177-185 insulin Homo sapiens 169-176 29159123-1 2016 Aims: To evaluate the pharmacokinetics and pharmacodynamics of basal insulin glargine with mealtime insulin glulisine or twice daily 75/25 premixed neutral protamine insulin lispro and insulin lispro in individuals with type 1 diabetes during three standardized meals over a 24 hour duration and compare to physiologic insulin and glucose responses in healthy non-diabetic individuals. Insulin Glargine 77-85 insulin Homo sapiens 69-76 28035286-6 2016 They were initially treated with a basal-bolus regimen of insulin (glargine and lispro/glulisine). Insulin Glargine 67-75 insulin Homo sapiens 58-65 27861474-0 2016 [Systematic review with meta-analysis: Subcutaneous insulin glargine coadministration for diabetic ketoacidosis]. Insulin Glargine 60-68 insulin Homo sapiens 52-59 27861474-2 2016 Coadministration of insulin glargine from the onset of management may prove beneficial, potentially avoiding rebound hyperglycemia, and hopefully improving the time to resolution of the disease. Insulin Glargine 28-36 insulin Homo sapiens 20-27 27861474-3 2016 METHODS: We searched MEDLINE, EMBASE, and CENTRAL for randomized controlled trials comparing coadministration of insulin glargine versus standard treatment in patients with diabetic ketoacidosis. Insulin Glargine 121-129 insulin Homo sapiens 113-120 27861474-4 2016 To be eligible, studies must assess the efficacy of insulin glargine and report clinically important outcomes. Insulin Glargine 60-68 insulin Homo sapiens 52-59 27861474-7 2016 Low-quality evidence from three trials suggested that subcutaneously administered insulin glargine, in addition to the standard treatment, significantly reduces the time to resolution of diabetic ketoacidosis (MD -4.19 hours; 95% CI: -7.81 to 0.57; p = 0.02). Insulin Glargine 90-98 insulin Homo sapiens 82-89 27861474-9 2016 CONCLUSIONS: subcutaneously administered insulin glargine, in addition to standard treatment, significantly reduces the time to resolution of diabetic ketoacidosis, with neutral effects on hypoglycemic episodes. Insulin Glargine 49-57 insulin Homo sapiens 41-48 26340704-0 2016 Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation. Insulin Glargine 105-113 insulin Homo sapiens 97-104 27462470-11 2016 Total utilization of insulin increased even more, mostly for aspart (600%) and newly introduced glargine and detemir, while human insulin usage sharply decreased. Insulin Glargine 96-104 insulin Homo sapiens 21-28 26566714-1 2016 Outcomes in patients using high-dose insulin glargine. Insulin Glargine 45-53 insulin Homo sapiens 37-44 26566714-3 2016 This analysis investigated characteristics, clinical outcomes and impact of concomitant oral antidiabetes drugs (OADs) in patients with T2DM treated with high-dose insulin glargine. Insulin Glargine 172-180 insulin Homo sapiens 164-171 26566714-4 2016 METHODS: Patient-level data were pooled from 15 randomised, treat-to-target trials in patients with T2DM treated with insulin glargine +- OADs for >= 24 weeks. Insulin Glargine 126-134 insulin Homo sapiens 118-125 26997933-0 2016 Hypersensitivity Reaction to Insulin Glargine and Insulin Detemir in a Pediatric Patient: A Case Report. Insulin Glargine 37-45 insulin Homo sapiens 29-36 29159123-1 2016 Aims: To evaluate the pharmacokinetics and pharmacodynamics of basal insulin glargine with mealtime insulin glulisine or twice daily 75/25 premixed neutral protamine insulin lispro and insulin lispro in individuals with type 1 diabetes during three standardized meals over a 24 hour duration and compare to physiologic insulin and glucose responses in healthy non-diabetic individuals. Insulin Glargine 77-85 insulin Homo sapiens 100-107 29159123-1 2016 Aims: To evaluate the pharmacokinetics and pharmacodynamics of basal insulin glargine with mealtime insulin glulisine or twice daily 75/25 premixed neutral protamine insulin lispro and insulin lispro in individuals with type 1 diabetes during three standardized meals over a 24 hour duration and compare to physiologic insulin and glucose responses in healthy non-diabetic individuals. Insulin Glargine 77-85 insulin Homo sapiens 100-107 29159123-1 2016 Aims: To evaluate the pharmacokinetics and pharmacodynamics of basal insulin glargine with mealtime insulin glulisine or twice daily 75/25 premixed neutral protamine insulin lispro and insulin lispro in individuals with type 1 diabetes during three standardized meals over a 24 hour duration and compare to physiologic insulin and glucose responses in healthy non-diabetic individuals. Insulin Glargine 77-85 insulin Homo sapiens 100-107 29159123-1 2016 Aims: To evaluate the pharmacokinetics and pharmacodynamics of basal insulin glargine with mealtime insulin glulisine or twice daily 75/25 premixed neutral protamine insulin lispro and insulin lispro in individuals with type 1 diabetes during three standardized meals over a 24 hour duration and compare to physiologic insulin and glucose responses in healthy non-diabetic individuals. Insulin Glargine 77-85 insulin Homo sapiens 100-107 29159123-8 2016 Conclusions: Glargine/glulisine pharmacokinetics in type 1 diabetes can closely approximate physiologic insulin responses in healthy individuals during a day in which three standardized meals are consumed. Insulin Glargine 13-21 insulin Homo sapiens 104-111 26139151-0 2015 A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Insulin Glargine 53-61 insulin Homo sapiens 45-52 26139151-0 2015 A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Insulin Glargine 53-61 insulin Homo sapiens 97-104 26085028-2 2015 METHODS: This open-label trial enrolled adults to an 8- or 12-week run-in period, during which oral therapies except metformin were stopped and insulin glargine dose was titrated. Insulin Glargine 152-160 insulin Homo sapiens 144-151 26139151-0 2015 A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Insulin Glargine 105-113 insulin Homo sapiens 97-104 26139151-1 2015 Insulin glargine 100 units/ml (Gla-100) has become a standard of care in diabetes treatment over the past decade, providing 24-h basal insulin coverage after once-daily subcutaneous injection for many people with diabetes, with a well-established efficacy and safety profile. Insulin Glargine 8-16 insulin Homo sapiens 0-7 26307603-0 2015 Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. Insulin Glargine 59-68 insulin Homo sapiens 69-76 26139151-1 2015 Insulin glargine 100 units/ml (Gla-100) has become a standard of care in diabetes treatment over the past decade, providing 24-h basal insulin coverage after once-daily subcutaneous injection for many people with diabetes, with a well-established efficacy and safety profile. Insulin Glargine 8-16 insulin Homo sapiens 135-142 26307603-1 2015 OBJECTIVE: LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products manufactured by distinct processes but with identical amino acid sequences. Insulin Glargine 11-20 insulin Homo sapiens 55-62 26307603-1 2015 OBJECTIVE: LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products manufactured by distinct processes but with identical amino acid sequences. Insulin Glargine 63-71 insulin Homo sapiens 55-62 26139151-2 2015 New insulin glargine 300 units/ml (Gla-300) is a basal insulin that provides the same number of units as Gla-100 in a third of the volume. Insulin Glargine 12-20 insulin Homo sapiens 4-11 26139151-2 2015 New insulin glargine 300 units/ml (Gla-300) is a basal insulin that provides the same number of units as Gla-100 in a third of the volume. Insulin Glargine 12-20 insulin Homo sapiens 55-62 26350101-5 2015 The use of basal insulin analogues (e.g. detemir and glargine) with relatively little peaking effects has made insulin therapy in elderly subjects a relatively straightforward process. Insulin Glargine 53-61 insulin Homo sapiens 17-24 26494149-6 2015 Following initiation of basal insulin (neutral protamine Hagedorn insulin, glargine, or detemir), there was a significant (P < 0.001) difference in HbA1c reduction and proportions of patients meeting HbA1c and FBG targets (<7% and <110 mg/dL, respectively) across all country cohorts by month 6. Insulin Glargine 75-83 insulin Homo sapiens 30-37 26307902-6 2015 RESULTS: After 24 weeks of insulin glargine titration, A1c change from baseline was greater in patients with FPG <130 mg/dL versus >=130 mg/dL (-1.35% versus -1.11%, respectively; P = .0275), but with increased confirmed hypoglycemia rates (blood glucose <70 mg/dL; 4.06 events/patient-year versus 3.31 events/patient-year; P = .0170). Insulin Glargine 35-43 insulin Homo sapiens 27-34 26350101-5 2015 The use of basal insulin analogues (e.g. detemir and glargine) with relatively little peaking effects has made insulin therapy in elderly subjects a relatively straightforward process. Insulin Glargine 53-61 insulin Homo sapiens 111-118 26474657-8 2015 CONCLUSIONS: The results of this study showed that insulin glargine and NPH insulin are equally effective in a basal-bolus insulin protocol to treat glucocorticoid-induced hyperglycemia in people with T2DM on a pneumology ward. Insulin Glargine 59-67 insulin Homo sapiens 51-58 26356031-9 2015 FPG and haemoglobin A1c at basal-supported oral therapy initiation were 11.2 mmol/L and 9.4%, respectively, with insulin glargine started at 0.190 IU/kg/day. Insulin Glargine 121-129 insulin Homo sapiens 113-120 26652788-0 2015 [Clinical importance of basal insulin analogues and insulin Toujeo 300 units/ml]. Insulin Glargine 60-66 insulin Homo sapiens 52-59 26652788-4 2015 Toujeo 300 units/ml is a new long-acting basal insulin glargine concentration of 300 units/ ml with a low glycemic variability, which in studies has demonstrated consistent control of diabetes in a significant reduction in the risk of hypoglycemia especially at night compared with insulin glargin of concentration 100 units/ml. Insulin Glargine 0-6 insulin Homo sapiens 48-55 26652788-4 2015 Toujeo 300 units/ml is a new long-acting basal insulin glargine concentration of 300 units/ ml with a low glycemic variability, which in studies has demonstrated consistent control of diabetes in a significant reduction in the risk of hypoglycemia especially at night compared with insulin glargin of concentration 100 units/ml. Insulin Glargine 0-6 insulin Homo sapiens 283-290 26652788-4 2015 Toujeo 300 units/ml is a new long-acting basal insulin glargine concentration of 300 units/ ml with a low glycemic variability, which in studies has demonstrated consistent control of diabetes in a significant reduction in the risk of hypoglycemia especially at night compared with insulin glargin of concentration 100 units/ml. Insulin Glargine 56-64 insulin Homo sapiens 48-55 26652788-4 2015 Toujeo 300 units/ml is a new long-acting basal insulin glargine concentration of 300 units/ ml with a low glycemic variability, which in studies has demonstrated consistent control of diabetes in a significant reduction in the risk of hypoglycemia especially at night compared with insulin glargin of concentration 100 units/ml. Insulin Glargine 56-63 insulin Homo sapiens 48-55 26819737-10 2015 CONCLUSIONS: Switching of the basal insulin regimen from glargine or detemir to degludec significantly improved the QOL of patients with type 2 diabetes mellitus who were receiving BOT, by reducing mental stress or anxiety about their treatment. Insulin Glargine 57-65 insulin Homo sapiens 36-43 26568812-5 2015 However, there are important differences in the pharmacokinetic and pharmacodynamic profiles of basal insulins (insulin glargine, insulin detemir and insulin degludec). Insulin Glargine 120-128 insulin Homo sapiens 102-109 26232910-0 2015 Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Insulin Glargine 106-114 insulin Homo sapiens 0-7 26232910-0 2015 Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Insulin Glargine 106-114 insulin Homo sapiens 98-105 26142890-11 2015 These data support the current guideline recommendations that clinicians evaluate therapeutic responses to pharmacologic interventions with metformin, sulfonylureas, or insulin glargine as early as week 12. Insulin Glargine 177-185 insulin Homo sapiens 169-176 26311720-1 2015 BACKGROUND: To deliver insulin glargine 300 U/mL (Gla-300), the widely used SoloSTAR( ) pen has been modified to allow for accurate and precise delivery of required insulin units in one-third of the volume compared with insulin glargine 100 U/mL, while improving usability. Insulin Glargine 31-39 insulin Homo sapiens 23-30 26638442-3 2015 The initiation of insulin therapy (glargine in > 50%) was justified by insufficient glycaemic control (96%) and its intensification (replacement of insulin NPH or premixed insulins by insulin glargine, eventually with the addition of a short-acting insulin analogue) aimed at improving glucose control (58%), avoiding hypoglycaemia (17%) or both (17%). Insulin Glargine 35-43 insulin Homo sapiens 18-25 26638442-3 2015 The initiation of insulin therapy (glargine in > 50%) was justified by insufficient glycaemic control (96%) and its intensification (replacement of insulin NPH or premixed insulins by insulin glargine, eventually with the addition of a short-acting insulin analogue) aimed at improving glucose control (58%), avoiding hypoglycaemia (17%) or both (17%). Insulin Glargine 195-203 insulin Homo sapiens 18-25 26309403-6 2015 Exenatide QW was better at improving average postprandial glucose than sitagliptin or titrated insulin glargine, but was inferior to exenatide twice daily. Insulin Glargine 103-111 insulin Homo sapiens 95-102 25563477-0 2015 Bilateral lower limbs edema with "wooden" character induced by insulin glargine treatment. Insulin Glargine 71-79 insulin Homo sapiens 63-70 26242987-9 2015 Glargine was the only clinically available insulin analogue for which an increased proliferative potential was found in breast cancer cell lines. Insulin Glargine 0-8 insulin Homo sapiens 43-50 25585592-0 2015 Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Insulin Glargine 116-124 insulin Homo sapiens 108-115 25585592-2 2015 We aimed to summarize scientific evidence on relative efficacy and safety of insulin glargine (IGlar) and other insulins in T2DM. Insulin Glargine 85-93 insulin Homo sapiens 77-84 26187303-5 2015 METHODS: This was a pilot study evaluating an intervention for patients requiring insulin glargine titration in the outpatient medical clinic of Bellevue Hospital Center in New York City. Insulin Glargine 90-98 insulin Homo sapiens 82-89 25974640-1 2015 AIMS: To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus ) insulin glargine (IGlar) in patients with type 1 diabetes (T1D). Insulin Glargine 44-53 insulin Homo sapiens 54-61 25981123-0 2015 Insulin glargine compared with premixed insulin for management of insulin-naive type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study. Insulin Glargine 8-16 insulin Homo sapiens 0-7 25981123-1 2015 AIMS: Demonstrate superiority of insulin glargine (+-glulisine) strategy versus premixed insulin strategy for percentage of patients reaching HbA1c <7% (<53 mmol/mol) at study end without any documented symptomatic hypoglycemia (bloof glucose [BG] <=3.1 mmol/L) in type 2 diabetes (T2DM) patients failing oral agents. Insulin Glargine 41-49 insulin Homo sapiens 33-40 26187303-4 2015 OBJECTIVE: The goals of this pilot study were to (1) evaluate if our Mobile Insulin Titration Intervention (MITI) intervention using text messaging and phone calls was effective in helping patients reach their optimal insulin glargine dose within 12 weeks, (2) assess the feasibility of the intervention within our clinic setting and patient population, (3) collect data on the cost savings associated with the intervention, and (4) measure patient satisfaction with the intervention. Insulin Glargine 226-234 insulin Homo sapiens 76-83 26187303-4 2015 OBJECTIVE: The goals of this pilot study were to (1) evaluate if our Mobile Insulin Titration Intervention (MITI) intervention using text messaging and phone calls was effective in helping patients reach their optimal insulin glargine dose within 12 weeks, (2) assess the feasibility of the intervention within our clinic setting and patient population, (3) collect data on the cost savings associated with the intervention, and (4) measure patient satisfaction with the intervention. Insulin Glargine 226-234 insulin Homo sapiens 218-225 26187303-10 2015 The primary outcome was whether a patient reached his/her optimal insulin glargine dose within 12 weeks. Insulin Glargine 74-82 insulin Homo sapiens 66-73 26187303-12 2015 A significantly greater proportion of patients in the intervention arm reached their optimal insulin glargine dose than patients in the usual care arm (88%, 29/33 vs 37%, 10/27; P<.001). Insulin Glargine 101-109 insulin Homo sapiens 93-100 26187303-18 2015 CONCLUSIONS: MITI is an effective way to help low-SES patients reach their optimal insulin glargine dose using basic SMS text messaging and phone calls. Insulin Glargine 91-99 insulin Homo sapiens 83-90 26187749-10 2015 The predictive power of the classifier genes was evaluated by testing all commercial insulin analogues in the in vitro model and defined X10 and glargine as the most potent mitogenic insulin analogues. Insulin Glargine 145-153 insulin Homo sapiens 183-190 25887358-12 2015 CONCLUSIONS: Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles. Insulin Glargine 89-97 insulin Homo sapiens 81-88 26120575-1 2015 BACKGROUND: Although glargine and detemir are both FDA-approved in the U.S. as long-acting insulin analogues, inherent differences in the insulins may lead to varying outcomes. Insulin Glargine 21-29 insulin Homo sapiens 91-98 26106233-0 2015 Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin. Insulin Glargine 33-41 insulin Homo sapiens 25-32 26106233-0 2015 Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin. Insulin Glargine 33-41 insulin Homo sapiens 113-120 26121460-6 2015 The mean insulin dose in the glargine/glulisine group was 0.76 +- 0.3 units/kg/day (glargine, 22 +- 9 units/day; glulisine, 31 +- 12 units/day) and was not different compared with NPH/regular group (0.75 +- 0.3 units/kg/day [NPH, 28 +- 12 units/day; regular, 23 +- 9 units/day]). Insulin Glargine 29-37 insulin Homo sapiens 9-16 25820927-0 2015 A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Insulin Glargine 134-142 insulin Homo sapiens 126-133 26013711-1 2015 OBJECTIVES: The objective was to determine the efficacy of coadministration of subcutaneous (SQ) insulin glargine in combination with intravenous (IV) insulin for treating diabetic ketoacidosis (DKA). Insulin Glargine 105-113 insulin Homo sapiens 97-104 26013711-6 2015 Additionally, the experimental group was given SQ insulin glargine within 2 hours of diagnosis. Insulin Glargine 58-66 insulin Homo sapiens 50-57 25694300-0 2015 Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes. Insulin Glargine 61-69 insulin Homo sapiens 53-60 26055391-1 2015 BACKGROUND: Pharmacological and clinical differences between insulin glargine and NPH insulin may translate into differences in patient reported outcomes, but existing data are equivocal. Insulin Glargine 69-77 insulin Homo sapiens 61-68 25820927-8 2015 CONCLUSION: Administration of sitagliptin prior to intensive titration of basal insulin glargine reduces the insulin dose requirement while providing superior glycemic control and less hypoglycemia, compared to an insulin-only regimen. Insulin Glargine 88-96 insulin Homo sapiens 80-87 25941955-0 2015 Concentrated insulin glargine (Toujeo) for diabetes. Insulin Glargine 21-29 insulin Homo sapiens 13-20 25041275-0 2015 Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Insulin Glargine 8-16 insulin Homo sapiens 0-7 25041275-0 2015 Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Insulin Glargine 8-16 insulin Homo sapiens 45-52 25041275-1 2015 BACKGROUND AND AIMS: Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in plasma of adults with type 1 diabetes. Insulin Glargine 29-37 insulin Homo sapiens 21-28 25041275-1 2015 BACKGROUND AND AIMS: Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in plasma of adults with type 1 diabetes. Insulin Glargine 29-37 insulin Homo sapiens 66-73 25041275-10 2015 CONCLUSION: In young children with type 1 diabetes, the principal component circulating in plasma after subcutaneous injection of insulin glargine is M1, the pharmacologically active component. Insulin Glargine 138-146 insulin Homo sapiens 130-137 25041275-12 2015 These data provide additional evidence on the safety profile of insulin glargine in young children (Clinical trial identifier: NCT00993473). Insulin Glargine 72-80 insulin Homo sapiens 64-71 25941955-0 2015 Concentrated insulin glargine (Toujeo) for diabetes. Insulin Glargine 31-37 insulin Homo sapiens 13-20 25941955-1 2015 Toujeo, the new 300 IU/mL formulation of insulin glargine, is as effective as insulin glargine 100 IU/mL (Lantus) in lowering HbA1c, and might cause less hypoglycemia. Insulin Glargine 0-6 insulin Homo sapiens 41-48 25941955-1 2015 Toujeo, the new 300 IU/mL formulation of insulin glargine, is as effective as insulin glargine 100 IU/mL (Lantus) in lowering HbA1c, and might cause less hypoglycemia. Insulin Glargine 49-57 insulin Homo sapiens 41-48 25955144-5 2015 The application of nonsurgical drainage and the administration of glargine insulin and antibiotics resolved the clinical signs. Insulin Glargine 66-74 insulin Homo sapiens 75-82 25172526-11 2015 CONCLUSIONS: In the Elecsys( ) E170 assay, relevant cross-reactivity was only detected with insulin glargine, whereas in the other analysers all analogues except glulisine showed significant interference. Insulin Glargine 100-108 insulin Homo sapiens 92-99 26548031-3 2015 Further, insulin initiation with IDegAsp once daily provides superior long-term glycaemic control compared to insulin glargine with similar FPG and insulin doses, and numerically lower rates of overall and nocturnal hypoglycaemia. Insulin Glargine 118-126 insulin Homo sapiens 110-117 25526758-0 2015 Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. Insulin Glargine 70-78 insulin Homo sapiens 62-69 26155506-0 2015 Effectiveness of Insulin Glargine on Recovery of Patients with Diabetic Ketoacidosis: A Randomized Controlled Trial. Insulin Glargine 25-33 insulin Homo sapiens 17-24 26155506-3 2015 This study was aimed to investigate the effects of insulin Glargine (GI) on recovery of patients with DKA. Insulin Glargine 59-67 insulin Homo sapiens 51-58 25526758-0 2015 Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. Insulin Glargine 70-78 insulin Homo sapiens 62-69 25573957-1 2015 AIMS: The aim was to compare early discontinuation and related treatment costs in type 2 diabetes in primary care after initiation of insulin glargine or human basal insulin (NPH). Insulin Glargine 142-150 insulin Homo sapiens 134-141 25526758-8 2015 Total daily insulin dose (TDD) and total daily bolus insulin dose (TDBD) were significantly lower with insulin degludec than with insulin glargine (TDD: 0.42 +- 0.20 vs 0.46 +- 0.22 U/kg/day, P = .028; TDBD: 0.27 +- 0.13 vs 0.30 +- 0.14 U/kg/day, P = .036). Insulin Glargine 138-146 insulin Homo sapiens 12-19 25573957-6 2015 RESULTS: Within 3 months after ID, 13% of glargine patients switched to other insulin treatment regimens (NPH: 18%; P < .05). Insulin Glargine 42-50 insulin Homo sapiens 78-85 25573957-10 2015 CONCLUSIONS: Treatment persistence within 3 months after basal insulin initiation was significantly higher under insulin glargine compared to NPH. Insulin Glargine 121-129 insulin Homo sapiens 63-70 25526758-8 2015 Total daily insulin dose (TDD) and total daily bolus insulin dose (TDBD) were significantly lower with insulin degludec than with insulin glargine (TDD: 0.42 +- 0.20 vs 0.46 +- 0.22 U/kg/day, P = .028; TDBD: 0.27 +- 0.13 vs 0.30 +- 0.14 U/kg/day, P = .036). Insulin Glargine 138-146 insulin Homo sapiens 53-60 25573957-11 2015 Diabetes-related prescription costs were significantly lower among patients who adhered to insulin glargine compared to persistent NPH patients. Insulin Glargine 99-107 insulin Homo sapiens 91-98 25526758-8 2015 Total daily insulin dose (TDD) and total daily bolus insulin dose (TDBD) were significantly lower with insulin degludec than with insulin glargine (TDD: 0.42 +- 0.20 vs 0.46 +- 0.22 U/kg/day, P = .028; TDBD: 0.27 +- 0.13 vs 0.30 +- 0.14 U/kg/day, P = .036). Insulin Glargine 138-146 insulin Homo sapiens 53-60 25526758-9 2015 CONCLUSIONS: Insulin degludec and insulin glargine provided effective and stable glycemic control. Insulin Glargine 42-50 insulin Homo sapiens 34-41 25359227-2 2015 AIMS: To evaluate real-world clinical outcomes for switching basal insulin analogues [insulin glargine (GLA) and insulin detemir (DET)] among US patients with type 2 diabetes mellitus (T2DM). Insulin Glargine 94-102 insulin Homo sapiens 67-74 25788506-7 2015 When compared with regular sliding-scale insulin (SSI), fixed-dose insulin glargine with or without insulin glulisine was found to reduce the blood glucose concentration in patients with type 2 diabetes and reduce postoperative complications in surgical patients with diabetes. Insulin Glargine 75-83 insulin Homo sapiens 67-74 25788506-7 2015 When compared with regular sliding-scale insulin (SSI), fixed-dose insulin glargine with or without insulin glulisine was found to reduce the blood glucose concentration in patients with type 2 diabetes and reduce postoperative complications in surgical patients with diabetes. Insulin Glargine 75-83 insulin Homo sapiens 67-74 25788506-10 2015 There is also a low quality of evidence to suggest that a fixed-dose analog regimen of insulin glargine with or without insulin glulisine is more effective than regular SSI for reducing blood glucose concentrations and postoperative complications. Insulin Glargine 95-103 insulin Homo sapiens 87-94 25941658-9 2015 In addition, U300 insulin glargine and pegylated lispro represent further developments in basal insulin pharmacotherapeutics. Insulin Glargine 26-34 insulin Homo sapiens 18-25 25255776-3 2015 METHODS: Patient-level self-monitored blood glucose data were pooled from six studies of insulin glargine for patients with HbA1C >= 7.0% after 24 weeks. Insulin Glargine 97-105 insulin Homo sapiens 89-96 25255776-6 2015 On insulin glargine treatment, highest postprandial blood glucose most often occurred post-dinner (44% of participants) and greatest postprandial increments post-breakfast (46% of participants) in all regions. Insulin Glargine 11-19 insulin Homo sapiens 3-10 25255776-7 2015 Participants with greatest postprandial increments post-breakfast were older and experienced less HbA1C improvement with insulin glargine than those with greatest postprandial increments after other meals. Insulin Glargine 129-137 insulin Homo sapiens 121-128 25680537-6 2015 The mean HbA1C at insulin initiation was 89-95 mmol/mol, but had decreased at 12 months by 26.6 mmol/mol with insulin glargine, 23.4 mmol/mol with pre-mixed insulin and 16.6 mmol/mol with insulin isophane (p < 0.05 vs. baseline for all groups). Insulin Glargine 118-126 insulin Homo sapiens 110-117 25680537-6 2015 The mean HbA1C at insulin initiation was 89-95 mmol/mol, but had decreased at 12 months by 26.6 mmol/mol with insulin glargine, 23.4 mmol/mol with pre-mixed insulin and 16.6 mmol/mol with insulin isophane (p < 0.05 vs. baseline for all groups). Insulin Glargine 118-126 insulin Homo sapiens 110-117 25680537-6 2015 The mean HbA1C at insulin initiation was 89-95 mmol/mol, but had decreased at 12 months by 26.6 mmol/mol with insulin glargine, 23.4 mmol/mol with pre-mixed insulin and 16.6 mmol/mol with insulin isophane (p < 0.05 vs. baseline for all groups). Insulin Glargine 118-126 insulin Homo sapiens 110-117 25680537-7 2015 Patients on insulin glargine were more likely to achieve the HbA1C target of <55 mmol/mol compared with patients on insulin isophane (16.7% vs. 4.8%; p = 0.04). Insulin Glargine 20-28 insulin Homo sapiens 12-19 25878390-4 2015 Here, we present a case of Type 2 DM who demonstrated immediate (Type 1) hypersensitivity reaction on the sites of subcutaneous injection of soluble and isophane insulin but insulin glargine was tolerated well and provided good glycemic control. Insulin Glargine 182-190 insulin Homo sapiens 174-181 25297660-0 2015 Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Insulin Glargine 54-62 insulin Homo sapiens 46-53 25297660-11 2015 CONCLUSION: Patient-led insulin glargine titration achieved near-target blood glucose levels in Asian patients with uncontrolled type 2 diabetes who were on 2 oral glucose-lowering drugs, demonstrating that Asian patients can self-uptitrate insulin dose effectively when guided. Insulin Glargine 32-40 insulin Homo sapiens 24-31 25297660-11 2015 CONCLUSION: Patient-led insulin glargine titration achieved near-target blood glucose levels in Asian patients with uncontrolled type 2 diabetes who were on 2 oral glucose-lowering drugs, demonstrating that Asian patients can self-uptitrate insulin dose effectively when guided. Insulin Glargine 32-40 insulin Homo sapiens 241-248 25250724-0 2015 A cross-national comparison of 17 countries" insulin glargine drug labels. Insulin Glargine 53-61 insulin Homo sapiens 45-52 25813258-5 2015 Last year, a biosimilar insulin analogue of glargine was approved for administration at the level of the European Medicines Agency (EMA) in accordance with the aforementioned procedures; its efficacy and safety profile have been found within the registration studies practically identical, or non-inferior, to the original insulin analogue. Insulin Glargine 44-52 insulin Homo sapiens 24-31 25813258-5 2015 Last year, a biosimilar insulin analogue of glargine was approved for administration at the level of the European Medicines Agency (EMA) in accordance with the aforementioned procedures; its efficacy and safety profile have been found within the registration studies practically identical, or non-inferior, to the original insulin analogue. Insulin Glargine 44-52 insulin Homo sapiens 323-330 25430705-2 2015 The aim of this study was to compare the effect of treatment with insulin degludec and long-acting insulin analogues glargine and detemir in type 1 diabetic (T1D) patients by means of a systematic review and meta-analysis. Insulin Glargine 117-125 insulin Homo sapiens 66-73 25150159-0 2015 New insulin glargine 300 Units mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units mL-1. Insulin Glargine 12-20 insulin Homo sapiens 4-11 25150159-1 2015 OBJECTIVE: To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a new insulin glargine comprising 300 units mL(-1) (Gla-300), compared with insulin glargine 100 units mL(-1) (Gla-100) at steady state in people with type 1 diabetes. Insulin Glargine 96-104 insulin Homo sapiens 88-95 25900868-1 2015 This patient with BMI 36 kg/m2 and T2DM on insulin glargine and glyburide as well as atenolol for HTN was able to lose 10% of his initial body weight with a low-carbohydrate diet and exercise and adjustment of medications in approximately a 36-week time frame. Insulin Glargine 51-59 insulin Homo sapiens 43-50 25900868-2 2015 Insulin glargine and glyburide were reduced gradually with blood glucose monitoring and replaced by an increase in metformin, start of liraglutide, and eventually phentermine/topiramate and canagliflozin (Figure). Insulin Glargine 8-16 insulin Homo sapiens 0-7 25828275-10 2015 Insulin glargine is not approved in pregnancy, but the existing studies did not show any contraindications. Insulin Glargine 8-16 insulin Homo sapiens 0-7 25810423-0 2015 Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin. Insulin Glargine 154-162 insulin Homo sapiens 146-153 25810423-10 2015 Hence, we have demonstrated the efficacy and safety of the add-on treatment with mitiglinide in type 2 diabetic patients, receiving the combination therapy of sitagliptin and insulin glargine. Insulin Glargine 183-191 insulin Homo sapiens 175-182 25741640-0 2015 Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain. Insulin Glargine 39-47 insulin Homo sapiens 31-38 25741640-1 2015 PRINCIPLES: We aimed to evaluate the efficacy of, and treatment satisfaction with, insulin glargine administered with SoloSTAR or ClikSTAR pens in patients with type 2 diabetes mellitus managed by primary care physicians in Switzerland. Insulin Glargine 91-99 insulin Homo sapiens 83-90 25741640-2 2015 METHODS: A total of 327 patients with inadequately controlled type 2 diabetes were enrolled by 72 physicians in this prospective observational study, which aimed to evaluate the efficacy of a 6-month course of insulin glargine therapy measured as development of glycaemic control (glycosylated haemoglobin [HbA1c] and fasting plasma glucose [FPG]) and weight change. Insulin Glargine 218-226 insulin Homo sapiens 210-217 25741640-4 2015 RESULTS: After 6 months, the mean daily dose of insulin glargine was 27.7+-14.3 U, and dose titration was completed in 228 (72.4%) patients. Insulin Glargine 56-64 insulin Homo sapiens 48-55 25741640-9 2015 Overall, 92.6% of physicians and 96.3% of patients were satisfied or very satisfied with the insulin glargine therapy. Insulin Glargine 101-109 insulin Homo sapiens 93-100 25425297-4 2015 RESULTS: The serum insulin glargine concentration (INS) and glucose infusion rate (GIR) developed more gradually into more constant and prolonged profiles with Gla-300 than with Gla-100. Insulin Glargine 27-35 insulin Homo sapiens 19-26 25425394-0 2015 Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Insulin Glargine 67-75 insulin Homo sapiens 59-66 25425394-1 2015 AIMS: To characterize the variability in exposure and metabolic effect of insulin glargine 300 U/ml (Gla-300) at steady state in people with type 1 diabetes (T1DM). Insulin Glargine 82-90 insulin Homo sapiens 74-81 25524950-0 2015 Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. Insulin Glargine 49-57 insulin Homo sapiens 41-48 25524950-7 2015 CONCLUSIONS: The PD of insulin glargine differs depending on time of administration. Insulin Glargine 31-39 insulin Homo sapiens 23-30 25350350-0 2015 Hypersensitivity reaction to a biosimilar insulin glargine. Insulin Glargine 50-58 insulin Homo sapiens 42-49 25387855-5 2015 During 18 months of treatment, insulin degludec + mealtime insulin aspart +- oral antidiabetic drugs in patients with T2D improves glycaemic control similarly, but confers lower risks of overall and nocturnal hypoglycaemia than with insulin glargine treatment. Insulin Glargine 241-249 insulin Homo sapiens 31-38 25387855-5 2015 During 18 months of treatment, insulin degludec + mealtime insulin aspart +- oral antidiabetic drugs in patients with T2D improves glycaemic control similarly, but confers lower risks of overall and nocturnal hypoglycaemia than with insulin glargine treatment. Insulin Glargine 241-249 insulin Homo sapiens 59-66 25689245-12 2015 CONCLUSION: These data suggest that, compared with regular insulin added to PN, glargine insulin results in similar glycemic control and rates of hyperglycemia and hypoglycemia in stable critical care patients. Insulin Glargine 80-88 insulin Homo sapiens 89-96 25657589-0 2015 Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. Insulin Glargine 18-26 insulin Homo sapiens 10-17 25657589-6 2015 Glargine insulin is a basal insulin analog widely used to treat patients with type 1 and type 2 diabetes. Insulin Glargine 0-8 insulin Homo sapiens 9-16 25657589-6 2015 Glargine insulin is a basal insulin analog widely used to treat patients with type 1 and type 2 diabetes. Insulin Glargine 0-8 insulin Homo sapiens 28-35 25359227-2 2015 AIMS: To evaluate real-world clinical outcomes for switching basal insulin analogues [insulin glargine (GLA) and insulin detemir (DET)] among US patients with type 2 diabetes mellitus (T2DM). Insulin Glargine 104-107 insulin Homo sapiens 67-74 25425297-0 2015 Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Insulin Glargine 24-32 insulin Homo sapiens 16-23 25425297-1 2015 AIMS: Two single-dose studies were conducted in Japan and Europe to compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of new insulin glargine 300 U/ml (Gla-300) and insulin glargine 100 U/ml (Gla-100) in people with type 1 diabetes mellitus. Insulin Glargine 150-158 insulin Homo sapiens 142-149 25437016-8 2014 The first child was treated with continuous subcutaneous insulin infusion, whereas the second infant was treated with subcutaneous insulin glargine injections. Insulin Glargine 139-147 insulin Homo sapiens 131-138 25449981-1 2015 AIMS: The aim of this study is to evaluate effectiveness and safety of basal supported oral therapy (BOT) using insulin glargine in insulin-naive Japanese patients, with and without microvascular complications. Insulin Glargine 120-128 insulin Homo sapiens 112-119 25449981-1 2015 AIMS: The aim of this study is to evaluate effectiveness and safety of basal supported oral therapy (BOT) using insulin glargine in insulin-naive Japanese patients, with and without microvascular complications. Insulin Glargine 120-128 insulin Homo sapiens 132-139 25449981-11 2015 CONCLUSION: Japanese insulin-naive patients without complications, on BOT with glargine, show higher chances of attaining HbA1c <7.0% than those with complications. Insulin Glargine 79-87 insulin Homo sapiens 21-28 26978173-0 2015 [Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen]. Insulin Glargine 147-155 insulin Homo sapiens 139-146 26978173-0 2015 [Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen]. Insulin Glargine 147-155 insulin Homo sapiens 139-146 26978173-1 2015 AIM: To implement in 2009-2012 the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen in patients with type 1 diabetes mellitus (DM) to evaluate the efficiency and safety of therapy with human insulin analogues. Insulin Glargine 86-94 insulin Homo sapiens 78-85 26978173-1 2015 AIM: To implement in 2009-2012 the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen in patients with type 1 diabetes mellitus (DM) to evaluate the efficiency and safety of therapy with human insulin analogues. Insulin Glargine 96-102 insulin Homo sapiens 78-85 25693613-9 2015 Insulin glargine therapy was associated with the incidence of a significantly lower number of documented symptomatic hypoglycemic events (glargine group: 0.840 events per patient and year of treatment vs. NPH group: 1.053 events per patient and year of treatment; p < 0.05). Insulin Glargine 8-16 insulin Homo sapiens 0-7 25693613-9 2015 Insulin glargine therapy was associated with the incidence of a significantly lower number of documented symptomatic hypoglycemic events (glargine group: 0.840 events per patient and year of treatment vs. NPH group: 1.053 events per patient and year of treatment; p < 0.05). Insulin Glargine 138-146 insulin Homo sapiens 0-7 25693613-13 2015 Overall annual direct medical costs were higher among patients treated with insulin glargine than among patients treated with insulin NPH. Insulin Glargine 84-92 insulin Homo sapiens 76-83 25693613-14 2015 However, costs of medical devices and medical procedures were lower in the insulin glargine group. Insulin Glargine 83-91 insulin Homo sapiens 75-82 25693613-15 2015 In addition, incidence of hypoglycemia was significantly lower among patients treated with insulin glargine. Insulin Glargine 99-107 insulin Homo sapiens 91-98 25193531-0 2014 New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Insulin Glargine 12-20 insulin Homo sapiens 4-11 25458329-8 2014 CONCLUSIONS: Insulin glargine improved endothelial functions, without leading to positive changes in cardiovascular risk markers. Insulin Glargine 21-29 insulin Homo sapiens 13-20 24957785-0 2015 Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Insulin Glargine 88-96 insulin Homo sapiens 80-87 24957785-0 2015 Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Insulin Glargine 88-96 insulin Homo sapiens 80-87 24957785-0 2015 Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Insulin Glargine 88-96 insulin Homo sapiens 80-87 24957785-1 2015 AIMS: To examine whether insulin glargine can lead to better control of glycated haemoglobin (HbA1c) than that achieved by neutral protamine Hagedorn (NPH) insulin, using a protocol designed to limit nocturnal hypoglycaemia. Insulin Glargine 33-41 insulin Homo sapiens 25-32 24957785-11 2015 This study confirms, in a globally heterogeneous population, the reduction achieved in nocturnal hypoglycaemia while attaining good glycaemic control with insulin glargine compared with NPH, even when titrating basal insulin to prevent nocturnal hypoglycaemia rather than treating according to normal fasting glucose levels. Insulin Glargine 163-171 insulin Homo sapiens 155-162 26176017-0 2015 Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine. Insulin Glargine 87-95 insulin Homo sapiens 79-86 26176017-10 2015 Both cumulative dose and time exposure to insulin glargine were associated with lower cardiovascular mortality. Insulin Glargine 50-58 insulin Homo sapiens 42-49 25208756-9 2014 A similar reduction occurred in the insulin glargine group (8.36 +- 0.95% to 7.55 +- 1.04% [67.9 +- 10.4 to 59.0 +- 11.4 mmol/mol]). Insulin Glargine 44-52 insulin Homo sapiens 36-43 25208756-12 2014 Documented symptomatic hypoglycaemia occurred in a higher proportion of patients in the insulin glargine group than in the albiglutide group (27.4% vs 17.5%, p = 0.0377). Insulin Glargine 96-104 insulin Homo sapiens 88-95 25515096-6 2014 RESULTS: Studies have shown that treatment with insulin glargine is associated with marked improvement in the lipid profile of people with T2DM. Insulin Glargine 56-64 insulin Homo sapiens 48-55 25515096-9 2014 The prospective ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial found that treatment with insulin glargine had a neutral effect with regard to CV outcomes in people with prediabetes or early diabetes, compared with standard care. Insulin Glargine 55-63 insulin Homo sapiens 110-117 25515096-9 2014 The prospective ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial found that treatment with insulin glargine had a neutral effect with regard to CV outcomes in people with prediabetes or early diabetes, compared with standard care. Insulin Glargine 118-126 insulin Homo sapiens 110-117 25451189-3 2014 The ORIGIN study investigated the impact of basal insulin glargine therapy targeting <= 5.3 mmol/L for fasting plasma glucose compared with standard care on CV outcomes in people with pre- or early diabetes, and demonstrated a neutral effect on CV outcomes with long-term use of insulin glargine early in the course of diabetes, with a low rate of severe hypoglycaemia and modest weight gain. Insulin Glargine 58-66 insulin Homo sapiens 50-57 25451189-3 2014 The ORIGIN study investigated the impact of basal insulin glargine therapy targeting <= 5.3 mmol/L for fasting plasma glucose compared with standard care on CV outcomes in people with pre- or early diabetes, and demonstrated a neutral effect on CV outcomes with long-term use of insulin glargine early in the course of diabetes, with a low rate of severe hypoglycaemia and modest weight gain. Insulin Glargine 58-66 insulin Homo sapiens 282-289 25151573-1 2014 PURPOSE: In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. Insulin Glargine 45-53 insulin Homo sapiens 37-44 25311556-1 2014 INTRODUCTION: Insulin glargine (100 U/ml; U100) was the first long-acting basal insulin analog to be introduced into clinical practice and it remains the most widely used. Insulin Glargine 22-30 insulin Homo sapiens 14-21 25311556-1 2014 INTRODUCTION: Insulin glargine (100 U/ml; U100) was the first long-acting basal insulin analog to be introduced into clinical practice and it remains the most widely used. Insulin Glargine 22-30 insulin Homo sapiens 80-87 25311556-3 2014 The focus of this review is insulin glargine [rDNA origin] injection 300 U/ml (U300), a novel formulation that contains a higher concentration of insulin than U100. Insulin Glargine 36-44 insulin Homo sapiens 28-35 24840321-0 2014 Insulin glargine in pediatric patients with type 1 diabetes in Japan. Insulin Glargine 8-16 insulin Homo sapiens 0-7 24840321-1 2014 BACKGROUND: We evaluated the safety and effectiveness of insulin glargine in Japanese pediatric patients with type 1 diabetes in clinical settings based on post-marketing surveillance data. Insulin Glargine 65-73 insulin Homo sapiens 57-64 24919603-8 2014 CONCLUSION: Insulin glargine-based regimens showed advantages over premixed insulin in a number of patient-reported outcome measures. Insulin Glargine 20-28 insulin Homo sapiens 12-19 25271117-3 2014 METHODS: Insulin-naive T2DM patients (HbA1c >7.5% [>58 mmol/mol] despite maximal oral therapy) from 22 general practices in Victoria, Australia commenced insulin glargine, with glulisine added as required. Insulin Glargine 168-176 insulin Homo sapiens 9-16 25119849-0 2014 Comment on: "Insulin glargine in a Brazilian state: should the government disinvest? Insulin Glargine 21-29 insulin Homo sapiens 13-20 25119850-0 2014 Authors" reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest? Insulin Glargine 40-48 insulin Homo sapiens 32-39 25078900-0 2014 New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Insulin Glargine 12-20 insulin Homo sapiens 4-11 25311556-3 2014 The focus of this review is insulin glargine [rDNA origin] injection 300 U/ml (U300), a novel formulation that contains a higher concentration of insulin than U100. Insulin Glargine 36-44 insulin Homo sapiens 146-153 29702781-0 2014 A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina. Insulin Glargine 104-112 insulin Homo sapiens 96-103 25151573-2 2014 The objective of this study was to assess the cost-effectiveness of insulin glargine compared with sitagliptin in type 2 diabetes patients, from the perspective of the publicly funded Canadian health care system. Insulin Glargine 76-84 insulin Homo sapiens 68-75 25151573-8 2014 FINDINGS: In the lifetime base-case analysis, treatment with insulin glargine resulted in cost savings of $1434 CAD in 2012 and a gain of 0.08 quality-adjusted life years per patient. Insulin Glargine 69-77 insulin Homo sapiens 61-68 25151573-9 2014 A probabilistic sensitivity analysis found the robustness of the base-case analysis, with 88% probability of insulin glargine being dominant (ie, cost savings and more quality-adjusted life years). Insulin Glargine 117-125 insulin Homo sapiens 109-116 25151573-10 2014 IMPLICATIONS: Insulin glargine is a clinically superior and cost-effective alternative to sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. Insulin Glargine 22-30 insulin Homo sapiens 14-21 25195151-0 2014 Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials. Insulin Glargine 37-45 insulin Homo sapiens 29-36 24683100-8 2014 Insulin analogs including M1 and M2 Glargine metabolites stimulate cancer cells similar to insulin. Insulin Glargine 36-44 insulin Homo sapiens 0-7 27200594-0 2014 New Meta-Analysis of Patient-Level Data on Efficacy And Hypoglycaemia with Insulin Glargine or Nph Insulin in Type 2 Diabetes Mellitus (T2DM) According to Concomitant Oral Therapy. Insulin Glargine 83-91 insulin Homo sapiens 75-82 27200645-0 2014 The Cost-Effectiveness of Exenatide Bid Versus Insulin Lispro Tid As Add-On Therapy to Titrated Insulin Glargine in Patients With Type 2 Diabetes - An Analysis From The Swedish Health Care Perspective. Insulin Glargine 104-112 insulin Homo sapiens 96-103 25329887-1 2014 BACKGROUND: Recent studies suggested that insulin glargine use could be associated with increased risk of cancer. Insulin Glargine 50-58 insulin Homo sapiens 42-49 25144413-0 2014 Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue. Insulin Glargine 80-88 insulin Homo sapiens 72-79 25144413-1 2014 CONTEXT: Insulin glargine (GLA) is rapidly metabolized in vivo to metabolite M1, which has in vitro metabolic and mitogenic profiles comparable with human insulin (HI). Insulin Glargine 17-25 insulin Homo sapiens 9-16 25144413-1 2014 CONTEXT: Insulin glargine (GLA) is rapidly metabolized in vivo to metabolite M1, which has in vitro metabolic and mitogenic profiles comparable with human insulin (HI). Insulin Glargine 17-25 insulin Homo sapiens 155-162 25144413-1 2014 CONTEXT: Insulin glargine (GLA) is rapidly metabolized in vivo to metabolite M1, which has in vitro metabolic and mitogenic profiles comparable with human insulin (HI). Insulin Glargine 27-30 insulin Homo sapiens 9-16 25144413-1 2014 CONTEXT: Insulin glargine (GLA) is rapidly metabolized in vivo to metabolite M1, which has in vitro metabolic and mitogenic profiles comparable with human insulin (HI). Insulin Glargine 27-30 insulin Homo sapiens 155-162 25144413-5 2014 D-GLA comprised >=98% of insulin after D-GLA injection; M1 comprised 76-92% after GLA injection. Insulin Glargine 2-5 insulin Homo sapiens 28-35 24725616-1 2014 AIMS: To compare the efficacy and safety of two insulin intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin glargine with metformin and/or pioglitazone. Insulin Glargine 157-165 insulin Homo sapiens 48-55 24949654-9 2014 CONCLUSIONS: Adding once-daily insulin glulisine was more effective in controlling the glycemic fluctuation in Japanese type 2 diabetes patients treated with insulin glargine together with sitagliptin. Insulin Glargine 166-174 insulin Homo sapiens 31-38 24949654-9 2014 CONCLUSIONS: Adding once-daily insulin glulisine was more effective in controlling the glycemic fluctuation in Japanese type 2 diabetes patients treated with insulin glargine together with sitagliptin. Insulin Glargine 166-174 insulin Homo sapiens 158-165 25187822-0 2014 Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes. Insulin Glargine 67-75 insulin Homo sapiens 59-66 25187822-0 2014 Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes. Insulin Glargine 67-75 insulin Homo sapiens 59-66 25269951-4 2014 Study patients (n = 134) received a basal-bolus regimen with insulin glargine during hospitalisation and treatment at discharge was adjusted according to a simple algorithm. Insulin Glargine 69-77 insulin Homo sapiens 61-68 25414938-2 2014 OBJECTIVE: To investigate the baseline clinical and demographic factors associated with weight gain during insulin glargine therapy, and the implications of weight change on clinical outcomes. Insulin Glargine 115-123 insulin Homo sapiens 107-114 25414938-6 2014 Patients starting insulin glargine treatment gained a mean +- standard deviation 1.8 +- 3.7 kg (4.0 +- 8.2 lb). Insulin Glargine 26-34 insulin Homo sapiens 18-25 25414938-13 2014 Therefore, insulin glargine can be used in these patient groups with type 2 diabetes without expectation of significant weight gain. Insulin Glargine 19-27 insulin Homo sapiens 11-18 25151573-1 2014 PURPOSE: In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. Insulin Glargine 45-53 insulin Homo sapiens 107-114 25151573-1 2014 PURPOSE: In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. Insulin Glargine 115-123 insulin Homo sapiens 37-44 25151573-1 2014 PURPOSE: In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. Insulin Glargine 115-123 insulin Homo sapiens 76-83 25151573-1 2014 PURPOSE: In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. Insulin Glargine 115-123 insulin Homo sapiens 107-114 25062651-0 2014 Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study. Insulin Glargine 44-52 insulin Homo sapiens 36-43 25062651-1 2014 PURPOSE: Insulin glargine is widely used as basal insulin. Insulin Glargine 17-25 insulin Homo sapiens 9-16 24571126-0 2014 Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Insulin Glargine 28-36 insulin Homo sapiens 20-27 25062651-2 2014 However, published dose titration regimens for insulin glargine are complex. Insulin Glargine 55-63 insulin Homo sapiens 47-54 25062651-3 2014 This study aimed to compare the efficacy and safety profile of a user-friendly, weight-based insulin glargine dose titration regimen with 2 published regimens. Insulin Glargine 101-109 insulin Homo sapiens 93-100 25062651-8 2014 The initial dose of insulin glargine was 0.2 U/kg. Insulin Glargine 28-36 insulin Homo sapiens 20-27 25062651-18 2014 The daily doses of insulin glargine at the study end point were 0.43 (0.13) U/kg with the weight-based regimen, 0.50 (0.20) U/kg with the glucose level-based regimen, and 0.47 (0.23) U/kg with the current dose-based regimen (P = 0.184). Insulin Glargine 27-35 insulin Homo sapiens 19-26 25062651-20 2014 IMPLICATIONS: The currently proposed weight-based insulin glargine dose titration regimen is effective, tolerable, and user-friendly at achieving FBG target levels in hospitalized patients with hyperglycemia. Insulin Glargine 58-66 insulin Homo sapiens 50-57 25082730-4 2014 METHODS: A retrospective cohort consisting of patients with T2DM aged 20 years of age and older with newly initiated treatment with long-acting insulin analogues (glargine and detemir) and intermediate-acting human insulin was identified from the National Health Insurance database between January 2004 and December 2006 and was subdivided into different cohorts. Insulin Glargine 163-171 insulin Homo sapiens 144-151 24571126-1 2014 Insulin glargine is processed in vivo into soluble 21(A) -Gly-human insulin (M1), the principal moiety responsible for metabolic effects, and subsequently into M2. Insulin Glargine 8-16 insulin Homo sapiens 68-75 24571126-2 2014 This sub-study compared metabolism and metabolite pharmacokinetic (PK) profiles of investigational new insulin glargine U300 (Gla-300) with insulin glargine 100 U/ml (Gla-100, Lantus , Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany) in people with type 1 diabetes. Insulin Glargine 111-119 insulin Homo sapiens 103-110 24571126-0 2014 Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Insulin Glargine 81-89 insulin Homo sapiens 73-80 24571126-1 2014 Insulin glargine is processed in vivo into soluble 21(A) -Gly-human insulin (M1), the principal moiety responsible for metabolic effects, and subsequently into M2. Insulin Glargine 8-16 insulin Homo sapiens 0-7 24947791-7 2014 At insulin concentrations where EGP was significantly suppressed, insulin glargine resulted in increased GDR. Insulin Glargine 74-82 insulin Homo sapiens 66-73 25285276-6 2014 Insulin could be utilized at any place when required and in this regard outcomes reduction with an initial glargine intervention (ORIGIN) study also suggested that basal insulin glargine could be safely used even in early stage. Insulin Glargine 107-115 insulin Homo sapiens 0-7 25285276-6 2014 Insulin could be utilized at any place when required and in this regard outcomes reduction with an initial glargine intervention (ORIGIN) study also suggested that basal insulin glargine could be safely used even in early stage. Insulin Glargine 178-186 insulin Homo sapiens 0-7 24856612-10 2014 CONCLUSIONS: This analysis of long-term insulin treatment confirms findings from short-term studies and demonstrates that glargine provides sustained, clinically meaningful reductions in risk of hypoglycemia compared with NPH in patients with T2DM. Insulin Glargine 122-130 insulin Homo sapiens 40-47 24898300-3 2014 RESEARCH DESIGN AND METHODS: Patients taking basal insulin (with or without oral agents) with HbA1c 7-10.5% (53-91 mmol/mol) entered a glargine standardization period, followed by randomization to albiglutide, 30 mg weekly (n = 282), subsequently uptitrated to 50 mg, if necessary, or thrice-daily prandial lispro (n = 281) while continuing metformin and/or pioglitazone. Insulin Glargine 135-143 insulin Homo sapiens 51-58 25294758-0 2014 [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)]. Insulin Glargine 15-23 insulin Homo sapiens 7-14 25294758-7 2014 RESULTS: Severe hypoglycaemia were observed during treatment with insulin glargine at 0.8 % patients. Insulin Glargine 74-82 insulin Homo sapiens 66-73 25294758-12 2014 A statistically significant improvement in the metabolic control was demonstrated when using insulin glargine. Insulin Glargine 101-109 insulin Homo sapiens 93-100 25294758-16 2014 Changes in therapy and subsequent treatment with insulin glargine were perceived positively by both physicians and patients. Insulin Glargine 57-65 insulin Homo sapiens 49-56 25294758-17 2014 CONCLUSION: In the common clinical practice setting, the initiation of treatment with insulin glargine using the basal-bolus regime in patients with previous insulin therapy resulted in a reduction in the incidence of hypoglycemic events, including severe hypoglycemia and severe nocturnal hypoglycemia, and improved metabolic control in patients with diabetes (reduced glycated hemoglobin, fasting glucose values and 6-point blood glucose profile). Insulin Glargine 94-102 insulin Homo sapiens 86-93 25294758-17 2014 CONCLUSION: In the common clinical practice setting, the initiation of treatment with insulin glargine using the basal-bolus regime in patients with previous insulin therapy resulted in a reduction in the incidence of hypoglycemic events, including severe hypoglycemia and severe nocturnal hypoglycemia, and improved metabolic control in patients with diabetes (reduced glycated hemoglobin, fasting glucose values and 6-point blood glucose profile). Insulin Glargine 94-102 insulin Homo sapiens 158-165 24949654-0 2014 Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin. Insulin Glargine 106-114 insulin Homo sapiens 30-37 24302583-5 2014 The adjusted mean daily basal insulin doses were 0.36, 0.39 and 0.31 IU/kg, mean daily total insulin dose was lowest for Gla (0.74 IU/kg), followed by NPH (0.76 IU/kg) and Det (0.81 IU/kg). Insulin Glargine 121-124 insulin Homo sapiens 93-100 24621255-4 2014 Insulin glargine was titrated in both arms per the Treat-to-Target algorithm. Insulin Glargine 8-16 insulin Homo sapiens 0-7 24931333-5 2014 Insulin glargine was not marketed until after the entry date. Insulin Glargine 8-16 insulin Homo sapiens 0-7 25040042-0 2014 The outcome of care in people with type 1 diabetes after switching to insulin glargine-based regimens in a real-life setting: a long-term observational study. Insulin Glargine 78-86 insulin Homo sapiens 70-77 25040042-2 2014 The aim of this study was to assess long-term efficacy and safety of insulin glargine after switching from other basal insulins in type 1 diabetes in a real-life setting. Insulin Glargine 77-85 insulin Homo sapiens 69-76 25040042-15 2014 In summary, insulin glargine can be recommended as an effective and safe basal insulin in type 1 diabetes in a real-life setting. Insulin Glargine 20-28 insulin Homo sapiens 12-19 24621255-14 2014 CONCLUSIONS: Addition of fixed-dose exenatide BID to optimized insulin glargine, regardless of the extent of insulin titration, significantly improved glycemia without increasing hypoglycemia risk, while mitigating insulin-induced weight gain in this post-hoc analysis. Insulin Glargine 71-79 insulin Homo sapiens 63-70 24302583-8 2014 CONCLUSIONS: In a "real-world" setting, the injection frequencies and doses of basal and total insulin per day are lowest with the use of insulin glargine compared with NPH-insulin or insulin detemir at similar glycaemic control and rates of severe hypoglycaemia. Insulin Glargine 146-154 insulin Homo sapiens 95-102 24302583-8 2014 CONCLUSIONS: In a "real-world" setting, the injection frequencies and doses of basal and total insulin per day are lowest with the use of insulin glargine compared with NPH-insulin or insulin detemir at similar glycaemic control and rates of severe hypoglycaemia. Insulin Glargine 146-154 insulin Homo sapiens 138-145 24771090-4 2014 RESULTS: Allocation to the insulin glargine group reduced the incidence of the primary microvascular composite outcome of kidney and eye disease in participants whose baseline HbA1c level was >=6.4% (46.4 mmol/mol; HR 0.90 [95% CI 0.81, 0.99]) but not in participants with a lower baseline HbA1c (HR 1.07 [95% CI 0.95, 1.20]; p value for interaction 0.031). Insulin Glargine 35-43 insulin Homo sapiens 27-34 25083136-0 2014 Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Insulin Glargine 88-96 insulin Homo sapiens 3-10 24684774-0 2014 Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. Insulin Glargine 46-54 insulin Homo sapiens 38-45 24684774-4 2014 RESULTS: The total undiscounted cost per participant in the insulin glargine arm was $13,491 ($13,080 to $14,254) versus $11,189 ($10,568 to $12,147) for standard care, an increase of $2303 ($1370 to $3235; p < 0.0001); the discounted increase was $2099 ($1276 to $2923; P < 0.0001). Insulin Glargine 68-76 insulin Homo sapiens 60-67 24684774-5 2014 The greater number of mainly generic oral anti-diabetic agents in the standard group partially offset the higher cost of basal insulin glargine. Insulin Glargine 135-143 insulin Homo sapiens 127-134 24684774-8 2014 CONCLUSIONS: From a global perspective basal insulin glargine use in ORIGIN incurred greater costs than standard care using older generic drugs. Insulin Glargine 53-61 insulin Homo sapiens 45-52 24944613-0 2014 Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease. Insulin Glargine 8-16 insulin Homo sapiens 0-7 24944613-0 2014 Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease. Insulin Glargine 8-16 insulin Homo sapiens 68-75 24944613-1 2014 In the present study, the clinical efficacy and safety of administering insulin glargine to early type 2 diabetes (T2D) mellitus patients with a high risk for cardiovascular disease were assessed. Insulin Glargine 80-88 insulin Homo sapiens 72-79 24944613-2 2014 A total of 42 early T2D patients at a high risk for cardiovascular disease were randomly divided into an insulin-glargine group and a standard-care group. Insulin Glargine 113-121 insulin Homo sapiens 105-112 24944613-3 2014 The patients in the insulin-glargine group received oral antidiabetic agents plus glargine once a day via a subcutaneous injection. Insulin Glargine 28-36 insulin Homo sapiens 20-27 24944613-7 2014 The fasting plasma glucose level in the insulin-glargine group was significantly lower than that observed in the standard-care group. Insulin Glargine 48-56 insulin Homo sapiens 40-47 24944613-9 2014 Although the level of the HOMA-beta did not differ between the two groups, the level of HOMA-IR in the insulin-glargine group was significantly lower than that observed in the standard-care group. Insulin Glargine 111-119 insulin Homo sapiens 103-110 24944613-10 2014 During the follow-up period, the incidence of hypoglycemia in the insulin-glargine group was significantly higher when compared with the standard-care group, however, no significant difference in the incidence of adverse cardiovascular events was observed. Insulin Glargine 74-82 insulin Homo sapiens 66-73 24944613-11 2014 Therefore, the results of the present study indicated that insulin glargine may effectively achieve glycemic control and improve insulin resistance without increasing the risk for cardiovascular events in early T2D patients that were considered to be at a high risk for cardiovascular disease. Insulin Glargine 67-75 insulin Homo sapiens 59-66 24944613-11 2014 Therefore, the results of the present study indicated that insulin glargine may effectively achieve glycemic control and improve insulin resistance without increasing the risk for cardiovascular events in early T2D patients that were considered to be at a high risk for cardiovascular disease. Insulin Glargine 67-75 insulin Homo sapiens 129-136 24898834-2 2014 In this planned substudy of the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, we assessed whether normalising glucose with insulin glargine or administering omega-3 fatty acids in this population may slow this process or affect the development of cognitive impairment. Insulin Glargine 154-162 insulin Homo sapiens 146-153 24898834-15 2014 In a subgroup analysis, allocation to insulin glargine versus standard care seemed to reduce the decline in the MMSE (but not the DSS) in participants with dysglycaemia but without evidence of diabetes (pinteraction=0.024). Insulin Glargine 46-54 insulin Homo sapiens 38-45 24702815-1 2014 BACKGROUND AND AIMS: After subcutaneous injection insulin glargine is rapidly metabolized to M1 and M2. Insulin Glargine 58-66 insulin Homo sapiens 50-57 24702815-10 2014 CONCLUSION: In T2DM people on long-term use of insulin glargine, even with higher doses (0.8 U/kg), glargine is nearly totally metabolized to the active metabolite M1. Insulin Glargine 55-63 insulin Homo sapiens 47-54 24702815-10 2014 CONCLUSION: In T2DM people on long-term use of insulin glargine, even with higher doses (0.8 U/kg), glargine is nearly totally metabolized to the active metabolite M1. Insulin Glargine 100-108 insulin Homo sapiens 47-54 25083136-0 2014 Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Insulin Glargine 88-96 insulin Homo sapiens 80-87 24642342-9 2014 CONCLUSIONS: Insulin glargine and aspart induced insulin antibodies more frequently, and insulin antibodies remained in patients for a long time. Insulin Glargine 21-29 insulin Homo sapiens 49-56 24642342-9 2014 CONCLUSIONS: Insulin glargine and aspart induced insulin antibodies more frequently, and insulin antibodies remained in patients for a long time. Insulin Glargine 21-29 insulin Homo sapiens 89-96 24866023-0 2014 The evolution of insulin glargine and its continuing contribution to diabetes care. Insulin Glargine 25-33 insulin Homo sapiens 17-24 24866023-5 2014 Insulin glargine was the first once-daily, long-acting insulin analog to be introduced into clinical practice more than 10 years ago and is specifically designed to provide basal insulin requirements. Insulin Glargine 8-16 insulin Homo sapiens 0-7 24866023-5 2014 Insulin glargine was the first once-daily, long-acting insulin analog to be introduced into clinical practice more than 10 years ago and is specifically designed to provide basal insulin requirements. Insulin Glargine 8-16 insulin Homo sapiens 55-62 24866023-5 2014 Insulin glargine was the first once-daily, long-acting insulin analog to be introduced into clinical practice more than 10 years ago and is specifically designed to provide basal insulin requirements. Insulin Glargine 8-16 insulin Homo sapiens 179-186 24866023-7 2014 Insulin glargine can be used in combination with prandial insulin preparations and non-insulin anti-diabetic agents according to individual requirements. Insulin Glargine 8-16 insulin Homo sapiens 0-7 25121146-22 2014 Insulin isophane remains the first-choice long-acting insulin, while insulin glargine is most appropriate for some patients with type 1 diabetes. Insulin Glargine 77-85 insulin Homo sapiens 69-76 24642342-4 2014 RESULTS: Insulin antibodies were detected in 48 of 118 patients (40.7%) who used insulin, and insulin glargine and aspart were more antigenic. Insulin Glargine 102-110 insulin Homo sapiens 94-101 24642342-9 2014 CONCLUSIONS: Insulin glargine and aspart induced insulin antibodies more frequently, and insulin antibodies remained in patients for a long time. Insulin Glargine 21-29 insulin Homo sapiens 13-20 24298995-10 2014 Endpoint total insulin doses were lower in patients treated with ILPS versus glargine (0.30 +- 0.17 vs. 0.37 +- 0.17 IU/kg/day, p < 0.001). Insulin Glargine 77-85 insulin Homo sapiens 15-22 24855159-4 2014 In addition, basal insulin analogs (glargine, detemir) have been reported to offer longer duration of action, less variability, more predictability, less hypoglycemia (especially nocturnal), and a favorable effect on weight. Insulin Glargine 36-44 insulin Homo sapiens 19-26 24855160-4 2014 In addition, basal insulin analogs (glargine, detemir) have been reported to offer longer duration of action, less variability, more predictability, less hypoglycemia (especially nocturnal), and a favorable effect on weight. Insulin Glargine 36-44 insulin Homo sapiens 19-26 25083136-5 2014 Here we report on three cases seen in our own clinical practice where insulin degludec was used in patients experiencing inadequacies with their current basal insulin therapy (insulin glargine). Insulin Glargine 184-192 insulin Homo sapiens 70-77 24497624-3 2014 OBJECTIVE: To assess the changes in kidney function and incidence of albuminuria in patients with T2DM treated for 1 year with exenatide twice daily (BID) or insulin glargine. Insulin Glargine 166-174 insulin Homo sapiens 158-165 24497624-11 2014 At follow-up, exenatide BID patients had a mean increase in UACR of 104 mg/g, insulin glargine patients had a decrease of 47 mg/g, but the difference was not significant (P = .19). Insulin Glargine 86-94 insulin Homo sapiens 78-85 24918797-0 2014 Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents. Insulin Glargine 56-64 insulin Homo sapiens 48-55 24918797-3 2014 Our study aim was to provide comparative data on efficacy and hypoglycemia when initiating insulin glargine (glargine) versus alternative treatment options (not including the newest antidiabetes agents, glucagon-like peptide [GLP]-1 receptor agonists, dipeptidyl peptidase [DPP]-4 inhibitors or sodium-glucose linked transporter [SGLT]-2 inhibitors) in insulin-naive patients with T2DM who remained uncontrolled with OADs. Insulin Glargine 99-107 insulin Homo sapiens 91-98 24918797-6 2014 RESULTS: A greater proportion of patients achieved a target HbA1c level <= 7.0% with glargine treatment than with pooled comparators, intensification of OADs, or lifestyle interventions; there was no difference when compared with NPH, premixed, or insulin lispro use. Insulin Glargine 88-96 insulin Homo sapiens 251-258 24719911-0 2014 Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Insulin Glargine 84-92 insulin Homo sapiens 76-83 24918797-8 2014 When stratified by baseline HbA1c level, efficacy/target attainment with glargine use was better than for pooled comparators across all HbA1c strata; OAD intensification, when baseline HbA1c level was >= 8.0%; and premixed insulin if baseline HbA1c level was < 8.0%; but similar to other insulins for all other categories. Insulin Glargine 73-81 insulin Homo sapiens 226-233 24918797-10 2014 CONCLUSION: When adequate glycemic control is not achieved using OADs in patients with T2DM, initiating insulin glargine is generally less likely to elicit hypoglycemia than initiating NPH, premixed, or prandial insulins, and the benefit-risk balance supports initiating insulin rather than intensification of OAD therapy when baseline HbA1c level is >= 8.0%. Insulin Glargine 112-120 insulin Homo sapiens 104-111 24918797-10 2014 CONCLUSION: When adequate glycemic control is not achieved using OADs in patients with T2DM, initiating insulin glargine is generally less likely to elicit hypoglycemia than initiating NPH, premixed, or prandial insulins, and the benefit-risk balance supports initiating insulin rather than intensification of OAD therapy when baseline HbA1c level is >= 8.0%. Insulin Glargine 112-120 insulin Homo sapiens 212-219 24918802-2 2014 We assessed the influence of patient baseline CVRFs on efficacy and rate of hypoglycemia with use of insulin glargine (glargine) added to ongoing OAD treatment compared with alternative therapeutic options; namely, intensification of lifestyle interventions or adding OADs, neutral protamine Hagedorn (NPH), lispro, or premixed insulin in patients failing OADs. Insulin Glargine 109-117 insulin Homo sapiens 101-108 24445656-1 2014 The aim of present study is to assess whether if basal insulin, glargine, could improve insulin secretory function of beta-cells compared with glimepiride when metformin alone was failed. Insulin Glargine 64-72 insulin Homo sapiens 55-62 24445656-1 2014 The aim of present study is to assess whether if basal insulin, glargine, could improve insulin secretory function of beta-cells compared with glimepiride when metformin alone was failed. Insulin Glargine 64-72 insulin Homo sapiens 88-95 24445656-11 2014 Insulin glargine was as effective as glimepiride in controlling hyperglycemia and maintaining beta-cell function in Korean patients with type 2 diabetes during 48 weeks study period, after failure of metformin monotherapy. Insulin Glargine 8-16 insulin Homo sapiens 0-7 24445656-12 2014 Hypoglycemic profile was favorable in the insulin glargine group and less weight gain was observed in the glimepiride group. Insulin Glargine 50-58 insulin Homo sapiens 42-49 24198301-11 2014 Between 2008 and 2012, drug expenditures increased 61%, driven primarily by use of insulin glargine and DPP-4 inhibitors. Insulin Glargine 91-99 insulin Homo sapiens 83-90 24229089-1 2014 BACKGROUND: It was the aim of this study to assess baseline predictors for glycosylated hemoglobin (HbA1c) reduction, treatment-to-target, and insulin glargine dose in patients with an HbA1c level of >= 7.5% (58 mmol/mol) at baseline despite 3 months of maximum tolerated dose of metformin under daily conditions. Insulin Glargine 151-159 insulin Homo sapiens 143-150 24229089-3 2014 Baseline variables independently associated with HbA1c (overall reduction and achievement of target values) and insulin glargine dose used were determined using a stepwise multivariate linear regression analysis. Insulin Glargine 120-128 insulin Homo sapiens 112-119 24229089-7 2014 CONCLUSIONS: Identified predictors of greater HbA1c reduction, target goal achievement, and insulin dose needed may help to optimize the balance of benefits and risks with the use of insulin glargine. Insulin Glargine 191-199 insulin Homo sapiens 92-99 24229089-7 2014 CONCLUSIONS: Identified predictors of greater HbA1c reduction, target goal achievement, and insulin dose needed may help to optimize the balance of benefits and risks with the use of insulin glargine. Insulin Glargine 191-199 insulin Homo sapiens 183-190 24719911-1 2014 AIMS: The basal insulin analogue LY2605541, a PEGylated insulin lispro with prolonged duration of action, was previously shown to be associated with modest weight loss in Phase 2, randomized, open-label trials in type 2 (N=288) and type 1 (N=137) diabetes mellitus (T2DM and T1DM), compared with modest weight gain with insulin glargine. Insulin Glargine 328-336 insulin Homo sapiens 16-23 24719911-6 2014 RESULTS: Weight loss was more common in LY2605541-treated patients than in patients treated with insulin glargine (T2DM: 56.9 vs. 40.2%, p=0.011; T1DM: 66.1 vs. 40.3%, p<0.001). Insulin Glargine 105-113 insulin Homo sapiens 97-104 24667573-12 2014 CONCLUSIONS: The cumulative dose exposure to insulin glargine was associated with a lower risk of cancer mortality in general, and of breast and pancreatic cancer in particular. Insulin Glargine 53-61 insulin Homo sapiens 45-52 24684803-6 2014 Insulin glargine was titrated to achieve a target fasting glucose level of 70-130 mg/dL as a first step (STEP0). Insulin Glargine 8-16 insulin Homo sapiens 0-7 25535536-0 2014 A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus. Insulin Glargine 39-47 insulin Homo sapiens 31-38 24170757-9 2014 CONCLUSIONS In stable patients with type 2 diabetes who are receiving doses of basal insulin glargine who require bolus insulin, a simple bolus insulin patient-managed titration algorithm is as effective as a physician-managed algorithm. Insulin Glargine 93-101 insulin Homo sapiens 85-92 24028669-2 2014 AIM: To assess patient-reported outcomes associated with initiating insulin glargine among insulin-naive patients with type 2 diabetes mellitus (T2DM). Insulin Glargine 76-84 insulin Homo sapiens 68-75 24028669-6 2014 RESULTS: A total of 1577 patients from four studies were included; 830 patients treated with insulin glargine and 747 with comparators. Insulin Glargine 101-109 insulin Homo sapiens 93-100 24028669-7 2014 At week 24, DTSQc scores improved in both groups with a significantly higher increase in treatment satisfaction for insulin glargine vs. comparators (13.5 vs. 12.1; p < 0.0001). Insulin Glargine 124-132 insulin Homo sapiens 116-123 24028669-8 2014 Multivariate regression analysis revealed that significant predictors of DTSQc improvement at week 24 were insulin glargine treatment (p < 0.0001), higher baseline DTSQs (p < 0.0001), and lower baseline body weight (p = 0.0103). Insulin Glargine 115-123 insulin Homo sapiens 107-114 24528773-0 2014 Incidence and predictors of hypoglycemia in Japanese patients with type 2 diabetes treated by insulin glargine and oral antidiabetic drugs in real-life: ALOHA post-marketing surveillance study sub-analysis. Insulin Glargine 102-110 insulin Homo sapiens 94-101 24528773-10 2014 CONCLUSION: Our results suggest that BOT using insulin glargine is an option of insulin therapy with 1% risk of hypoglycemia in patients with T2DM with inadequate glycemic control. Insulin Glargine 55-63 insulin Homo sapiens 47-54 24385261-0 2014 Insulin glargine in a Brazilian state: should the government disinvest? Insulin Glargine 8-16 insulin Homo sapiens 0-7 24385261-3 2014 This growth has been driven by an increasing number of successful law suits and a 536% price difference between insulin glargine and neutral protamine Hagedorn (NPH) insulin. Insulin Glargine 120-128 insulin Homo sapiens 112-119 24385261-6 2014 Alternatively, the review could provide potential arguments to defend against future law suits should the authorities decide to delist insulin glargine. Insulin Glargine 143-151 insulin Homo sapiens 135-142 24385261-14 2014 No study could be classified as double-blind, and only one study documented the increased efficacy of insulin glargine in relation to both glycaemic control and hypoglycaemic episodes. Insulin Glargine 110-118 insulin Homo sapiens 102-109 24385261-17 2014 We therefore recommend to the State Authority to delist insulin glargine or renegotiate a price reduction with the manufacturer. Insulin Glargine 64-72 insulin Homo sapiens 56-63 24026961-4 2014 In the 1980s, recombinant DNA technology enabled modifications to the insulin molecule resulting in the soluble long-acting insulin analogues, glargine and detemir. Insulin Glargine 143-151 insulin Homo sapiens 70-77 29872460-0 2014 A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. Insulin Glargine 107-115 insulin Homo sapiens 99-106 29872460-2 2014 The objective of this study was to analyse efficacy and hypoglycaemia outcomes in people with type 2 diabetes receiving insulin glargine (IG) with metformin (MET), sulphonylurea (SU) or MET+SU. Insulin Glargine 128-136 insulin Homo sapiens 120-127 24614911-7 2014 CONCLUSION: The combination therapy of metformin and glimepiride plus glargine insulin resulted in a significant improvement in overall glycemic control as compared with the other combinations. Insulin Glargine 70-78 insulin Homo sapiens 79-86 24013981-0 2014 Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus. Insulin Glargine 57-65 insulin Homo sapiens 49-56 24013981-1 2014 OBJECTIVE: To evaluate the effect of diabetes duration on efficacy and safety in patients with type 2 diabetes mellitus (T2DM) using insulin glargine versus comparator (oral antidiabetic drugs [OADs], dietary changes, or other insulins). Insulin Glargine 141-149 insulin Homo sapiens 133-140 24013981-2 2014 METHODS: Data were pooled from randomized controlled clinical trials conducted in adults with T2DM with at least 24-week treatment with insulin glargine or a comparator, where predefined insulin titration algorithms were utilized to achieve fasting plasma glucose (FPG) concentrations of <=100 mg/dL. Insulin Glargine 144-152 insulin Homo sapiens 136-143 24013981-9 2014 However, treatment with insulin glargine lowered A1C values more effectively than comparator treatments with fewer hypoglycemic episodes. Insulin Glargine 32-40 insulin Homo sapiens 24-31 24013981-11 2014 Insulin glargine was associated with reduced A1C and fewer hypoglycemic events than comparators, regardless of disease duration. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23841569-0 2014 Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Insulin Glargine 66-74 insulin Homo sapiens 36-43 23949559-1 2014 OBJECTIVE Several studies have been published in 2009 suggesting a possible association between insulin glargine and increased risk of malignancies, including breast cancer. Insulin Glargine 104-112 insulin Homo sapiens 96-103 23949559-2 2014 The objective of this study was to assess the relation between the individual insulins (glargine, aspart, lispro, and human insulin) and development of breast cancer. Insulin Glargine 88-96 insulin Homo sapiens 78-85 23949559-6 2014 RESULTS Adjusted odds ratios of breast cancer for each type of insulin versus no use of that insulin were 1.04 (95% CI 0.76-1.44) for glargine, 1.23 (0.79-1.92) for lispro, 0.95 (0.64-1.40) for aspart, and 0.81 (0.55-1.20) for human insulin. Insulin Glargine 134-142 insulin Homo sapiens 63-70 23949559-6 2014 RESULTS Adjusted odds ratios of breast cancer for each type of insulin versus no use of that insulin were 1.04 (95% CI 0.76-1.44) for glargine, 1.23 (0.79-1.92) for lispro, 0.95 (0.64-1.40) for aspart, and 0.81 (0.55-1.20) for human insulin. Insulin Glargine 134-142 insulin Homo sapiens 93-100 23949559-6 2014 RESULTS Adjusted odds ratios of breast cancer for each type of insulin versus no use of that insulin were 1.04 (95% CI 0.76-1.44) for glargine, 1.23 (0.79-1.92) for lispro, 0.95 (0.64-1.40) for aspart, and 0.81 (0.55-1.20) for human insulin. Insulin Glargine 134-142 insulin Homo sapiens 93-100 24574355-0 2014 The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Insulin Glargine 33-41 insulin Homo sapiens 25-32 24574355-1 2014 OBJECTIVE Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. Insulin Glargine 48-56 insulin Homo sapiens 40-47 24574355-11 2014 CONCLUSIONS Insulin glargine and n-3 fatty acids have a neutral association with overall and cancer-specific outcomes, including cancer-specific mortality. Insulin Glargine 20-28 insulin Homo sapiens 12-19 24170757-9 2014 CONCLUSIONS In stable patients with type 2 diabetes who are receiving doses of basal insulin glargine who require bolus insulin, a simple bolus insulin patient-managed titration algorithm is as effective as a physician-managed algorithm. Insulin Glargine 93-101 insulin Homo sapiens 120-127 24170757-9 2014 CONCLUSIONS In stable patients with type 2 diabetes who are receiving doses of basal insulin glargine who require bolus insulin, a simple bolus insulin patient-managed titration algorithm is as effective as a physician-managed algorithm. Insulin Glargine 93-101 insulin Homo sapiens 120-127 24314537-9 2013 In two cases, the method revealed the long-acting insulin glargine (Lantus) metabolite M2 (DesB31-32 Lantus), and human insulin was detected in one case. Insulin Glargine 58-66 insulin Homo sapiens 50-57 25330627-3 2014 In patients with type 1 diabetes or with type 2 diabetes, at steady-state, the mean terminal half-life of insulin degludec was 25 hours, i.e., approximately twice as long as for insulin glargine (half-life of 12.1 hours). Insulin Glargine 186-194 insulin Homo sapiens 178-185 24876551-3 2014 Using a large database of US retirees, this retrospective longitudinal study examined 1-year follow-up outcomes in patients with T2DM aged 65 years or older who were either insulin naive and initiated insulin glargine via disposable pen (pen initiators [PI]) or vial (vial initiators [VI]) or were already insulin glargine users but either continued with a vial (vial continuers [VC]) or switched to a disposable pen (pen switchers [PS]). Insulin Glargine 209-217 insulin Homo sapiens 201-208 24876551-3 2014 Using a large database of US retirees, this retrospective longitudinal study examined 1-year follow-up outcomes in patients with T2DM aged 65 years or older who were either insulin naive and initiated insulin glargine via disposable pen (pen initiators [PI]) or vial (vial initiators [VI]) or were already insulin glargine users but either continued with a vial (vial continuers [VC]) or switched to a disposable pen (pen switchers [PS]). Insulin Glargine 209-217 insulin Homo sapiens 201-208 24876551-8 2014 In elderly patients with T2DM receiving insulin glargine therapy, initiating or switching to a disposable pen was associated with better treatment persistence and adherence than initiating or continuing with vial-and-syringe, without increased total health care costs. Insulin Glargine 48-56 insulin Homo sapiens 40-47 24876551-9 2014 Among insulin-naive patients, initiating insulin glargine by disposable pen was also associated with significantly reduced risk of hypoglycemia compared with vial-and-syringe patients. Insulin Glargine 49-57 insulin Homo sapiens 6-13 23806740-0 2014 Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy. Insulin Glargine 70-78 insulin Homo sapiens 62-69 23806740-1 2014 BACKGROUND AND AIM: The aim of this study was to compare the use of insulin glargine and intermediate/long-acting human insulin (HI) in relation to the incidence of complications in diabetic patients. Insulin Glargine 76-84 insulin Homo sapiens 68-75 24314537-9 2013 In two cases, the method revealed the long-acting insulin glargine (Lantus) metabolite M2 (DesB31-32 Lantus), and human insulin was detected in one case. Insulin Glargine 68-74 insulin Homo sapiens 50-57 23952326-1 2013 AIMS: The aim of this study was to compare long-term safety and efficacy of the basal insulin analogue degludec with glargine in insulin-naive subjects with Type 2 diabetes. Insulin Glargine 117-125 insulin Homo sapiens 86-93 23998560-0 2013 Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naive subjects with type 2 diabetes. Insulin Glargine 85-93 insulin Homo sapiens 77-84 23683002-8 2013 Despite improvements in HbA1c, rates of symptomatic nocturnal hypoglycaemia were significantly lower with insulin glargine than with NPH insulin in patients with longer T2DM duration. Insulin Glargine 114-122 insulin Homo sapiens 106-113 23683002-9 2013 CONCLUSION: There is a lower risk for nocturnal hypoglycaemia with insulin glargine than with NPH insulin. Insulin Glargine 75-83 insulin Homo sapiens 67-74 23683002-10 2013 When considering diabetes duration, insulin glargine (compared to NPH insulin) may be particularly beneficial in patients with a longer duration of T2DM. Insulin Glargine 44-52 insulin Homo sapiens 36-43 24127136-4 2013 Sitagliptin was initiated and maintained at a dose of 50 mg/day, and insulin glargine was started at a dose of 4 U at bedtime and adjusted if needed. Insulin Glargine 77-85 insulin Homo sapiens 69-76 24139704-7 2013 Plasma glucose remained constant during the clamp (CV: insulin detemir 3.7%; insulin glargine 3.8%). Insulin Glargine 85-93 insulin Homo sapiens 77-84 24139704-8 2013 Following injection of insulin detemir, GIR increased, reaching a mean peak of 2.29 mg/kg/min (95% CI 1.64, 2.94) at 11.6h (range 8.9 to 14.3) compared to 1.71 mg/kg/min (95% CI 1.4, 2.0) at 10.2 h (8.1 to 12.3) for insulin glargine (P=0.025 for GIR(max)). Insulin Glargine 224-232 insulin Homo sapiens 23-30 24139704-9 2013 Plasma C-peptide decreased during the study period, remaining significantly lower than the fasting level at the study end after both analogues, insulin detemir (P=0.01) and insulin glargine (P=0.02). Insulin Glargine 181-189 insulin Homo sapiens 173-180 24139704-11 2013 Insulin detemir showed greater between subject variability and achieved a significantly higher maximum GIR than insulin glargine. Insulin Glargine 120-128 insulin Homo sapiens 0-7 24139704-11 2013 Insulin detemir showed greater between subject variability and achieved a significantly higher maximum GIR than insulin glargine. Insulin Glargine 120-128 insulin Homo sapiens 112-119 24344941-9 2013 While the addition of stagliptin resulted in a small weight loss (0.4 kg), the addition of insulin glargine resulted in a weight gain (0.8 kg). Insulin Glargine 99-107 insulin Homo sapiens 91-98 23730996-2 2013 KEY OBJECTIVE: To evaluate hypoglycemia with insulin glargine vs. neutral protamine Hagedorn (NPH) insulin in young children, using continuous glucose monitoring (CGM). Insulin Glargine 53-61 insulin Homo sapiens 45-52 24170756-0 2013 Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Insulin Glargine 24-32 insulin Homo sapiens 16-23 24170756-1 2013 OBJECTIVE: To examine whether use of insulin glargine, compared with another long-acting insulin, is associated with risk of breast, prostate, colorectal cancer, or all cancers combined. Insulin Glargine 45-53 insulin Homo sapiens 37-44 24170756-6 2013 Among those initiating insulin, ever use or >=2 years of glargine was not associated with increased risk of prostate or colorectal cancer or all cancers combined. Insulin Glargine 60-68 insulin Homo sapiens 23-30 24183259-2 2013 METHODS: This is a pooled analysis from nine similarly designed phase 3 and 4 randomized, controlled studies evaluating insulin glargine and an active comparator (NPH insulin, insulin lispro, premixed insulin, oral antidiabetes drugs, dietary intervention) in adults with T2DM. Insulin Glargine 128-136 insulin Homo sapiens 120-127 24183259-5 2013 Females receiving insulin glargine were less likely than males to achieve a glycemic target of HbA1c<=7.0% (53mmol/mol) (54.3% vs 60.8%, respectively, p=0.0162); there was no difference between females and males receiving comparators (52.7% vs 51.3%, respectively, p=0.4625). Insulin Glargine 26-34 insulin Homo sapiens 18-25 24260289-2 2013 The publication of highly controversial epidemiological studies in 2009 raised the possibility that use of the insulin analog glargine increases this risk further. Insulin Glargine 126-134 insulin Homo sapiens 111-118 24475676-0 2013 [Insulin glargine. Insulin Glargine 9-17 insulin Homo sapiens 1-8 23710902-4 2013 RESULTS: The rate of nocturnal confirmed hypoglycaemia was 25% lower with insulin degludec than with insulin glargine (P = 0.02). Insulin Glargine 109-117 insulin Homo sapiens 101-108 23952326-1 2013 AIMS: The aim of this study was to compare long-term safety and efficacy of the basal insulin analogue degludec with glargine in insulin-naive subjects with Type 2 diabetes. Insulin Glargine 117-125 insulin Homo sapiens 129-136 24124963-0 2013 Dose accuracy and injection force of different insulin glargine pens. Insulin Glargine 55-63 insulin Homo sapiens 47-54 24131755-0 2013 Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma. Insulin Glargine 8-16 insulin Homo sapiens 0-7 24131755-2 2013 The aim of this retrospective study was to examine whether patients with diabetes mellitus (DM) using insulin glargine have a higher tumor stage of breast carcinoma in comparison to patients using other types of insulin. Insulin Glargine 110-118 insulin Homo sapiens 102-109 24131755-4 2013 Insulin glargine was used in 13 patients, while the other 66 patients were on other types of insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23489521-6 2013 Most studies of insulin glargine in pregnancy are small, retrospective and include women with pre-existing diabetes and gestational diabetes. Insulin Glargine 24-32 insulin Homo sapiens 16-23 23489521-7 2013 There appear to be no major safety concerns and so it seems reasonable to continue insulin glargine if required to achieve excellent glycaemic control. Insulin Glargine 91-99 insulin Homo sapiens 83-90 23999452-12 2013 The severe hypoglycaemia hazard for all four outcomes was higher with standard care than with insulin glargine. Insulin Glargine 102-110 insulin Homo sapiens 94-101 23999452-14 2013 Although allocation to insulin glargine vs. standard care was associated with an increased risk of severe and non-severe hypoglycaemia, the relative risk of CV outcomes with hypoglycaemia was lower with insulin glargine-based glucose-lowering therapy than with the standard glycaemic control. Insulin Glargine 31-39 insulin Homo sapiens 23-30 23999452-14 2013 Although allocation to insulin glargine vs. standard care was associated with an increased risk of severe and non-severe hypoglycaemia, the relative risk of CV outcomes with hypoglycaemia was lower with insulin glargine-based glucose-lowering therapy than with the standard glycaemic control. Insulin Glargine 211-219 insulin Homo sapiens 203-210 24086105-12 2013 However, during follow-up, many patients (48.8%) who initially switched from insulin glargine to PMX crossed back over to use GLA and/or RAI as part of their regimen. Insulin Glargine 85-93 insulin Homo sapiens 77-84 23489438-2 2013 METHODS: Pooled patient-level data from 12 prospective, randomized, controlled studies that used insulin glargine in a treat-to-target titration regimen seeking fasting glucose levels <=5.5 mmol/l (100 mg/dl) were analysed. Insulin Glargine 105-113 insulin Homo sapiens 97-104 23489438-9 2013 CONCLUSIONS: Systematically titrated insulin glargine, added to oral agents, was effective over a wide range of baseline HbA1c. Insulin Glargine 45-53 insulin Homo sapiens 37-44 23564915-5 2013 Insulin glargine was added and systematically titrated during a 12-week run-in, after which candidates with fasting glucose <= 7.8 mmol/L and HbA1c 7-9% were randomized to lixisenatide 20 microg or placebo for 24 weeks while insulin titration continued. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23564915-12 2013 CONCLUSIONS: Adding lixisenatide to insulin glargine improved overall and postprandial hyperglycemia and deserves consideration as an alternative to prandial insulin for patients not reaching HbA1c goals with recently initiated basal insulin. Insulin Glargine 44-52 insulin Homo sapiens 36-43 23564916-7 2013 RESULTS: Compared with standard care, insulin glargine reduced the primary CIMT outcome, but the difference was not statistically significant (difference = 0.0030 +- 0.0021 mm/year; P = 0.145) and significantly reduced the secondary CIMT outcomes (differences of 0.0033 +- 0.0017 mm/year [P = 0.049] and 0.0045 +- 0.0021 mm/year [P = 0.032], respectively). Insulin Glargine 46-54 insulin Homo sapiens 38-45 23564916-9 2013 CONCLUSIONS: In people with CV disease and/or CV risk factors and dysglycemia, insulin glargine used to target normoglycemia modestly reduced CIMT progression, whereas daily supplementation with n-3FA had no effect on CIMT progression. Insulin Glargine 87-95 insulin Homo sapiens 79-86 23877991-0 2013 Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Insulin Glargine 61-69 insulin Homo sapiens 40-47 23877991-1 2013 OBJECTIVE: To add to the evidence on comparative long-term effects of insulin analog glargine versus human NPH insulin on the risk for cancer. Insulin Glargine 85-93 insulin Homo sapiens 70-77 23877991-11 2013 CONCLUSIONS: Patients initiating insulin glargine rather than NPH do not seem to be at an increased risk for cancer. Insulin Glargine 41-49 insulin Homo sapiens 33-40 23911535-1 2013 OBJECTIVE: To determine differences in inpatient glycemic control and response to two different glargine-based insulin regimens in general medicine and surgery patients with type 2 diabetes (T2D). Insulin Glargine 96-104 insulin Homo sapiens 111-118 24124384-6 2013 Compared with PMX, persistence was higher and consumption of insulin was lower for GLA (both P < 0.0001). Insulin Glargine 83-86 insulin Homo sapiens 61-68 24124384-9 2013 CONCLUSION: In US patients with type 2 diabetes mellitus, initiating insulin with once-daily GLA, rather than a PMX, is associated with increased treatment persistence and similar clinical and hypoglycemic outcomes, but lower diabetes pharmacy and supply costs. Insulin Glargine 93-96 insulin Homo sapiens 69-76 24142600-6 2013 CONCLUSIONS: Insulin detemir has evident superiority on reducing body weight than insulin glargine. Insulin Glargine 90-98 insulin Homo sapiens 82-89 24142600-7 2013 As the doses are concerned, daily insulin dose of insulin detemir is higher than insulin glargine. Insulin Glargine 89-97 insulin Homo sapiens 34-41 24142600-7 2013 As the doses are concerned, daily insulin dose of insulin detemir is higher than insulin glargine. Insulin Glargine 89-97 insulin Homo sapiens 50-57 24142600-7 2013 As the doses are concerned, daily insulin dose of insulin detemir is higher than insulin glargine. Insulin Glargine 89-97 insulin Homo sapiens 50-57 24373396-3 2013 Then two kinds of preadipocytes were cultured or induced to differentiation with different doses of insulin glargine. Insulin Glargine 108-116 insulin Homo sapiens 100-107 24373396-6 2013 (2) MTT results showed that insulin glargine could inhibit the proliferation of omental preadipocytes in a dose-dependent fashion. Insulin Glargine 36-44 insulin Homo sapiens 28-35 24373396-7 2013 After 72 h incubation, compared with negative control, the absorbance (A) value of 1000 nmol/L insulin glargine group decreased greatly (0.144 +- 0.021 vs 0.267 +- 0.040, P < 0.01). Insulin Glargine 103-111 insulin Homo sapiens 95-102 24373396-11 2013 CONCLUSION: Insulin glargine could inhibit the proliferation of omental preadipocytes, and enhance the differentiation of subcutaneous and omental preadipocytes. Insulin Glargine 20-28 insulin Homo sapiens 12-19 24086105-0 2013 Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine. Insulin Glargine 153-161 insulin Homo sapiens 85-92 24086105-0 2013 Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine. Insulin Glargine 153-161 insulin Homo sapiens 85-92 24016754-7 2013 RESULTS: During 17 months of analogue insulin treatment the HbA1c was decreased by 0.34% (detemir -0.44%; glargine -0.17%). Insulin Glargine 106-114 insulin Homo sapiens 38-45 24016754-13 2013 Both detemir and glargine can provide similar improvement in metabolic control with the same insulin dose but with relatively more weight gain with glargine. Insulin Glargine 17-25 insulin Homo sapiens 93-100 23859434-0 2013 Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. Insulin Glargine 133-141 insulin Homo sapiens 125-132 23859434-2 2013 METHODS: Pooled data were evaluated from six previously published, retrospective, observational studies using US health plan insurance claims databases to investigate adults with T2DM who initiated insulin glargine. Insulin Glargine 206-214 insulin Homo sapiens 198-205 23859434-5 2013 Multivariate analyses using baseline characteristics as covariates determined predictors of hypoglycemia after initiating insulin glargine. Insulin Glargine 130-138 insulin Homo sapiens 122-129 23859434-10 2013 The average annual hypoglycemia-related cost associated with initiating insulin glargine was $293, with GLA-P being 46% lower than GLA-V ($225 vs $417; p = 0.001). Insulin Glargine 80-88 insulin Homo sapiens 72-79 23859434-15 2013 CONCLUSIONS: Patients with T2DM initiating insulin glargine treatment showed low rates of hypoglycemia, especially when using a disposable pen device. Insulin Glargine 51-59 insulin Homo sapiens 43-50 24073952-0 2013 [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Insulin Glargine 47-55 insulin Homo sapiens 39-46 24073952-0 2013 [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Insulin Glargine 47-55 insulin Homo sapiens 174-181 24073952-3 2013 In Czech Republic 200 patients, for whom the participating physician according to their own consideration, had decided to prescribe insulin glargine in replacement of insulin detemir, were included in this project. Insulin Glargine 140-148 insulin Homo sapiens 132-139 24073952-4 2013 OBJECTIVES: The primary endpoint was to assess the change in HbA1c over the 6- month period in T2DM patients treated with insulin glargin after switch from insulin detemir. Insulin Glargine 130-137 insulin Homo sapiens 122-129 24073952-4 2013 OBJECTIVES: The primary endpoint was to assess the change in HbA1c over the 6- month period in T2DM patients treated with insulin glargin after switch from insulin detemir. Insulin Glargine 130-137 insulin Homo sapiens 156-163 24073952-6 2013 RESULTS: Insulin glargine therapy resulted in a statistically significant improvement in compensation of diabetes characterized by a mean HbA1c decrease of about 0.82 (+- 0.93) % (p < 0.001) and a mean decrease of recorded fasting glycemia about 1.91 (+- 2.81) mmol/ l (p < 0.001). Insulin Glargine 17-25 insulin Homo sapiens 9-16 24073952-8 2013 The mean daily insulin glargine dose used at the end of the observation increased in comparison with last mean daily dose of insulin detemir [+2.99 (+- 7.54) U; p < 0.001]. Insulin Glargine 23-31 insulin Homo sapiens 15-22 24073952-14 2013 CONCLUSION: Under reallife conditions, switching from insulin detemir to once daily insulin glargine in poorly controlled T2DM patients resulted in clinically relevant improvements in glycemic control without an increase in weight and hypoglycemia risk. Insulin Glargine 92-100 insulin Homo sapiens 84-91 23430192-8 2013 Proinsulin/C-peptide and HOMA B as marker of endogenous insulin secretion were significantly more improved by GLA. Insulin Glargine 110-113 insulin Homo sapiens 0-10 23430192-8 2013 Proinsulin/C-peptide and HOMA B as marker of endogenous insulin secretion were significantly more improved by GLA. Insulin Glargine 110-113 insulin Homo sapiens 11-20 23430192-10 2013 Early basal insulin treatment with GLA in T2D patients provided a better control of FPG, overall IG load and biomarker of beta-cell function compared to the standard treatment with MET. Insulin Glargine 35-38 insulin Homo sapiens 12-19 23653049-1 2013 AIMS/HYPOTHESIS: In vitro, insulin glargine (A21Gly,B31Arg,B32Arg human insulin) has an insulin receptor (IR) profile similar to that of human insulin, but a slightly higher affinity for the IGF-1 receptor (IGF1R). Insulin Glargine 35-43 insulin Homo sapiens 27-34 24968533-0 2013 Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels. Insulin Glargine 31-39 insulin Homo sapiens 23-30 24968533-7 2013 The average dose requirement of insulin glargine was 33.55 +/- 11.94 units (mean +/- SD). Insulin Glargine 40-48 insulin Homo sapiens 32-39 24968533-8 2013 The average insulin glargine dose requirement per kg body weight was 0.48 +/- 0.17 units/kg body weight. Insulin Glargine 20-28 insulin Homo sapiens 12-19 23653049-1 2013 AIMS/HYPOTHESIS: In vitro, insulin glargine (A21Gly,B31Arg,B32Arg human insulin) has an insulin receptor (IR) profile similar to that of human insulin, but a slightly higher affinity for the IGF-1 receptor (IGF1R). Insulin Glargine 35-43 insulin Homo sapiens 72-79 23653049-1 2013 AIMS/HYPOTHESIS: In vitro, insulin glargine (A21Gly,B31Arg,B32Arg human insulin) has an insulin receptor (IR) profile similar to that of human insulin, but a slightly higher affinity for the IGF-1 receptor (IGF1R). Insulin Glargine 35-43 insulin Homo sapiens 72-79 23653049-6 2013 Glargine treatment resulted in phosphorylation levels of IR and Akt that were comparable with those achieved with human insulin, although delayed in time in some tissues. Insulin Glargine 0-8 insulin Homo sapiens 120-127 23669130-3 2013 CASE REPORT: A 56-year-old man with type 2 diabetes mellitus presented to the Emergency Department after a multidrug overdose including up to 3,300 units insulin glargine. Insulin Glargine 162-170 insulin Homo sapiens 154-161 23997930-9 2013 After classification according to renal function, the insulin dosage at eGFR less than 60 ml/min was 29.7% lower in glargine-treated and 27.3% lower in detemir-treated patients compared with eGFR greater than 90 ml/min. Insulin Glargine 116-124 insulin Homo sapiens 54-61 23564573-0 2013 Long-term glycemic control in Japanese type 2 diabetes patients after switching treatment from twice-daily premixed insulin to once daily insulin glargine. Insulin Glargine 146-154 insulin Homo sapiens 138-145 23350795-0 2013 Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Insulin Glargine 86-94 insulin Homo sapiens 78-85 23350795-4 2013 METHODS: Patient-level data from 2251 participants in 11 studies in which insulin glargine was started and titrated using similar treat-to-target methods was pooled and analysed with logistic regression models. Insulin Glargine 82-90 insulin Homo sapiens 74-81 23350795-9 2013 CONCLUSIONS: These findings confirm low rates of clinically important hypoglycaemia using this method, and suggest that higher risk of hypoglycaemia may be suspected when patients needing insulin are younger, less obese and taking metformin and a sulphonylurea, and especially when A1c levels <=7.0% are attained with glargine dosage <=0.4 units/kg. Insulin Glargine 321-329 insulin Homo sapiens 188-195 23569175-0 2013 Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling. Insulin Glargine 26-34 insulin Homo sapiens 18-25 23569175-1 2013 We investigated 1) the ability of purified glargine (GLA), metabolites 1 (M1) and 2 (M2), IGF-I, and NPH insulin to activate the insulin receptor (IR)-A and IR-B and IGF-I receptor (IGF-IR) in vitro; 2) plasma concentrations of GLA, M1, and M2 during long-term insulin therapy in type 2 diabetic patients; and 3) IR-A and IR-B activation in vitro induced by serum from patients treated with GLA or NPH insulin. Insulin Glargine 43-51 insulin Homo sapiens 129-136 23799930-0 2013 Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. Insulin Glargine 99-107 insulin Homo sapiens 91-98 23799930-13 2013 CONCLUSIONS: Patients treated for type 2 diabetes with exenatide BID or insulin glargine differ in their adherence to therapy. Insulin Glargine 80-88 insulin Homo sapiens 72-79 23397557-6 2013 ORIGIN demonstrated neutral results for the primary endpoint, but reduced microangiopathy in patients with an HbA1c value of >=6.4 % with basal insulin glargine. Insulin Glargine 155-163 insulin Homo sapiens 147-154 23539233-8 2013 Insulin glargine was associated with better glycemic control and a reduced incidence of daytime and any hypoglycemia versus comparator interventions in both younger and older T2DM patients. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23807942-3 2013 There is a continuous and highly predictable slow dissociation of insulin monomers from this depot; insulin levels rise immediately reaching tmax at 10-12 hours, followed by a slow decline with a t1/2 of 17-21 hours, roughly double the duration of action of insulin glargine. Insulin Glargine 266-274 insulin Homo sapiens 66-73 23807942-3 2013 There is a continuous and highly predictable slow dissociation of insulin monomers from this depot; insulin levels rise immediately reaching tmax at 10-12 hours, followed by a slow decline with a t1/2 of 17-21 hours, roughly double the duration of action of insulin glargine. Insulin Glargine 266-274 insulin Homo sapiens 100-107 23807942-3 2013 There is a continuous and highly predictable slow dissociation of insulin monomers from this depot; insulin levels rise immediately reaching tmax at 10-12 hours, followed by a slow decline with a t1/2 of 17-21 hours, roughly double the duration of action of insulin glargine. Insulin Glargine 266-274 insulin Homo sapiens 100-107 23808735-5 2013 An ORIGIN study with insulin glargine documented the safety of therapy of longacting insulin analog and also reduction of development of new diabetes from prediabetes. Insulin Glargine 29-37 insulin Homo sapiens 21-28 23808735-5 2013 An ORIGIN study with insulin glargine documented the safety of therapy of longacting insulin analog and also reduction of development of new diabetes from prediabetes. Insulin Glargine 29-37 insulin Homo sapiens 85-92 23425653-0 2013 Glycemic control with use of insulin glargine after cardiothoracic surgery: a retrospective study. Insulin Glargine 37-45 insulin Homo sapiens 29-36 23425653-2 2013 The objective of the study was to compare outcomes before and after the implementation of a protocol using subcutaneous (SC) glargine at transition from intravenous insulin infusion (IVII). Insulin Glargine 125-133 insulin Homo sapiens 165-172 23759407-6 2013 After adjustment, annual cost savings in favor of insulin glargine amounted to $423.94 compared with NPH insulin (p = .3019). Insulin Glargine 58-66 insulin Homo sapiens 50-57 23759407-7 2013 DISCUSSION: The adjusted results show that an ICT with insulin glargine results in lower annual costs than ICT with NPH insulin (this difference was not statistically significant). Insulin Glargine 63-71 insulin Homo sapiens 55-62 23759407-8 2013 However, in the context of glucose-lowering effect and a lower hypoglycemia rate, insulin glargine is preferred to NPH insulin for patients with T1DM undergoing ICT. Insulin Glargine 90-98 insulin Homo sapiens 82-89 23633415-12 2013 CONCLUSIONS: Insulin GLA results in better persistence and adherence, compared with NPH insulin, with no overall cost disadvantages. Insulin Glargine 21-24 insulin Homo sapiens 13-20 23564573-2 2013 METHODS: The study was conducted at Tokai University hospital in 20 patients with type 2 diabetes, whose treatment regimens were switched from twice-a-day premixed insulin formulation to once-a-day insulin glargine. Insulin Glargine 206-214 insulin Homo sapiens 198-205 23564573-7 2013 CONCLUSION: The findings suggest that in type 2 diabetes, once-a-day insulin glargine could be more useful than twice-a-day premixed insulin formulation. Insulin Glargine 77-85 insulin Homo sapiens 69-76 23522121-9 2013 Additionally, significantly more patients using exenatide QW compared to sitagliptin, pioglitazone, or insulin glargine attained the composite goal of HbA1c <7% or <=6.5%, without weight gain or hypoglycemia. Insulin Glargine 111-119 insulin Homo sapiens 103-110 23679181-4 2013 The patient was diagnosed as having MODY3 and was successfully treated with insulin glargine. Insulin Glargine 84-92 insulin Homo sapiens 76-83 23193209-6 2013 Fasting blood glucose variability and A1C were reduced with LY2605541 compared with insulin glargine (both P < 0.001). Insulin Glargine 92-100 insulin Homo sapiens 84-91 23193209-7 2013 Mealtime insulin dose decreased with LY2605541 and increased with insulin glargine. Insulin Glargine 74-82 insulin Homo sapiens 9-16 23193209-7 2013 Mealtime insulin dose decreased with LY2605541 and increased with insulin glargine. Insulin Glargine 74-82 insulin Homo sapiens 66-73 23193209-8 2013 Mean weight decreased 1.2 kg with LY2605541 and increased 0.7 kg with insulin glargine (P < 0.001). Insulin Glargine 78-86 insulin Homo sapiens 70-77 30349602-1 2013 Introduction: The Glulisine in Combination with Insulin Glargine in an Intensified Insulin Regimen (GINGER) study compared insulin glargine plus insulin glulisine with premixed insulin in the treatment of patients with Type 2 diabetes mellitus (T2DM). Insulin Glargine 56-64 insulin Homo sapiens 48-55 23039360-3 2013 METHODS: Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8-week treatment period with insulin glargine. Insulin Glargine 133-141 insulin Homo sapiens 125-132 23336845-1 2013 A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Insulin Glargine 83-91 insulin Homo sapiens 75-82 23336845-14 2013 CONCLUSIONS: Switching from insulin glargine vial-and-syringe administration to pen delivery resulted in improved treatment adherence and persistence, with comparable clinical and economic outcomes. Insulin Glargine 36-44 insulin Homo sapiens 28-35 30349602-1 2013 Introduction: The Glulisine in Combination with Insulin Glargine in an Intensified Insulin Regimen (GINGER) study compared insulin glargine plus insulin glulisine with premixed insulin in the treatment of patients with Type 2 diabetes mellitus (T2DM). Insulin Glargine 56-64 insulin Homo sapiens 83-90 30349602-5 2013 Results: The overall hypoglycaemic event rate (episodes per patient-year) for patients receiving glargine plus glulisine was numerically but not significantly lower (-24.5 %) compared with the overall premixed insulin group (14.0+-24.2 versus 18.5+-36.9; p=0.12) and significantly lower (-43.3 %) compared with the biphasic insulin aspart 70/30 subgroup (24.7+-48.5; p=0.02). Insulin Glargine 97-105 insulin Homo sapiens 324-331 30349602-6 2013 In patients with >=1 episode of hypoglycaemia during treatment, the overall hypoglycaemic event rate was significantly lower (-26.5 %) in patients receiving glargine plus glulisine versus overall premixed insulin (18.5+-26.3 versus 25.1+-41.1; p=0.044) and significantly lower (-40.7 %) than in patients receiving biphasic insulin aspart 70/30 (31.1+-52.7; p=0.009). Insulin Glargine 160-168 insulin Homo sapiens 208-215 30349602-6 2013 In patients with >=1 episode of hypoglycaemia during treatment, the overall hypoglycaemic event rate was significantly lower (-26.5 %) in patients receiving glargine plus glulisine versus overall premixed insulin (18.5+-26.3 versus 25.1+-41.1; p=0.044) and significantly lower (-40.7 %) than in patients receiving biphasic insulin aspart 70/30 (31.1+-52.7; p=0.009). Insulin Glargine 160-168 insulin Homo sapiens 326-333 23394441-1 2013 INTRODUCTION: In 2009, several epidemiological studies suggested a higher frequency of malignancy in insulin glargine -treated patients. Insulin Glargine 109-117 insulin Homo sapiens 101-108 23370139-3 2013 Joint guidelines issued in 2009 by two leading organizations of endocrinology specialists recommend the use of insulin analogs (e.g., detemir, glargine) versus neutral protamine Hagedorn insulin, citing a more predictable time course and a lower potential for hypoglycemia; growing evidence indicates that the use of insulin analogs may offer other advantages such as enhanced dosing flexibility (with the possibility of self-titration by some patients) and less weight gain. Insulin Glargine 143-151 insulin Homo sapiens 111-118 23593690-0 2013 Insulin glargine in children aged 2 to 5 years. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23713181-6 2013 The study investigated whether the insulin glargine treatment leads to an increased number of cancer occurrences. Insulin Glargine 43-51 insulin Homo sapiens 35-42 23713181-10 2013 CONCLUSION: The study has confirmed the safety of the insulin glargine treatment combined with metformin in the early stages of diabetes, without an increased number of atherosclerosis or cancer occurrences, and with minimal weight gain. Insulin Glargine 62-70 insulin Homo sapiens 54-61 23217386-0 2012 MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation. Insulin Glargine 65-73 insulin Homo sapiens 57-64 22966091-0 2013 Does insulin glargine increase the risk of cancer compared with other basal insulins? Insulin Glargine 13-21 insulin Homo sapiens 5-12 22966091-2 2013 OBJECTIVE: To explore in France the relationship between insulin glargine use and overall and specific cancer risks in type 2 diabetic patients compared with other basal insulins. Insulin Glargine 65-73 insulin Homo sapiens 57-64 22966091-6 2013 RESULTS: The median follow-up was 2.67 years in patients exposed to insulin glargine. Insulin Glargine 76-84 insulin Homo sapiens 68-75 22966091-7 2013 Absolute event rates for all cancer in patients exposed to glargine versus other basal insulin users were 1,622 and 1,643 per 100,000 person-years, respectively. Insulin Glargine 59-67 insulin Homo sapiens 87-94 23627191-14 2013 CONCLUSIONS: In a Belgian and Dutch clinical practice setting, patients with type 2 diabetes that is poorly controlled on premixed insulin experienced significant improvements in glycaemic control, without a concomitant increase in hypoglycaemic events or weight, when switched from premixed insulin to basal-bolus glargine plus rapid-acting insulin. Insulin Glargine 315-323 insulin Homo sapiens 131-138 24098877-2 2013 The established long-acting insulin analogue preparations (detemir and glargine) can present specific management problems because, in overdose, their effects are extremely prolonged, often lasting 48-96 hours. Insulin Glargine 71-79 insulin Homo sapiens 28-35 23324510-0 2013 Converting continuous insulin infusion to subcutaneous insulin glargine after cardiac surgery using percentage-based versus weight-based dosing: a pilot trial. Insulin Glargine 63-71 insulin Homo sapiens 55-62 23324510-3 2013 OBJECTIVE: To compare the efficacy and safety of dosing insulin glargine by weight versus percentage of TDI in cardiac surgery patients transitioning from continuous insulin infusion to subcutaneous insulin. Insulin Glargine 64-72 insulin Homo sapiens 56-63 23324510-13 2013 CONCLUSIONS: In this small cohort, dosing insulin glargine by weight proved to be safe, but larger scale studies are needed before adopting weight-based dosing in this patient population. Insulin Glargine 50-58 insulin Homo sapiens 42-49 23517895-3 2013 Both rapid-acting (lispro, aspart and glulisine) and long acting (glargine and determir) insulin analogues are included in this review. Insulin Glargine 66-74 insulin Homo sapiens 89-96 23640946-6 2013 Insulin glargine group had significantly more episodes of hypoglycemia compared with exenatide group (p=0.039). Insulin Glargine 8-16 insulin Homo sapiens 0-7 23640946-11 2013 CONCLUSIONS: Exenatide provided similar reduction in HbA1c, but fewer episodes of hypoglycemia, compared with insulin glargine. Insulin Glargine 118-126 insulin Homo sapiens 110-117 24109660-1 2013 The robustness of a model-based control protocol as a less intensive TGC protocol using insulin Glargine for provision of basal insulin is simulated in this study. Insulin Glargine 96-104 insulin Homo sapiens 88-95 24109660-1 2013 The robustness of a model-based control protocol as a less intensive TGC protocol using insulin Glargine for provision of basal insulin is simulated in this study. Insulin Glargine 96-104 insulin Homo sapiens 128-135 23256473-7 2013 CONCLUSION: A simple SPE LC-MS analysis was developed for direct, simultaneous quantification of insulin glargine, detemir, aspart and glulisine. Insulin Glargine 105-113 insulin Homo sapiens 97-104 24186595-4 2013 RESULTS: Mean (SD) baseline HbA1c was 7.9% (0.86) for exenatide and 7.8% (1.02) for insulin glargine. Insulin Glargine 92-100 insulin Homo sapiens 84-91 24186595-10 2013 CONCLUSION: This exploratory analysis confirms that findings from the global study apply to patients treated with exenatide BID and glargine in Poland, showing that exenatide BID was as effective as insulin glargine. Insulin Glargine 207-215 insulin Homo sapiens 199-206 24601167-0 2013 Improved glycaemic control with insulin glargine as part of a basal-bolus regimen in T2DM patients inadequately controlled on premixed therapy. Insulin Glargine 40-48 insulin Homo sapiens 32-39 24601167-1 2013 OBJECTIVES: Monitoring efficacy of insulin glargine administered to patients with diabetes mellitus type 2 (DMT2) in combination with rapid-action insulin and analogues, where the hitherto fixed-mixture insulin therapy failed to achieve a satisfactory glycaemic control (HbA1c < 7%) following a six-month fixed-mixture insulin therapy. Insulin Glargine 43-51 insulin Homo sapiens 35-42 24601167-8 2013 Insulin glargine mean starting dose was 32,4 +/- 11,5 U. Insulin Glargine 8-16 insulin Homo sapiens 0-7 24601167-12 2013 CONCLUSION: Results from the study suggest that basal-bolus regimen consisting of insulin glargine significantly improves glycaemic control without increasing hypoglycemia risk in DMT2 population with inadequate glycaemic control on previous premixed therapy. Insulin Glargine 90-98 insulin Homo sapiens 82-89 24259985-0 2013 Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Insulin Glargine 31-39 insulin Homo sapiens 23-30 24259985-1 2013 BACKGROUND: For patients with type 2 diabetes who are uncontrolled on a combination of two oral antidiabetic agents, addition of the long-acting basal insulin glargine is a well established treatment option. Insulin Glargine 159-167 insulin Homo sapiens 151-158 24259985-2 2013 However, data on the efficacy and safety of a combination of metformin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and insulin glargine are limited in real-world settings. Insulin Glargine 128-136 insulin Homo sapiens 120-127 24259985-15 2013 CONCLUSION: The results of this observational study show that insulin glargine, when added to a fixed-dose combination of metformin and a DPP-4 inhibitor, resulted in a significant and clinically relevant improvement of glycemic control. Insulin Glargine 70-78 insulin Homo sapiens 62-69 23217386-2 2012 This study was to investigate the roles of mitogen-activated protein kinase kinase (MEK) 1 and 2 in the regulation of human insulin- and insulin glargine-induced proliferation of human bladder cancer T24 cells. Insulin Glargine 145-153 insulin Homo sapiens 124-144 23217386-9 2012 CONCLUSION: MEK1 inhibits while MEK2 contributes to normal and human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation. Insulin Glargine 90-98 insulin Homo sapiens 82-89 22988932-2 2012 METHODS: Subjects received subcutaneous injections of insulin glargine (individualized doses) before dinner. Insulin Glargine 62-70 insulin Homo sapiens 54-61 23086139-0 2012 Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Insulin Glargine 22-30 insulin Homo sapiens 14-21 23043166-10 2012 End-of-trial mean daily insulin doses were 0.59 and 0.60 units/kg for degludec and glargine, respectively. Insulin Glargine 83-91 insulin Homo sapiens 24-31 23086139-1 2012 OBJECTIVE: To investigate concentration of plasma insulin glargine after its subcutaneous dosing compared with concentration of its metabolites 1 (M1) and 2 (M2) in subjects with type 2 diabetes. Insulin Glargine 58-66 insulin Homo sapiens 50-57 23093664-0 2012 Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Insulin Glargine 27-35 insulin Homo sapiens 19-26 23116646-2 2012 METHODS: In this international randomized, parallel-group, non-inferiority study, 811 patients with poorly controlled type 2 diabetes using basal insulin were switched to insulin glargine (GLAR) for 6 months while continuing OADs. Insulin Glargine 179-187 insulin Homo sapiens 171-178 23093664-0 2012 Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Insulin Glargine 140-148 insulin Homo sapiens 19-26 23159131-6 2012 New use of insulin glargine was associated with an increased risk of pancreatic cancer (RR: 1.63, 95%CI: 1.05-2.51, I(2)=0%) and prostate cancers (RR: 2.68, 95%CI: 1.50-4.79, I(2)=0%) but a decreased risk of colorectal cancer (RR: 0.78, 95%CI: 0.64-0.94, I(2)=15%). Insulin Glargine 19-27 insulin Homo sapiens 11-18 23093664-1 2012 OBJECTIVE: In vivo, after subcutaneous injection, insulin glargine (21(A)-Gly-31(B)-Arg-32(B)-Arg-human insulin) is enzymatically processed into 21(A)-Gly-human insulin (metabolite 1 [M1]). Insulin Glargine 58-66 insulin Homo sapiens 50-57 23159131-8 2012 New use of insulin glargine was associated with a decreased risk of colorectal cancer but an increased risk of prostate cancer. Insulin Glargine 19-27 insulin Homo sapiens 11-18 23093664-1 2012 OBJECTIVE: In vivo, after subcutaneous injection, insulin glargine (21(A)-Gly-31(B)-Arg-32(B)-Arg-human insulin) is enzymatically processed into 21(A)-Gly-human insulin (metabolite 1 [M1]). Insulin Glargine 58-66 insulin Homo sapiens 104-111 23093664-1 2012 OBJECTIVE: In vivo, after subcutaneous injection, insulin glargine (21(A)-Gly-31(B)-Arg-32(B)-Arg-human insulin) is enzymatically processed into 21(A)-Gly-human insulin (metabolite 1 [M1]). Insulin Glargine 58-66 insulin Homo sapiens 104-111 23093664-11 2012 Glargine is rapidly and nearly completely processed to M1 (21(A)-Gly-human insulin), which mediates the metabolic effect of injected glargine. Insulin Glargine 0-8 insulin Homo sapiens 75-82 23280862-16 2012 Clinical trials have established the superiority of incretin mimetics particularly liraglutide against comparators including glimepiride, rosiglitazone and insulin Glargine in terms of efficacy. Insulin Glargine 164-172 insulin Homo sapiens 156-163 23093664-11 2012 Glargine is rapidly and nearly completely processed to M1 (21(A)-Gly-human insulin), which mediates the metabolic effect of injected glargine. Insulin Glargine 133-141 insulin Homo sapiens 75-82 23199612-7 2012 The ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trial aimed to establish whether an initial insulin treatment with glargine, as compared with standard treatments, was able to delay the onset of cardiovascular disease. Insulin Glargine 46-54 insulin Homo sapiens 113-120 23122972-1 2012 STUDY OBJECTIVE: To evaluate three evening insulin glargine dosing strategies for achievement of target (100-179 mg/dL; 5.5 - 9.8 mmol/L) and widened (80-249 mg/dL; 4.4 - 13.7 mmol/L) preoperative fasting blood glucose (FBG) ranges on the day of surgery. Insulin Glargine 51-59 insulin Homo sapiens 43-50 23122972-7 2012 In the prehospital setting, patients administered the instructed insulin glargine dose on the evening before surgery. Insulin Glargine 73-81 insulin Homo sapiens 65-72 23122972-13 2012 An insulin glargine adjustment strategy based on usual glycemic control may better prevent severe preoperative hyperglycemia in patients receiving basal/bolus regimens. Insulin Glargine 11-19 insulin Homo sapiens 3-10 23199612-7 2012 The ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trial aimed to establish whether an initial insulin treatment with glargine, as compared with standard treatments, was able to delay the onset of cardiovascular disease. Insulin Glargine 136-144 insulin Homo sapiens 113-120 22699288-2 2012 We randomized inpatients with type 2 diabetes and chronic renal failure to treatment with two different dose levels of insulin glargine and glulisine and studied control of hyperglycemia and the frequency of hypoglycemia. Insulin Glargine 127-135 insulin Homo sapiens 119-126 23107314-12 2012 The combination of insulin glargine with lispro and glulisine was more frequently used in the mid-west region (p<0.001). Insulin Glargine 27-35 insulin Homo sapiens 19-26 22775367-0 2012 Evaluation of a new reusable insulin pen (ClikSTAR) in Canadian patients with type 1 and type 2 diabetes mellitus receiving insulin glargine. Insulin Glargine 132-140 insulin Homo sapiens 29-36 22307438-0 2012 Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22307438-2 2012 Insulin glargine can simulate normal basal insulin secretion. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22307438-2 2012 Insulin glargine can simulate normal basal insulin secretion. Insulin Glargine 8-16 insulin Homo sapiens 43-50 22307438-6 2012 Any increase in glargine dose was coupled with a reduction in the dose of any regular or rapid-acting insulin analogue as far as possible while maintaining a constant daily insulin dose. Insulin Glargine 16-24 insulin Homo sapiens 102-109 22307438-6 2012 Any increase in glargine dose was coupled with a reduction in the dose of any regular or rapid-acting insulin analogue as far as possible while maintaining a constant daily insulin dose. Insulin Glargine 16-24 insulin Homo sapiens 173-180 22865296-0 2012 Insulin glargine and risk of cancer: a meta-analysis. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22865296-1 2012 AIMS: Recently, more and more attention has been drawn on the long-term effects of insulin glargine. Insulin Glargine 91-99 insulin Homo sapiens 83-90 22865296-2 2012 Here we strived to estimate the association of cancer occurrence with the use of insulin glargine. Insulin Glargine 89-97 insulin Homo sapiens 81-88 22865296-3 2012 METHODS: We searched all the publications regarding the association between cancer occurrence and the use of insulin glargine using the US National Library of Medicine"s PubMed database. Insulin Glargine 117-125 insulin Homo sapiens 109-116 22865296-9 2012 The result provides confidence for the development of insulin glargine, but needs confirmation by further clinical studies. Insulin Glargine 62-70 insulin Homo sapiens 54-61 22699288-10 2012 CONCLUSIONS: Reduction of initial glargine/glulisine insulin weight-based dosing in hospitalized patients with diabetes and renal insufficiency reduced the frequency of hypoglycemia by 50% without compromising the control of hyperglycemia. Insulin Glargine 34-42 insulin Homo sapiens 53-60 22685233-0 2012 Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. Insulin Glargine 31-39 insulin Homo sapiens 71-78 22661022-4 2012 Choice of insulin was most influenced by duration of action: human recombinant protamine zinc insulin was ranked first (42%) and glargine second (27%). Insulin Glargine 129-137 insulin Homo sapiens 10-17 23326108-0 2012 Insulin glargine overdose. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23326108-1 2012 Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23326108-1 2012 Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 58-65 23326108-2 2012 The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual. Insulin Glargine 56-64 insulin Homo sapiens 29-36 23326108-3 2012 Insulin glargine is given as a 24-h dosing regimen and has no documented half-life or peak effect. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23326108-4 2012 Hypoglycemia is the most common adverse effect of insulin, including insulin glargine. Insulin Glargine 77-85 insulin Homo sapiens 50-57 23326108-4 2012 Hypoglycemia is the most common adverse effect of insulin, including insulin glargine. Insulin Glargine 77-85 insulin Homo sapiens 69-76 22594461-0 2012 Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Insulin Glargine 76-84 insulin Homo sapiens 68-75 22685233-19 2012 CONCLUSIONS: Once-daily s.c. insulin glargine administered during i.v. Insulin Glargine 37-45 insulin Homo sapiens 29-36 22413808-0 2012 Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis. Insulin Glargine 57-65 insulin Homo sapiens 49-56 22056549-1 2012 BACKGROUND: Insulin glargine is a long-acting insulin that can cause prolonged hypoglycemia when misdosed or overdosed subcutaneously. Insulin Glargine 20-28 insulin Homo sapiens 12-19 22056549-1 2012 BACKGROUND: Insulin glargine is a long-acting insulin that can cause prolonged hypoglycemia when misdosed or overdosed subcutaneously. Insulin Glargine 20-28 insulin Homo sapiens 46-53 22056549-3 2012 OBJECTIVES: We present a case of a patient inadvertently given a large intravenous dose of insulin glargine (100 units) who had an unremarkable course. Insulin Glargine 99-107 insulin Homo sapiens 91-98 22056549-4 2012 CASE REPORT: A 46-year-old woman with a history of type 2 diabetes was found to be hyperglycemic and was mistakenly given an intravenous bolus of 100 units of insulin glargine. Insulin Glargine 167-175 insulin Homo sapiens 159-166 22056549-6 2012 CONCLUSION: To our knowledge, this is the first report of a significant intravenous insulin glargine administration. Insulin Glargine 92-100 insulin Homo sapiens 84-91 22056549-8 2012 This case, along with prior studies on healthy volunteers, suggests that unlike subcutaneous overdoses, intravenous insulin glargine misdose/overdose may not need prolonged observation; an observation time of 6 h may be sufficient in these patients. Insulin Glargine 124-132 insulin Homo sapiens 116-123 22686416-10 2012 Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. Insulin Glargine 49-57 insulin Homo sapiens 41-48 22763825-0 2012 Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Insulin Glargine 47-55 insulin Homo sapiens 39-46 22763825-3 2012 Insulin glargine can simulate normal basal insulin secretion with its flat time-action profiles. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22763825-3 2012 Insulin glargine can simulate normal basal insulin secretion with its flat time-action profiles. Insulin Glargine 8-16 insulin Homo sapiens 43-50 22763825-10 2012 CONCLUSION: Our results suggest that basal insulin supplementation using insulin glargine is a useful method to control not only FBS but also HbA1c. Insulin Glargine 81-89 insulin Homo sapiens 43-50 22763825-10 2012 CONCLUSION: Our results suggest that basal insulin supplementation using insulin glargine is a useful method to control not only FBS but also HbA1c. Insulin Glargine 81-89 insulin Homo sapiens 73-80 22763826-0 2012 Effectiveness of basal-supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes. Insulin Glargine 66-74 insulin Homo sapiens 58-65 22763826-1 2012 OBJECTIVE: To determine the clinical usefulness of basal-supported oral therapy (BOT) using insulin glargine in Japanese patients with type 2 diabetes. Insulin Glargine 100-108 insulin Homo sapiens 92-99 22763826-8 2012 CONCLUSION: BOT with insulin glargine is a useful strategy that can achieve good glycemic control in clinical practice without causing serious hypoglycemia. Insulin Glargine 29-37 insulin Homo sapiens 21-28 23091824-0 2012 ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use. Insulin Glargine 50-58 insulin Homo sapiens 42-49 22938664-17 2012 CONCLUSIONS: Compared with the conventional subcutaneous insulin injection protocol, this protocol with insulin glargine combined regular insulin subcutaneous injection can control the glucose level effectively during EN in critical patients. Insulin Glargine 112-120 insulin Homo sapiens 104-111 22938664-17 2012 CONCLUSIONS: Compared with the conventional subcutaneous insulin injection protocol, this protocol with insulin glargine combined regular insulin subcutaneous injection can control the glucose level effectively during EN in critical patients. Insulin Glargine 112-120 insulin Homo sapiens 104-111 22763825-0 2012 Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Insulin Glargine 47-55 insulin Homo sapiens 24-31 22763825-0 2012 Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Insulin Glargine 47-55 insulin Homo sapiens 39-46 22524524-0 2012 Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis. Insulin Glargine 18-26 insulin Homo sapiens 10-17 22524524-1 2012 UNLABELLED: AIM/INTRODUCTION: Subsample analysis was performed to examine whether dose optimization of insulin glargine (Lantus( ); Sanofi-Aventis K.K., Tokyo, Japan) contributed to achieving a target glycosylated hemoglobin (HbA1c) (<7.0%) by using the data from the Add-on Lantus to Oral Hypoglycemic Agents (ALOHA) study, a 24-week observational study of Japanese type 2 diabetes patients. Insulin Glargine 111-119 insulin Homo sapiens 103-110 22524524-6 2012 The starting dose and the change of insulin glargine dose were significantly greater in Group 2 than in Group 3 (0.142 vs. 0.086 U/kg/day [P<0.001] and +5.0 vs. +1.1 U/day [P<0.001], respectively), whereas the baseline HbA1c levels and body mass index were comparable (9.3% vs. 9.4% and 23.5 kg/m(2) vs. 23.3 kg/m(2), respectively). Insulin Glargine 44-52 insulin Homo sapiens 36-43 22413808-2 2012 METHODS: Patient-level data from seven prospective, randomized, controlled studies using treat-to-target methods were pooled to evaluate the efficacy of insulin glargine. Insulin Glargine 161-169 insulin Homo sapiens 153-160 30754169-6 2012 This article summarizes the current strategies for initiating and optimizing the use of the basal insulin analog, insulin glargine, in Type 2 diabetes, leading to the intermediate stage of insulin therapy with the introduction of meal-related, rapid-acting insulin analogs in a stepwise manner prior to a full replacement basal-bolus regimen. Insulin Glargine 122-130 insulin Homo sapiens 98-105 22548951-0 2012 Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine. Insulin Glargine 136-144 insulin Homo sapiens 128-135 22548951-1 2012 OBJECTIVE: To observe the effect of the dawn phenomenon on basal glucose and postbreakfast hyperglycemia in patients with type 1 diabetes treated with once-nightly insulin glargine and premeal insulin lispro. Insulin Glargine 172-180 insulin Homo sapiens 164-171 22548951-2 2012 METHODS: In 49 study subjects consuming a fixed isocaloric (50% carbohydrate) diet of usual food, the insulin glargine dose was titrated from daily continuous glucose monitoring downloads to achieve a basal glucose goal of <130 mg/dL 4 hours after meals and during serial meal omissions but with fewer than 10% of readings at <70 mg/dL during 24 hours. Insulin Glargine 110-118 insulin Homo sapiens 102-109 30754169-6 2012 This article summarizes the current strategies for initiating and optimizing the use of the basal insulin analog, insulin glargine, in Type 2 diabetes, leading to the intermediate stage of insulin therapy with the introduction of meal-related, rapid-acting insulin analogs in a stepwise manner prior to a full replacement basal-bolus regimen. Insulin Glargine 122-130 insulin Homo sapiens 114-121 30754169-6 2012 This article summarizes the current strategies for initiating and optimizing the use of the basal insulin analog, insulin glargine, in Type 2 diabetes, leading to the intermediate stage of insulin therapy with the introduction of meal-related, rapid-acting insulin analogs in a stepwise manner prior to a full replacement basal-bolus regimen. Insulin Glargine 122-130 insulin Homo sapiens 114-121 30754169-6 2012 This article summarizes the current strategies for initiating and optimizing the use of the basal insulin analog, insulin glargine, in Type 2 diabetes, leading to the intermediate stage of insulin therapy with the introduction of meal-related, rapid-acting insulin analogs in a stepwise manner prior to a full replacement basal-bolus regimen. Insulin Glargine 122-130 insulin Homo sapiens 114-121 22683131-0 2012 Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22683131-12 2012 The estimated rate of all symptomatic hypoglycaemic episodes was greater with insulin glargine than with sitagliptin (4 21 [SE 0 54] vs 0 50 [SE 0 09] events per patient-year; p<0 0001). Insulin Glargine 86-94 insulin Homo sapiens 78-85 22683131-11 2012 At study end, adjusted mean reduction in HbA(1c) was greater for patients on insulin glargine (n=227; -1 72%, SE 0 06) than for those on sitagliptin (n=253; -1 13%, SE 0 06) with a mean difference of -0 59% (95% CI -0 77 to -0 42, p<0 0001). Insulin Glargine 85-93 insulin Homo sapiens 77-84 23148201-1 2012 The three currently marketed long-acting insulin analogs, glargine, detemir and insulin lispro protamine suspension (ILPS), represent the most significant advances in basal insulin supplementation since the 1940s and 1950s and the introduction of the intermediate-acting NPH (neutral protamine Hagedorn) insulin. Insulin Glargine 58-66 insulin Homo sapiens 41-48 22659796-4 2012 Pharmacologically achievable concentrations of insulin, aspart and glargine significantly increased the number of ALL cells, and aspart and glargine did so at lower concentrations than human insulin. Insulin Glargine 140-148 insulin Homo sapiens 47-54 22519390-1 2012 AIMS: The safety and efficacy of exenatide BID (exenatide) and insulin glargine (glargine) have been studied in clinical trials with few elderly patients. Insulin Glargine 71-79 insulin Homo sapiens 63-70 22519390-1 2012 AIMS: The safety and efficacy of exenatide BID (exenatide) and insulin glargine (glargine) have been studied in clinical trials with few elderly patients. Insulin Glargine 81-89 insulin Homo sapiens 63-70 22142056-7 2012 The effect of glargine on HbA1c and on hypoglycaemia vanished with increasing number of insulin injections. Insulin Glargine 14-22 insulin Homo sapiens 88-95 22232027-0 2012 Insulin glargine or neutral protamine Hagedorn in patients with severe insulin resistance: Is there a benefit? Insulin Glargine 8-16 insulin Homo sapiens 0-7 22432107-0 2012 Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Insulin Glargine 123-131 insulin Homo sapiens 115-122 22232027-0 2012 Insulin glargine or neutral protamine Hagedorn in patients with severe insulin resistance: Is there a benefit? Insulin Glargine 8-16 insulin Homo sapiens 71-78 22232027-5 2012 Insulin glargine was replaced with the same dosage of NPH insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22232027-8 2012 CONCLUSION: NPH insulin might be superior to the long-acting analogue insulin glargine in cases of severe insulin resistance, but randomized studies are needed to confirm our finding and clarify the involved mechanisms. Insulin Glargine 78-86 insulin Homo sapiens 70-77 22768894-0 2012 In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. Insulin Glargine 37-45 insulin Homo sapiens 29-36 22440988-8 2012 Titrating insulin glargine to the morning glucose led to hypoglycemia during the rest of the day (2 PM to 4 AM). Insulin Glargine 18-26 insulin Homo sapiens 10-17 22440988-11 2012 CONCLUSIONS: Smaller insulin glargine doses to achieve control are in contrast to those much larger doses reported in clinical trials in multiple daily injection-treated type 1 diabetes in which the morning fasting glucose is the basal insulin target. Insulin Glargine 29-37 insulin Homo sapiens 21-28 22440988-11 2012 CONCLUSIONS: Smaller insulin glargine doses to achieve control are in contrast to those much larger doses reported in clinical trials in multiple daily injection-treated type 1 diabetes in which the morning fasting glucose is the basal insulin target. Insulin Glargine 29-37 insulin Homo sapiens 236-243 22768894-7 2012 Postprandial release of proinsulin was significantly greater in T2DM patients treated with SU plus MET than in those treated with GLA plus MET (p = .003). Insulin Glargine 130-133 insulin Homo sapiens 24-34 22768894-0 2012 In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. Insulin Glargine 37-45 insulin Homo sapiens 102-112 22435393-6 2012 Presently GLP-1 analogues like exenatide/long acting exenatide and liraglutide have been co-administered with basal insulin like glargine and detemir respectively, and are approved by regulatory agencies. Insulin Glargine 129-137 insulin Homo sapiens 116-123 22056422-0 2012 The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Insulin Glargine 54-62 insulin Homo sapiens 46-53 22449098-0 2012 A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Insulin Glargine 74-82 insulin Homo sapiens 32-39 22449098-0 2012 A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Insulin Glargine 74-82 insulin Homo sapiens 66-73 22449098-0 2012 A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Insulin Glargine 74-82 insulin Homo sapiens 66-73 22449098-4 2012 RESULTS: Switching to insulin glargine was associated with significant reductions in levels of glycosylated haemoglobin (HbA(1c); 8.4 +- 0.6 to 7.9 +- 1.0%; p < 0.001) and fasting plasma glucose (FPG; 9.50 +- 2.10 to 6.58 +- 2.07 mmol/L; p < 0.001). Insulin Glargine 30-38 insulin Homo sapiens 22-29 22449098-6 2012 Treatment satisfaction was improved with insulin glargine (DTSQ 8-item scores, all p < 0.001). Insulin Glargine 49-57 insulin Homo sapiens 41-48 22449098-9 2012 Switching to insulin glargine was also associated with better patient treatment satisfaction compared with previous treatment. Insulin Glargine 21-29 insulin Homo sapiens 13-20 22203325-1 2012 PURPOSE: To develop a long-acting formulation of native human insulin with a similar pharmacodynamics (PD) profile as the insulin analogue insulin glargine (Lantus , Sanofi-Aventis) with the expectation of retaining native human insulin"s superior safety profile as insulin glargine is able to activate the insulin-like growth factor 1 (IGF-1) receptor and is linked to a number of malignancies at a higher rate than regular human insulin. Insulin Glargine 147-155 insulin Homo sapiens 122-129 22203325-1 2012 PURPOSE: To develop a long-acting formulation of native human insulin with a similar pharmacodynamics (PD) profile as the insulin analogue insulin glargine (Lantus , Sanofi-Aventis) with the expectation of retaining native human insulin"s superior safety profile as insulin glargine is able to activate the insulin-like growth factor 1 (IGF-1) receptor and is linked to a number of malignancies at a higher rate than regular human insulin. Insulin Glargine 147-155 insulin Homo sapiens 122-129 22203325-1 2012 PURPOSE: To develop a long-acting formulation of native human insulin with a similar pharmacodynamics (PD) profile as the insulin analogue insulin glargine (Lantus , Sanofi-Aventis) with the expectation of retaining native human insulin"s superior safety profile as insulin glargine is able to activate the insulin-like growth factor 1 (IGF-1) receptor and is linked to a number of malignancies at a higher rate than regular human insulin. Insulin Glargine 147-155 insulin Homo sapiens 122-129 22203325-1 2012 PURPOSE: To develop a long-acting formulation of native human insulin with a similar pharmacodynamics (PD) profile as the insulin analogue insulin glargine (Lantus , Sanofi-Aventis) with the expectation of retaining native human insulin"s superior safety profile as insulin glargine is able to activate the insulin-like growth factor 1 (IGF-1) receptor and is linked to a number of malignancies at a higher rate than regular human insulin. Insulin Glargine 147-155 insulin Homo sapiens 122-129 22203325-1 2012 PURPOSE: To develop a long-acting formulation of native human insulin with a similar pharmacodynamics (PD) profile as the insulin analogue insulin glargine (Lantus , Sanofi-Aventis) with the expectation of retaining native human insulin"s superior safety profile as insulin glargine is able to activate the insulin-like growth factor 1 (IGF-1) receptor and is linked to a number of malignancies at a higher rate than regular human insulin. Insulin Glargine 147-155 insulin Homo sapiens 122-129 22203325-3 2012 RESULTS: PGC-formulations of native human insulin are able to control blood glucose to the same extent and for the same amount of time after s.c. injection as the insulin analogue insulin glargine. Insulin Glargine 188-196 insulin Homo sapiens 163-170 22203325-3 2012 RESULTS: PGC-formulations of native human insulin are able to control blood glucose to the same extent and for the same amount of time after s.c. injection as the insulin analogue insulin glargine. Insulin Glargine 188-196 insulin Homo sapiens 163-170 22056422-2 2012 METHODS: Continuous hazard functions for risk of breast and prostate cancer were estimated in relation to exposure of insulin glargine among diabetic patients included in the record system, Diab-Base, as well as in the general population in Sweden. Insulin Glargine 126-134 insulin Homo sapiens 118-125 22056422-3 2012 RESULTS: In 7942 female diabetic patients, mean follow-up 7.0 years, 2014 patients initiated insulin glargine with a mean follow-up of 3.5 years. Insulin Glargine 101-109 insulin Homo sapiens 93-100 22056422-5 2012 Risk of prostate cancer decreased significantly with longer exposure to insulin glargine (p=0.032), although average risk versus non-glargine was non-significantly higher (HR 1.37, 95% CI 0.78-2.39). Insulin Glargine 80-88 insulin Homo sapiens 72-79 22056422-7 2012 With higher dose of insulin glargine, there was an increase in risk of prostate (p=0.037) and breast cancer (p=0.019). Insulin Glargine 28-36 insulin Homo sapiens 20-27 22222504-0 2012 Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22497435-0 2012 Insulin glargine use and short-term incidence of breast cancer - a four-year population-based observation. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22081557-6 2012 RESULTS: Both insulin glargine and TZDs improved lipid profiles from baseline values. Insulin Glargine 22-30 insulin Homo sapiens 14-21 22081557-7 2012 Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p < 0.0003), 7.5% greater reduction in non-HDL-C (p < 0.0001), and 7.8% greater reduction in total cholesterol (p < 0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p < 0.0001). Insulin Glargine 43-51 insulin Homo sapiens 35-42 22081557-7 2012 Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p < 0.0003), 7.5% greater reduction in non-HDL-C (p < 0.0001), and 7.8% greater reduction in total cholesterol (p < 0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p < 0.0001). Insulin Glargine 43-51 insulin Homo sapiens 294-301 22081557-7 2012 Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p < 0.0003), 7.5% greater reduction in non-HDL-C (p < 0.0001), and 7.8% greater reduction in total cholesterol (p < 0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p < 0.0001). Insulin Glargine 302-310 insulin Homo sapiens 35-42 22081557-9 2012 Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22081557-9 2012 Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Insulin Glargine 77-85 insulin Homo sapiens 69-76 22222504-6 2012 All-type cancer HRs with insulin glargine vs human insulin ranged from 0.59 (95% CI 0.28, 1.25) in incident exclusive users to 0.58 (95% CI 0.34, 1.01) in all predominant users. Insulin Glargine 33-41 insulin Homo sapiens 25-32 22222504-8 2012 Adjusted HRs for death or cancer associated with insulin glargine compared with human insulin ranged from 0.58 (95% CI 0.32, 1.06) to 0.56 (95% CI 0.36, 0.87). Insulin Glargine 57-65 insulin Homo sapiens 49-56 22081557-11 2012 CONCLUSION: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs. Insulin Glargine 74-82 insulin Homo sapiens 66-73 22222504-3 2012 METHODS: We used Cox proportional hazards time-dependent models that were stratified on propensity score quartiles for use of insulin glargine vs human insulin, and adjusted for insulin, biguanide and sulfonylurea possession rates to assess the risk of cancer or death in all or incident exclusive or predominant (>= 80% use time) users of insulin glargine compared with equivalent human insulin users. Insulin Glargine 134-142 insulin Homo sapiens 126-133 22081557-11 2012 CONCLUSION: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs. Insulin Glargine 74-82 insulin Homo sapiens 168-175 22222504-10 2012 The overall risk of death or cancer in patients on insulin glargine was about half that of patients on human insulin, thereby excluding a competitive risk bias. Insulin Glargine 59-67 insulin Homo sapiens 51-58 22222505-0 2012 Request for clarification from Ruiter et al regarding "Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study". Insulin Glargine 93-101 insulin Homo sapiens 85-92 22275452-1 2012 Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Insulin Glargine 56-64 insulin Homo sapiens 48-55 22060105-2 2012 Slow-release synthetic insulin glargine can be a therapeutic tool in this metabolic condition. Insulin Glargine 31-39 insulin Homo sapiens 23-30 21781150-1 2012 BACKGROUND: A 26-year-old man with Type 1 diabetes presented with an overdose of 4800 units of the long-acting insulin analogue, glargine (Lantus). Insulin Glargine 129-137 insulin Homo sapiens 111-118 21781150-1 2012 BACKGROUND: A 26-year-old man with Type 1 diabetes presented with an overdose of 4800 units of the long-acting insulin analogue, glargine (Lantus). Insulin Glargine 139-145 insulin Homo sapiens 111-118 22340448-6 2012 An expected reduction in dosing frequency, as well as in the basal insulin dose was reported for glargine vs. NPH, with 97.3% of glargine-treated patients on once-daily injections and 81.2% on NPH receiving twice-daily therapy. Insulin Glargine 97-105 insulin Homo sapiens 67-74 22649410-6 2012 The long-acting insulin analogs glargine and detemir have a protracted duration of action and a relatively smooth serum concentration profile. Insulin Glargine 32-40 insulin Homo sapiens 16-23 22181063-1 2012 BACKGROUND: This pilot study aimed to verify if glycemic control can be achieved in type 2 diabetes patients after acute myocardial infarction (AMI), using insulin glargine (iGlar) associated with regular insulin (iReg), compared with the standard intensive care unit protocol, which uses continuous insulin intravenous delivery followed by NPH insulin and iReg (St. Care). Insulin Glargine 164-172 insulin Homo sapiens 156-163 22033621-3 2012 For example, when Ruitar and colleagues (Diabetologia DOI: 10.1007/s00125-011-2312-4 ) focused specifically on breast cancer rather than all incident cancer risk, they were able to show a positive association with insulin glargine for breast cancer although there was no association with all incident cancer risk. Insulin Glargine 222-230 insulin Homo sapiens 214-221 23071426-4 2012 His out patient medications included megesterol, omeprazole, morphine sulfate and insulin glargine. Insulin Glargine 90-98 insulin Homo sapiens 82-89 23251042-6 2012 We have observed that the binding pattern of insulin receptor (L1-CR-L2 ectodomain) with lispro and glargine is different when compared with human insulin. Insulin Glargine 100-108 insulin Homo sapiens 45-52 21956710-2 2012 We investigated whether insulin glargine (A21Gly,B31Arg,B32Arg human insulin) is associated with an increased risk of cancer in a large population-based cohort study. Insulin Glargine 32-40 insulin Homo sapiens 69-76 21956710-4 2012 In a cohort of incident users of insulin, the association between insulin glargine and other insulin analogues, respectively, and cancer was analysed in comparison with human insulin using Cox proportional hazard models with cumulative duration of drug use as a time-varying determinant. Insulin Glargine 74-82 insulin Homo sapiens 33-40 21956710-4 2012 In a cohort of incident users of insulin, the association between insulin glargine and other insulin analogues, respectively, and cancer was analysed in comparison with human insulin using Cox proportional hazard models with cumulative duration of drug use as a time-varying determinant. Insulin Glargine 74-82 insulin Homo sapiens 66-73 22826635-4 2012 Exenatide was the first agent in this class and has recently been approved for use in combination with insulin glargine by the US Food and Drug Administration and the European Medicines Agency. Insulin Glargine 111-119 insulin Homo sapiens 103-110 21956710-4 2012 In a cohort of incident users of insulin, the association between insulin glargine and other insulin analogues, respectively, and cancer was analysed in comparison with human insulin using Cox proportional hazard models with cumulative duration of drug use as a time-varying determinant. Insulin Glargine 74-82 insulin Homo sapiens 66-73 21956710-4 2012 In a cohort of incident users of insulin, the association between insulin glargine and other insulin analogues, respectively, and cancer was analysed in comparison with human insulin using Cox proportional hazard models with cumulative duration of drug use as a time-varying determinant. Insulin Glargine 74-82 insulin Homo sapiens 66-73 21956710-7 2012 Use of insulin glargine was associated with a lower risk of malignancies in general in comparison with human insulin (HR 0.75, 95% CI 0.71, 0.80). Insulin Glargine 15-23 insulin Homo sapiens 7-14 21956710-10 2012 CONCLUSION/INTERPRETATION: Users of insulin glargine and users of other insulin analogues had a lower risk of cancer in general than those using human insulin. Insulin Glargine 44-52 insulin Homo sapiens 36-43 21956710-12 2012 However, as in previous studies, we demonstrated an increased risk of breast cancer in users of insulin glargine in comparison with users of human insulin. Insulin Glargine 104-112 insulin Homo sapiens 96-103 21956710-0 2012 Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Insulin Glargine 38-46 insulin Homo sapiens 30-37 21956710-2 2012 We investigated whether insulin glargine (A21Gly,B31Arg,B32Arg human insulin) is associated with an increased risk of cancer in a large population-based cohort study. Insulin Glargine 32-40 insulin Homo sapiens 24-31 22590494-2 2012 We report a series of experiments forming a comprehensive characterisation of the long acting insulin analogues, glargine and detemir, in comparison with human insulin, IGF-1, and the super-mitogenic insulin, X10. Insulin Glargine 113-121 insulin Homo sapiens 94-101 23209929-5 2012 Among insulin analogues, glargine has a higher affinity for the IGF-1 receptor and a greater mitogenic potency in vitro than human insulin, but it is extensively metabolized in vitro to products with low IGF-1 receptor affinity. Insulin Glargine 25-33 insulin Homo sapiens 6-13 23209929-6 2012 Overall, epidemiological studies suggest a possible increase of risk with glargine, with respect to human insulin, only at high doses and for some forms of cancer (i.e., breast). Insulin Glargine 74-82 insulin Homo sapiens 106-113 22685467-0 2012 Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy. Insulin Glargine 83-91 insulin Homo sapiens 75-82 23284776-0 2012 Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. Insulin Glargine 8-16 insulin Homo sapiens 0-7 23284776-7 2012 Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, P = 0.03; very low-quality evidence). Insulin Glargine 8-16 insulin Homo sapiens 0-7 23284776-10 2012 Insulin glargine use was associated with lower odds of other site-specific cancer. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22848683-0 2012 Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. Insulin Glargine 86-94 insulin Homo sapiens 10-17 22848683-0 2012 Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. Insulin Glargine 86-94 insulin Homo sapiens 31-38 22848683-9 2012 RESULTS: Among the five insulin analogues tested, only glargine stimulated IR/IGF1R hybrids with an EC50 that was significantly lower than insulin and close to that of IGF1. Insulin Glargine 55-63 insulin Homo sapiens 24-31 22239291-7 2012 RESULTS: At end point, participants aged 65 and older receiving insulin glargine had greater reductions in HbA1c and FBG than those receiving similar doses of NPH insulin. Insulin Glargine 72-80 insulin Homo sapiens 64-71 22870214-3 2012 METHODOLOGY/PRINCIPAL FINDINGS: The patients who initiated insulin glargine in basal-supported oral therapy (BOT) regimen (n = 3506) were analyzed. Insulin Glargine 67-75 insulin Homo sapiens 59-66 22590494-4 2012 RESULTS: Detemir and glargine each displayed a balanced affinity for insulin receptor (IR) isoforms A and B. Insulin Glargine 21-29 insulin Homo sapiens 69-76 21963105-7 2011 CONCLUSIONS: People who began treatment with glargine and those with better on-treatment HbA(1c) remained on their first insulin for longer than those who began detemir or NPH. Insulin Glargine 45-53 insulin Homo sapiens 121-128 21810024-13 2011 CONCLUSIONS: In T1D patients under clinical practice conditions, insulin glargine was non-inferior to insulin detemir regarding blood glucose variability, as assessed by CV of FBG. Insulin Glargine 73-81 insulin Homo sapiens 65-72 21812890-6 2011 Insulin glargine once daily, +-metformin and subcutaneous injections of premeal or postmeal insulin glulisine were given for 52 weeks. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21992870-1 2011 AIM: To perform a network meta-analysis between long-acting insulin analogues (glargine and detemir) and Neutral Protamine Hagedorn (NPH) insulin on adults with type 1 diabetes. Insulin Glargine 79-87 insulin Homo sapiens 60-67 21994424-2 2011 RESEARCH DESIGN AND METHODS: In this double-blind study, 587 patients taking stable-dose insulin glargine (+-metformin >=1,500 mg/day) were randomized (1:1:1:1:1) to MK-0941 10, 20, 30, or 40 mg or matching placebo t.i.d. Insulin Glargine 97-105 insulin Homo sapiens 89-96 21803140-3 2011 SBE4-beta-CyD increased the solubility and suppressed aggregation of insulin glargine in phosphate buffer at pH 9.5, probably due to the interaction of SBE4-beta-CyD with aromatic amino acid residues such as tyrosine of insulin glargine. Insulin Glargine 77-85 insulin Homo sapiens 69-76 21751887-9 2011 In comparative trials, EQW improved hemoglobin A1c more than EBID, sitagliptin, pioglitazone, or insulin glargine and reduced fasting plasma glucose more than EBID. Insulin Glargine 105-113 insulin Homo sapiens 97-104 21550952-0 2011 Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Insulin Glargine 38-46 insulin Homo sapiens 30-37 21550952-1 2011 OBJECTIVE: To investigate health care utilization, cost, and clinical outcomes among non-insulin-treated patients with type 2 diabetes mellitus who initiated insulin glargine therapy with use of either a disposable pen or vial and syringe in a managed care setting in the United States. Insulin Glargine 166-174 insulin Homo sapiens 158-165 21550952-5 2011 Patients initiating insulin glargine therapy with a disposable pen were significantly less likely to discontinue or switch treatment during the 12-month follow-up period versus patients in the vial and syringe group (P<.001). Insulin Glargine 28-36 insulin Homo sapiens 20-27 21550952-10 2011 CONCLUSION: Initiation of insulin glargine therapy with a disposable pen in patients with type 2 diabetes was associated with better treatment persistence and decreased hypoglycemia in comparison with the vial and syringe method, without any increase in total health care utilization or costs. Insulin Glargine 34-42 insulin Homo sapiens 26-33 21803140-0 2011 Effect of sulfobutyl ether-beta-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats. Insulin Glargine 75-83 insulin Homo sapiens 67-74 21803140-1 2011 Insulin glargine is the first long-acting basal insulin analogue used for subcutaneous administration once daily in patients with type 1 or type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21803140-1 2011 Insulin glargine is the first long-acting basal insulin analogue used for subcutaneous administration once daily in patients with type 1 or type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 48-55 21803140-4 2011 In addition, SBE4-beta-CyD accelerated the dissolution rate of insulin glargine from its precipitates, compared to that of insulin glargine alone. Insulin Glargine 71-79 insulin Homo sapiens 63-70 21803140-2 2011 To obtain the further bioavailability and the sustained glucose lowering effect of insulin glargine, in the present study, we investigated the effect of sulfobutyl ether-beta-cyclodextrin (SBE4-beta-CyD), with the degree of substitution of sulfobutyl ether group of 3.9, on pharmaceutical properties of insulin glargine and the release of insulin glargine after subcutaneous injection to rats. Insulin Glargine 91-99 insulin Homo sapiens 83-90 21803140-4 2011 In addition, SBE4-beta-CyD accelerated the dissolution rate of insulin glargine from its precipitates, compared to that of insulin glargine alone. Insulin Glargine 131-139 insulin Homo sapiens 63-70 21803140-5 2011 Furthermore, we revealed that subcutaneous administration of an insulin glargine solution with SBE4-beta-CyD to rats enhanced the bioavailability of insulin glargine and sustained the glucose lowering effect, possibly due to the inhibitory effects of SBE4-beta-CyD on the enzymatic degradation at the injection site. Insulin Glargine 72-80 insulin Homo sapiens 64-71 21803140-5 2011 Furthermore, we revealed that subcutaneous administration of an insulin glargine solution with SBE4-beta-CyD to rats enhanced the bioavailability of insulin glargine and sustained the glucose lowering effect, possibly due to the inhibitory effects of SBE4-beta-CyD on the enzymatic degradation at the injection site. Insulin Glargine 72-80 insulin Homo sapiens 149-156 21803140-5 2011 Furthermore, we revealed that subcutaneous administration of an insulin glargine solution with SBE4-beta-CyD to rats enhanced the bioavailability of insulin glargine and sustained the glucose lowering effect, possibly due to the inhibitory effects of SBE4-beta-CyD on the enzymatic degradation at the injection site. Insulin Glargine 157-165 insulin Homo sapiens 64-71 21803140-5 2011 Furthermore, we revealed that subcutaneous administration of an insulin glargine solution with SBE4-beta-CyD to rats enhanced the bioavailability of insulin glargine and sustained the glucose lowering effect, possibly due to the inhibitory effects of SBE4-beta-CyD on the enzymatic degradation at the injection site. Insulin Glargine 157-165 insulin Homo sapiens 149-156 21803140-6 2011 These results suggest that SBE4-beta-CyD can be a useful excipient for sustained release of insulin glargine. Insulin Glargine 100-108 insulin Homo sapiens 92-99 21481127-0 2011 An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Insulin Glargine 29-37 insulin Homo sapiens 21-28 22768014-0 2011 Treatment of transient neonatal diabetes mellitus with subcutaneous insulin glargine in an extremely low birth weight neonate. Insulin Glargine 76-84 insulin Homo sapiens 68-75 22768014-6 2011 For the first time, the successful management of TNDM in an extremely low birth weight (ELBW) neonate with the long-acting subcutaneous insulin analog, insulin glargine, is reported. Insulin Glargine 160-168 insulin Homo sapiens 136-143 22768014-6 2011 For the first time, the successful management of TNDM in an extremely low birth weight (ELBW) neonate with the long-acting subcutaneous insulin analog, insulin glargine, is reported. Insulin Glargine 160-168 insulin Homo sapiens 152-159 21436765-3 2011 In the attempted suicide, he injected 800 U of insulin lispro and 3800 U of insulin glargine subcutaneously over several parts of his abdomen. Insulin Glargine 84-92 insulin Homo sapiens 76-83 21614572-1 2011 AIMS/HYPOTHESIS: There have been growing concerns regarding the long-term effects of insulin glargine (A21Gly,B31Arg,B32Arg human insulin) on the risk of breast cancer. Insulin Glargine 93-101 insulin Homo sapiens 85-92 21614572-1 2011 AIMS/HYPOTHESIS: There have been growing concerns regarding the long-term effects of insulin glargine (A21Gly,B31Arg,B32Arg human insulin) on the risk of breast cancer. Insulin Glargine 93-101 insulin Homo sapiens 130-137 21978524-13 2011 Thus insulin glargine (GLA) seems to offer good value for money. Insulin Glargine 13-21 insulin Homo sapiens 5-12 21978524-13 2011 Thus insulin glargine (GLA) seems to offer good value for money. Insulin Glargine 23-26 insulin Homo sapiens 5-12 20493654-1 2011 BACKGROUND: Insulin glargine is a relatively new medication in the treatment of diabetes mellitus, and there have only been six case reports of overdoses in the literature with this specific insulin. Insulin Glargine 20-28 insulin Homo sapiens 12-19 20493654-1 2011 BACKGROUND: Insulin glargine is a relatively new medication in the treatment of diabetes mellitus, and there have only been six case reports of overdoses in the literature with this specific insulin. Insulin Glargine 20-28 insulin Homo sapiens 191-198 20493654-3 2011 CASE REPORT: A 51-year-old woman with insulin-dependent diabetes and a history of suicide attempts by medication overdose presented to the Emergency Department the morning after she had self-administered 2700 units of her insulin glargine in an attempted suicide. Insulin Glargine 230-238 insulin Homo sapiens 38-45 21681370-2 2011 In this context, the long-acting insulin analog glargine and other antidiabetics have been discussed to promote tumorigenesis. Insulin Glargine 48-56 insulin Homo sapiens 33-40 21614572-6 2011 The risk tended to increase after 5 years (HR 1.8; 95% CI 0.8-4.0), and significantly so for the women who had been on insulin before starting glargine (HR 2.7; 95% CI 1.1-6.5). Insulin Glargine 143-151 insulin Homo sapiens 119-126 21614572-8 2011 However, longer-term use may increase this risk, particularly in women with longstanding use of insulin before starting insulin glargine. Insulin Glargine 128-136 insulin Homo sapiens 120-127 21481127-6 2011 RESULTS: For the pooled analysis, patients on 0/1 OAD and those on MET monotherapy at baseline had the largest 24-week reductions in HbA1c following the addition of insulin glargine (~0.44 U/kg). Insulin Glargine 173-181 insulin Homo sapiens 165-172 21481127-12 2011 CONCLUSION: Adding insulin glargine to MET monotherapy early in treatment may provide efficacy/safety benefits over regimens including SU. Insulin Glargine 27-35 insulin Homo sapiens 19-26 21991713-13 2011 CONCLUSIONS: Insulin glargine or determir-based treatment does not show any superiority over other anti-diabetes treatment. Insulin Glargine 21-29 insulin Homo sapiens 13-20 21843305-2 2011 AIMS: To study prospectively the impact of initiating insulin glargine in suboptimally controlled insulin-naive patients with Type 2 diabetes on health-related quality of life in relation to glycaemic control. Insulin Glargine 62-70 insulin Homo sapiens 54-61 21843305-2 2011 AIMS: To study prospectively the impact of initiating insulin glargine in suboptimally controlled insulin-naive patients with Type 2 diabetes on health-related quality of life in relation to glycaemic control. Insulin Glargine 62-70 insulin Homo sapiens 98-105 21843305-4 2011 Patients started insulin glargine and were followed up for 6 months. Insulin Glargine 25-33 insulin Homo sapiens 17-24 21843305-12 2011 CONCLUSIONS: Results of this observational study demonstrate combined glycaemic and health-related quality of life benefits of initiating insulin glargine in patients with Type 2 diabetes in routine primary care. Insulin Glargine 146-154 insulin Homo sapiens 138-145 21775752-0 2011 Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Insulin Glargine 56-64 insulin Homo sapiens 48-55 21775752-1 2011 OBJECTIVE: In vitro evidence suggests insulin glargine promotes tumors; observational human studies are conflicting. Insulin Glargine 46-54 insulin Homo sapiens 38-45 21775756-0 2011 Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Insulin Glargine 51-59 insulin Homo sapiens 43-50 21775756-2 2011 We examined whether chronic basal insulin treatment with insulin glargine improves glucose-induced insulin secretion. Insulin Glargine 65-73 insulin Homo sapiens 34-41 21775756-2 2011 We examined whether chronic basal insulin treatment with insulin glargine improves glucose-induced insulin secretion. Insulin Glargine 65-73 insulin Homo sapiens 57-64 21775756-3 2011 RESEARCH DESIGN AND METHODS: Fourteen patients with type 2 diabetes on metformin monotherapy received an add-on therapy with insulin glargine over 8 weeks. Insulin Glargine 133-141 insulin Homo sapiens 125-132 21775756-8 2011 In contrast, insulin and C-peptide responses to intravenous glucose administration were significantly greater after the glargine treatment period (P < 0.0001, respectively). Insulin Glargine 120-128 insulin Homo sapiens 13-20 21864739-8 2011 However, most insulin glargine studies have reported a weight gain. Insulin Glargine 22-30 insulin Homo sapiens 14-21 21410859-0 2011 Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes. Insulin Glargine 87-95 insulin Homo sapiens 79-86 21410859-3 2011 Individuals with a diabetes diagnostic claim and initiated basal insulin therapy with glargine or NPH from 2001 to 2005 dispensed at least one oral antidiabetic drug prescription during 6 months prior to basal insulin initiation and enrolled in the same health insurance plan from 6 months before to 12 months or more after insulin initiation were identified. Insulin Glargine 86-94 insulin Homo sapiens 65-72 22027323-2 2011 METHODS: This was a 6-8-week multicenter (n = 652), observational, prospective Pan-European and Canadian registry study in patients with diabetes mellitus (n = 6542) who recently switched to or started treatment with insulin glargine and/or insulin glulisine using SoloSTAR or were insulin naive. Insulin Glargine 225-233 insulin Homo sapiens 217-224 22027323-7 2011 During the study, SoloSTAR was used to administer insulin glargine and/or insulin glulisine by 97.3% and 36.0% of patients, respectively (both: 27.0%). Insulin Glargine 58-66 insulin Homo sapiens 50-57 21712179-12 2011 Human studies showed that the analogue insulin glargin increases the risk of certain cancers. Insulin Glargine 47-54 insulin Homo sapiens 39-46 21443584-0 2011 Lower HbA1c after 1 year, in children with type 1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study. Insulin Glargine 80-88 insulin Homo sapiens 72-79 21443584-1 2011 OBJECTIVE: Insulin glargine offers sustained insulin delivery for 24 h. Change to glargine treatment consistently results in lower fasting glucose and fewer hypoglycemic episodes in children with type 1 diabetes compared to continuation of NPH, although glargine has not been shown to improve HbA1c in randomized trials. Insulin Glargine 19-27 insulin Homo sapiens 11-18 21443584-1 2011 OBJECTIVE: Insulin glargine offers sustained insulin delivery for 24 h. Change to glargine treatment consistently results in lower fasting glucose and fewer hypoglycemic episodes in children with type 1 diabetes compared to continuation of NPH, although glargine has not been shown to improve HbA1c in randomized trials. Insulin Glargine 19-27 insulin Homo sapiens 45-52 21443584-1 2011 OBJECTIVE: Insulin glargine offers sustained insulin delivery for 24 h. Change to glargine treatment consistently results in lower fasting glucose and fewer hypoglycemic episodes in children with type 1 diabetes compared to continuation of NPH, although glargine has not been shown to improve HbA1c in randomized trials. Insulin Glargine 82-90 insulin Homo sapiens 11-18 21443584-1 2011 OBJECTIVE: Insulin glargine offers sustained insulin delivery for 24 h. Change to glargine treatment consistently results in lower fasting glucose and fewer hypoglycemic episodes in children with type 1 diabetes compared to continuation of NPH, although glargine has not been shown to improve HbA1c in randomized trials. Insulin Glargine 82-90 insulin Homo sapiens 11-18 21443584-7 2011 Reported total insulin doses were similar at nadir (0.5 U/kg BW x 24 h), but significantly lower at 12 months in glargine treated (0.64 +- 0.23 vs. 0.86 +- 0.3 U/kg BW x 24 h; p < 0.001). Insulin Glargine 113-121 insulin Homo sapiens 15-22 21443584-9 2011 This observation should be viewed in the light of a significantly lower dose of total daily insulin in the glargine group. Insulin Glargine 107-115 insulin Homo sapiens 92-99 21735405-13 2011 Insulin glargine was dosed once-daily in the evening. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21735405-16 2011 Treatment with insulin glargine resulted in a lower daily basal insulin dose and a lower number of injection site reactions.There was no significant difference in the variability of FPG or glucose values in 24-hour profiles between treatment groups. Insulin Glargine 23-31 insulin Homo sapiens 15-22 21735405-16 2011 Treatment with insulin glargine resulted in a lower daily basal insulin dose and a lower number of injection site reactions.There was no significant difference in the variability of FPG or glucose values in 24-hour profiles between treatment groups. Insulin Glargine 23-31 insulin Homo sapiens 64-71 21735405-20 2011 However, to achieve the same glycaemic control insulin detemir was often injected twice-daily in a higher dose but with less weight gain, while insulin glargine was injected once-daily, with somewhat fewer injection site reactions. Insulin Glargine 152-160 insulin Homo sapiens 144-151 23449422-3 2011 Basal insulin analogs, detemir (Det) and glargine (Glar), have been associated with less hypoglycemia compared with neutral protamine hagedorn insulin, and Det with less weight gain, especially in patients with higher body mass index (BMI). Insulin Glargine 41-49 insulin Homo sapiens 6-13 23449422-3 2011 Basal insulin analogs, detemir (Det) and glargine (Glar), have been associated with less hypoglycemia compared with neutral protamine hagedorn insulin, and Det with less weight gain, especially in patients with higher body mass index (BMI). Insulin Glargine 51-55 insulin Homo sapiens 6-13 21506898-9 2011 RESULTS: The adjusted incidence rate ratio (and 95% confidence interval) for women who used insulin glargine alone compared with those who used other types of insulin, was 1.60 (1.10-2.32) for breast cancer but included 1.0 for malignancy outcomes other than breast cancer for men and women when analyzing cohort I with follow-up in 2006-2008. Insulin Glargine 100-108 insulin Homo sapiens 92-99 21846617-2 2011 METHODS: After cardiac surgery, 36 adult patients without diabetes were randomly assigned to receive either standard treatment (control group) or insulin glargine once daily in addition to standard treatment (basal insulin group). Insulin Glargine 154-162 insulin Homo sapiens 146-153 21846617-10 2011 CONCLUSION: Once-daily insulin glargine is safe and may decrease the duration of insulin infusion and reduce nursing time in patients without diabetes who have hyperglycemia after cardiac surgery. Insulin Glargine 31-39 insulin Homo sapiens 23-30 21846617-10 2011 CONCLUSION: Once-daily insulin glargine is safe and may decrease the duration of insulin infusion and reduce nursing time in patients without diabetes who have hyperglycemia after cardiac surgery. Insulin Glargine 31-39 insulin Homo sapiens 81-88 21506898-0 2011 Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21506898-1 2011 AIMS/HYPOTHESIS: To further investigate the association of cancer occurrence with the use of insulin glargine. Insulin Glargine 101-109 insulin Homo sapiens 93-100 21727749-7 2011 In selected patients with type 1 and type 2 diabetes, the long-acting insulin analogues glargine and detemir, as well as the premixed insulin analogues, can be used with minimal risk of metabolic derangement or hypoglycemia; the risk is higher in type 1 diabetes. Insulin Glargine 88-96 insulin Homo sapiens 70-77 21610015-13 2011 Recently, it has been suggested that the use of the basal-release insulins, particularly insulin glargine may be associated with an increased risk of cancer. Insulin Glargine 97-105 insulin Homo sapiens 66-73 21773964-1 2011 Glargine is widely used as a long-acting insulin analogue in the treatment of diabetes mellitus. Insulin Glargine 0-8 insulin Homo sapiens 41-48 21709708-0 2011 Diabetes: long-term use of insulin glargine might increase the risk of breast cancer. Insulin Glargine 35-43 insulin Homo sapiens 27-34 21376417-0 2011 Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Insulin Glargine 104-112 insulin Homo sapiens 96-103 21376417-6 2011 RESULTS: Both drugs effectively reduced postprandial glucose levels compared with the insulin glargine monotherapy. Insulin Glargine 94-102 insulin Homo sapiens 86-93 21668335-1 2011 Insulin glargine is the first 24-h recombinant DNA insulin analog introduced to the market. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21568722-6 2011 Biodel (Danbury, CT) has two long-acting basal insulin formulations in the pipeline, both in the preclinical phase of development: BIOD-Adjustable Basal, a modified formulation of insulin glargine, is available in long-, medium-, and short-acting forms and could be mixed, and BIOD-Smart Basal releases insulin proportional to the subcutaneous glucose concentration. Insulin Glargine 188-196 insulin Homo sapiens 180-187 21568722-6 2011 Biodel (Danbury, CT) has two long-acting basal insulin formulations in the pipeline, both in the preclinical phase of development: BIOD-Adjustable Basal, a modified formulation of insulin glargine, is available in long-, medium-, and short-acting forms and could be mixed, and BIOD-Smart Basal releases insulin proportional to the subcutaneous glucose concentration. Insulin Glargine 188-196 insulin Homo sapiens 180-187 21498786-6 2011 Glucagon, C-peptide, free fatty acids, and beta-hydroxy-butyrate were more suppressed with glargine than detemir. Insulin Glargine 91-99 insulin Homo sapiens 10-19 21668335-6 2011 These studies also showed greater reduction in A1c with twice-daily premixed insulins compared with glargine, when insulin glargine was administered without mealtime insulin coverage. Insulin Glargine 123-131 insulin Homo sapiens 77-84 21668335-1 2011 Insulin glargine is the first 24-h recombinant DNA insulin analog introduced to the market. Insulin Glargine 8-16 insulin Homo sapiens 51-58 21668335-6 2011 These studies also showed greater reduction in A1c with twice-daily premixed insulins compared with glargine, when insulin glargine was administered without mealtime insulin coverage. Insulin Glargine 123-131 insulin Homo sapiens 115-122 21668335-2 2011 Substitution of glycine for asparagine and addition of two arginine residues raise the isoelectric point of insulin glargine and result in microprecipitates, delaying absorption from subcutaneous tissue. Insulin Glargine 116-124 insulin Homo sapiens 108-115 21668335-7 2011 Insulin glargine was also compared with another insulin analog, insulin detemir. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21668335-10 2011 Insulin glargine is well tolerated, has low immunogenicity, reduced risks for acute myocardial infarction, and a lower risk of hypoglycemia compared with NPH insulin in individuals with type 2 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21668337-7 2011 Once-daily insulin glargine was the first "long-acting" insulin analog in clinical practice, followed by once- or twice-daily insulin detemir and, more recently, insulin degludec, which is now being evaluated for administration at less frequent intervals. Insulin Glargine 19-27 insulin Homo sapiens 11-18 21668337-7 2011 Once-daily insulin glargine was the first "long-acting" insulin analog in clinical practice, followed by once- or twice-daily insulin detemir and, more recently, insulin degludec, which is now being evaluated for administration at less frequent intervals. Insulin Glargine 19-27 insulin Homo sapiens 56-63 21668337-7 2011 Once-daily insulin glargine was the first "long-acting" insulin analog in clinical practice, followed by once- or twice-daily insulin detemir and, more recently, insulin degludec, which is now being evaluated for administration at less frequent intervals. Insulin Glargine 19-27 insulin Homo sapiens 56-63 21668340-3 2011 Addition of basal insulin (glargine, detemir, or NPH/neutral protamine lispro insulin) to previous treatment is accepted as the simplest way to start insulin therapy in those patients. Insulin Glargine 27-35 insulin Homo sapiens 18-25 21668335-5 2011 Lower risk of hypoglycemia with glargine was also consistently demonstrated by trials comparing insulin glargine and premixed analog insulins. Insulin Glargine 32-40 insulin Homo sapiens 96-103 21309835-7 2011 Studies on the analogue insulin glargine have been controversial. Insulin Glargine 32-40 insulin Homo sapiens 24-31 21613047-7 2011 The transplacental transfer of insulin glargine appears to be negligible, although it is possible that antibody-bound insulin glargine may gain access to the fetal compartment. Insulin Glargine 126-134 insulin Homo sapiens 118-125 21613047-9 2011 CONCLUSIONS: Use of insulin glargine during pregnancy should be seriously considered in uncontrolled diabetes during pregnancy and in those patients taking insulin glargine before conception, because the benefits from improved glycemic control would be expected to outweigh any, as yet, unproven risks of insulin glargine exposure. Insulin Glargine 28-36 insulin Homo sapiens 20-27 21613047-9 2011 CONCLUSIONS: Use of insulin glargine during pregnancy should be seriously considered in uncontrolled diabetes during pregnancy and in those patients taking insulin glargine before conception, because the benefits from improved glycemic control would be expected to outweigh any, as yet, unproven risks of insulin glargine exposure. Insulin Glargine 28-36 insulin Homo sapiens 156-163 21613047-9 2011 CONCLUSIONS: Use of insulin glargine during pregnancy should be seriously considered in uncontrolled diabetes during pregnancy and in those patients taking insulin glargine before conception, because the benefits from improved glycemic control would be expected to outweigh any, as yet, unproven risks of insulin glargine exposure. Insulin Glargine 28-36 insulin Homo sapiens 156-163 21613047-9 2011 CONCLUSIONS: Use of insulin glargine during pregnancy should be seriously considered in uncontrolled diabetes during pregnancy and in those patients taking insulin glargine before conception, because the benefits from improved glycemic control would be expected to outweigh any, as yet, unproven risks of insulin glargine exposure. Insulin Glargine 164-172 insulin Homo sapiens 156-163 21613047-9 2011 CONCLUSIONS: Use of insulin glargine during pregnancy should be seriously considered in uncontrolled diabetes during pregnancy and in those patients taking insulin glargine before conception, because the benefits from improved glycemic control would be expected to outweigh any, as yet, unproven risks of insulin glargine exposure. Insulin Glargine 164-172 insulin Homo sapiens 156-163 21613047-9 2011 CONCLUSIONS: Use of insulin glargine during pregnancy should be seriously considered in uncontrolled diabetes during pregnancy and in those patients taking insulin glargine before conception, because the benefits from improved glycemic control would be expected to outweigh any, as yet, unproven risks of insulin glargine exposure. Insulin Glargine 164-172 insulin Homo sapiens 156-163 21613047-9 2011 CONCLUSIONS: Use of insulin glargine during pregnancy should be seriously considered in uncontrolled diabetes during pregnancy and in those patients taking insulin glargine before conception, because the benefits from improved glycemic control would be expected to outweigh any, as yet, unproven risks of insulin glargine exposure. Insulin Glargine 164-172 insulin Homo sapiens 156-163 21309835-9 2011 Moreover, recently published clinical studies on the association of insulin glargine (Lantus ) and cancer suggest that treatment with insulin glargine is not associated with increased cancer risk. Insulin Glargine 86-92 insulin Homo sapiens 68-75 21309835-9 2011 Moreover, recently published clinical studies on the association of insulin glargine (Lantus ) and cancer suggest that treatment with insulin glargine is not associated with increased cancer risk. Insulin Glargine 142-150 insulin Homo sapiens 134-141 21613047-0 2011 Insulin glargine use during pregnancy. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21613047-1 2011 OBJECTIVE: To review the literature regarding the use of insulin glargine during pregnancy, specifically addressing the issues and concerns surrounding mitogenicity, placental transfer, and maternal and fetal safety. Insulin Glargine 65-73 insulin Homo sapiens 57-64 21613047-5 2011 RESULTS: A total of 23 reports with 1001 pregnancies managed with insulin glargine contained relevant information regarding the maternal and fetal safety of its use during pregnancy. Insulin Glargine 74-82 insulin Homo sapiens 66-73 21205127-5 2011 Exenatide or insulin glargine treatment decreased body weight by 6%. Insulin Glargine 21-29 insulin Homo sapiens 13-20 21396703-12 2011 Estimated mean HbA(1C) treatment differences from insulin degludec by comparison with insulin glargine were 0 08% (95% CI -0 23 to 0 40) for the three dose per week schedule, 0 17% (-0 15 to 0 48) for group A, and 0 28% (-0 04 to 0 59) for group B. Insulin Glargine 94-102 insulin Homo sapiens 86-93 21146881-0 2011 Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21309835-8 2011 In vitro data pointed to an elevated mitogenicity of insulin glargine, whereas in vivo data did not confirm cancerogenous effects. Insulin Glargine 61-69 insulin Homo sapiens 53-60 21309835-9 2011 Moreover, recently published clinical studies on the association of insulin glargine (Lantus ) and cancer suggest that treatment with insulin glargine is not associated with increased cancer risk. Insulin Glargine 76-84 insulin Homo sapiens 68-75 21205954-0 2011 Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Insulin Glargine 18-26 insulin Homo sapiens 10-17 21138825-6 2011 PATIENTS: Adults with type 2 diabetes and an HbA1(c) level of 7.1% to 10.5% who were receiving insulin glargine alone or in combination with metformin or pioglitazone (or both agents). Insulin Glargine 103-111 insulin Homo sapiens 95-102 21329624-5 2011 Relative risk reductions of hypoglycemia adjusted for HbA1c using insulin glargine compared with NPH insulin were based on a published negative binomial meta-regression analysis. Insulin Glargine 74-82 insulin Homo sapiens 66-73 21329624-11 2011 RESULTS: Insulin glargine was associated with an improvement in quality of life (0.098 QALYs per patient) and additional life expectancy (0.05 life years gained per patient) compared to NPH insulin. Insulin Glargine 17-25 insulin Homo sapiens 9-16 21329624-15 2011 The base case and sensitivity analyses demonstrated that insulin glargine proved to be cost-effective with respect to accepted willingness to pay thresholds and therefore represents good value for money. Insulin Glargine 65-73 insulin Homo sapiens 57-64 21219237-4 2011 We examine how critical analyses are consistent with the notion that the use of insulin glargine is associated with a possible increased risk of tumors in humans. Insulin Glargine 88-96 insulin Homo sapiens 80-87 21219237-7 2011 Furthermore, research is needed to clarify whether insulin glargine is more strongly associated with cancer risk compared with other insulins. Insulin Glargine 59-67 insulin Homo sapiens 51-58 21205954-3 2011 New insulin analogues such as the long-acting analogue insulin glargine may represent beneficial treatment options in pregnancy by ensuring that patients achieve excellent glycemic control without risk of maternal hypoglycemia. Insulin Glargine 63-71 insulin Homo sapiens 4-11 21205954-3 2011 New insulin analogues such as the long-acting analogue insulin glargine may represent beneficial treatment options in pregnancy by ensuring that patients achieve excellent glycemic control without risk of maternal hypoglycemia. Insulin Glargine 63-71 insulin Homo sapiens 55-62 21205954-4 2011 OBJECTIVE: To determine the fetal safety of insulin glargine use in the treatment of diabetes in pregnancy compared with NPH insulin therapy. Insulin Glargine 52-60 insulin Homo sapiens 44-51 20970870-1 2011 The aim of this study was to compare coefficient of variation of fasting capillary blood glucose (FBG) between insulin glargine and NPH in T2DM with poorly controlled by oral antidiabetic drugs. Insulin Glargine 119-127 insulin Homo sapiens 111-118 20570843-2 2011 It has been reported with insulin Lispro (Eli Lilly, Indianapolis, Indiana, USA) and insulin Glargine (Sanofi-Aventis, Paris, France). Insulin Glargine 93-101 insulin Homo sapiens 85-92 20970870-2 2011 The results demonstrated that insulin glargine was more potent in improving glycemic control than NPH with stable FBG. Insulin Glargine 38-46 insulin Homo sapiens 30-37 20938889-0 2011 Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Insulin Glargine 46-54 insulin Homo sapiens 38-45 21175268-6 2011 While sitagliptin addition resulted in a small weight loss (0.3 kg), insulin glargine addition resulted in a weight gain (0.7 kg). Insulin Glargine 77-85 insulin Homo sapiens 69-76 21792327-1 2011 OBJECTIVE: This study aimed to compare the glucose-lowering effect and glycemic variability of insulin glargine with those of insulin detemir. Insulin Glargine 103-111 insulin Homo sapiens 95-102 21792327-7 2011 Mean blood glucose calculated from CGM values was significantly lower with insulin glargine compared with insulin detemir (9.6 +- 2.4 mmol/L versus 10.4 +- 2.8 mmol/L, P = 0.038). Insulin Glargine 83-91 insulin Homo sapiens 75-82 21792327-9 2011 The MODD value was significantly lower with insulin glargine than with insulin detemir (2.2 +- 1.1 mmol/L vs 3.6 +- 1.7 mmol/L, P = 0.011). Insulin Glargine 52-60 insulin Homo sapiens 44-51 21792327-11 2011 CONCLUSION: This study suggests that insulin glargine leads to more effective and more stable glycemic control than the same dose of insulin detemir. Insulin Glargine 45-53 insulin Homo sapiens 37-44 21175274-0 2011 Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Insulin Glargine 21-29 insulin Homo sapiens 13-20 21175274-12 2011 CONCLUSIONS: ATLAS will provide information on the relative safety and efficacy of a patient- versus physician-led titration strategy for insulin glargine-based basal insulin initiation in patients who are not controlled with two OADs in Asia and Russia. Insulin Glargine 146-154 insulin Homo sapiens 138-145 21226564-0 2011 Placental transfer of the insulin analog glargine in the ex vivo perfused placental cotyledon model. Insulin Glargine 41-49 insulin Homo sapiens 26-33 21226564-1 2011 OBJECTIVE: The aim was to characterize the transfer of the insulin analog glargine across the placenta using the placental perfusion model. Insulin Glargine 74-82 insulin Homo sapiens 59-66 20938889-0 2011 Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Insulin Glargine 46-54 insulin Homo sapiens 64-71 20938889-0 2011 Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Insulin Glargine 46-54 insulin Homo sapiens 64-71 20938889-3 2011 This article aims to critically review studies on the mitogenic effects of the insulin analogue insulin glargine (glargine) and its metabolites. Insulin Glargine 104-112 insulin Homo sapiens 79-86 20938889-3 2011 This article aims to critically review studies on the mitogenic effects of the insulin analogue insulin glargine (glargine) and its metabolites. Insulin Glargine 104-112 insulin Homo sapiens 96-103 20938889-3 2011 This article aims to critically review studies on the mitogenic effects of the insulin analogue insulin glargine (glargine) and its metabolites. Insulin Glargine 114-122 insulin Homo sapiens 79-86 20938889-3 2011 This article aims to critically review studies on the mitogenic effects of the insulin analogue insulin glargine (glargine) and its metabolites. Insulin Glargine 114-122 insulin Homo sapiens 96-103 20938889-7 2011 Furthermore, glargine in vivo is rapidly transformed into its metabolites, the metabolic and mitogenic characteristics of which have been shown to be broadly equal to those of human insulin. Insulin Glargine 13-21 insulin Homo sapiens 182-189 20938889-8 2011 Thus, the suggestion of increased relative mitogenic potency of insulin glargine seen in some cell lines does not appear to carry over to the in vivo situation in animals and humans. Insulin Glargine 72-80 insulin Homo sapiens 64-71 22267935-2 2011 Modifications of the insulin molecule have resulted in two long-acting insulin analogs (glargine and detemir) and three rapid-acting insulins (aspart, lispro, and glulisine) with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles. Insulin Glargine 88-96 insulin Homo sapiens 21-28 22267935-4 2011 METHODS: This study reviews effects of the multiple demographic and clinical parameters in the insulin analogs glargine, detemir, lispro, aspart, and glulisine in patients with T2DM. Insulin Glargine 111-119 insulin Homo sapiens 95-102 21361858-1 2011 BACKGROUND: Two basal insulin analogues, insulin glargine once daily and insulin detemir once or twice daily, are marketed in Canada. Insulin Glargine 49-57 insulin Homo sapiens 22-29 22187651-0 2011 Effects of Selected Anionic beta-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats. Insulin Glargine 99-107 insulin Homo sapiens 91-98 22187651-1 2011 Insulin glargine is a synthetic long-acting insulin product used for patients with diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 22187651-1 2011 Insulin glargine is a synthetic long-acting insulin product used for patients with diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 44-51 22187651-2 2011 In this study, to obtain the further desirable blood-glucose lowering profile of insulin glargine, we investigated the effects of beta-cyclodextrin sulfate (Sul-beta-CyD) and sulfobutylether beta-cyclodextrin (SBE7-beta-CyD) on physicochemical properties of insulin glargine and pharmacokinetics/pharmacodynamics of insulin glargine after subcutaneous injection to rats. Insulin Glargine 89-97 insulin Homo sapiens 81-88 22187651-3 2011 Sul-beta-CyD and SBE7-beta-CyD increased solubility of insulin glargine. Insulin Glargine 63-71 insulin Homo sapiens 55-62 22187651-4 2011 SBE7-beta-CyD suppressed the formation of oligomer and enhanced the dissolution rate of insulin glargine from its precipitate, compared to that of Sul-beta-CyD. Insulin Glargine 96-104 insulin Homo sapiens 88-95 22187651-5 2011 Additionally, we revealed that after subcutaneous administration of an insulin glargine solution, SBE7-beta-CyD, but not Sul-beta-CyD, increased bioavailability and sustained the blood-glucose lowering effect, possibly due to the inhibitory effects of SBE7-beta-CyD on the enzymatic degradation at the injection site. Insulin Glargine 79-87 insulin Homo sapiens 71-78 22187651-6 2011 These results suggest that SBE7-beta-CyD could be a useful excipient for sustained release of insulin glargine. Insulin Glargine 102-110 insulin Homo sapiens 94-101 21563878-2 2011 RESEARCH DESIGN AND METHODS: The IMS CORE Diabetes Model was used to project clinical and economic outcomes for patients with type 2 diabetes treated with EQW or insulin glargine. Insulin Glargine 170-178 insulin Homo sapiens 162-169 21563878-12 2011 Three BMI subgroups investigated (<30, 30-35 and >35 kg/m(2)) reported ICERs for EQW compared with insulin glargine ranging from $9425 to $12,956 per QALY gained. Insulin Glargine 113-121 insulin Homo sapiens 105-112 21563878-13 2011 CONCLUSIONS: At the prices investigated, the cost per QALY gained for EQW when compared with insulin glargine in type 2 diabetes in the UK setting, was within the range normally considered cost effective by NICE. Insulin Glargine 101-109 insulin Homo sapiens 93-100 21303636-2 2011 METHODS: Structured one-on-one interviews were conducted with 400 patients with diabetes in the United States, using either a differentiated (n = 100) or undifferentiated (n = 100) SoloSTAR (insulin glargine vs insulin glulisine) or (n = 200) FlexPen (insulin detemir vs insulin aspart). Insulin Glargine 200-208 insulin Homo sapiens 192-199 21361858-1 2011 BACKGROUND: Two basal insulin analogues, insulin glargine once daily and insulin detemir once or twice daily, are marketed in Canada. Insulin Glargine 49-57 insulin Homo sapiens 41-48 21361858-2 2011 OBJECTIVE: To estimate the long-term costs of insulin glargine once daily (QD) versus insulin detemir once or twice daily (QD or BID) for type 1 (T1DM) and type 2 (T2DM) diabetes mellitus from a Canadian provincial government"s perspective. Insulin Glargine 54-62 insulin Homo sapiens 46-53 21098374-0 2010 Risk of cancer in patients receiving insulin glargine. Insulin Glargine 45-53 insulin Homo sapiens 37-44 21823538-0 2011 Glargine basal-bolus insulin regimen versus insulin pump therapy: comparison of glycemic control. Insulin Glargine 0-8 insulin Homo sapiens 21-28 21269980-9 2011 CONCLUSION: Glargine therapy better mimics the physiological insulin secretion patterns, and when combined with oral antidiabetic drugs, can be more effective and safer than premixed insulin. Insulin Glargine 12-20 insulin Homo sapiens 61-68 21738645-0 2011 Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. Insulin Glargine 36-44 insulin Homo sapiens 28-35 21738645-1 2011 BACKGROUND: Preclinical and observational studies raise the concern about the safety of insulin glargine in terms of cancer initiation and promotion. Insulin Glargine 96-104 insulin Homo sapiens 88-95 21738645-2 2011 This study is designed to examine cancer incidence associated with use of insulin glargine vs. intermediate/long-acting human insulin (HI). Insulin Glargine 82-90 insulin Homo sapiens 74-81 21738645-3 2011 METHODOLOGY: A retrospective cohort study using the Taiwan National Health Insurance claims database was conducted to identify adult patients with type 2 diabetes mellitus and without a history of cancer who initiated insulin glargine (n = 10,190) or intermediate/long-acting HI (n = 49,253) during 2004-2007. Insulin Glargine 226-234 insulin Homo sapiens 218-225 21738645-8 2011 For men, however, the adjusted hazard ratio of insulin glargine use as compared with intermediate/long-acting HI was 2.15 (95% CI 1.01-4.59) for pancreatic cancer, and 2.42 (95% CI 1.50-8.40) for prostate cancer. Insulin Glargine 55-63 insulin Homo sapiens 47-54 21738645-10 2011 CONCLUSIONS: Insulin glargine use did not increase the risk of overall cancer incidence as compared with HI. Insulin Glargine 21-29 insulin Homo sapiens 13-20 21098374-1 2010 PURPOSE: The risk of malignancy in patients using insulin glargine was evaluated. Insulin Glargine 58-66 insulin Homo sapiens 50-57 21098374-7 2010 In vivo, insulin glargine has been shown to have greater mitogenic potential than human insulin. Insulin Glargine 17-25 insulin Homo sapiens 9-16 21098374-8 2010 It is unknown whether this occurs in vitro, because the insulin glargine molecule is transformed once injected. Insulin Glargine 64-72 insulin Homo sapiens 56-63 21098374-9 2010 Studies published in 2009 suggest that patients on insulin glargine could be at greater risk for cancer than patients on other antidiabetes therapies, but the trial results are conflicting. Insulin Glargine 59-67 insulin Homo sapiens 51-58 21098374-11 2010 CONCLUSION: Studies on the relationship between insulin glargine and cancer have been inconclusive. Insulin Glargine 56-64 insulin Homo sapiens 48-55 21055982-0 2010 Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20835859-3 2010 Furthermore, several recent epidemiological studies have suggested a potential increase in cancer risk for treatment of diabetes patients with long-acting analogue insulin glargine (A21Gly,B31Arg,B32Arg human insulin). Insulin Glargine 172-180 insulin Homo sapiens 164-171 20835859-3 2010 Furthermore, several recent epidemiological studies have suggested a potential increase in cancer risk for treatment of diabetes patients with long-acting analogue insulin glargine (A21Gly,B31Arg,B32Arg human insulin). Insulin Glargine 172-180 insulin Homo sapiens 209-216 20835859-7 2010 IGF-I receptor (IGF-IR) internalisation following insulin glargine treatment was assessed by confocal microscopy. Insulin Glargine 58-66 insulin Homo sapiens 50-57 20835859-11 2010 Dose-dependency experiments showed that insulin glargine was able to phosphorylate the IGF-IR at fivefold lower doses than those required to activate the insulin receptor. Insulin Glargine 48-56 insulin Homo sapiens 40-47 20835859-12 2010 We also showed that insulin glargine can lead to prolonged activation of the receptors and therefore promote abnormal signalling. Insulin Glargine 28-36 insulin Homo sapiens 20-27 20835859-13 2010 Confocal imaging experiments showed that insulin glargine, but not regular insulin induced IGF-IR internalisation similarly to IGF-I. Insulin Glargine 49-57 insulin Homo sapiens 41-48 21761363-0 2010 Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21761363-1 2010 The insulin analog glargine has a higher binding affinity than regular insulin for the insulin-like growth factor 1 receptor in vitro, raising questions about increased mitogenicity in vivo. Insulin Glargine 19-27 insulin Homo sapiens 4-11 21761363-2 2010 Observational studies in humans have recently reported a potential differential association between insulin glargine and malignancies, but available evidence remains inconclusive. Insulin Glargine 108-116 insulin Homo sapiens 100-107 21055982-7 2010 Long-acting analogues: At <10 nM insulin glargine was as potent as HI in activating the IRs and IGF-IR. Insulin Glargine 44-52 insulin Homo sapiens 36-43 21055982-8 2010 At 10-100 nM insulin glargine was significantly more potent than HI in activating the IR-B (p<0.05) and IGF-IR (p<0.001). Insulin Glargine 21-29 insulin Homo sapiens 13-20 21055982-9 2010 Insulin glargine was more potent than insulin detemir in activating all three receptors (p<0.001). Insulin Glargine 8-16 insulin Homo sapiens 0-7 21055982-11 2010 CONCLUSIONS: Insulin glargine was more potent in activating the IGF-IR than HI and insulin detemir. Insulin Glargine 21-29 insulin Homo sapiens 13-20 21055982-12 2010 Since KIRA bioassays do not mimic the exact in vivo situation, further research is needed to find out whether our data have implications for clinical use of insulin glargine. Insulin Glargine 165-173 insulin Homo sapiens 157-164 20969435-4 2010 Insulin glargine was the first long-acting insulin analog with a 24-h duration of action, offering once-daily injection, and has now been in clinical use for over 10 years. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20969435-4 2010 Insulin glargine was the first long-acting insulin analog with a 24-h duration of action, offering once-daily injection, and has now been in clinical use for over 10 years. Insulin Glargine 8-16 insulin Homo sapiens 43-50 20969435-6 2010 Randomized controlled trials have demonstrated that glycemic control with insulin glargine is at least comparable to that with neutral protamine Hagedorn (NPH) insulin in adults and in children and adolescents, and with continuous subcutaneous insulin infusion in adults. Insulin Glargine 82-90 insulin Homo sapiens 74-81 20969435-7 2010 However, these same trials show a significantly lower risk for hypoglycemia with insulin glargine compared with NPH insulin in adults. Insulin Glargine 89-97 insulin Homo sapiens 81-88 20973689-4 2010 The insulin analog glargine was the focus of four observational studies published in 2009 that outlined an increase in the rates of cancer associated with its use. Insulin Glargine 19-27 insulin Homo sapiens 4-11 20920444-2 2010 ClikSTAR (sanofi-aventis) is a novel reusable insulin pen for injecting either long-acting insulin glargine or short-acting insulin glulisine. Insulin Glargine 100-108 insulin Homo sapiens 47-54 20621572-2 2010 The publication of a possible association between the use of a long-acting insulin analogue (glargine) and breast cancer has caused uneasiness among the medical community regarding the safety of these analogues. Insulin Glargine 93-101 insulin Homo sapiens 75-82 20687863-9 2010 CONCLUSIONS: CSII provided improved glucose control compared to glargine with a lower mean plasma glucose and longer periods of glucose values within target on a somewhat lower insulin dose. Insulin Glargine 64-72 insulin Homo sapiens 177-184 20678116-7 2010 Total insulin dose increased in the type 1 glargine group. Insulin Glargine 43-51 insulin Homo sapiens 6-13 20494360-1 2010 OBJECTIVE: The objective of the present study was to investigate the effects of one-year treatment with exenatide or Insulin Glargine, followed by a 5-week off-drug period, on postprandial lipidaemia, glycaemia and measures of oxidative stress. Insulin Glargine 125-133 insulin Homo sapiens 117-124 20494360-4 2010 RESULTS: 51-Week exenatide treatment resulted in a significant reduction of prandial glucose, triglycerides, apo-B48, calculated VLDL-C, FFA and MDA excursions whereas Insulin Glargine predominantly reduced fasting glucose, FFA and MDA. Insulin Glargine 176-184 insulin Homo sapiens 168-175 20494360-8 2010 Following cessation of both exenatide and Insulin Glargine measures returned to pre-treatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy. Insulin Glargine 50-58 insulin Homo sapiens 42-49 20551014-8 2010 Incident cancer was associated with a dose of glargine >or=0.3 IU/kg/day even after adjusting for Charlson comorbidity score, other types of insulin administration, and metformin exposure (odds ratio 5.43 [95% CI 2.18-13.53], P < 0.001). Insulin Glargine 46-54 insulin Homo sapiens 144-151 20551014-10 2010 CONCLUSIONS: The possibility of association between cancer and higher glargine doses suggests that dosages should always be considered when assessing the possible association of insulin and its analogues with cancer. Insulin Glargine 70-78 insulin Homo sapiens 178-185 20618882-4 2010 Key glucose-clamp studies that compare two basal insulin analogues - insulin glargine and insulin detemir - to Neutral Protamine Hagedorn insulin and to each other are then presented. Insulin Glargine 77-85 insulin Homo sapiens 49-56 20590745-12 2010 CONCLUSIONS: In this study, treatment with insulin glargine in people with T2DM was associated with a significant reduction in HbA1c without differential increase in weight gain in obese and non-obese subgroups. Insulin Glargine 51-59 insulin Homo sapiens 43-50 20424219-7 2010 Insulin glargine significantly reduced endothelin-1 by 7%. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19703761-1 2010 BACKGROUND AND AIMS: Once-daily (OD) basal insulin glargine (GLA) can be used as part of a multiple daily injection regimen in patients with type 1 diabetes mellitus. Insulin Glargine 51-59 insulin Homo sapiens 43-50 19703761-1 2010 BACKGROUND AND AIMS: Once-daily (OD) basal insulin glargine (GLA) can be used as part of a multiple daily injection regimen in patients with type 1 diabetes mellitus. Insulin Glargine 61-64 insulin Homo sapiens 43-50 20795850-0 2010 Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20795850-3 2010 Recently, the insulin analog glargine was reported in several epidemiologic studies to be associated with an increased risk of cancer. Insulin Glargine 29-37 insulin Homo sapiens 14-21 20939447-0 2010 Cancer risk in diabetic patients treated with insulin glargine? Insulin Glargine 54-62 insulin Homo sapiens 46-53 20615108-1 2010 BACKGROUND: We designed a system for diabetes patients treated with glargine, a long-acting insulin, to make an automatic adjustment of insulin dose based on glucose level data and to provide the patients with the needed insulin dose by using a short message service (SMS). Insulin Glargine 68-76 insulin Homo sapiens 92-99 24688145-2 2010 Insulin glargine is a standard agent used to supplement basal insulin in type 2 diabetes mellitus (T2DM). Insulin Glargine 8-16 insulin Homo sapiens 0-7 20615108-1 2010 BACKGROUND: We designed a system for diabetes patients treated with glargine, a long-acting insulin, to make an automatic adjustment of insulin dose based on glucose level data and to provide the patients with the needed insulin dose by using a short message service (SMS). Insulin Glargine 68-76 insulin Homo sapiens 136-143 20615108-1 2010 BACKGROUND: We designed a system for diabetes patients treated with glargine, a long-acting insulin, to make an automatic adjustment of insulin dose based on glucose level data and to provide the patients with the needed insulin dose by using a short message service (SMS). Insulin Glargine 68-76 insulin Homo sapiens 136-143 20508081-0 2010 Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. Insulin Glargine 106-114 insulin Homo sapiens 98-105 20939447-1 2010 Insulin glargine was the first long-acting human insulin analogue to be authorised in the European Union, in the early 2000s, for the treatment of diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20939447-1 2010 Insulin glargine was the first long-acting human insulin analogue to be authorised in the European Union, in the early 2000s, for the treatment of diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 49-56 20939447-3 2010 Four European epidemiological studies published in 2009 examined the risk of cancer in diabetic patients treated with insulin glargine. Insulin Glargine 126-134 insulin Homo sapiens 118-125 20561185-2 2010 In people, insulin glargine is longer acting and has a relatively flat time-action profile, while insulin detemir has significantly less within-subject variability. Insulin Glargine 19-27 insulin Homo sapiens 11-18 20636954-11 2010 Insulin glargine metrics increased year-on-year, whereas neutral protamine Hagedorn (NPH) declined. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20357371-0 2010 Dose-response effects of insulin glargine in type 2 diabetes. Insulin Glargine 33-41 insulin Homo sapiens 25-32 20357371-1 2010 OBJECTIVE: To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Insulin Glargine 97-105 insulin Homo sapiens 89-96 20350924-0 2010 Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Insulin Glargine 39-47 insulin Homo sapiens 31-38 20350924-1 2010 OBJECTIVE: To compare glycemic control with add-on insulin glargine versus pioglitazone treatment in patients with type 2 diabetes. Insulin Glargine 59-67 insulin Homo sapiens 51-58 20350924-5 2010 RESULTS: At end point, insulin glargine yielded a significantly greater reduction in A1C in comparison with pioglitazone (-2.48% versus -1.86%, respectively; 95% confidence interval, -0.93 to -0.31; P = .0001, 48-week modified intent-to-treat population). Insulin Glargine 31-39 insulin Homo sapiens 23-30 20350924-6 2010 Insulin glargine also yielded significantly greater reductions in fasting plasma glucose at all time points (end point difference, -34.9 mg/dL; 95% confidence interval, -47.6 to -22.2; P<.0001). Insulin Glargine 8-16 insulin Homo sapiens 0-7 20350924-9 2010 CONCLUSION: The addition of insulin glargine early in the diabetes treatment paradigm in patients for whom sulfonylurea or metformin monotherapy had failed resulted in significantly greater improvements in glycemic control in comparison with the addition of pioglitazone. Insulin Glargine 36-44 insulin Homo sapiens 28-35 20350924-10 2010 Although severe hypoglycemia was more frequent in patients with insulin glargine therapy, hypoglycemic events occurred in <5% of patients in the insulin glargine treatment group. Insulin Glargine 72-80 insulin Homo sapiens 64-71 20350924-10 2010 Although severe hypoglycemia was more frequent in patients with insulin glargine therapy, hypoglycemic events occurred in <5% of patients in the insulin glargine treatment group. Insulin Glargine 156-164 insulin Homo sapiens 148-155 20561185-12 2010 CONCLUSION AND CLINICAL IMPORTANCE: Insulin detemir and insulin glargine have shorter durations of action than in people when assessed by the clamp method, but in some cats these insulin analogs could be useful as once-a-day drugs. Insulin Glargine 64-72 insulin Homo sapiens 56-63 20609969-2 2010 We aimed to test the hypothesis that improvement in haemoglobin A(1c) (HbA(1c)) achieved with once weekly exenatide was superior to that achieved with insulin glargine titrated to glucose targets. Insulin Glargine 159-167 insulin Homo sapiens 151-158 20609969-12 2010 12 (5%) of 233 patients allocated to exenatide and two (1%) of 223 taking insulin glargine discontinued participation because of adverse events (p=0.012). Insulin Glargine 82-90 insulin Homo sapiens 74-81 20177658-3 2010 In another study, the risk of cancer overall increased with dose for any type of insulin and, among high doses, insulin glargine (A21Gly,B31Arg,B32Arg human insulin)-only users had a higher risk than subjects on human insulin. Insulin Glargine 120-128 insulin Homo sapiens 112-119 20363044-4 2010 Mean self-measured plasma glucose (SMPG) at bedtime was significantly lower with BIAsp 30 than insulin glargine (7.98+/-0.34 mmol/L vs. 9.16+/-0.33 mmol/L, p=0.0078). Insulin Glargine 103-111 insulin Homo sapiens 95-102 20685497-1 2010 BACKGROUND: Insulin glargine and lispro mix 75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection [LM75/25]) represent 2 common starter insulin regimen classes: basal and premixed. Insulin Glargine 20-28 insulin Homo sapiens 12-19 20150302-3 2010 However, no formal glucose clamp studies have been performed to determine whether mixing with glargine has an adverse effect on the early pharmacodynamic action of rapid-acting insulin in humans. Insulin Glargine 94-102 insulin Homo sapiens 177-184 20188617-0 2010 Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes. Insulin Glargine 15-23 insulin Homo sapiens 7-14 20188617-1 2010 AIM: The aim of this study was to examine the safety of insulin glargine during pregnancy in women with type 1 diabetes mellitus (T1DM). Insulin Glargine 64-72 insulin Homo sapiens 56-63 20188617-2 2010 METHODS: This retrospective multicentre study involved women with T1DM treated with insulin glargine before conception and throughout pregnancy. Insulin Glargine 92-100 insulin Homo sapiens 84-91 20188617-8 2010 CONCLUSION: Insulin glargine use throughout pregnancy does not appear to be associated with an increased rate of severe congenital malformations. Insulin Glargine 20-28 insulin Homo sapiens 12-19 20200301-9 2010 CONCLUSIONS: In insulin-naive type 2 diabetic patients, glargine reached similar control as detemir, with more weight gain, but required significantly lower doses. Insulin Glargine 56-64 insulin Homo sapiens 16-23 20177658-3 2010 In another study, the risk of cancer overall increased with dose for any type of insulin and, among high doses, insulin glargine (A21Gly,B31Arg,B32Arg human insulin)-only users had a higher risk than subjects on human insulin. Insulin Glargine 120-128 insulin Homo sapiens 112-119 20415692-0 2010 Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes. Insulin Glargine 15-23 insulin Homo sapiens 7-14 20425675-0 2010 [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes]. Insulin Glargine 35-43 insulin Homo sapiens 27-34 20425675-5 2010 TREATMENT AND COURSE: The patient was initially treated with a combination of insulin glargine and metformin. Insulin Glargine 86-94 insulin Homo sapiens 78-85 20425675-13 2010 CONCLUSIONS: Initial combination treatment with insulin glargine, metformin and exenatide may be beneficial in a subgroup of patients with newly diagnosed type 2 diabetes, markedly elevated blood glucose and free fatty acid levels (glucolipotoxicity). Insulin Glargine 56-64 insulin Homo sapiens 48-55 20182859-1 2010 AIMS/HYPOTHESIS: Negative effects on the progression of adenocarcinomas by hyperinsulinaemia and the insulin analogue glargine (A21Gly,B31Arg,B32Arg human insulin) have recently been suggested. Insulin Glargine 118-126 insulin Homo sapiens 101-108 20425680-8 2010 For the long-acting analogue insulin glargine, in vitro data, though controversial, pointed to an increased mitogenicity that was, however, not confirmed by in vivo studies. Insulin Glargine 37-45 insulin Homo sapiens 29-36 20425680-9 2010 Recently, six clinical studies have been published that analysed the association between the application of insulin glargine (Lantus) and cancer development. Insulin Glargine 116-124 insulin Homo sapiens 108-115 20425680-12 2010 Future studies are required to investigate whether a subpopulation characterised by a less rapid metabolization of insulin glargine in vivo may be at increased cancer risk. Insulin Glargine 123-131 insulin Homo sapiens 115-122 20185733-4 2010 Patients using insulin glargine or detemir (n = 5,317) had a higher DKA incidence than individuals using NPH insulin (n = 5,365, 6.6 +/- 0.4 vs. 3.6 +/- 0.3, P < 0.001). Insulin Glargine 23-31 insulin Homo sapiens 15-22 20185733-6 2010 CONCLUSIONS Despite their long-acting pharmacokinetics, the use of insulin glargine or detemir is not associated with a lower incidence of DKA compared with NPH insulin. Insulin Glargine 75-83 insulin Homo sapiens 67-74 20080164-3 2010 One long-acting insulin analog, glargine insulin, was also absorbed from the nose when applied individually in the presence of 0.125% TDM (T(max)=60min). Insulin Glargine 32-40 insulin Homo sapiens 16-23 20072962-2 2010 METHODS: 15 type 1 and 14 type 2 diabetic patients receiving intensive insulin therapy with insulin glargine were enrolled. Insulin Glargine 100-108 insulin Homo sapiens 71-78 20072962-8 2010 CONCLUSION: The present study demonstrated lower within-subject variability of insulin detemir compared to insulin glargine, suggesting that the basal insulin replacement with insulin detemir may provide a useful therapeutic strategy for uncontrolled type 1 diabetes with high glucose variability. Insulin Glargine 115-123 insulin Homo sapiens 107-114 20463425-8 2010 Data from our review suggest that insulin analogs, particularly insulin glargine, may play more of a mitogenic than a carcinogenic role in association with different types of cancer, suggesting an amplified rate of existing tumor growth in the presence of insulin analogs. Insulin Glargine 72-80 insulin Homo sapiens 34-41 20463425-8 2010 Data from our review suggest that insulin analogs, particularly insulin glargine, may play more of a mitogenic than a carcinogenic role in association with different types of cancer, suggesting an amplified rate of existing tumor growth in the presence of insulin analogs. Insulin Glargine 72-80 insulin Homo sapiens 64-71 20463425-8 2010 Data from our review suggest that insulin analogs, particularly insulin glargine, may play more of a mitogenic than a carcinogenic role in association with different types of cancer, suggesting an amplified rate of existing tumor growth in the presence of insulin analogs. Insulin Glargine 72-80 insulin Homo sapiens 64-71 20080164-3 2010 One long-acting insulin analog, glargine insulin, was also absorbed from the nose when applied individually in the presence of 0.125% TDM (T(max)=60min). Insulin Glargine 32-40 insulin Homo sapiens 41-48 20369755-6 2010 Other insulin analogues, particularly glargine and possibly detemir have a flat profile of up to 24 hours, providing improved basal insulin delivery. Insulin Glargine 38-46 insulin Homo sapiens 6-13 20209060-0 2010 In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. Insulin Glargine 54-62 insulin Homo sapiens 46-53 20209060-1 2010 BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. Insulin Glargine 20-28 insulin Homo sapiens 12-19 20209060-1 2010 BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. Insulin Glargine 20-28 insulin Homo sapiens 61-68 20209060-1 2010 BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. Insulin Glargine 30-36 insulin Homo sapiens 12-19 20209060-1 2010 BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. Insulin Glargine 30-36 insulin Homo sapiens 61-68 20209060-2 2010 After subcutaneous injection insulin glargine is partly converted into the two main metabolites M1 ([Gly(A21)]insulin) and M2 ([Gly(A21),des-Thr(B30)]insulin). Insulin Glargine 37-45 insulin Homo sapiens 29-36 20209060-2 2010 After subcutaneous injection insulin glargine is partly converted into the two main metabolites M1 ([Gly(A21)]insulin) and M2 ([Gly(A21),des-Thr(B30)]insulin). Insulin Glargine 37-45 insulin Homo sapiens 110-117 20209060-2 2010 After subcutaneous injection insulin glargine is partly converted into the two main metabolites M1 ([Gly(A21)]insulin) and M2 ([Gly(A21),des-Thr(B30)]insulin). Insulin Glargine 37-45 insulin Homo sapiens 110-117 20209060-4 2010 METHODS: The affinity of human insulin, insulin glargine and its metabolites to the IR isoforms A and B or IGF1R was analyzed in a competitive binding assay using SPA technology. Insulin Glargine 48-56 insulin Homo sapiens 40-47 20209060-8 2010 CONCLUSIONS: The binding of insulin glargine and its metabolites M1 and M2 to the IR were similar and correlated well with their corresponding autophosphorylation and metabolic activities in vitro. Insulin Glargine 36-44 insulin Homo sapiens 28-35 20209060-10 2010 Insulin glargine showed a higher affinity for IGF1R than insulin, resulting in a lower EC(50) value for autophosphorylation of the receptor and a more potent stimulation of thymidine incorporation in Saos-2 cells. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20209060-10 2010 Insulin glargine showed a higher affinity for IGF1R than insulin, resulting in a lower EC(50) value for autophosphorylation of the receptor and a more potent stimulation of thymidine incorporation in Saos-2 cells. Insulin Glargine 8-16 insulin Homo sapiens 57-64 20209060-12 2010 These findings strongly support the idea that insulin glargine metabolites contribute with the same potency as insulin glargine to blood glucose control but lead to significantly reduced growth-promoting activity. Insulin Glargine 54-62 insulin Homo sapiens 46-53 20001763-0 2010 Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Insulin Glargine 104-112 insulin Homo sapiens 39-46 20001763-0 2010 Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Insulin Glargine 104-112 insulin Homo sapiens 96-103 20137765-13 2010 CONCLUSIONS: The current model estimated that insulin glargine was associated with lower annual treatment costs of euro 486 (36%) compared to the use of insulin detemir while the same glycemic control is expected to be achieved. Insulin Glargine 54-62 insulin Homo sapiens 46-53 20307414-0 2010 Insulin glargine and incidence of cancer--an ongoing debate. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20546261-11 2010 CONCLUSIONS: Treatment to target of FPG < 5.3 mmol/l with insulin glargine was not associated with significantly increased risk of hypoglycaemia. Insulin Glargine 69-77 insulin Homo sapiens 61-68 20546261-12 2010 Strict control of FPG with insulin glargine was effective to control postprandial glucose excursion, but had no significant effect on sd and MAGE. Insulin Glargine 35-43 insulin Homo sapiens 27-34 20546271-2 2010 However, with the introduction of insulin analogues such as glargine (with a basal insulin profile), supper may be unnecessary. Insulin Glargine 60-68 insulin Homo sapiens 34-41 20546271-2 2010 However, with the introduction of insulin analogues such as glargine (with a basal insulin profile), supper may be unnecessary. Insulin Glargine 60-68 insulin Homo sapiens 83-90 20219490-4 2010 Insulin glargine and insulin detemir are long-acting, and are used in people as basal insulin replacement. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20345066-1 2010 Insulin Glargine is recommended as a once-daily basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20345066-1 2010 Insulin Glargine is recommended as a once-daily basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 54-61 20578781-5 2010 METHODS: Using treatment effects taken from a published clinical trial, the validated IMS-CORE Diabetes Model was used to simulate the long-term cost effectiveness of insulin glargine with OADs, versus premixed insulin. Insulin Glargine 175-183 insulin Homo sapiens 167-174 21595146-2 2010 The mechanical disposable pen SoloStar containing the insulin analogs glargine or glulisine (each 100 IE/ml) provides modern design with user-friendly handling features. Insulin Glargine 70-78 insulin Homo sapiens 54-61 20948845-4 2010 A recent series of publications in Diabetologia addresses the possibility that glargine, the most widely used long-acting insulin analogue, may confer a greater risk than other insulin preparations, particularly for breast cancer. Insulin Glargine 79-87 insulin Homo sapiens 122-129 20196485-0 2010 [Insulin allergy whose local/systemic reactions were reduced by desensitization with long-acting insulin analog, glargine]. Insulin Glargine 113-121 insulin Homo sapiens 1-8 20196485-0 2010 [Insulin allergy whose local/systemic reactions were reduced by desensitization with long-acting insulin analog, glargine]. Insulin Glargine 113-121 insulin Homo sapiens 97-104 20578781-13 2010 RESULTS: Base-case analyses showed that, compared with premixed insulin only, insulin glargine in combination with OADs was associated with a 0.051-year increase in LE and a 0.043 increase in QALYs. Insulin Glargine 86-94 insulin Homo sapiens 78-85 20578781-14 2010 Insulin glargine plus OADs showed a very slight increase in total direct costs ($Can 343 +/- 2572), resulting in ICERs of $Can 6750 per life-year gained (LYG) and $Can 7923 per QALY gained. Insulin Glargine 8-16 insulin Homo sapiens 0-7 20578781-15 2010 However, considerable uncertainty around the ICERs was demonstrated by insulin glargine having a 50% probability of being cost effective at a willingness-to-pay threshold of $Can 10,000 per QALY, and a 54% probability at a $Can 20,000 threshold. Insulin Glargine 79-87 insulin Homo sapiens 71-78 19921965-4 2010 The inclusion criteria were members with type 2 diabetes who had at least one pharmacy claim for insulin glargine, insulin detemir, exenatide, or isophane insulin human (NPH insulin) from January 1, 2006 through June 30, 2006. Insulin Glargine 105-113 insulin Homo sapiens 97-104 20224847-0 2010 Insulin glargine and the risk of cancer. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19919375-2 2010 The aim of this study was to compare the amount of insulin utilized in a large cohort of patients with type 2 diabetes treated with either DET or GLAR in the real-world setting considering the use of other antidiabetic agents. Insulin Glargine 146-150 insulin Homo sapiens 51-58 19921965-20 2010 Patients who received insulin glargine, insulin detemir, or exenatide were more likely to persist than patients receiving NPH insulin. Insulin Glargine 30-38 insulin Homo sapiens 22-29 21301163-7 2010 A sliding scale of fast-acting insulin followed by intensified therapy using insulin glargine and insulin aspart was performed in the early phase, but the treatment was switched to twice-daily biphasic insulin aspart 30 injection because no diabetic complication was present, although the patient was already totally blind and required assistance from his family for self-injection and to improve his quality of life (QOL). Insulin Glargine 85-93 insulin Homo sapiens 77-84 19808914-0 2010 Insulin glargine safety in pregnancy: a transplacental transfer study. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19808914-1 2010 OBJECTIVE: Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. Insulin Glargine 19-27 insulin Homo sapiens 11-18 19808914-1 2010 OBJECTIVE: Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. Insulin Glargine 19-27 insulin Homo sapiens 59-66 19808914-1 2010 OBJECTIVE: Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. Insulin Glargine 19-27 insulin Homo sapiens 139-146 19808914-1 2010 OBJECTIVE: Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. Insulin Glargine 29-35 insulin Homo sapiens 11-18 19808914-1 2010 OBJECTIVE: Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. Insulin Glargine 29-35 insulin Homo sapiens 59-66 19808914-4 2010 Therefore, the objective of this study was to determine whether insulin glargine crosses the human placenta using the human perfused placental lobule technique. Insulin Glargine 72-80 insulin Homo sapiens 64-71 19808914-6 2010 Insulin glargine, at a therapeutic concentration of 150 pmol/l (20 microU/ml) was added to the maternal circulation. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19808914-7 2010 Additional experiments were carried out at insulin glargine concentrations 1,000-fold higher than therapeutic levels (150, 225, and 300 nmol/l). Insulin Glargine 51-59 insulin Homo sapiens 43-50 19808914-8 2010 A subsequent perfusion for which the maternal circuit remained open and insulin glargine was continuously infused at 150 pmol/l was completed for further confirmation of findings. Insulin Glargine 80-88 insulin Homo sapiens 72-79 19808914-9 2010 The appearance of insulin glargine in the fetal circulation was analyzed by a chemiluminescence immunoassay. Insulin Glargine 26-34 insulin Homo sapiens 18-25 19808914-10 2010 RESULTS: Results from perfusions carried out at therapeutic concentrations (150 pmol/l) of insulin glargine showed no detectable insulin glargine in the fetal circuit. Insulin Glargine 99-107 insulin Homo sapiens 91-98 19808914-11 2010 After perfusion with very high insulin glargine concentrations of 150, 225, and 300 nmol/l, the rate of transfer remained low at 0.079 +/- 0.01, 0.14, and 0.064 pmol . Insulin Glargine 39-47 insulin Homo sapiens 31-38 19808914-14 2010 CONCLUSIONS: Insulin glargine, when used at therapeutic concentrations, is not likely to cross the placenta. Insulin Glargine 21-29 insulin Homo sapiens 13-20 21701633-0 2010 Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs. Insulin Glargine 0-8 insulin Homo sapiens 76-83 19774358-0 2010 Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine. Insulin Glargine 98-106 insulin Homo sapiens 0-7 21701633-3 2010 Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action. Insulin Glargine 110-118 insulin Homo sapiens 93-100 21301163-7 2010 A sliding scale of fast-acting insulin followed by intensified therapy using insulin glargine and insulin aspart was performed in the early phase, but the treatment was switched to twice-daily biphasic insulin aspart 30 injection because no diabetic complication was present, although the patient was already totally blind and required assistance from his family for self-injection and to improve his quality of life (QOL). Insulin Glargine 85-93 insulin Homo sapiens 77-84 19930005-7 2009 Mean baseline HbA1c was 8.65 (0.68)% in the exenatide group and 8.48 (0.66)% in the insulin glargine group. Insulin Glargine 92-100 insulin Homo sapiens 84-91 19756478-1 2009 AIMS/HYPOTHESIS: Recent publications of data extracted from population registries have suggested a possible relationship between treatment with insulin glargine and increased incidence of cancer/breast cancer. Insulin Glargine 152-160 insulin Homo sapiens 144-151 19756478-12 2009 CONCLUSIONS/INTERPRETATION: In these 31 RCTs, insulin glargine was not associated with an increased incidence of cancer, including breast cancer, compared with the comparator group. Insulin Glargine 54-62 insulin Homo sapiens 46-53 21092702-5 2010 Also, the problem of the reports about the increased risk of cancer after the treatment with a long-acting insulin analogue glargine was discussed (Lantus). Insulin Glargine 124-132 insulin Homo sapiens 107-114 21092702-5 2010 Also, the problem of the reports about the increased risk of cancer after the treatment with a long-acting insulin analogue glargine was discussed (Lantus). Insulin Glargine 148-154 insulin Homo sapiens 107-114 19821654-5 2009 Estimated mean reduction in HbA(1c) from baseline to end of treatment was -1.41% with BIAsp 30 and -1.25% with insulin glargine (BIAsp 30 - insulin glargine = -0.16%, 95% CI [-0.30; -0.02], p = 0.029). Insulin Glargine 119-127 insulin Homo sapiens 111-118 19821654-5 2009 Estimated mean reduction in HbA(1c) from baseline to end of treatment was -1.41% with BIAsp 30 and -1.25% with insulin glargine (BIAsp 30 - insulin glargine = -0.16%, 95% CI [-0.30; -0.02], p = 0.029). Insulin Glargine 148-156 insulin Homo sapiens 140-147 19821654-7 2009 Significantly lower plasma glucose levels were observed with BIAsp 30 post-dinner (BIAsp 30 - insulin glargine = -0.52 mmol/L, 95% CI [-1.02; -0.03], p = 0.04) and at bedtime (BIAsp 30 - insulin glargine = -0.78 mmol/L, 95% CI [-1.25; -0.31], p < 0.01). Insulin Glargine 102-110 insulin Homo sapiens 94-101 19821654-8 2009 The relative risk (RR) of experiencing a nocturnal hypoglycemic episode (00:00-06.00 a.m.) was significantly higher with BIAsp 30 than with insulin glargine (1.1 versus 0.5 episodes/year, RR = 2.41, 95% CI [1.34; 4.34], p = 0.003), but overall hypoglycemia rates were low. Insulin Glargine 148-156 insulin Homo sapiens 140-147 19838665-1 2009 AIMS/HYPOTHESIS: Recent epidemiological studies suggest that treatment with insulin glargine (A21Gly,B31Arg,B32Arg human insulin) may promote cancer growth. Insulin Glargine 84-92 insulin Homo sapiens 76-83 19838665-1 2009 AIMS/HYPOTHESIS: Recent epidemiological studies suggest that treatment with insulin glargine (A21Gly,B31Arg,B32Arg human insulin) may promote cancer growth. Insulin Glargine 84-92 insulin Homo sapiens 121-128 19838665-8 2009 In the second analysis, five studies were included with a total of 1,219 patients treated with insulin detemir and 830 patients treated with insulin glargine. Insulin Glargine 149-157 insulin Homo sapiens 141-148 20007644-0 2009 Putting insulin glargine and malignancies into perspective. Insulin Glargine 16-24 insulin Homo sapiens 8-15 20002478-0 2009 Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan. Insulin Glargine 31-39 insulin Homo sapiens 23-30 20002478-1 2009 AIMS: To determine the safety and efficacy of insulin glargine and glimepiride in patients with Type 2 diabetes before and after Ramadan and during fasting for Ramadan. Insulin Glargine 54-62 insulin Homo sapiens 46-53 20007646-0 2009 When "flawed" translates into "flood": the unproven association between cancer incidence and glargine insulin therapy. Insulin Glargine 93-101 insulin Homo sapiens 102-109 19761358-1 2009 OBJECTIVE: The primary aim was to evaluate duration of action of a single 0.8 U/kg dose of insulin lispro protamine suspension (ILPS) in type 2 diabetes (T2DM) patients; secondarily to compare onset and duration of action of ILPS, glargine (G), and detemir (D) (0.8 U/kg) and evaluate pharmacokinetic (PK) and pharmacodynamic (PD) dose responses of ILPS. Insulin Glargine 231-239 insulin Homo sapiens 91-98 19947816-4 2009 Data from a comparative trial of liraglutide and insulin glargine have suggested that liraglutide provides greater glycemic control with less weight gain, and another study demonstrated that liraglutide provides greater improvements in glycemic control with less hypoglycemia than exenatide and with comparable weight loss. Insulin Glargine 57-65 insulin Homo sapiens 49-56 19932352-0 2009 Insulin glargine and cancer. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19905891-11 2009 CONCLUSIONS: The L2T3 study will extend the evidence on both the efficacy and the effects on quality of life and treatment satisfaction of the long-acting insulin analogs glargine and detemir. Insulin Glargine 171-179 insulin Homo sapiens 155-162 19875618-0 2009 Insulin glargine controversy: a tribute to the editorial team at Diabetologia. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19732121-6 2009 RESULTS: Treatment with exenatide compared with insulin glargine was projected to be associated with improvements in life expectancy of 0.016 years and quality-adjusted life expectancy of 0.280 quality-adjusted life years (QALYs), increased lifetime direct medical costs of euro 3854 (euro 22 095 vs. euro 18 242) and an incremental cost-effectiveness ratio (ICER) of euro 13 746 per QALY. Insulin Glargine 56-64 insulin Homo sapiens 48-55 19732121-7 2009 If quality of life was not taken into account, exenatide was associated with an ICER of euro 238 201 per life year gained vs. insulin glargine. Insulin Glargine 134-142 insulin Homo sapiens 126-133 19625243-9 2009 CONCLUSION: Sulfonylurea with and without use of a small dose of insulin glargine rapidly improved blood glucose levels and beta-cell function in patients with DM2. Insulin Glargine 73-81 insulin Homo sapiens 65-72 19766755-3 2009 We retrospectively examined in-patient medical claims for AMI in a cohort of oral agent-treated patients with type 2 diabetes mellitus after the initiation of basal insulin therapy with either NPH (n = 5,461) or insulin glargine (n = 14,730) in a national administrative claims database comprising >30 managed healthcare plans in the United States. Insulin Glargine 220-228 insulin Homo sapiens 212-219 20017431-0 2009 [Long-term evaluation of patients with type 1 diabetes mellitus treated with insulin glargine]. Insulin Glargine 85-93 insulin Homo sapiens 77-84 20017431-1 2009 AIMS OF THE STUDY: To evaluate long-term effects of treatment with insulin analogue glargine in patients with type 1 diabetes mellitus and to follow up their further course of life. Insulin Glargine 84-92 insulin Homo sapiens 67-74 20017431-3 2009 Treatment was changed again in patients in whom a year-long treatment with insulin glargine did not bring improvement in diabetes control. Insulin Glargine 83-91 insulin Homo sapiens 75-82 20017431-11 2009 Switch from insulin glargine to detemir twice daily. Insulin Glargine 20-28 insulin Homo sapiens 12-19 20017431-12 2009 Initial HbA1c was 7.3 (6.9-8.5)%, 7.4 (6.8-8.7)% after 1 year of treatment with insulin glargine, 7.7 (7.2-8.1)% before the treatment switch and 7.8 (6.7-8.5)% (NS) after 3 years of treatment. Insulin Glargine 88-96 insulin Homo sapiens 80-87 20017431-15 2009 Switch from insulin glargine to an insulin pump. Insulin Glargine 20-28 insulin Homo sapiens 12-19 20017431-22 2009 CONCLUSION: Insulin glargine brings improved control of diabetes. Insulin Glargine 20-28 insulin Homo sapiens 12-19 20017431-23 2009 The dose of insulin glargine did not differ from NPH insulin. Insulin Glargine 20-28 insulin Homo sapiens 12-19 19883893-0 2009 Insulin glargine induced persistent intractable hypoglycemia, with variable presentations in older diabetic patients: an experience of 4 cases. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19662377-0 2009 The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings. Insulin Glargine 56-64 insulin Homo sapiens 48-55 19688338-1 2009 AIMS/HYPOTHESIS: The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and glimepiride. Insulin Glargine 143-151 insulin Homo sapiens 135-142 19588120-0 2009 Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19603149-0 2009 Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Insulin Glargine 15-23 insulin Homo sapiens 7-14 19900235-6 2009 From the end of exercise to 150 min, five (11%) on insulin detemir developed minor hypoglycaemia, seven (14%) for NPH and nine (19%) for glargine. Insulin Glargine 137-145 insulin Homo sapiens 51-58 19900235-9 2009 CONCLUSIONS: Insulin detemir was associated with less hypoglycaemia than insulin glargine but not NPH insulin in relatively well-controlled people with Type 1 diabetes during and after exercise. Insulin Glargine 81-89 insulin Homo sapiens 73-80 19689485-0 2009 Where now for insulin glargine--a time for pragmatic medicine? Insulin Glargine 22-30 insulin Homo sapiens 14-21 19360379-0 2009 Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19360379-3 2009 Insulin-resistant Zucker fatty rats were sc injected 0.45 mg/kg/d of glargine (once) or glulisine (twice) for 1 week before, and 3 weeks after balloon injury. Insulin Glargine 69-77 insulin Homo sapiens 0-7 19360379-11 2009 Compared to control nitrotyrosine staining intensity was significantly lower in both groups of insulin-treated rats; the lowest level was in the glargine group. Insulin Glargine 145-153 insulin Homo sapiens 95-102 19360379-12 2009 Insulin glargine attenuates carotid intimal hyperplasia in nondiabetic Zucker fatty rat independent of glucose levels and support a valuable function for insulin in vascular disease that merits additional investigations. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19360379-12 2009 Insulin glargine attenuates carotid intimal hyperplasia in nondiabetic Zucker fatty rat independent of glucose levels and support a valuable function for insulin in vascular disease that merits additional investigations. Insulin Glargine 8-16 insulin Homo sapiens 154-161 19572099-6 2009 Insulin glargine during pregnancy is not recommended but, in the last years, larger surveys (retrospective and case-control studies) have been published on this field and, to date, results of about 335 pregnancies with type 1 diabetes are available showing an incidence of congenital malformation similar to that obtained with human insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19370512-0 2009 Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Insulin Glargine 65-73 insulin Homo sapiens 57-64 19370512-1 2009 We compared perinatal outcomes in pregnancies in which insulin glargine was used in the management of patients with pregnancies in which standard insulin therapy was used at a single institution. Insulin Glargine 63-71 insulin Homo sapiens 55-62 19370512-13 2009 This preliminary report suggests that use of insulin glargine during pregnancy can be considered if maternal metabolic control is suboptimal using the standard split-mix regimen. Insulin Glargine 53-61 insulin Homo sapiens 45-52 19565214-8 2009 After adjusting for dose, a dose-dependent increase in cancer risk was found for treatment with glargine compared with human insulin (p < 0.0001): the adjusted HR was 1.09 (95% CI 1.00 to 1.19) for a daily dose of 10 IU, 1.19 (95% CI 1.10 to 1.30) for a daily dose of 30 IU, and 1.31 (95% CI 1.20 to 1.42) for a daily dose of 50 IU. Insulin Glargine 96-104 insulin Homo sapiens 125-132 19603149-8 2009 Overall, there was no increase in breast cancer rates associated with insulin glargine use (HR 1.49, 95% CI 0.79-2.83, though insulin glargine only users had a higher rate than those using non-glargine insulin only (HR 3.39, 95% CI 1.46-7.85, p = 0.004). Insulin Glargine 134-142 insulin Homo sapiens 126-133 19603149-1 2009 AIMS/HYPOTHESIS: The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine have a greater cancer risk than patients using other types of insulin. Insulin Glargine 118-126 insulin Homo sapiens 110-117 19603149-6 2009 RESULTS: Those receiving any insulin glargine (n = 3,959) had the same incidence rate for all cancers as those not receiving insulin glargine (HR 1.02, 95% CI 0.77-1.36, p = 0.9 in the fixed cohort) The subset of patients using insulin glargine alone (n = 447) had a significantly higher incidence of all cancers than those using other insulins only (n = 32,295) (HR 1.55, 95% CI 1.01-2.37, p = 0.045), and those using insulin glargine with other insulins (n = 3,512) had a slightly lower incidence (HR 0.81, 95% CI 0.55-1.18, p = 0.26). Insulin Glargine 37-45 insulin Homo sapiens 29-36 19603149-8 2009 Overall, there was no increase in breast cancer rates associated with insulin glargine use (HR 1.49, 95% CI 0.79-2.83, though insulin glargine only users had a higher rate than those using non-glargine insulin only (HR 3.39, 95% CI 1.46-7.85, p = 0.004). Insulin Glargine 134-142 insulin Homo sapiens 126-133 19603149-8 2009 Overall, there was no increase in breast cancer rates associated with insulin glargine use (HR 1.49, 95% CI 0.79-2.83, though insulin glargine only users had a higher rate than those using non-glargine insulin only (HR 3.39, 95% CI 1.46-7.85, p = 0.004). Insulin Glargine 134-142 insulin Homo sapiens 126-133 19603149-8 2009 Overall, there was no increase in breast cancer rates associated with insulin glargine use (HR 1.49, 95% CI 0.79-2.83, though insulin glargine only users had a higher rate than those using non-glargine insulin only (HR 3.39, 95% CI 1.46-7.85, p = 0.004). Insulin Glargine 134-142 insulin Homo sapiens 126-133 19588120-1 2009 AIMS/HYPOTHESIS: In the light of a report suggesting that insulin glargine may increase cancer occurrence, the EASD asked us to perform this study. Insulin Glargine 66-74 insulin Homo sapiens 58-65 19772451-12 2009 CONCLUSIONS: Preprandial inhaled insulin provides an alternative for patients not optimized on insulin glargine alone. Insulin Glargine 103-111 insulin Homo sapiens 33-40 19588120-7 2009 The 95% CIs crossed 1.0 for the RR calculated in all analyses of users of insulin glargine in combination with other types of insulin. Insulin Glargine 82-90 insulin Homo sapiens 74-81 19588120-8 2009 CONCLUSIONS/INTERPRETATION: In Sweden, during 2006 and 2007, women using insulin glargine alone (no other types of insulin) had an increased incidence rate of breast cancer as compared with women using types of insulin other than insulin glargine. Insulin Glargine 81-89 insulin Homo sapiens 73-80 19588120-8 2009 CONCLUSIONS/INTERPRETATION: In Sweden, during 2006 and 2007, women using insulin glargine alone (no other types of insulin) had an increased incidence rate of breast cancer as compared with women using types of insulin other than insulin glargine. Insulin Glargine 238-246 insulin Homo sapiens 73-80 20923531-0 2009 Cancer mortality and insulin glargine. Insulin Glargine 29-37 insulin Homo sapiens 21-28 19220776-6 2009 Fasting glucose variability was also lower after treatment with insulin detemir than previously (on either NPH or glargine, p < 0.05). Insulin Glargine 114-122 insulin Homo sapiens 64-71 19616841-0 2009 Insulin glargine and malignancy: an unwarranted alarm. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19696708-0 2009 Insulin glargine (Lantus) and cancer risk. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19696708-0 2009 Insulin glargine (Lantus) and cancer risk. Insulin Glargine 18-24 insulin Homo sapiens 0-7 19947313-0 2009 [Insulin glargine and cancer: a storm in a glass of water?]. Insulin Glargine 9-17 insulin Homo sapiens 1-8 19947313-1 2009 Insulin glargine is widely used as basal insulin in the treatment of type 1 and type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19947313-1 2009 Insulin glargine is widely used as basal insulin in the treatment of type 1 and type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 41-48 19698060-0 2009 Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes. Insulin Glargine 87-95 insulin Homo sapiens 79-86 19683632-0 2009 Insulin glargine and cancer: another side to the story? Insulin Glargine 8-16 insulin Homo sapiens 0-7 19893914-0 2009 [Use of insulin glargine in type 1 diabetes children with less than eight years old]. Insulin Glargine 16-24 insulin Homo sapiens 8-15 19893914-1 2009 OBJECTIVES: To evaluate prospectively the efficacy and safety of insulin glargine use for the metabolic control of type 1 diabetes mellitus (T1DM) children younger than eight years old. Insulin Glargine 73-81 insulin Homo sapiens 65-72 19893914-10 2009 CONCLUSIONS: The treatment of T1DM children with insulin glargine was considered as efficacious as with NPH. Insulin Glargine 57-65 insulin Homo sapiens 49-56 19893914-11 2009 However, a better safety profile, disclosed by the lower incidence of nocturnal and severe hypoglycemia episodes, was observed for insulin glargine. Insulin Glargine 139-147 insulin Homo sapiens 131-138 19591544-0 2009 Insulin glargine and cancer--an unsubstantiated allegation. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19698060-5 2009 RESULTS: The insulin glargine dose in the CSII + G group was 30.6 +/- 12.4% (range, 13.9-53.3%) of daily basal insulin dose. Insulin Glargine 21-29 insulin Homo sapiens 13-20 19698060-9 2009 CONCLUSIONS: CSII therapy with or without daily insulin glargine improved glycemic control without changes in the rate of hypoglycemia and DKA, suggesting that this treatment regimen is feasible and may also prevent development of hyperglycemia and ketosis or even DKA. Insulin Glargine 56-64 insulin Homo sapiens 48-55 19586980-0 2009 German agency suspects that insulin analogue glargine increases risk of cancer. Insulin Glargine 45-53 insulin Homo sapiens 28-35 19367171-1 2009 BACKGROUND AND OBJECTIVE: Insulin glargine as a basal insulin exhibits constant absorption with no pronounced peaks in blood insulin levels and 24-h duration of action. Insulin Glargine 34-42 insulin Homo sapiens 26-33 19367171-1 2009 BACKGROUND AND OBJECTIVE: Insulin glargine as a basal insulin exhibits constant absorption with no pronounced peaks in blood insulin levels and 24-h duration of action. Insulin Glargine 34-42 insulin Homo sapiens 54-61 19367171-2 2009 We checked the effect of insulin glargine through the comparison of insulin glargine with glucose-insulin-potassium (GIK) on perioperative glucose control in insulin-treated type 2 diabetic patients. Insulin Glargine 33-41 insulin Homo sapiens 25-32 19367171-4 2009 The insulin glargine group (n = 15) was treated with insulin glargine (two-thirds of the total daily insulin dose required) subcutaneous administration with 5% dextrose solution infusion. Insulin Glargine 12-20 insulin Homo sapiens 4-11 19367171-4 2009 The insulin glargine group (n = 15) was treated with insulin glargine (two-thirds of the total daily insulin dose required) subcutaneous administration with 5% dextrose solution infusion. Insulin Glargine 12-20 insulin Homo sapiens 53-60 19367171-4 2009 The insulin glargine group (n = 15) was treated with insulin glargine (two-thirds of the total daily insulin dose required) subcutaneous administration with 5% dextrose solution infusion. Insulin Glargine 12-20 insulin Homo sapiens 53-60 19367171-11 2009 CONCLUSION: Insulin glargine was as effective as GIK regimen for perioperative glycaemic control during major surgery in insulin-dependent type 2 diabetic patients. Insulin Glargine 20-28 insulin Homo sapiens 12-19 19367171-11 2009 CONCLUSION: Insulin glargine was as effective as GIK regimen for perioperative glycaemic control during major surgery in insulin-dependent type 2 diabetic patients. Insulin Glargine 20-28 insulin Homo sapiens 121-128 19640359-12 2009 The resultant incremental cost-effectiveness ratio was CHF 19,450 per QALY gained for exenatide versus insulin glargine. Insulin Glargine 111-119 insulin Homo sapiens 103-110 19552405-0 2009 Use of a temporary "solubilizing" peptide tag for the Fmoc solid-phase synthesis of human insulin glargine via use of regioselective disulfide bond formation. Insulin Glargine 98-106 insulin Homo sapiens 90-97 19552405-7 2009 The applicability of the method was demonstrated by the novel preparation of insulin glargine via solid-phase synthesis of each of the two chains--including the notoriously poorly soluble A-chain--followed by their combination in solution via regioselective disulfide bond formation. Insulin Glargine 85-93 insulin Homo sapiens 77-84 19389820-1 2009 OBJECTIVE: Insulin pump therapy (continuous subcutaneous insulin infusion [CSII]) and multiple daily injections (MDIs) with insulin glargine as basal insulin and mealtime insulin lispro have not been prospectively compared in people naive to either regimen in a multicenter study. Insulin Glargine 132-140 insulin Homo sapiens 124-131 19701528-0 2009 A possible link between insulin glargine and malignancy: the facts. Insulin Glargine 32-40 insulin Homo sapiens 24-31 19707699-0 2009 A possible link between insulin glargine and malignancy : the facts: comment from Prof Francois Bonnici. Insulin Glargine 32-40 insulin Homo sapiens 24-31 19320663-5 2009 RESULTS: Inhaled insulin improved overall and postprandial glucose control significantly better than insulin glargine (p < 0.0001). Insulin Glargine 109-117 insulin Homo sapiens 101-108 19348964-6 2009 The number of clinical trials in the databases was inconsistent: 0 for doripenem to 45 for insulin glargine. Insulin Glargine 99-107 insulin Homo sapiens 91-98 19389820-1 2009 OBJECTIVE: Insulin pump therapy (continuous subcutaneous insulin infusion [CSII]) and multiple daily injections (MDIs) with insulin glargine as basal insulin and mealtime insulin lispro have not been prospectively compared in people naive to either regimen in a multicenter study. Insulin Glargine 132-140 insulin Homo sapiens 124-131 19286270-4 2009 We consider this the first case of successful insulin desensitization by glargine administration. Insulin Glargine 73-81 insulin Homo sapiens 46-53 19322513-22 2009 Indeed, it has been demonstrated that insulin glargine, given once daily, reduces the risk of hypoglycaemia compared with other formulations, and can facilitate a more aggressive insulin treatment in this class of patients. Insulin Glargine 46-54 insulin Homo sapiens 38-45 19322513-22 2009 Indeed, it has been demonstrated that insulin glargine, given once daily, reduces the risk of hypoglycaemia compared with other formulations, and can facilitate a more aggressive insulin treatment in this class of patients. Insulin Glargine 46-54 insulin Homo sapiens 179-186 18825302-14 2009 plus single-dose insulin glargine regimen was safe for low-risk type 2 diabetic patients who insisted on fasting during Ramadan. Insulin Glargine 25-33 insulin Homo sapiens 17-24 19326365-0 2009 Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin. Insulin Glargine 119-127 insulin Homo sapiens 111-118 19326365-4 2009 RESULTS: Incidence rates of heart failure, stroke, and AMI in the insulin glargine group were 306.9 (95%CI: [278.9, 334.8]), 174.8 (95%CI: [153.7, 195.8]), and 105.2 (95%CI: [88.9, 121.5]) cases per 10,000 person-years, respectively. Insulin Glargine 74-82 insulin Homo sapiens 66-73 19326365-5 2009 After adjustment for covariates, the incidence rates of CVD events in the insulin glargine were comparable to those in the other long/intermediate acting insulin group (reference), except for AMI, which tended to be lower in the insulin glargine group (RR = 0.81, 95%CI: [0.65, 1.02]). Insulin Glargine 82-90 insulin Homo sapiens 74-81 19326365-7 2009 CONCLUSION: This study suggested that insulin glargine use might be associated with a lower risk of AMI, compared to the other long/intermediate acting insulin use, and that insulin regimen of rapid/short acting insulin, premixed insulin, or mixed use of insulin except insulin glargine was associated with a higher risk of stroke using the same reference. Insulin Glargine 46-54 insulin Homo sapiens 38-45 19326365-7 2009 CONCLUSION: This study suggested that insulin glargine use might be associated with a lower risk of AMI, compared to the other long/intermediate acting insulin use, and that insulin regimen of rapid/short acting insulin, premixed insulin, or mixed use of insulin except insulin glargine was associated with a higher risk of stroke using the same reference. Insulin Glargine 278-286 insulin Homo sapiens 38-45 19196887-8 2009 Both exenatide and insulin glargine reduced A1C similarly: -0.8 +/- 0.1 and -0.7 +/- 0.2%, respectively (P = 0.55). Insulin Glargine 27-35 insulin Homo sapiens 19-26 19196887-11 2009 A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy. Insulin Glargine 110-118 insulin Homo sapiens 102-109 19196887-13 2009 After cessation of both exenatide and insulin glargine therapy, beta-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy. Insulin Glargine 46-54 insulin Homo sapiens 38-45 19537357-5 2009 Serum insulin levels over the 72-h CGMS period were higher for EXU than for GLA (1,091+/-589 pmol/mL/h vs. 737+/-386 pmol/mL/h; ratio, 148; 95% confidence interval [CI], 130-169). Insulin Glargine 76-79 insulin Homo sapiens 6-13 20144285-4 2009 In August 2006, the Cleveland Clinic began using long-acting insulin glargine as the insulin infusion was terminated in the ICU. Insulin Glargine 69-77 insulin Homo sapiens 61-68 20144285-4 2009 In August 2006, the Cleveland Clinic began using long-acting insulin glargine as the insulin infusion was terminated in the ICU. Insulin Glargine 69-77 insulin Homo sapiens 85-92 20144285-6 2009 The analyses evaluated the safety and efficacy of a protocol using a transition to subcutaneous insulin glargine of 50% of the calculated 24 h requirement at the end of the ICU insulin infusion protocol in preparation for transfer to the RNF. Insulin Glargine 104-112 insulin Homo sapiens 96-103 20144285-10 2009 Efficacy was likely reduced because of the upper limit of insulin glargine dosage imposed by some providers as a safety consideration. Insulin Glargine 66-74 insulin Homo sapiens 58-65 19265181-0 2009 Intentional overdose with insulin glargine. Insulin Glargine 34-42 insulin Homo sapiens 26-33 19459761-6 2009 RESULTS: Exenatide treatment reduced ADRR overall (exenatide, mean +/- SEM, 16.33 +/- 0.45; insulin glargine, 18.54 +/- 0.49; P = 0.001). Insulin Glargine 100-108 insulin Homo sapiens 92-99 19473110-10 2009 CONCLUSIONS: Combination therapy of once-daily insulin glargine versus three-times daily insulin lispro both with OADs, in the management of insulin-dependent type 2 diabetes offers the potential for substantial cost savings from the German SHI perspective. Insulin Glargine 55-63 insulin Homo sapiens 47-54 19454394-4 2009 RESULTS: Patients on the twice-daily insulin lispro mix 75/25 (75% insulin lispro protamine suspension/25% insulin lispro) plus metformin regimen had significantly lower standard deviation, M-value, and J-index than patients on the insulin glargine plus metformin regimen, but not lower coefficient of variation or mean amplitude of glycemic excursion. Insulin Glargine 240-248 insulin Homo sapiens 37-44 19438161-2 2009 STUDY DESIGN: This is a retrospective review of the medical data from 240 pregnant diabetics who received glargine as a basal insulin. Insulin Glargine 106-114 insulin Homo sapiens 126-133 19291638-2 2009 Clinical studies have shown that glycaemic control of type-2 diabetes mellitus can be improved using simple algorithms for titration of insulin Glargine (Lantus). Insulin Glargine 144-152 insulin Homo sapiens 136-143 19291638-13 2009 During the 6-month treatment with insulin Glargine (Lantus) 196 patients (62%) achieved the SSED guidelines for glycaemic control. Insulin Glargine 42-50 insulin Homo sapiens 34-41 19291638-13 2009 During the 6-month treatment with insulin Glargine (Lantus) 196 patients (62%) achieved the SSED guidelines for glycaemic control. Insulin Glargine 52-58 insulin Homo sapiens 34-41 19030772-4 2009 Both insulins provided similar improvements in glycaemic control; however, PPBG was significantly lower after a standard meal test (performed at 13:00 h the day after insulin injection) with glargine versus NPH (p=0.02). Insulin Glargine 191-199 insulin Homo sapiens 5-12 19203299-0 2009 Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Insulin Glargine 156-164 insulin Homo sapiens 148-155 19203299-1 2009 OBJECTIVE: Examine real-world effectiveness and hypoglycemia cost burden in patients with type 2 diabetes newly initiated on exenatide or insulin glargine. Insulin Glargine 146-154 insulin Homo sapiens 138-145 19393853-10 2009 Insulin detemir and insulin glargine also were associated with comparable mean adjusted all-cause pharmacy costs ($3074 and $2899), medical costs ($2319 and $3704), and total health care costs ($6014 and $7023). Insulin Glargine 28-36 insulin Homo sapiens 20-27 19203299-6 2009 The mean Deyo-Charlson comorbidity index score was 1.45 for exenatide versus 1.82 for insulin glargine (p < 0.001). Insulin Glargine 94-102 insulin Homo sapiens 86-93 19393853-11 2009 However, insulin glargine was associated with significantly higher mean adjusted diabetes-related medical costs compared with insulin detemir ($1510 vs $707, respectively; P = 0.03), as well as significantly higher mean adjusted total diabetes-related health care costs ($3408 vs $2261; P = 0.03). Insulin Glargine 17-25 insulin Homo sapiens 9-16 19203299-8 2009 For patients with two or more pharmacy claims for exenatide or insulin glargine, the 12-month medication possession ratio (MPR) was 68 +/- 29% for exenatide and 58 +/- 28% for insulin glargine (p < 0.001). Insulin Glargine 71-79 insulin Homo sapiens 63-70 19203299-8 2009 For patients with two or more pharmacy claims for exenatide or insulin glargine, the 12-month medication possession ratio (MPR) was 68 +/- 29% for exenatide and 58 +/- 28% for insulin glargine (p < 0.001). Insulin Glargine 184-192 insulin Homo sapiens 63-70 19203299-8 2009 For patients with two or more pharmacy claims for exenatide or insulin glargine, the 12-month medication possession ratio (MPR) was 68 +/- 29% for exenatide and 58 +/- 28% for insulin glargine (p < 0.001). Insulin Glargine 184-192 insulin Homo sapiens 176-183 19203299-11 2009 CONCLUSIONS: This study provides the first real-world observational comparison of type 2 diabetes patients newly initiated on exenatide or insulin glargine. Insulin Glargine 147-155 insulin Homo sapiens 139-146 19277932-5 2009 With regard to treatment satisfaction, insulin glargine was superior in one head-to-head comparison with NPH (neutral protamine Hagedorn) and one head-to-head comparison with NPH as an add-on to oral glimepiride. Insulin Glargine 47-55 insulin Homo sapiens 39-46 19106380-5 2009 CONCLUSIONS: Insulin glargine is associated with greater reductions in glucose variability than NPH/Lente insulin in pediatric patients with type 1 diabetes. Insulin Glargine 21-29 insulin Homo sapiens 13-20 19277932-7 2009 Regarding health related quality of life (HRQoL), insulin glargine was shown to be superior to rosiglitazone as an add-on to metformin and sulfonylurea. Insulin Glargine 58-66 insulin Homo sapiens 50-57 19277932-9 2009 CONCLUSION: There are only a limited number of high quality studies showing that insulin glargine is superior regarding treatment satisfaction and HRQoL of patients with diabetes mellitus. Insulin Glargine 89-97 insulin Homo sapiens 81-88 19330710-0 2009 Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19284367-0 2009 Insulin Glargine: a review 8 years after its introduction. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19284367-1 2009 Insulin Glargine was the first long-acting insulin analog produced by recombinant DNA technology, approved for use by the US FDA in April 2000 and by the European Agency for the Evaluation of Medicinal Products in June, 2000. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19284367-1 2009 Insulin Glargine was the first long-acting insulin analog produced by recombinant DNA technology, approved for use by the US FDA in April 2000 and by the European Agency for the Evaluation of Medicinal Products in June, 2000. Insulin Glargine 8-16 insulin Homo sapiens 43-50 19284367-3 2009 The principal advantage of insulin Glargine over neutral protamine Hagedorn (NPH) insulin is in a lower frequency of hypoglycemic reactions, thus affording improved safety. Insulin Glargine 35-43 insulin Homo sapiens 27-34 19284367-6 2009 Although insulin Glargine is typically administered as a single nighttime dose, it can be given in the morning or at any other time convenient for the patient. Insulin Glargine 17-25 insulin Homo sapiens 9-16 19284367-8 2009 In obese, insulin-resistant patients, it may be best to administer insulin Glargine in two separate doses, owing to the high volumes of injected insulin required. Insulin Glargine 75-83 insulin Homo sapiens 10-17 19284367-8 2009 In obese, insulin-resistant patients, it may be best to administer insulin Glargine in two separate doses, owing to the high volumes of injected insulin required. Insulin Glargine 75-83 insulin Homo sapiens 67-74 19284367-8 2009 In obese, insulin-resistant patients, it may be best to administer insulin Glargine in two separate doses, owing to the high volumes of injected insulin required. Insulin Glargine 75-83 insulin Homo sapiens 67-74 19284367-9 2009 Insulin Glargine does not treat postprandial hyperglycemia. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19284367-11 2009 Insulin Glargine is effective in hospitalized and postsurgical patients on account of its lack of pronounced insulin peaks and long duration of action. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19284367-13 2009 Insulin Glargine is thought to coprecipitate supplementary short-acting insulins when co-administered in the same syringe. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19284367-16 2009 Such a therapy may be less costly, but the major advantage of insulin Glargine remains the greater safety of a lower frequency of hypoglycemic reactions. Insulin Glargine 70-78 insulin Homo sapiens 62-69 19330710-1 2009 OBJECTIVE: To compare maternal and neonatal outcomes of pregestational and gestational diabetics treated with insulin glargine versus Neutral Protamine Hagedorn (NPH) insulin. Insulin Glargine 118-126 insulin Homo sapiens 110-117 19330710-7 2009 Among pregestational diabetics treated with insulin glargine, significantly fewer macrosomic infants (relative risk [RR], 0.38; 95% confidence intervals (CI), 0.17-0.87; p = 0.04) and lower rates of neonatal hyperbilirubinemia (RR, 0.27; 95% CI, 0.07-0.98; p = 0.05) were noted when compared with those treated with NPH. Insulin Glargine 52-60 insulin Homo sapiens 44-51 19330710-11 2009 Among pregestational diabetics, insulin glargine use was associated with lower rates of macrosomia, neonatal hypoglycemia and neonatal hyperbilirubinemia. Insulin Glargine 40-48 insulin Homo sapiens 32-39 19905038-0 2009 A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Insulin Glargine 115-123 insulin Homo sapiens 107-114 19152692-1 2009 BACKGROUND: Insulin glargine (glargine) and insulin NPH (NPH) are two basal insulin treatments. Insulin Glargine 20-28 insulin Homo sapiens 12-19 19152692-1 2009 BACKGROUND: Insulin glargine (glargine) and insulin NPH (NPH) are two basal insulin treatments. Insulin Glargine 30-38 insulin Homo sapiens 12-19 19220880-0 2009 Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Insulin Glargine 35-43 insulin Homo sapiens 50-57 19220880-1 2009 BACKGROUND: Insulin glargine (glargine) and premixed insulins (premix) are alternative insulin treatments. Insulin Glargine 20-28 insulin Homo sapiens 12-19 19220880-1 2009 BACKGROUND: Insulin glargine (glargine) and premixed insulins (premix) are alternative insulin treatments. Insulin Glargine 30-38 insulin Homo sapiens 12-19 19220880-13 2009 CONCLUSION: In everyday practice, patients with type 1 or type 2 diabetes inadequately controlled by premix insulins experienced significant improvement in glycaemic control over 12 months after switching to a glargine-based insulin regimen. Insulin Glargine 210-218 insulin Homo sapiens 108-115 19221353-15 2009 Insulin glargine was associated with an incremental cost of Can$642,994 per quality-adjusted life-year. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18979406-0 2009 Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18979406-5 2009 Twenty-seven women used insulin glargine. Insulin Glargine 32-40 insulin Homo sapiens 24-31 18979406-6 2009 A total of 13 women used insulin glargine during the first trimester. Insulin Glargine 33-41 insulin Homo sapiens 25-32 18979406-10 2009 Insulin glargine appears to be an effective insulin analogue for use in women whose pregnancies are complicated by diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18979406-10 2009 Insulin glargine appears to be an effective insulin analogue for use in women whose pregnancies are complicated by diabetes. Insulin Glargine 8-16 insulin Homo sapiens 44-51 19905038-3 2009 OBJECTIVE: To compare costs among patients with type 2 diabetes mellitus treated with exenatide or insulin glargine from a US third-party payer perspective. Insulin Glargine 107-115 insulin Homo sapiens 99-106 19905038-6 2009 In addition, included patients were required to have no diagnoses of type 1 diabetes, to have received at least two prescriptions for an oral antidiabetic agent in the 6 months prior to first use of either exenatide or insulin glargine and to have continuous insurance coverage from 6 months before, to 12 months after, initiation on ITT medication. Insulin Glargine 227-235 insulin Homo sapiens 219-226 19905038-1 2009 BACKGROUND: Exenatide (Byetta) and insulin glargine (Lantus) are antidiabetic agents that are typically used after lack of response to an oral antidiabetic agent(s). Insulin Glargine 43-51 insulin Homo sapiens 35-42 19905038-1 2009 BACKGROUND: Exenatide (Byetta) and insulin glargine (Lantus) are antidiabetic agents that are typically used after lack of response to an oral antidiabetic agent(s). Insulin Glargine 53-59 insulin Homo sapiens 35-42 19120431-6 2009 The two basal insulin analogues, glargine and detemir, developed by adjusting the isoelectric point and adding a fatty acid residue, respectively, have a protracted duration of action and a relatively smooth profile. Insulin Glargine 33-41 insulin Homo sapiens 14-21 19145584-9 2009 Glargine, like insulin and IGF-I, induced phosphorylation of both ERK and AKT, suggesting that the analogue is able to stimulate both the ras-raf-mitogen-activated protein kinase (MAPK) and PI3K-AKT pathways. Insulin Glargine 0-8 insulin Homo sapiens 15-22 19120433-7 2009 Insulin detemir- and insulin glargine-treated subjects had similar mean 24-h glucose values (133 +/- 21 mg/dL compared with 126+/-20 mg/dL respectively, p = 0.385) and similar glucose values during the basal period (105 +/- 23 mg/dL compared with 98 +/- 19 mg/dL, respectively p = 0.204).Target basal glycaemic control was achieved in all subjects in a mean of 3.8 days for detemir and 3.5 days for glargine (p = 0.360). Insulin Glargine 29-37 insulin Homo sapiens 21-28 19224503-0 2009 Mitogenic potency of insulin glargine. Insulin Glargine 29-37 insulin Homo sapiens 21-28 19224503-5 2009 Insulin glargine was the only one presenting a significant increase in affinity to insulin-like growth factor type 1 (IGF-1) receptor. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19224503-5 2009 Insulin glargine was the only one presenting a significant increase in affinity to insulin-like growth factor type 1 (IGF-1) receptor. Insulin Glargine 8-16 insulin Homo sapiens 83-90 19224503-6 2009 However, there was controversy regarding the safety of insulin glargine use because of its potential risk of mitogenicity but it proved to be true only for human osteosarcoma cells Saos/B10. Insulin Glargine 63-71 insulin Homo sapiens 55-62 17976762-1 2009 Insulin glargine (Lantus, Aventis Pharmaceuticals, Bridgewater, NJ) is a long-acting once-daily dosed form of insulin intended to maintain a constant baseline insulin level. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19193822-4 2009 Long-acting insulin analogs (ie, detemir, glargine) have relatively flat time-action profiles and last up to 24 hours, thus simulating endogenous basal insulin more precisely than neutral protamine Hagedorn insulin and producing less nocturnal hypoglycemia. Insulin Glargine 42-50 insulin Homo sapiens 12-19 19193822-4 2009 Long-acting insulin analogs (ie, detemir, glargine) have relatively flat time-action profiles and last up to 24 hours, thus simulating endogenous basal insulin more precisely than neutral protamine Hagedorn insulin and producing less nocturnal hypoglycemia. Insulin Glargine 42-50 insulin Homo sapiens 152-159 17976762-1 2009 Insulin glargine (Lantus, Aventis Pharmaceuticals, Bridgewater, NJ) is a long-acting once-daily dosed form of insulin intended to maintain a constant baseline insulin level. Insulin Glargine 8-16 insulin Homo sapiens 110-117 17976762-1 2009 Insulin glargine (Lantus, Aventis Pharmaceuticals, Bridgewater, NJ) is a long-acting once-daily dosed form of insulin intended to maintain a constant baseline insulin level. Insulin Glargine 8-16 insulin Homo sapiens 159-166 19081277-5 2009 The approach is illustrated with the A chain of human insulin and the A chain of human insulin analogue glargine. Insulin Glargine 104-112 insulin Homo sapiens 87-94 18926586-0 2008 Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone? Insulin Glargine 150-158 insulin Homo sapiens 142-149 19436668-1 2009 BACKGROUND: The insulin analogs, glargine and detemir, are associated with reduced hypoglycemia incidence compared with NPH insulin. Insulin Glargine 33-41 insulin Homo sapiens 16-23 19436668-3 2009 MATERIAL AND METHODS: A retrospective chart review was conducted that included 73 (31 female) patients (mean age 48 years, diabetes duration 19 years) treated for 12 to 24 months with insulin glargine (n = 43) or detemir (n = 30). Insulin Glargine 192-200 insulin Homo sapiens 184-191 19436668-6 2009 Changing from NPH insulin was associated with a -0.3% (p = 0.036) reduction in HbA1c for glargine (baseline 8.8%) and -0.4% (p = 0.040) for detemir (baseline 8.3%) treated patients; insulin dosages increased, respectively by 4.1 (p = 0.045) and 4.3 units (p = 0.004) (mean values). Insulin Glargine 89-97 insulin Homo sapiens 18-25 19590589-2 2009 The advent of the long-acting insulin analogues, insulin detemir and glargine, in the last decade has revolutionized insulin therapy in type 2 diabetes. Insulin Glargine 69-77 insulin Homo sapiens 30-37 23074525-18 2009 To combat nocturnal hypoglycemia and other issues related to absorption, alternative insulins have been developed, such as the slow-acting insulin glargine. Insulin Glargine 147-155 insulin Homo sapiens 85-92 23074525-48 2009 2008) showed no difference between CSII pumps and MDI on Hba1c levels and was the only study using insulin glargine (consistent with results of parallel RCT in abstract by Bolli 2004). Insulin Glargine 107-115 insulin Homo sapiens 99-106 18766296-10 2008 The data show that the long-acting insulin analogues glargine and detemir both offer a low risk of hypoglycaemia and improved glycaemic control. Insulin Glargine 53-61 insulin Homo sapiens 35-42 18926586-7 2008 RESULTS: The reduction in HbA1c was slightly greater in the insulin glargine group and used as co-variate when analysing other variables. Insulin Glargine 68-76 insulin Homo sapiens 60-67 18926586-10 2008 CONCLUSIONS: The results demonstrate characteristic differences in the effects of insulin glargine vs. pioglitazone on measures of beta-cell function and insulin sensitivity as well as cardiac load. Insulin Glargine 90-98 insulin Homo sapiens 82-89 18926586-10 2008 CONCLUSIONS: The results demonstrate characteristic differences in the effects of insulin glargine vs. pioglitazone on measures of beta-cell function and insulin sensitivity as well as cardiac load. Insulin Glargine 90-98 insulin Homo sapiens 154-161 18355326-0 2008 Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects. Insulin Glargine 66-74 insulin Homo sapiens 58-65 19092494-6 2008 Glargine users" MPR was higher than other insulin users" MPR (66% vs 54%, P < 0.0001). Insulin Glargine 0-8 insulin Homo sapiens 42-49 19092494-7 2008 Among all insulin users, those using glargine had significantly lower total ($6771 vs $7969, P = 0.0046) and circulatory-specific ($312 vs $636, P < 0.0001) costs. Insulin Glargine 37-45 insulin Homo sapiens 10-17 19092494-8 2008 CONCLUSIONS: Insulin MPR and the use of insulin glargine were associated with lower health care costs. Insulin Glargine 48-56 insulin Homo sapiens 40-47 19128743-0 2008 [A study of variability in glycaemia in children and adolescents with diabetes mellitus type 1 on treatment with insulin glargine]. Insulin Glargine 121-129 insulin Homo sapiens 113-120 19128743-1 2008 OBJECTIVE: To determine the usefulness of insulin glargine (IG) to reduce hipoglycaemias and hyperglycaemic events in children and adolescents with type 1 diabetes. Insulin Glargine 50-58 insulin Homo sapiens 42-49 18355326-4 2008 RESULTS: Identical serum insulin glargine concentration and time-action profiles established average, individual and population equivalence in insulin exposure and effect. Insulin Glargine 33-41 insulin Homo sapiens 25-32 18355326-7 2008 The diurnal relative fluctuation of the serum insulin glargine concentration was 20% (95% CI: 19-21%). Insulin Glargine 54-62 insulin Homo sapiens 46-53 18355326-8 2008 CONCLUSION: Insulin glargine in either formulation presents with a high day-to-day reproducibility of a uniform release after injection enabling an effective basal insulin supplementation. Insulin Glargine 20-28 insulin Homo sapiens 12-19 18355326-8 2008 CONCLUSION: Insulin glargine in either formulation presents with a high day-to-day reproducibility of a uniform release after injection enabling an effective basal insulin supplementation. Insulin Glargine 20-28 insulin Homo sapiens 164-171 18936501-20 2008 CONCLUSION: Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes. Insulin Glargine 74-82 insulin Homo sapiens 83-90 18715525-1 2008 OBJECTIVE: SoloSTAR (SR) is a new pre-filled insulin pen device for administration of insulin glargine and insulin glulisine. Insulin Glargine 94-102 insulin Homo sapiens 45-52 18715525-1 2008 OBJECTIVE: SoloSTAR (SR) is a new pre-filled insulin pen device for administration of insulin glargine and insulin glulisine. Insulin Glargine 94-102 insulin Homo sapiens 86-93 18715525-1 2008 OBJECTIVE: SoloSTAR (SR) is a new pre-filled insulin pen device for administration of insulin glargine and insulin glulisine. Insulin Glargine 94-102 insulin Homo sapiens 86-93 18611975-0 2008 Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. Insulin Glargine 64-72 insulin Homo sapiens 56-63 18715209-1 2008 The new rDNA and DNA-derived "basal" insulin analogs, glargine and detemir, represent significant advancement in the treatment of diabetes compared with conventional NPH insulin. Insulin Glargine 54-62 insulin Homo sapiens 37-44 18611975-1 2008 AIMS/HYPOTHESIS: Insulin glargine is a long-acting human insulin analog often administered at bedtime to patients with type 2 diabetes. Insulin Glargine 25-33 insulin Homo sapiens 17-24 18611975-1 2008 AIMS/HYPOTHESIS: Insulin glargine is a long-acting human insulin analog often administered at bedtime to patients with type 2 diabetes. Insulin Glargine 25-33 insulin Homo sapiens 57-64 18611975-8 2008 By contrast, in the morning, insulin glargine was more effective, increasing Rd by 5.8 micromol/kg(-1).min(-1) (95% confidence interval 4.7-6.9) and reducing EGP -5.7 (-5.0 to -6.4) compared with NPH insulin. Insulin Glargine 37-45 insulin Homo sapiens 29-36 18762540-0 2008 Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes. Insulin Glargine 20-28 insulin Homo sapiens 12-19 18589448-0 2008 Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18589448-5 2008 However, an analysis of covariance, adjusting for baseline A1C, revealed a strong study arm effect on the slopes of the regression lines, indicating that the reduction in A1C was significantly greater with insulin glargine in those patients with higher baseline A1C values. Insulin Glargine 214-222 insulin Homo sapiens 206-213 18589448-6 2008 The rate of confirmed glucose values <70 mg/dL was higher in the patients receiving insulin glargine (P = .0298). Insulin Glargine 95-103 insulin Homo sapiens 87-94 18589448-8 2008 CONCLUSIONS: Insulin glargine is well tolerated in MDI regimens for pediatric patients with T1DM and may be more efficacious than NPH/Lente in those with elevated A1C. Insulin Glargine 21-29 insulin Homo sapiens 13-20 18585815-0 2008 Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Insulin Glargine 82-90 insulin Homo sapiens 65-72 18585815-0 2008 Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Insulin Glargine 82-90 insulin Homo sapiens 122-129 18585815-1 2008 Glargine and detemir are long-acting human insulin analogues with a smooth peakless profile of action. Insulin Glargine 0-8 insulin Homo sapiens 43-50 18803989-1 2008 BACKGROUND: Insulin glargine is a once-daily basal insulin analog with prolonged duration of action and absence of an evident peak. Insulin Glargine 20-28 insulin Homo sapiens 12-19 18694484-9 2008 Using the most conservative of assumptions, the cost-effectiveness ratio of exenatide vs. insulin glargine at the current UK NHS price was -29,149 pounds/QALY (insulin glargine dominant) and thus exenatide is not cost-effective when compared with insulin glargine, at the current UK NHS price. Insulin Glargine 98-106 insulin Homo sapiens 90-97 18694484-11 2008 Given no significant difference in glycaemic control and applying the additional effectiveness of exenatide over insulin glargine, with respect to weight loss, and using the current UK NHS prices, insulin glargine was found to be dominant over exenatide in all modelled scenarios. Insulin Glargine 205-213 insulin Homo sapiens 197-204 18803989-1 2008 BACKGROUND: Insulin glargine is a once-daily basal insulin analog with prolonged duration of action and absence of an evident peak. Insulin Glargine 20-28 insulin Homo sapiens 51-58 18803989-6 2008 OBJECTIVE: The aim of this study was to retrospectively evaluate (years 2004-2007) the effectiveness and safety of insulin glargine compared with neutral protamine Hagedorn (NPH) in women affected by type 1 diabetes mellitus (T1DM) during pregnancy. Insulin Glargine 123-131 insulin Homo sapiens 115-122 18316392-7 2008 The insulin receptor was downregulated to a similar degree by glargine and regular human insulin at high insulin concentrations (P < 0.0001 for glargine, P = 0.002 for regular human insulin). Insulin Glargine 147-155 insulin Homo sapiens 4-11 18686217-0 2008 [Long acting insulin analogues: results of clinical studies with insulin glargine]. Insulin Glargine 73-81 insulin Homo sapiens 13-20 18686217-0 2008 [Long acting insulin analogues: results of clinical studies with insulin glargine]. Insulin Glargine 73-81 insulin Homo sapiens 65-72 18686217-3 2008 Several studies have shown that the therapy with insulin glargine ist associated with a markedly lower rate of hypoglycaemia compared to NPH insulin. Insulin Glargine 57-65 insulin Homo sapiens 49-56 18686220-4 2008 In each analysis either cost or benefit of treating diabetes mellitus with oral antidiabetic drug(s) supported by insulin glargine were compared to those with conventional insulin treatment using premixed insulin twice daily. Insulin Glargine 122-130 insulin Homo sapiens 114-121 18686221-6 2008 It was found that there were significant differences between the insulin glargine and the NPH insulin-based regimens regarding quality of life and satisfaction with the treatment, a difference that ranged from small to moderate in favour of insulin glargine. Insulin Glargine 73-81 insulin Homo sapiens 65-72 18493882-0 2008 Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18316392-1 2008 OBJECTIVE: It was reported that the long-acting insulin analogue glargine induces cell proliferation in a human osteosarcoma cell line and therefore might induce or accelerate tumor growth. Insulin Glargine 65-73 insulin Homo sapiens 48-55 18316392-7 2008 The insulin receptor was downregulated to a similar degree by glargine and regular human insulin at high insulin concentrations (P < 0.0001 for glargine, P = 0.002 for regular human insulin). Insulin Glargine 62-70 insulin Homo sapiens 4-11 18959605-5 2008 The mean net change (95% confidence interval) for FPG, HbA(1c) and body weight for patients treated with NPH insulin as compared with glargine was 0.21 mmol/l (-0.02 to 0.45), 0.08% (-0.04 to 0.21) and -0.33 kg (-0.61 to -0.06), respectively, with negative values favouring NPH and positive values favouring glargine. Insulin Glargine 308-316 insulin Homo sapiens 109-116 18680444-0 2008 Insulin glargine and its role in glycaemic management of Type 2 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18680444-1 2008 BACKGROUND: Insulin glargine (Lantus) was the first recombinant-DNA long-acting insulin analogue to be licensed for use in the treatment of diabetes mellitus. Insulin Glargine 20-28 insulin Homo sapiens 12-19 18680444-1 2008 BACKGROUND: Insulin glargine (Lantus) was the first recombinant-DNA long-acting insulin analogue to be licensed for use in the treatment of diabetes mellitus. Insulin Glargine 20-28 insulin Homo sapiens 80-87 18680444-1 2008 BACKGROUND: Insulin glargine (Lantus) was the first recombinant-DNA long-acting insulin analogue to be licensed for use in the treatment of diabetes mellitus. Insulin Glargine 30-36 insulin Homo sapiens 12-19 18680444-1 2008 BACKGROUND: Insulin glargine (Lantus) was the first recombinant-DNA long-acting insulin analogue to be licensed for use in the treatment of diabetes mellitus. Insulin Glargine 30-36 insulin Homo sapiens 80-87 18680444-2 2008 OBJECTIVE: This review considers the use of insulin glargine in the treatment of type 2 diabetes (T2DM). Insulin Glargine 52-60 insulin Homo sapiens 44-51 18680444-7 2008 However, insulin glargine is a welcome addition to the plethora of treatment options available for T2DM. Insulin Glargine 17-25 insulin Homo sapiens 9-16 18577151-0 2008 Insulin glargine: cornerstone treatment for type 2 diabetes patients. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18577153-4 2008 Overall, the studies included in this review show that insulin glargine is associated with a lower risk of hypoglycaemia vs. both neutral protamine Hagedorn insulin and premixed insulin formulations, alongside clinically important improvements in glycaemic control. Insulin Glargine 63-71 insulin Homo sapiens 55-62 18577153-5 2008 Furthermore, insulin glargine is associated with greater improvements in glycaemic control vs. intensification of oral therapy. Insulin Glargine 21-29 insulin Homo sapiens 13-20 18577153-6 2008 Thus, insulin glargine should be a preferred option when starting insulin therapy for people with T2DM. Insulin Glargine 14-22 insulin Homo sapiens 6-13 18577153-6 2008 Thus, insulin glargine should be a preferred option when starting insulin therapy for people with T2DM. Insulin Glargine 14-22 insulin Homo sapiens 66-73 18577154-0 2008 Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18577154-2 2008 The extensive clinical experience gained with insulin glargine, in particular, the low risk of hypoglycaemia and consistent improvements in HbA(1c), suggests that insulin glargine can be initiated aggressively to help patients reach such HbA(1c) targets. Insulin Glargine 54-62 insulin Homo sapiens 46-53 18577154-2 2008 The extensive clinical experience gained with insulin glargine, in particular, the low risk of hypoglycaemia and consistent improvements in HbA(1c), suggests that insulin glargine can be initiated aggressively to help patients reach such HbA(1c) targets. Insulin Glargine 54-62 insulin Homo sapiens 163-170 18577154-2 2008 The extensive clinical experience gained with insulin glargine, in particular, the low risk of hypoglycaemia and consistent improvements in HbA(1c), suggests that insulin glargine can be initiated aggressively to help patients reach such HbA(1c) targets. Insulin Glargine 171-179 insulin Homo sapiens 46-53 18577154-2 2008 The extensive clinical experience gained with insulin glargine, in particular, the low risk of hypoglycaemia and consistent improvements in HbA(1c), suggests that insulin glargine can be initiated aggressively to help patients reach such HbA(1c) targets. Insulin Glargine 171-179 insulin Homo sapiens 163-170 18577154-3 2008 However, many clinicians may be unaware of how easy it is to initiate insulin glargine. Insulin Glargine 78-86 insulin Homo sapiens 70-77 18577154-4 2008 Indeed, the once-daily injection of insulin glargine plus once-daily measurement of blood glucose should provide little difficulty for patients. Insulin Glargine 44-52 insulin Homo sapiens 36-43 18577155-0 2008 Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine. Insulin Glargine 78-86 insulin Homo sapiens 0-7 18577155-5 2008 Insulin glargine is associated with a low risk of hypoglycaemia compared with neutral protamine Hagedorn insulin, for example, and could thus provide a treatment of choice for healthcare providers when considering the increasing prevalence of diabetes in the elderly population. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18577155-6 2008 A regimen based on insulin glargine plus oral agents provides clinicians with a tool to help meet therapeutic targets in this population without increasing risk of hypoglycaemia. Insulin Glargine 27-35 insulin Homo sapiens 19-26 18577156-0 2008 Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine. Insulin Glargine 88-96 insulin Homo sapiens 0-7 18577156-6 2008 Moreover, weight gain can be minimized by earlier insulinization and the use of basal insulin, such as insulin glargine, instead of premixed insulin. Insulin Glargine 111-119 insulin Homo sapiens 86-93 18577156-6 2008 Moreover, weight gain can be minimized by earlier insulinization and the use of basal insulin, such as insulin glargine, instead of premixed insulin. Insulin Glargine 111-119 insulin Homo sapiens 86-93 18577156-7 2008 Data specific to the obese patient with T2DM are presented; they are currently limited but do indicate that insulin glargine therapy is associated with improved glycaemic control as well as less weight gain than other insulins, such as premixed insulin and prandial insulin regimens. Insulin Glargine 116-124 insulin Homo sapiens 108-115 18577157-4 2008 Insulin glargine, which offers people with diabetes a once-a-day injection regimen with low risk of hypoglycaemia, is more likely to overcome such initial barriers than other more complex insulin regimens. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18577157-4 2008 Insulin glargine, which offers people with diabetes a once-a-day injection regimen with low risk of hypoglycaemia, is more likely to overcome such initial barriers than other more complex insulin regimens. Insulin Glargine 8-16 insulin Homo sapiens 188-195 18577157-5 2008 Once-daily insulin glargine, in combination with modern glucose-dependent oral agents that do not need to be chased with food to prevent hypoglycaemia, does not require the fixed mealtimes and set amounts of carbohydrates necessary with twice-daily injection mixes and older sulphonylureas. Insulin Glargine 19-27 insulin Homo sapiens 11-18 18577157-8 2008 A systematic electronic literature search identified reports of studies evaluating PROs associated with insulin glargine in comparison with other treatments. Insulin Glargine 112-120 insulin Homo sapiens 104-111 18577157-9 2008 The studies show that insulin glargine is usually associated with greater improvements in treatment satisfaction and other PROs compared with intensifying oral therapy or alternative insulin regimens. Insulin Glargine 30-38 insulin Homo sapiens 22-29 18577158-5 2008 Overall, the studies included in this review show that the initiation of insulin glargine is cost-effective and is expected to lead to substantial improvements in both life years (LYs) and quality-adjusted LYs compared with neutral protamine Hagedorn insulin. Insulin Glargine 81-89 insulin Homo sapiens 73-80 18568451-6 2008 RESULTS: Therapy conversion to insulin detemir +/- OADs was projected to improve life expectancy by 0.28 years compared with OADs alone, and by 0.13 years compared with the NPH and glargine regimens. Insulin Glargine 181-189 insulin Homo sapiens 31-38 18568451-7 2008 Transfer to insulin detemir was associated with improvements in quality-adjusted life expectancy of 0.21 quality-adjusted life years (QALYs) over OADs alone, 0.28 QALYs over NPH +/- OADs, and 0.29 QALYs over glargine +/- OADs. Insulin Glargine 208-216 insulin Homo sapiens 12-19 18393172-0 2008 Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Insulin Glargine 41-49 insulin Homo sapiens 24-31 18393172-1 2008 The aim of the study was to investigate if the insulin analogue glargine, with an increased affinity for the IGF-I receptor (IGF-IR), affects the cell growth to a larger extent than human insulin in malignant cells expressing IGF-IRs. Insulin Glargine 64-72 insulin Homo sapiens 47-54 18394265-2 2008 After 26 weeks of treatment, insulin glargine reduced fasting glucose to a greater extent than exenatide without significant effect on PPG excursion. Insulin Glargine 37-45 insulin Homo sapiens 29-36 18479280-5 2008 RESULTS: Biphasic insulin aspart 70/30 treatment when compared with insulin glargine treatment was associated with improvements in discounted life expectancy of 0.21 years (13.10 vs. 12.89 years) and QALE of 0.21 quality-adjusted life years (QALYs) (9.16 vs. 8.96 QALYs). Insulin Glargine 76-84 insulin Homo sapiens 68-75 18479280-9 2008 These results were driven by improved HbA1c levels associated with BIAsp 70/30 compared with insulin glargine and the accompanying reduction in diabetes-related complications despite increases in body mass index. Insulin Glargine 101-109 insulin Homo sapiens 93-100 18221431-0 2008 Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Insulin Glargine 33-41 insulin Homo sapiens 6-13 18221431-1 2008 BACKGROUND: Insulin glargine is a long-acting insulin analogue increasingly used instead of neutral protamine Hagedorn (NPH) insulin in young subjects with type 1 diabetes. Insulin Glargine 20-28 insulin Homo sapiens 12-19 18221431-1 2008 BACKGROUND: Insulin glargine is a long-acting insulin analogue increasingly used instead of neutral protamine Hagedorn (NPH) insulin in young subjects with type 1 diabetes. Insulin Glargine 20-28 insulin Homo sapiens 46-53 18221431-2 2008 OBJECTIVE: We evaluated the clinical course of diabetes in children and adolescents who were switched from NPH to insulin glargine. Insulin Glargine 122-130 insulin Homo sapiens 114-121 18221431-12 2008 CONCLUSIONS: A switch to insulin glargine retains a similar glycemic control and does not change the number of severe hypoglycemias. Insulin Glargine 33-41 insulin Homo sapiens 25-32 18411384-1 2008 : randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Insulin Glargine 47-55 insulin Homo sapiens 39-46 18414816-2 2008 This article describes how insulin analogues (insulins lispro, aspart, glulisine, glargine and detemir) may have a role to play in overcoming barriers to insulin acceptance and improving adherence with therapy, and examines their cost-effectiveness as determined in published studies. Insulin Glargine 82-90 insulin Homo sapiens 27-34 18414816-2 2008 This article describes how insulin analogues (insulins lispro, aspart, glulisine, glargine and detemir) may have a role to play in overcoming barriers to insulin acceptance and improving adherence with therapy, and examines their cost-effectiveness as determined in published studies. Insulin Glargine 82-90 insulin Homo sapiens 46-53 18355327-0 2008 Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Insulin Glargine 22-30 insulin Homo sapiens 14-21 18615401-2 2008 Shortacting insulin (lispro, aspart and glulisine) and long-acting insulin (glargine and detemir) have been developed for the management of diabetes. Insulin Glargine 76-84 insulin Homo sapiens 67-74 18615401-7 2008 The long-acting insulin analogues provide basal insulin levels for 24 h when administered once (glargine) or two (detemir) daily. Insulin Glargine 96-104 insulin Homo sapiens 16-23 18615401-7 2008 The long-acting insulin analogues provide basal insulin levels for 24 h when administered once (glargine) or two (detemir) daily. Insulin Glargine 96-104 insulin Homo sapiens 48-55 18160047-0 2008 Differences in circulating insulin levels following glargine administration. Insulin Glargine 52-60 insulin Homo sapiens 27-34 18160047-4 2008 CONCLUSIONS: Insulin levels measured by Elecsys in patients treated by glargine are directly related to glargine biotransformation into detectable metabolite (M1). Insulin Glargine 71-79 insulin Homo sapiens 13-20 18160047-4 2008 CONCLUSIONS: Insulin levels measured by Elecsys in patients treated by glargine are directly related to glargine biotransformation into detectable metabolite (M1). Insulin Glargine 104-112 insulin Homo sapiens 13-20 18374840-9 2008 Mean haemoglobin A(1c) decrease in the insulin glargine group was -1.7% (from 8.7% [SD 1.0] to 7.0% [0.7]) and -1.9% in the insulin lispro group (from 8.7% [1.0] to 6.8% [0.9]), which was within the predefined limit of 0.4% for non-inferiority (difference=0.157; 95% Cl -0.008 to 0.322). Insulin Glargine 47-55 insulin Homo sapiens 39-46 18281121-2 2008 Since the introduction of human recombinant insulin the number of cases has decreased although cases have been reported in association with the use of rapid acting insulin analogues and continuous subcutaneous insulin infusion (CSII), recently one case has been reported with the use of insulin glargine. Insulin Glargine 295-303 insulin Homo sapiens 44-51 18374840-16 2008 We conclude that insulin glargine provides a simple and effective option that is more satisfactory to patients than is lispro for early initiation of insulin therapy, since it was associated with a lower risk of hypoglycaemia, fewer injections, less blood glucose self monitoring, and greater patient satisfaction than was insulin lispro. Insulin Glargine 25-33 insulin Homo sapiens 150-157 18374840-12 2008 The incidence of hypoglycaemic events was less with insulin glargine than with lispro (5.2 [95% CI 1.9-8.9] vs 24.0 [21-28] events per patient per year; p<0.0001). Insulin Glargine 60-68 insulin Homo sapiens 52-59 18374840-14 2008 The improvement of treatment satisfaction was greater for insulin glargine than for insulin lispro (mean difference 3.13; 95% CI 2.04-4.22). Insulin Glargine 66-74 insulin Homo sapiens 58-65 18374840-16 2008 We conclude that insulin glargine provides a simple and effective option that is more satisfactory to patients than is lispro for early initiation of insulin therapy, since it was associated with a lower risk of hypoglycaemia, fewer injections, less blood glucose self monitoring, and greater patient satisfaction than was insulin lispro. Insulin Glargine 25-33 insulin Homo sapiens 17-24 18374840-16 2008 We conclude that insulin glargine provides a simple and effective option that is more satisfactory to patients than is lispro for early initiation of insulin therapy, since it was associated with a lower risk of hypoglycaemia, fewer injections, less blood glucose self monitoring, and greater patient satisfaction than was insulin lispro. Insulin Glargine 25-33 insulin Homo sapiens 150-157 17692577-3 2008 We hypothesized that insulin glargine would improve blood glucose control and weight in patients with CFRD without causing hypoglycemia. Insulin Glargine 29-37 insulin Homo sapiens 21-28 17928940-4 2008 Mean age when starting on glargine insulin was 15.5 +/- 3. Insulin Glargine 26-34 insulin Homo sapiens 35-42 18180864-0 2008 Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Insulin Glargine 100-108 insulin Homo sapiens 92-99 18180864-7 2008 The mean therapeutic dosage of insulin glargine in group A was 14.9 IU/day (SD = 5.0 IU/day). Insulin Glargine 39-47 insulin Homo sapiens 31-38 18180864-13 2008 These results suggest that, compared to increasing OAD dosage, the addition of insulin glargine to current OAD therapy is as effective but safer in terms of the risk for hypoglycemia in elderly patients with T2DM. Insulin Glargine 87-95 insulin Homo sapiens 79-86 18308679-0 2008 Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study: response to Porcellati et al. Insulin Glargine 79-87 insulin Homo sapiens 63-70 18348079-10 2008 It is suggested that combination of GLP-1 receptor agonists and insulin analogues, specifically insulin glargine, may represent a new therapeutic option for preservation of beta-cell mass in type 2 diabetic patients. Insulin Glargine 104-112 insulin Homo sapiens 64-71 18348079-10 2008 It is suggested that combination of GLP-1 receptor agonists and insulin analogues, specifically insulin glargine, may represent a new therapeutic option for preservation of beta-cell mass in type 2 diabetic patients. Insulin Glargine 104-112 insulin Homo sapiens 96-103 18335029-5 2008 We evoke a hyperinsulinemic-normoglycemic non-invasive clamp by subcutaneously injecting adult male rats with long-lasting human insulin glargine that remains stable in plasma by several hours. Insulin Glargine 137-145 insulin Homo sapiens 16-23 18307459-0 2008 In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Insulin Glargine 191-199 insulin Homo sapiens 183-190 18299307-1 2008 OBJECTIVE: Insulin glargine is difficult to use for children due to the number of injections required because it is claimed to be immiscible with rapid-acting insulin analogs. Insulin Glargine 19-27 insulin Homo sapiens 11-18 18299307-2 2008 For this study, we hypothesized that treating new-onset type 1 diabetes with twice-daily insulin glargine plus a rapid-acting insulin analog mixed in the same syringe would result in better glycosylated hemoglobin than twice-daily neutral protamine Hagedorn with a rapid-acting insulin analog (standard treatment). Insulin Glargine 97-105 insulin Homo sapiens 89-96 18299307-8 2008 Two patients in the insulin glargine group required lunch rapid-acting insulin analog in the last month of the study. Insulin Glargine 28-36 insulin Homo sapiens 20-27 18299307-8 2008 Two patients in the insulin glargine group required lunch rapid-acting insulin analog in the last month of the study. Insulin Glargine 28-36 insulin Homo sapiens 71-78 18299307-9 2008 Although both groups were encouraged to contact the principal investigator with all queries, more in the insulin glargine arm opted to do so. Insulin Glargine 113-121 insulin Homo sapiens 105-112 18299307-10 2008 CONCLUSIONS: Glycemic control with insulin glargine mixed with a rapid-acting insulin analog given twice daily seems significantly more effective than the standard therapy in newly diagnosed type 1 diabetes. Insulin Glargine 43-51 insulin Homo sapiens 35-42 18465353-6 2008 The benefits of long-acting insulin analogues glargine and detemir vs. NPH, are: (1) lower fasting BG combined with lower risk of hypoglycaemia in the interprandial state (night); (2) lower variability of BG. Insulin Glargine 46-54 insulin Homo sapiens 28-35 18465357-4 2008 Only insulin glargine showed a significantly higher proliferative effect on MCF-7 breast cancer cells compared to regular insulin among a panel of short- or long-acting insulin analogues, that are in clinical use. Insulin Glargine 13-21 insulin Homo sapiens 5-12 18465358-4 2008 Furthermore, special features of insulin analogues regarding their signalling properties are discussed with focus on the proliferative effects of insulin glargine as well as some recent data of insulin detemir. Insulin Glargine 154-162 insulin Homo sapiens 33-40 18465359-7 2008 The patent-protected insulin analogues Lispro, Glulisine, Aspart, Glargine and Detemir are artificial insulin derivatives with altered biological responses compared to natural insulin (e.g. divergent insulin and /or IGF-1 receptor-binding characteristics, signalling patterns, and mitogenicity). Insulin Glargine 66-74 insulin Homo sapiens 21-28 18465359-7 2008 The patent-protected insulin analogues Lispro, Glulisine, Aspart, Glargine and Detemir are artificial insulin derivatives with altered biological responses compared to natural insulin (e.g. divergent insulin and /or IGF-1 receptor-binding characteristics, signalling patterns, and mitogenicity). Insulin Glargine 66-74 insulin Homo sapiens 102-109 18465359-7 2008 The patent-protected insulin analogues Lispro, Glulisine, Aspart, Glargine and Detemir are artificial insulin derivatives with altered biological responses compared to natural insulin (e.g. divergent insulin and /or IGF-1 receptor-binding characteristics, signalling patterns, and mitogenicity). Insulin Glargine 66-74 insulin Homo sapiens 102-109 18465359-7 2008 The patent-protected insulin analogues Lispro, Glulisine, Aspart, Glargine and Detemir are artificial insulin derivatives with altered biological responses compared to natural insulin (e.g. divergent insulin and /or IGF-1 receptor-binding characteristics, signalling patterns, and mitogenicity). Insulin Glargine 66-74 insulin Homo sapiens 102-109 18215174-5 2008 Insulin glargine was used prior to pregnancy in 69% of women, started during pregnancy in 30%, and stopped at booking in one patient. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17980928-0 2008 Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17980928-0 2008 Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Insulin Glargine 8-16 insulin Homo sapiens 127-134 18096110-3 2008 A subgroup of 4782 type 1 patients were transferred from a basal-bolus regimen with NPH insulin (n = 3117) or insulin glargine (n = 1665) to insulin detemir basal-bolus therapy; or from a human insulin basal-bolus regimen (n = 570) to insulin detemir/insulin aspart (part of the pre-study NPH group). Insulin Glargine 118-126 insulin Homo sapiens 110-117 18096110-3 2008 A subgroup of 4782 type 1 patients were transferred from a basal-bolus regimen with NPH insulin (n = 3117) or insulin glargine (n = 1665) to insulin detemir basal-bolus therapy; or from a human insulin basal-bolus regimen (n = 570) to insulin detemir/insulin aspart (part of the pre-study NPH group). Insulin Glargine 118-126 insulin Homo sapiens 110-117 18290862-1 2008 Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. Insulin Glargine 102-110 insulin Homo sapiens 94-101 18227475-2 2008 It is pertinent to ask, however, if multiple daily injection (MDI) regimens based on new long-acting insulin analogs such as glargine and detemir have now replaced the need for CSII. Insulin Glargine 125-133 insulin Homo sapiens 101-108 18171434-3 2008 This strategy is facilitated by introduction of long-acting insulin glargine and biphasic insulin aspart 70/30. Insulin Glargine 68-76 insulin Homo sapiens 60-67 18361065-0 2008 [Perioperative glycemic control by insulin glargine in type 2 diabetic patients]. Insulin Glargine 43-51 insulin Homo sapiens 35-42 18361065-1 2008 OBJECTIVE: To investigate the feasibility of perioperative glycemic control with insulin glargine in type 2 diabetic patients. Insulin Glargine 89-97 insulin Homo sapiens 81-88 18361065-6 2008 CONCLUSION: With satisfied fasting blood glucose level and fewer episode of hypoglycemia, perioperative glycemic control by insulin glargine in type 2 diabetic patients is safe, effective, and convenient. Insulin Glargine 132-140 insulin Homo sapiens 124-131 18273733-0 2008 Insulin glargine improves glycaemic control after coronary surgery in patients with diabetes or pre-diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18273733-1 2008 OBJECTIVES: Determine if pre-emptive daily insulin glargine surpasses regular insulin when needed for glycaemic control after cardiac surgery. Insulin Glargine 51-59 insulin Homo sapiens 43-50 18273733-10 2008 CONCLUSION: The routine protocol with pre-emptive glargine insulin studied here provides a major improvement in glycaemic control with a minimal incidence of hypoglycaemia and without an excessive increase in nursing burden. Insulin Glargine 50-58 insulin Homo sapiens 59-66 18698880-5 2008 Insulin glargine was the first basal analogue approved for clinical use and has shown better fasting glucose control and less risk of hypoglycaemia than conventional human neutral protamine Hagedorn (NPH) insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 18840012-14 2008 CONCLUSION: Switching to insulin detemir from glargine is likely to result in lapse of glycaemic control despite a higher daily insulin dose, increased number of injections and need for frequent evaluations. Insulin Glargine 46-54 insulin Homo sapiens 25-32 18031595-3 2008 RESEARCH DESIGN AND METHODS: This was a post hoc analysis of a 16-week, double-blind, placebo-controlled study in patients with type 2 diabetes (N = 211) using insulin glargine (without mealtime insulin) +/- oral agents. Insulin Glargine 168-176 insulin Homo sapiens 160-167 18197742-4 2008 Data from clinical trials and meta-analyses have demonstrated that the basal insulin analog insulin glargine results in a reduced rate of severe hypoglycemic events compared with conventional insulin therapy such as neutral protamine Hagedorn (NPH) insulin. Insulin Glargine 100-108 insulin Homo sapiens 77-84 18197742-4 2008 Data from clinical trials and meta-analyses have demonstrated that the basal insulin analog insulin glargine results in a reduced rate of severe hypoglycemic events compared with conventional insulin therapy such as neutral protamine Hagedorn (NPH) insulin. Insulin Glargine 100-108 insulin Homo sapiens 92-99 18197742-4 2008 Data from clinical trials and meta-analyses have demonstrated that the basal insulin analog insulin glargine results in a reduced rate of severe hypoglycemic events compared with conventional insulin therapy such as neutral protamine Hagedorn (NPH) insulin. Insulin Glargine 100-108 insulin Homo sapiens 92-99 18197742-4 2008 Data from clinical trials and meta-analyses have demonstrated that the basal insulin analog insulin glargine results in a reduced rate of severe hypoglycemic events compared with conventional insulin therapy such as neutral protamine Hagedorn (NPH) insulin. Insulin Glargine 100-108 insulin Homo sapiens 92-99 18197742-5 2008 Overall, use of insulin glargine compared with NPH insulin appears to reduce the risk of nocturnal and severe hypoglycemia by 40% to 60% and may result in cost savings. Insulin Glargine 24-32 insulin Homo sapiens 16-23 18197742-6 2008 Analyses of hypoglycemia rates from "real-world" clinical practice databases and retrospective analyses of medical claims data also have revealed reduced rates with insulin glargine, consistent with the findings from clinical trials. Insulin Glargine 173-181 insulin Homo sapiens 165-172 17988433-0 2007 Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice. Insulin Glargine 30-38 insulin Homo sapiens 22-29 21318060-1 2008 BACKGROUND: Insulin glargine provides effective glycemic control when administered at bedtime in adults. Insulin Glargine 20-28 insulin Homo sapiens 12-19 21318060-2 2008 OBJECTIVE: This study aims to investigate whether insulin glargine is equally effective if administered in the morning or at bedtime in combination with preprandial anologue insulin. Insulin Glargine 58-66 insulin Homo sapiens 50-57 18577350-0 2008 [Lipoatrophy after use of long acting insulin glargine analogue in a 32-year-old patient with type 1 diabetes]. Insulin Glargine 46-54 insulin Homo sapiens 38-45 18577350-3 2008 Early symptoms of lipoatrophy appeared after 1.5-2 months of insulin glargine use, in spite of frequently changed hypodermic needles and injection sites on both thighs. Insulin Glargine 69-77 insulin Homo sapiens 61-68 17988433-10 2007 CONCLUSIONS: In this retrospective study of medical records, patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c) levels without weight gain versus previous treatment with NPH insulin or insulin lente. Insulin Glargine 112-120 insulin Homo sapiens 104-111 17988433-10 2007 CONCLUSIONS: In this retrospective study of medical records, patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c) levels without weight gain versus previous treatment with NPH insulin or insulin lente. Insulin Glargine 112-120 insulin Homo sapiens 293-300 17988433-10 2007 CONCLUSIONS: In this retrospective study of medical records, patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c) levels without weight gain versus previous treatment with NPH insulin or insulin lente. Insulin Glargine 112-120 insulin Homo sapiens 293-300 17973208-1 2008 BACKGROUND: Addition of the long-acting basal human insulin analogue insulin glargine (LANTUS) to the treatment regimen of patients with inadequate glycaemic control on oral antidiabetic drugs (OADs) alone has previously been evaluated as effective, safe and convenient. Insulin Glargine 77-85 insulin Homo sapiens 52-59 17973208-1 2008 BACKGROUND: Addition of the long-acting basal human insulin analogue insulin glargine (LANTUS) to the treatment regimen of patients with inadequate glycaemic control on oral antidiabetic drugs (OADs) alone has previously been evaluated as effective, safe and convenient. Insulin Glargine 77-85 insulin Homo sapiens 69-76 17973208-1 2008 BACKGROUND: Addition of the long-acting basal human insulin analogue insulin glargine (LANTUS) to the treatment regimen of patients with inadequate glycaemic control on oral antidiabetic drugs (OADs) alone has previously been evaluated as effective, safe and convenient. Insulin Glargine 87-93 insulin Homo sapiens 52-59 17973208-1 2008 BACKGROUND: Addition of the long-acting basal human insulin analogue insulin glargine (LANTUS) to the treatment regimen of patients with inadequate glycaemic control on oral antidiabetic drugs (OADs) alone has previously been evaluated as effective, safe and convenient. Insulin Glargine 87-93 insulin Homo sapiens 69-76 19450076-0 2008 Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. Insulin Glargine 94-102 insulin Homo sapiens 86-93 19450076-7 2008 The average unadjusted total annual costs per patient were euro 1,868.41 (95% CI 1,744.27-1,992.56) for insulin glargine-based vs. euro 2,063.72 (95% CI 1,922.91-2,204.54) for NPH-based therapies. Insulin Glargine 112-120 insulin Homo sapiens 104-111 19450076-8 2008 Average adjusted total annual costs per patient between insulin glargine- (euro 1,241.13) and NPH-based therapies (euro 1,607.86) were statistically significantly different (p=0.0004). Insulin Glargine 64-72 insulin Homo sapiens 56-63 19450076-9 2008 The economic advantage for insulin glargine-based therapies resulted mainly from fewer blood glucose measurements and other diabetes-related materials (e.g. needles). Insulin Glargine 35-43 insulin Homo sapiens 27-34 19450076-11 2008 CONCLUSIONS: The LIVE-SPP study suggests that insulin glargine-based therapies may offer an economic advantage over NPH-based therapies. Insulin Glargine 54-62 insulin Homo sapiens 46-53 18184530-0 2007 Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM). Insulin Glargine 8-16 insulin Homo sapiens 0-7 18042082-8 2007 RESULTS: Compared with the run-in period on NPH, the three glargine treatment blocks were associated with lower (P < 0.0001) and less variable (P < 0.05) pre-breakfast glucose levels, and with an 8-15% reduction in total daily insulin dose (P < 0.0001). Insulin Glargine 59-67 insulin Homo sapiens 233-240 18042082-10 2007 CONCLUSION: Insulin glargine pre-bed can be used in three-injections-daily regimens in prepubertal children to lower and stabilize pre-breakfast glucose levels. Insulin Glargine 20-28 insulin Homo sapiens 12-19 18042082-11 2007 However, to avoid the risk of nocturnal hypoglycaemia, the pre-bed glargine dose should be lowered by giving a further long-acting insulin, such as NPH, in the morning. Insulin Glargine 67-75 insulin Homo sapiens 131-138 18000343-0 2007 Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Insulin Glargine 30-38 insulin Homo sapiens 22-29 18000343-11 2007 Our results suggested that insulin glargine is more effective than NPH insulin as intensive replacement of basal insulin, particularly in those Japanese patients with difficult glycemic control with NPH insulin, equally in both type 1 and type 2 diabetes. Insulin Glargine 35-43 insulin Homo sapiens 27-34 18032083-0 2007 A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro. Insulin Glargine 26-34 insulin Homo sapiens 18-25 18032083-0 2007 A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro. Insulin Glargine 26-34 insulin Homo sapiens 121-128 18032083-0 2007 A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro. Insulin Glargine 26-34 insulin Homo sapiens 121-128 18032083-7 2007 CONCLUSIONS: Partial replacement with a morning dose of insulin glargine protects against the development of ketosis for as much as 12 h after postprandial interruption of CSII. Insulin Glargine 64-72 insulin Homo sapiens 56-63 18042082-0 2007 A randomized cross-over trial to identify the optimal use of insulin glargine in prepubertal children using a three-times daily insulin regimen. Insulin Glargine 69-77 insulin Homo sapiens 61-68 18042082-1 2007 AIMS: The long-acting insulin analogue glargine reduces nocturnal hypoglycaemia and stabilizes morning blood glucose levels in patients with Type 1 diabetes (T1DM) on multiple injection therapy. Insulin Glargine 39-47 insulin Homo sapiens 22-29 17481764-0 2007 Insulin glargine in enteric tube feeding. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21221178-0 2007 Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. Insulin Glargine 8-16 insulin Homo sapiens 0-7 21221178-3 2007 AIMS: This review assesses the evidence for the use of insulin glargine in type 1 and type 2 diabetes mellitus. Insulin Glargine 63-71 insulin Homo sapiens 55-62 21221178-4 2007 EVIDENCE REVIEW: Once-daily insulin glargine has a prolonged, peakless activity profile, making it a candidate as a long-acting (basal) insulin. Insulin Glargine 36-44 insulin Homo sapiens 28-35 21221178-4 2007 EVIDENCE REVIEW: Once-daily insulin glargine has a prolonged, peakless activity profile, making it a candidate as a long-acting (basal) insulin. Insulin Glargine 36-44 insulin Homo sapiens 136-143 21221178-7 2007 In patients with type 2 diabetes requiring insulin therapy, once-daily insulin glargine has proven to be clinically superior to NPH insulin in terms of providing at least as effective glycemic control, but with significantly fewer episodes of nocturnal hypoglycemia. Insulin Glargine 79-87 insulin Homo sapiens 43-50 21221178-7 2007 In patients with type 2 diabetes requiring insulin therapy, once-daily insulin glargine has proven to be clinically superior to NPH insulin in terms of providing at least as effective glycemic control, but with significantly fewer episodes of nocturnal hypoglycemia. Insulin Glargine 79-87 insulin Homo sapiens 71-78 21221178-8 2007 A variety of economic analyses have confirmed the cost effectiveness of insulin glargine in type 1 and type 2 diabetes and in particular it was shown to be significantly superior to NPH insulin. Insulin Glargine 80-88 insulin Homo sapiens 72-79 21221178-9 2007 CLINICAL VALUE: Insulin glargine has established itself as a first-line choice in patients with type 1 diabetes, including children (>6 years) and adolescents, and is a recommended treatment option. Insulin Glargine 24-32 insulin Homo sapiens 16-23 21221178-11 2007 Thus, insulin glargine is a valuable addition to the therapeutic armamentarium available to physicians and it has the potential to significantly improve the quality of life of patients with diabetes. Insulin Glargine 14-22 insulin Homo sapiens 6-13 18158075-13 2007 Both exenatide and insulin glargine were associated with significant reductions from baseline in FSG (-2.9 [0.2] and -4.1 [0.2] mmol/L, respectively; both, P < 0.001), although the reduction was significantly greater with insulin glargine compared with exenatide (LS mean difference, 1.2 [0.3] mmol/L; 95% CI, 0.7 to 1.7; P < 0.001). Insulin Glargine 27-35 insulin Homo sapiens 19-26 18158075-13 2007 Both exenatide and insulin glargine were associated with significant reductions from baseline in FSG (-2.9 [0.2] and -4.1 [0.2] mmol/L, respectively; both, P < 0.001), although the reduction was significantly greater with insulin glargine compared with exenatide (LS mean difference, 1.2 [0.3] mmol/L; 95% CI, 0.7 to 1.7; P < 0.001). Insulin Glargine 27-35 insulin Homo sapiens 225-232 18158075-13 2007 Both exenatide and insulin glargine were associated with significant reductions from baseline in FSG (-2.9 [0.2] and -4.1 [0.2] mmol/L, respectively; both, P < 0.001), although the reduction was significantly greater with insulin glargine compared with exenatide (LS mean difference, 1.2 [0.3] mmol/L; 95% CI, 0.7 to 1.7; P < 0.001). Insulin Glargine 233-241 insulin Homo sapiens 19-26 18158075-17 2007 CONCLUSIONS: In this open-label, crossover study, treatment with exenatide or insulin glargine for 16 weeks was associated with similar significant improvements from baseline in HbA(1c), independent of treatment order. Insulin Glargine 86-94 insulin Homo sapiens 78-85 18158075-19 2007 Exenatide therapy was associated with significant reductions in body weight and PPG excursions compared with insulin glargine, whereas insulin glargine was associated with a significantly greater reduction in FSG compared with exenatide. Insulin Glargine 143-151 insulin Homo sapiens 135-142 17644447-2 2007 We report the case of a patient suffering from type 1 diabetes who was found comatose with a plasma glucose close to zero after having injected herself massive doses of both aspart and glargine insulin analogues. Insulin Glargine 185-193 insulin Homo sapiens 194-201 17644447-4 2007 This observation emphasizes again that clinicians should be aware of the extremely prolonged action of long acting insulin analogue glargine after intentional massive injection in order to avoid a too early interruption of glucose infusion and a subsequent risk of relapse of severe hypoglycaemic episodes. Insulin Glargine 132-140 insulin Homo sapiens 115-122 17490781-0 2007 Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Insulin Glargine 95-103 insulin Homo sapiens 58-65 17490781-5 2007 A1c reduction was greater in the insulin glargine arm. Insulin Glargine 41-49 insulin Homo sapiens 33-40 18058596-0 2007 Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study. Insulin Glargine 58-66 insulin Homo sapiens 50-57 17922476-4 2007 Therefore, this article will review the relevant preclinical and clinical data to assess the mitogenic potential of insulin glargine, a basal insulin analogue, compared with regular human insulin (RHI). Insulin Glargine 124-132 insulin Homo sapiens 116-123 17922476-4 2007 Therefore, this article will review the relevant preclinical and clinical data to assess the mitogenic potential of insulin glargine, a basal insulin analogue, compared with regular human insulin (RHI). Insulin Glargine 124-132 insulin Homo sapiens 142-149 17922476-4 2007 Therefore, this article will review the relevant preclinical and clinical data to assess the mitogenic potential of insulin glargine, a basal insulin analogue, compared with regular human insulin (RHI). Insulin Glargine 124-132 insulin Homo sapiens 142-149 17922476-7 2007 Although one study reported increased binding affinity of insulin glargine for the IGF-1R and increased mitogenic potential in cells with excess IGF-1Rs (Saos/B10 osteosarcoma cells), most in vitro binding-affinity and cell-culture studies have demonstrated behaviour of insulin glargine comparable to that of RHI for both IR and IGF-1R binding, insulin signalling, and metabolic and mitogenic potential.Currently published in vivo carcinogenic studies and human clinical trial data have shown that insulin glargine is not associated with increased risk for either cancer or the development or progression of diabetic retinopathy. Insulin Glargine 66-74 insulin Homo sapiens 58-65 18058596-1 2007 BACKGROUND: Addition of the long-acting basal human insulin analogue insulin glargine (LANTUS) to the treatment regimen of patients with inadequate glycaemic control on oral antidiabetic drugs (OADs) alone has previously been evaluated as effective, safe and convenient. Insulin Glargine 77-85 insulin Homo sapiens 52-59 18058596-1 2007 BACKGROUND: Addition of the long-acting basal human insulin analogue insulin glargine (LANTUS) to the treatment regimen of patients with inadequate glycaemic control on oral antidiabetic drugs (OADs) alone has previously been evaluated as effective, safe and convenient. Insulin Glargine 77-85 insulin Homo sapiens 69-76 18058596-1 2007 BACKGROUND: Addition of the long-acting basal human insulin analogue insulin glargine (LANTUS) to the treatment regimen of patients with inadequate glycaemic control on oral antidiabetic drugs (OADs) alone has previously been evaluated as effective, safe and convenient. Insulin Glargine 87-93 insulin Homo sapiens 52-59 18058596-1 2007 BACKGROUND: Addition of the long-acting basal human insulin analogue insulin glargine (LANTUS) to the treatment regimen of patients with inadequate glycaemic control on oral antidiabetic drugs (OADs) alone has previously been evaluated as effective, safe and convenient. Insulin Glargine 87-93 insulin Homo sapiens 69-76 18058601-0 2007 The rate of improvement in metabolic control in children with diabetes mellitus type 1 on insulin glargine depends on age. Insulin Glargine 98-106 insulin Homo sapiens 90-97 17927832-0 2007 The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Insulin Glargine 94-102 insulin Homo sapiens 86-93 17927832-8 2007 Additionally, significant Treatment effects favouring insulin glargine (p < 0.001) and a Treatment x Questionnaire interaction (p < 0.019), with the DTSQc showing more benefits, were found in the type 1 trial. Insulin Glargine 62-70 insulin Homo sapiens 54-61 17668418-1 2007 BACKGROUND: The basal insulin analogues glargine and detemir have been subject to a series of trials comparing their clinical profiles to the conventional preparation, neutral protamine Hagedorn (NPH). Insulin Glargine 40-48 insulin Homo sapiens 22-29 17851816-0 2007 Use of insulin glargine during pregnancy. Insulin Glargine 15-23 insulin Homo sapiens 7-14 17851816-2 2007 The long-acting insulin analogue glargine has 24-h persistence and a peakless action profile, and could contribute to more stable daily plasma glucose levels and improved glycemic control. Insulin Glargine 33-41 insulin Homo sapiens 16-23 17851816-3 2007 We evaluated the metabolic control associated with insulin glargine during pregnancy in comparison with conventional basal insulin therapy. Insulin Glargine 59-67 insulin Homo sapiens 51-58 17851816-5 2007 RESULTS: Overall,glycemic control was not different between the groups, though the decrease in HbA1c from the first to the third trimester was greater with insulin glargine (0.8 versus 0.3%, p=0.04). Insulin Glargine 164-172 insulin Homo sapiens 156-163 17851816-7 2007 CONCLUSIONS: Our findings suggest that, as regards metabolic control, insulin glargine in women with type 1 diabetes is comparable with NPH insulin as basal insulin therapy. Insulin Glargine 78-86 insulin Homo sapiens 70-77 17623819-0 2007 Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Insulin Glargine 79-87 insulin Homo sapiens 63-70 17623819-1 2007 OBJECTIVE: To compare pharmacokinetics and pharmacodynamics of insulin analogs glargine and detemir, 24 subjects with type 1 diabetes (aged 38 +/- 10 years, BMI 22.4 +/- 1.6 kg/m2, and A1C 7.2 +/- 0.7%) were studied after a 2-week treatment with either glargine or detemir once daily (randomized, double-blind, crossover study). Insulin Glargine 79-87 insulin Homo sapiens 63-70 17623819-7 2007 Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001). Insulin Glargine 121-129 insulin Homo sapiens 16-23 17906278-1 2007 BACKGROUND: The purpose of this study was to evaluate the effectiveness of insulin lispro and insulin glargine at controlling blood glucose in patients with type 2 diabetes mellitus in a cardiovascular intensive care unit (CICU) and receiving enteral tube feedings. Insulin Glargine 102-110 insulin Homo sapiens 94-101 17697063-0 2007 Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Insulin Glargine 22-30 insulin Homo sapiens 14-21 17697063-3 2007 Here, we report the results of a subanalysis of the trial, which investigated whether insulin glargine can be initiated and titrated as effectively in primary [general practitioner (GP)] as secondary (hospital) care in patients with T2DM in the UK. Insulin Glargine 94-102 insulin Homo sapiens 86-93 17697063-5 2007 Insulin glargine was titrated to target fasting blood glucose (FBG) levels of <or=5.5 mmol/l according to algorithm 1 (clinic-driven titration) or algorithm 2 (patient-managed titration). Insulin Glargine 8-16 insulin Homo sapiens 0-7 17697063-8 2007 With the exception of absolute reductions in HbA1c and reductions in basal and prandial insulin made on switching to insulin glargine, there were few significant differences in subjects managed in primary compared with secondary care. Insulin Glargine 125-133 insulin Homo sapiens 88-95 17697063-9 2007 CONCLUSIONS: This study shows that despite differences in diabetes duration and baseline glycaemic control, an insulin glargine-based therapy can be safely and effectively initiated in a diverse range of suboptimally controlled subjects with T2DM in both primary and secondary care settings in the UK. Insulin Glargine 119-127 insulin Homo sapiens 111-118 17137771-0 2007 Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 30736120-0 2007 Insulin glargine: a basal insulin for the management of diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 30736120-0 2007 Insulin glargine: a basal insulin for the management of diabetes. Insulin Glargine 8-16 insulin Homo sapiens 26-33 30736120-3 2007 Insulin glargine is the first available synthetic insulin that can truly be described as basal - administered as a once-daily subcutaneous injection it raises the background, or basal, insulin level without a significant peak action and less hypoglycemia than previously used basal insulins. Insulin Glargine 8-16 insulin Homo sapiens 0-7 30736120-3 2007 Insulin glargine is the first available synthetic insulin that can truly be described as basal - administered as a once-daily subcutaneous injection it raises the background, or basal, insulin level without a significant peak action and less hypoglycemia than previously used basal insulins. Insulin Glargine 8-16 insulin Homo sapiens 50-57 30736120-3 2007 Insulin glargine is the first available synthetic insulin that can truly be described as basal - administered as a once-daily subcutaneous injection it raises the background, or basal, insulin level without a significant peak action and less hypoglycemia than previously used basal insulins. Insulin Glargine 8-16 insulin Homo sapiens 185-192 30736120-4 2007 Insulin glargine is the first basal insulin that can be administered as a single injection daily as part of an intensive basal-bolus insulin regimen in Type 1 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 30736120-4 2007 Insulin glargine is the first basal insulin that can be administered as a single injection daily as part of an intensive basal-bolus insulin regimen in Type 1 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 36-43 30736120-5 2007 In Type 2 diabetes, insulin glargine, administered once daily with one or two oral hypoglycemic drugs, can enable more than 50% of patients to achieve an A1c of less than 7%. Insulin Glargine 28-36 insulin Homo sapiens 20-27 30736120-6 2007 The titration of the insulin glargine dose to an appropriate level over a period of weeks is essential to its successful use in Type 2 diabetes. Insulin Glargine 29-37 insulin Homo sapiens 21-28 17216593-5 2007 Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present. Insulin Glargine 83-91 insulin Homo sapiens 64-71 17705693-2 2007 METHODS: Basal therapy was twice-daily insulin glargine. Insulin Glargine 47-55 insulin Homo sapiens 39-46 17216593-5 2007 Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present. Insulin Glargine 83-91 insulin Homo sapiens 129-136 17508198-0 2007 Insulin glargine supplementation during early management phase of diabetic ketoacidosis in children. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17508198-1 2007 OBJECTIVE: To study the effect of subcutaneous administration of insulin glargine on the rate of resolution of acidosis and intravenous insulin infusion requirement in children with moderate and severe diabetic ketoacidosis (DKA). Insulin Glargine 73-81 insulin Homo sapiens 65-72 17508198-1 2007 OBJECTIVE: To study the effect of subcutaneous administration of insulin glargine on the rate of resolution of acidosis and intravenous insulin infusion requirement in children with moderate and severe diabetic ketoacidosis (DKA). Insulin Glargine 73-81 insulin Homo sapiens 136-143 17508198-5 2007 RESULTS: The outcomes of children who received 0.3 units/kg of subcutaneous insulin glargine in the first 6 h of management in addition to the standard treatment (n=12) were compared with those of children who received standard treatment alone (n=59). Insulin Glargine 84-92 insulin Homo sapiens 76-83 17508198-8 2007 The mean time for acidosis correction (venous pH>or=7.3) in the insulin glargine group was shorter than the standard therapy group (12.4+/-2.9 h and 17.1+/-6.2 h respectively, p<0.001). Insulin Glargine 75-83 insulin Homo sapiens 67-74 17508198-9 2007 The insulin infusion time was shorter in the insulin glargine group (14.8+/-6.0 h vs 24.4+/-9.0 h, p<0.001). Insulin Glargine 53-61 insulin Homo sapiens 4-11 17508198-9 2007 The insulin infusion time was shorter in the insulin glargine group (14.8+/-6.0 h vs 24.4+/-9.0 h, p<0.001). Insulin Glargine 53-61 insulin Homo sapiens 45-52 17508198-11 2007 CONCLUSIONS: In our small series of children with moderate and severe DKA, supplementing with subcutaneous insulin glargine led to a faster resolution of acidosis without any adverse effects. Insulin Glargine 115-123 insulin Homo sapiens 107-114 17848840-7 2007 The work illustrates the first long-term study comparing the efficacy of CSII to MDI using glargine as basal insulin in children. Insulin Glargine 91-99 insulin Homo sapiens 109-116 17381500-5 2007 Home-measured fasting plasma glucose (PG) was lower with insulin glargine than with insulin detemir (7.0 vs. 7.7 mmol/l, P < 0.001). Insulin Glargine 65-73 insulin Homo sapiens 57-64 17849743-0 2007 Usefulness of the long-acting insulin analogue glargine in basal-bolus therapy for Japanese children and adolescents with type 1 diabetes mellitus. Insulin Glargine 47-55 insulin Homo sapiens 30-37 17849743-1 2007 The aim of this study was to evaluate the efficacy of long-acting insulin analogue glargine (G) changing from NPH in basal-bolus therapy for Japanese children and adolescents with type 1 diabetes mellitus (DM1). Insulin Glargine 83-91 insulin Homo sapiens 66-73 17360218-0 2007 Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Insulin Glargine 0-8 insulin Homo sapiens 64-71 17360218-1 2007 AIM: Glargine, a long-acting insulin analogue, is metabolized in the bloodstream and in subcutaneous tissue. Insulin Glargine 5-13 insulin Homo sapiens 29-36 17360218-4 2007 METHODS: Formation of M1 glargine metabolite in vitro was studied with Elecsys Insulin immunoassay in pools of sera and sera from patients spiked with glargine. Insulin Glargine 25-33 insulin Homo sapiens 79-86 17692716-0 2007 Dosing of insulin glargine in the treatment of type 2 diabetes. Insulin Glargine 18-26 insulin Homo sapiens 10-17 17692716-7 2007 Studies were assessed and included in this review if they provided information regarding the method of dose titration of insulin glargine used. Insulin Glargine 129-137 insulin Homo sapiens 121-128 17372150-1 2007 OBJECTIVE: We sought to test the hypothesis that start of insulin glargine with sustained nightly insulin action results in changes in circulating concentrations of IGF-I and IGF binding proteins (IGFBPs) in adolescents with type 1 diabetes-changes that may support improvement of A1C. Insulin Glargine 66-74 insulin Homo sapiens 58-65 17372150-1 2007 OBJECTIVE: We sought to test the hypothesis that start of insulin glargine with sustained nightly insulin action results in changes in circulating concentrations of IGF-I and IGF binding proteins (IGFBPs) in adolescents with type 1 diabetes-changes that may support improvement of A1C. Insulin Glargine 66-74 insulin Homo sapiens 98-105 17381500-12 2007 CONCLUSIONS: Treatment with twice-daily insulin detemir or once-daily insulin glargine, each in combination with insulin aspart, resulted in similar glycaemic control. Insulin Glargine 78-86 insulin Homo sapiens 70-77 16806646-0 2007 Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. Insulin Glargine 26-34 insulin Homo sapiens 18-25 17701878-6 2007 RESULTS: HbA1c in the insulin glargine group improved statistically significant by -0.49%; [95%CI, -0.26, -0.71; p<0.001; HbA1c at endpoint 6.95+/-0.71%], whereas in the NPH group the reduction by -0.12% [95%CI, -0.31, 0.06; p=0.189; HbA1c at endpoint 7.22+/-0.74%] was statistically not significant. Insulin Glargine 30-38 insulin Homo sapiens 22-29 17701878-10 2007 CONCLUSIONS: Following a structured in-patient diabetes training programme glycaemic control in people with Type 2 diabetes mellitus on a basal-bolus regimen improved significantly only with insulin glargine suggesting that training alone may not be sufficient to further improve metabolic control in relatively well controlled patients on NPH insulin. Insulin Glargine 199-207 insulin Homo sapiens 191-198 17303785-0 2007 Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Insulin Glargine 72-80 insulin Homo sapiens 57-64 17550426-0 2007 Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. Insulin Glargine 23-31 insulin Homo sapiens 15-22 17702122-0 2007 [Clinical experience in treatment with the long-term insulin analogue glargin in a diabetes centre]. Insulin Glargine 70-77 insulin Homo sapiens 53-60 17702122-1 2007 OBJECTIVE: To assess the experience obtained by a diabetes centre in the treatment of patients with type 1 diabetes with the long-term insulin analogue glargin. Insulin Glargine 152-159 insulin Homo sapiens 135-142 17702122-11 2007 The total daily dose of insulin prior to treatment and after 6 months of therapy with glargin decreased from 44 (35-56) IU/day to 42 (34-53) IU/day (p = 0.01). Insulin Glargine 86-93 insulin Homo sapiens 24-31 17494893-10 2007 Basal-bolus plus correction insulin therapy usually involves a single daily dose of insulin glargine at bedtime to prevent gluconeogenesis and ketogenesis, bolus injections of a rapid-acting insulin shortly before or after meals to meet prandial requirements, and correction bolus injections of rapid-acting insulin as needed for blood glucose elevations before or between meals. Insulin Glargine 92-100 insulin Homo sapiens 84-91 17494893-10 2007 Basal-bolus plus correction insulin therapy usually involves a single daily dose of insulin glargine at bedtime to prevent gluconeogenesis and ketogenesis, bolus injections of a rapid-acting insulin shortly before or after meals to meet prandial requirements, and correction bolus injections of rapid-acting insulin as needed for blood glucose elevations before or between meals. Insulin Glargine 92-100 insulin Homo sapiens 84-91 17494893-10 2007 Basal-bolus plus correction insulin therapy usually involves a single daily dose of insulin glargine at bedtime to prevent gluconeogenesis and ketogenesis, bolus injections of a rapid-acting insulin shortly before or after meals to meet prandial requirements, and correction bolus injections of rapid-acting insulin as needed for blood glucose elevations before or between meals. Insulin Glargine 92-100 insulin Homo sapiens 84-91 17599852-0 2007 Once-daily insulin glargine versus 6-hour sliding scale regular insulin for control of hyperglycemia after a bariatric surgical procedure: a randomized clinical trial. Insulin Glargine 19-27 insulin Homo sapiens 11-18 17391170-5 2007 HbAlc was significantly reduced from baseline in each of the subgroups (-1.29,-0.60 and-0.59% for patients previously taking OADs only, NPH insulin +/- OADs and insulin glargine +/- OADs respectively; p < 0.0001), as was fasting blood glucose (FBG) (-58.1,-29.1 and-24.6 mg/dl; p < 0.0001) and FBG variability-8.2 mg/dl,-5.7 mg/dl; p < 0.0001 and -5.1 mg/dl; p = 0.0008). Insulin Glargine 169-177 insulin Homo sapiens 161-168 17599852-1 2007 OBJECTIVE: To determine whether once-daily insulin glargine could provide better glycemic control after an abdominal surgical procedure than the traditional use of sliding scale regular insulin (SSRI). Insulin Glargine 51-59 insulin Homo sapiens 43-50 17599852-5 2007 RESULTS: Overall, the mean blood glucose level after SSRI therapy was 154 +/- 33 mg/dL, and the mean blood glucose value after insulin glargine treatment was 134 +/- 30 mg/dL (P<0.01). Insulin Glargine 135-143 insulin Homo sapiens 127-134 17599852-6 2007 The mean blood glucose level for patients first treated with intravenous insulin infusion in the ICU was 125 mg/dL, in comparison with 145 mg/dL in the non-ICU patients whose treatment began directly with 0.3 U/kg of insulin glargine. Insulin Glargine 225-233 insulin Homo sapiens 73-80 17599852-6 2007 The mean blood glucose level for patients first treated with intravenous insulin infusion in the ICU was 125 mg/dL, in comparison with 145 mg/dL in the non-ICU patients whose treatment began directly with 0.3 U/kg of insulin glargine. Insulin Glargine 225-233 insulin Homo sapiens 217-224 17599852-8 2007 CONCLUSION: In this study, control of postoperative hyperglycemia was significantly better with use of insulin glargine in comparison with SSRI therapy, and hypoglycemia was very infrequent. Insulin Glargine 111-119 insulin Homo sapiens 103-110 17599855-1 2007 OBJECTIVE: To evaluate glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes receiving multiple daily insulin injections during glargine and Ultralente use as basal insulin in a clinical trial. Insulin Glargine 159-167 insulin Homo sapiens 133-140 17261126-0 2007 Use of insulin glargine during pregnancy: a case-control pilot study. Insulin Glargine 15-23 insulin Homo sapiens 7-14 17493554-10 2007 Based on available evidence, insulin glargine has shown equal clinical efficacy to that of NPH insulin and similar reductions in A1C and is associated with similar or lower FPG levels. Insulin Glargine 37-45 insulin Homo sapiens 29-36 17493554-11 2007 Recent studies also have demonstrated that less frequent nocturnal hypoglycemia incidence is associated with insulin glargine compared with NPH insulin. Insulin Glargine 117-125 insulin Homo sapiens 109-116 17438481-7 2007 In each group, half the animals were given subcutaneous injections of the long-lasting basal insulin glargine; the other half, the appropriate vehicle. Insulin Glargine 101-109 insulin Homo sapiens 93-100 17546241-5 2007 After switching to insulin glargine therapy, mean A1c dropped from 10.2 +/- 2.0 to 9.1 +/- 1.8%, with significant impact (p= 0.019). Insulin Glargine 27-35 insulin Homo sapiens 19-26 17546241-6 2007 We observed a significant reduction of 0.11 U/kg/day in total insulin dose, dropped from 0.75 U/kg of NPH to 0.64 U/kg of glargine, with significant correlation (p< 0.05). Insulin Glargine 122-130 insulin Homo sapiens 62-69 17261126-1 2007 OBJECTIVE: To determine whether the use of insulin glargine during pregnancy is associated with an increase in the incidence of fetal macrosomia or adverse neonatal outcome. Insulin Glargine 51-59 insulin Homo sapiens 43-50 17261126-9 2007 The overall incidence of fetal macrosomia was 12/32 (37.5%) in the insulin glargine group and 13/32 (40.6%) in the control group. Insulin Glargine 75-83 insulin Homo sapiens 67-74 17261126-11 2007 CONCLUSIONS: The results of this pilot study indicate that insulin glargine treatment during pregnancy does not appear to be associated with increased fetal macrosomia or neonatal morbidity. Insulin Glargine 67-75 insulin Homo sapiens 59-66 17011662-0 2007 Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17011662-4 2007 HbA(1c) levels decreased in the insulin glargine and NPH groups over the study period in the per-protocol (PP; -1.10% versus 0.92%) and full-analysis (FA; -0.99% versus -0.77%) populations. Insulin Glargine 40-48 insulin Homo sapiens 32-39 17011662-8 2007 Daily insulin dose increased from 9.6+/-1.5 to 32.1+/-17.6 U in the insulin glargine group and from 9.8+/-1.9 to 32.8+/-18.9 U in the NPH insulin group. Insulin Glargine 76-84 insulin Homo sapiens 6-13 17011662-9 2007 CONCLUSION: These results confirm earlier reports that insulin glargine provides superior glycemic control with less hypoglycemia and demonstrates that these benefits are consistent between different ethnicities. Insulin Glargine 63-71 insulin Homo sapiens 55-62 17276718-0 2007 Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen. Insulin Glargine 60-68 insulin Homo sapiens 52-59 17259481-1 2007 OBJECTIVE: We sought to assess health-related quality of life (HRQOL) in patients with type 2 diabetes treated with insulin glargine or rosiglitazone as add-on therapy to sulfonylurea plus metformin. Insulin Glargine 124-132 insulin Homo sapiens 116-123 17298589-0 2007 Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17259481-7 2007 CONCLUSIONS: Although addition of insulin glargine and rosiglitazone achieved comparable improvements in glycemic control, insulin glargine was associated with greater improvements in HRQOL, indicating that other factors (e.g., safety profile and nonglycemic actions) may further enhance HRQOL in patients with type 2 diabetes. Insulin Glargine 131-139 insulin Homo sapiens 123-130 17298589-7 2007 CONCLUSIONS: Addition of nateglinide before meals to once-daily insulin glargine in people with long-standing diabetes already requiring insulin therapy improves blood glucose control in the early part of the day after breakfast and lunch, but does not provide good control of blood glucose levels overall. Insulin Glargine 72-80 insulin Homo sapiens 64-71 17298589-7 2007 CONCLUSIONS: Addition of nateglinide before meals to once-daily insulin glargine in people with long-standing diabetes already requiring insulin therapy improves blood glucose control in the early part of the day after breakfast and lunch, but does not provide good control of blood glucose levels overall. Insulin Glargine 72-80 insulin Homo sapiens 137-144 17276718-10 2007 CONCLUSION: These data confirm that insulin glargine in combination with either FAA or RHI is equally effective and safe, whether it is administered at dinner or bedtime. Insulin Glargine 44-52 insulin Homo sapiens 36-43 17298589-1 2007 OBJECTIVE: To determine the effect of adding nateglinide to therapy with insulin glargine in adults with Type 2 diabetes previously treated with insulin and with poor blood glucose control. Insulin Glargine 81-89 insulin Homo sapiens 73-80 17235522-0 2007 Comment on: Distiller LA, Joffe BI (2006) From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a "routine" diabetes clinic? Insulin Glargine 66-74 insulin Homo sapiens 75-82 17479442-8 2007 Long-acting insulin analogues (glargine) increased threefold. Insulin Glargine 31-39 insulin Homo sapiens 12-19 17479442-14 2007 Insulin glargine was more often prescribed in combination with oral agents, whereas NPH insulin was more frequently prescribed with short-acting insulin, indicating different prescription patterns in primary care. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17565917-2 2007 With the use of outcome data and patient characteristics reported from an ongoing prospective observational trial, a validated computer simulation model of diabetes was used to project the clinical and cost outcomes associated with therapy conversion to insulin detemir over a 35-y period from (1) OHA only, (2) neutral protamine Hagedorn insulin (NPH)+/-OHA, and (3) insulin glargine+/-OHA. Insulin Glargine 376-384 insulin Homo sapiens 254-261 17565917-5 2007 Treatment with insulin detemir+/-OHA was associated with increases in quality-adjusted life expectancy of 0.309, 0.350, and 0.333 quality-adjusted life-years (QALYs) versus treatment with OHA alone, NPH+/-OHA, and insulin glargine+/-OHA, respectively. Insulin Glargine 222-230 insulin Homo sapiens 15-22 17349253-0 2007 [Insulin glargine in intensively-treated type 1 diabetes mellitus]. Insulin Glargine 9-17 insulin Homo sapiens 1-8 17349253-1 2007 OBJECTIVES: To evaluate the use of insulin glargine in intensively-treated children and adolescents. Insulin Glargine 43-51 insulin Homo sapiens 35-42 17349253-13 2007 Glargine insulin improves metabolic control in intensively-treated children and adolescents with type 1 diabetes. Insulin Glargine 0-8 insulin Homo sapiens 9-16 17577469-0 2007 Health care resource utilization and expenditures associated with the use of insulin glargine. Insulin Glargine 85-93 insulin Homo sapiens 77-84 17577469-2 2007 OBJECTIVE: We studied initiation of insulin glargine to evaluate its association with subsequent health service utilization and estimated expenditures. Insulin Glargine 44-52 insulin Homo sapiens 36-43 17577469-6 2007 RESULTS: Compared with other insulin users, insulin glargine initiators had higher HbA(1c) values (8.72% vs 8.16%) prior to the index date, but greater subsequent HbA(1c) reduction (-0.50% vs -0.22%). Insulin Glargine 52-60 insulin Homo sapiens 29-36 17577469-6 2007 RESULTS: Compared with other insulin users, insulin glargine initiators had higher HbA(1c) values (8.72% vs 8.16%) prior to the index date, but greater subsequent HbA(1c) reduction (-0.50% vs -0.22%). Insulin Glargine 52-60 insulin Homo sapiens 44-51 17577469-9 2007 CONCLUSIONS: Insulin glargine use was associated with decreased inpatient days but increased outpatient care, and the value of the net change in utilization to VA offset the additional medication expenditures. Insulin Glargine 21-29 insulin Homo sapiens 13-20 17577469-10 2007 Initiation of insulin glargine improves glycemic control and may reduce time in hospital without additional use of health resources. Insulin Glargine 22-30 insulin Homo sapiens 14-21 17474539-0 2007 Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Insulin Glargine 47-55 insulin Homo sapiens 39-46 17474539-1 2007 OBJECTIVE: The objective of this study was to evaluate the cost-effectiveness of insulin glargine compared with NPH insulin in patients with type 2 diabetes and in whom OAD (oral anti-diabetics) had failed in Switzerland. Insulin Glargine 89-97 insulin Homo sapiens 81-88 17474539-5 2007 For insulin glargine, HbA1c reductions of 0.96% (pessimistic case) and 1.24% (optimistic case) were simulated for three different HbA1c baseline values (10, 9 and 8%). Insulin Glargine 12-20 insulin Homo sapiens 4-11 17474539-13 2007 RESULTS: Cost comparison demonstrated that insulin glargine is the dominant strategy for the optimistic case scenario starting at a baseline HbA1c value of 10% as savings in the management of complications exceeded the difference in acquisition costs after 8 years of treatment. Insulin Glargine 51-59 insulin Homo sapiens 43-50 17474539-17 2007 The 10-year simulations demonstrated that the deltaHbA1c reductions of 0.4 and 0.12% achieved with insulin glargine led to a reduction of long-term complications, mortality and associated costs as well as to an improved quality of life. Insulin Glargine 107-115 insulin Homo sapiens 99-106 17474539-18 2007 Insulin glargine proved to be cost-effective and represents good to excellent value for money compared to NPH insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17580534-1 2007 BACKGROUND/AIM: Insulin glargine is a long-acting insulin analog that mimics normal basal insulin secretion without pronounced peaks. Insulin Glargine 24-32 insulin Homo sapiens 16-23 17580534-1 2007 BACKGROUND/AIM: Insulin glargine is a long-acting insulin analog that mimics normal basal insulin secretion without pronounced peaks. Insulin Glargine 24-32 insulin Homo sapiens 50-57 17580534-1 2007 BACKGROUND/AIM: Insulin glargine is a long-acting insulin analog that mimics normal basal insulin secretion without pronounced peaks. Insulin Glargine 24-32 insulin Homo sapiens 90-97 17580534-5 2007 insulin glargine once daily (n = 18). Insulin Glargine 8-16 insulin Homo sapiens 0-7 17580534-10 2007 Total daily insulin doses were similar in all groups but only in the glargine group there was an increase of basal and decrease of meal related insulin doses. Insulin Glargine 69-77 insulin Homo sapiens 12-19 17580534-10 2007 Total daily insulin doses were similar in all groups but only in the glargine group there was an increase of basal and decrease of meal related insulin doses. Insulin Glargine 69-77 insulin Homo sapiens 144-151 17580534-12 2007 CONCLUSION: Basal insulin supplementation in type 1 diabetes mellitus with either twice daily NPH insulin or glargine can result in similar glycemic control when combined with meal time insulin aspart. Insulin Glargine 109-117 insulin Homo sapiens 18-25 17300174-1 2007 The search for target analytes to uncover the misuse of long acting insulin analogues (Lantus, Insulin Glargine; Levemir, Insulin Detemir) in doping control samples led to the identification of several degradation products of insulin or its synthetic analogues. Insulin Glargine 87-93 insulin Homo sapiens 68-75 17300174-1 2007 The search for target analytes to uncover the misuse of long acting insulin analogues (Lantus, Insulin Glargine; Levemir, Insulin Detemir) in doping control samples led to the identification of several degradation products of insulin or its synthetic analogues. Insulin Glargine 87-93 insulin Homo sapiens 226-233 17300174-1 2007 The search for target analytes to uncover the misuse of long acting insulin analogues (Lantus, Insulin Glargine; Levemir, Insulin Detemir) in doping control samples led to the identification of several degradation products of insulin or its synthetic analogues. Insulin Glargine 103-111 insulin Homo sapiens 68-75 17355742-1 2007 OBJECTIVES: The aim of this study was to evaluate the long-term clinical and economic outcomes associated with exenatide or insulin glargine, added to oral therapy in individuals with type 2 diabetes inadequately controlled with combination oral agents in the UK setting. Insulin Glargine 132-140 insulin Homo sapiens 124-131 17458480-0 2007 Adoption of a new technology in a Veterans Affairs national formulary system with local implementation: the insulin glargine example. Insulin Glargine 116-124 insulin Homo sapiens 108-115 17494126-0 2007 Importance of carbohydrate exposure before and after conversion from intravenous insulin therapy to subcutaneous administration of insulin glargine. Insulin Glargine 139-147 insulin Homo sapiens 131-138 17458480-3 2007 The examination found differences in the use of insulin glargine across the 21 treatment facilities and in the approach to implementing the criteria for nonformulary use of insulin glargine used at the individual VA treatment facility level. Insulin Glargine 181-189 insulin Homo sapiens 173-180 17316105-5 2007 Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. Insulin Glargine 38-46 insulin Homo sapiens 0-7 16815586-13 2007 In this fasting sample of patients with type 2 diabetes, glimepiride, repaglinide, and insulin glargine did not produce significant changes in glucose and lipid parameters. Insulin Glargine 95-103 insulin Homo sapiens 87-94 17316105-5 2007 Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. Insulin Glargine 38-46 insulin Homo sapiens 30-37 17316105-5 2007 Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. Insulin Glargine 38-46 insulin Homo sapiens 89-96 17316105-5 2007 Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. Insulin Glargine 38-46 insulin Homo sapiens 89-96 17302653-11 2007 CONCLUSION: In elderly patients, addition of once-daily morning glargine+OAD is a simple regimen to initiate insulin therapy, restoring glycemic control more effectively and with less hypoglycemia than twice-daily 70/30 alone. Insulin Glargine 64-72 insulin Homo sapiens 109-116 17185877-0 2007 Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Insulin Glargine 80-88 insulin Homo sapiens 72-79 17185877-0 2007 Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Insulin Glargine 80-88 insulin Homo sapiens 147-154 17185877-1 2007 We have previously reported the therapeutic efficacy of mitiglinide combined with once daily insulin glargine (mitiglinide regimen) after switching from multiple daily insulin regimen of aspart insulin and glargine (intensive insulin regimen) in inpatients with type 2 diabetes mellitus in two consecutive days. Insulin Glargine 101-109 insulin Homo sapiens 93-100 17185877-5 2007 In conclusion, mitiglinide and insulin glargine combination therapy maintained fair glycemic control for as long as 6 months in subpopulation of Japanese patients with type 2 diabetes. Insulin Glargine 39-47 insulin Homo sapiens 31-38 17378499-0 2007 Question: is insulin glargine more effective? Insulin Glargine 21-29 insulin Homo sapiens 13-20 17279454-5 2007 The difference between the two regression functions yielded the effect of switching treatment to insulin glargine compared to continuing with NPH insulin. Insulin Glargine 105-113 insulin Homo sapiens 97-104 17279454-6 2007 Male gender, low BMI and high baseline HbA1c levels were significant predictors for a greater decrease in HbA1c when changing to insulin glargine. Insulin Glargine 137-145 insulin Homo sapiens 129-136 17279454-7 2007 For example, for men with a BMI of 25 and an HbA1c of 8.0%, there was a calculated mean benefit in HbA1c of 0.26 percentage points by changing to insulin glargine, whereas women with a BMI 30 had no benefit of such a change. Insulin Glargine 154-162 insulin Homo sapiens 146-153 17279454-8 2007 Thus, changing to insulin glargine had best effect in male patients with low BMI. Insulin Glargine 26-34 insulin Homo sapiens 18-25 17603230-0 2007 Use of insulin glargine in Japanese patients with type 1 diabetes. Insulin Glargine 15-23 insulin Homo sapiens 7-14 17603230-1 2007 OBJECTIVE: To evaluate the results of treatment with an insulin glargine-based regimen as compared with those of an NPH insulin-based regimen. Insulin Glargine 64-72 insulin Homo sapiens 56-63 17603230-2 2007 METHODS: We reviewed the charts of 83 Japanese patients with Type 1 diabetes treated with insulin glargine for 12 months. Insulin Glargine 98-106 insulin Homo sapiens 90-97 17603230-7 2007 Of the 36 patients who were receiving twice or three times daily injections of NPH insulin, 30 could be switched to a single-daily injection of insulin glargine. Insulin Glargine 152-160 insulin Homo sapiens 144-151 17603230-8 2007 The frequency of severe hypoglycemia with unconsciousness became lower after switching to the insulin glargine-based regimen than during treatment with the NPH-based regimen. Insulin Glargine 102-110 insulin Homo sapiens 94-101 17603230-9 2007 The average ratio of the daily usage of insulin glargine to that of total insulin after 12 months was smaller than that reported from other countries (0.34 +/- 0.09). Insulin Glargine 48-56 insulin Homo sapiens 40-47 17603230-9 2007 The average ratio of the daily usage of insulin glargine to that of total insulin after 12 months was smaller than that reported from other countries (0.34 +/- 0.09). Insulin Glargine 48-56 insulin Homo sapiens 74-81 17603230-10 2007 CONCLUSION: These results obtained from a larger number of patients as compared to previous Japanese studies confirm earlier reports that insulin glargine provides equivalent glycemic control to human NPH insulin, with a lower incidence of severe hypoglycemia. Insulin Glargine 146-154 insulin Homo sapiens 138-145 17603230-11 2007 Thus, treatment with insulin glargine provides some benefits to Japanese patients with Type 1 diabetes. Insulin Glargine 29-37 insulin Homo sapiens 21-28 17379930-8 2007 The effect of exenatide on HbA1c is the same as adding a long-acting insulin analogue (glargine), but the increase in weight after adding insulin is not seen after exenatide, where even a small decrease in weight is found. Insulin Glargine 87-95 insulin Homo sapiens 69-76 17369885-7 2007 Two new basal insulin analogues have come to the market: insulin glargine, which has been widely used for some years now, and detemir. Insulin Glargine 65-73 insulin Homo sapiens 14-21 17369885-7 2007 Two new basal insulin analogues have come to the market: insulin glargine, which has been widely used for some years now, and detemir. Insulin Glargine 65-73 insulin Homo sapiens 57-64 17199716-0 2007 Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17199716-1 2007 AIMS: This observational study aimed to investigate the long-term efficacy and safety of adding insulin glargine (LANTUS((R))) to support oral antidiabetic (OAD) treatment in patients with type 2 diabetes in everyday practice. Insulin Glargine 104-112 insulin Homo sapiens 96-103 17199716-2 2007 METHODS: A 9-month, open-label, multicentre, observational study, with an optional 20-month extension phase, in which add-on insulin glargine therapy was initiated in 12,216 patients with type 2 diabetes inadequately controlled on OADs. Insulin Glargine 133-141 insulin Homo sapiens 125-132 17199716-3 2007 The insulin glargine dose was adjusted at the physician"s discretion, reflecting everyday practice. Insulin Glargine 12-20 insulin Homo sapiens 4-11 17199716-7 2007 Addition of insulin glargine to OAD therapy led to reductions in mean HbA(1c) (-1.5% from 8.7%) and FBG (-69 mg/dl from 202 mg/dl) levels after 3 months, which were maintained after 9 months [HbA(1c): -1.7%; FBG: -71 mg/dl (-3.9 mmol/l)] without an increase in BMI. Insulin Glargine 20-28 insulin Homo sapiens 12-19 17199716-11 2007 CONCLUSIONS: In everyday practice, patients with type 2 diabetes who are inadequately controlled on OADs benefit from add-on basal insulin treatment with insulin glargine as they demonstrate improved glycaemic control without weight gain. Insulin Glargine 162-170 insulin Homo sapiens 131-138 17199716-11 2007 CONCLUSIONS: In everyday practice, patients with type 2 diabetes who are inadequately controlled on OADs benefit from add-on basal insulin treatment with insulin glargine as they demonstrate improved glycaemic control without weight gain. Insulin Glargine 162-170 insulin Homo sapiens 154-161 17223044-5 2007 RESULTS: The proportion of patients achieving a HbA(1c) below 7.0% at 28 weeks was greater with BIAsp 30 than with insulin glargine (65% vs 41%, P=0.003). Insulin Glargine 123-131 insulin Homo sapiens 115-122 17223044-6 2007 The mean reduction in HbA(1c) was greater for BIAsp 30 than for insulin glargine: -2.89+/-1.6% vs -2.46+/-1.6%, respectively (P=0.035). Insulin Glargine 72-80 insulin Homo sapiens 64-71 17223044-9 2007 Nocturnal hypoglycemia was reported by 25% of subjects in the BIAsp 30 group and by 10% in the insulin glargine group (P=0.021). Insulin Glargine 103-111 insulin Homo sapiens 95-102 18042313-0 2007 [Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes]. Insulin Glargine 9-17 insulin Homo sapiens 1-8 18042313-8 2007 CONCLUSION: In preadolescent children with unsatisfactorily controlled type 1 diabetes glargine constitutes a useful and safe alternative to NPH, providing better early morning and good total glycemic control, not increasing the risk of severe hypoglycemia; taking it into account the health care systems should participate in its costs for those who can not afford or tolerate an insulin pump. Insulin Glargine 87-95 insulin Homo sapiens 381-388 17158695-0 2006 Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Insulin Glargine 124-132 insulin Homo sapiens 116-123 17335310-5 2007 At a given Hb(A1C) level, treatment with insulin glargine results in a lower risk of hypoglycaemia in type 1 and 2 diabetes compared with NPH insulin. Insulin Glargine 49-57 insulin Homo sapiens 41-48 17335310-6 2007 It has been proposed that the lower hypoglycaemic risk will allow more patients to achieve target Hb(A1C) levels with insulin glargine compared with NPH insulin. Insulin Glargine 126-134 insulin Homo sapiens 118-125 17335310-7 2007 The objective of this study was to assess the cost effectiveness of insulin glargine compared with NPH insulin in patients with type 1 or 2 diabetes who had inadequate glycaemic control. Insulin Glargine 76-84 insulin Homo sapiens 68-75 17335310-16 2007 However, patients treated with insulin glargine had greater total and quality-adjusted life expectancy than those who received NPH insulin (incremental LY = 0.08 and QALYs = 0.07 in type 1 diabetes and incremental LY = 0.25 and QALYs = 0.23 in type 2 diabetes). Insulin Glargine 39-47 insulin Homo sapiens 31-38 17335310-18 2007 CONCLUSIONS: The cost-effectiveness ratios for insulin glargine use for type 1 and 2 diabetes provide evidence for its adoption from a Canadian healthcare payer perspective. Insulin Glargine 55-63 insulin Homo sapiens 47-54 17158695-12 2006 Mean postindex insulin use was higher in patients receiving premixed insulin than in those treated with insulin glargine (48.1 versus 43.8 units per day) (p < 0.05). Insulin Glargine 112-120 insulin Homo sapiens 15-22 17158695-13 2006 CONCLUSION: Patients with type 2 diabetes mellitus who were newly initiated on insulin glargine had a lower rate of hypoglycemic events compared with patients newly initiated on a premixed fixed-combination insulin product. Insulin Glargine 87-95 insulin Homo sapiens 79-86 17158695-13 2006 CONCLUSION: Patients with type 2 diabetes mellitus who were newly initiated on insulin glargine had a lower rate of hypoglycemic events compared with patients newly initiated on a premixed fixed-combination insulin product. Insulin Glargine 87-95 insulin Homo sapiens 207-214 17158695-14 2006 Treatment of 15 patients with insulin glargine instead of premixed insulin for one year would avoid one hypoglycemic event per year. Insulin Glargine 38-46 insulin Homo sapiens 30-37 17166343-8 2006 CONCLUSION: The newer long-acting insulin analogs, insulin detemir and glargine, appear to provide better glycemic control than NPH insulin without increasing the risk of hypoglycemia. Insulin Glargine 71-79 insulin Homo sapiens 34-41 17149471-10 2006 Glargine is available for patients with type 1 and insulin requiring type 2 diabetes, while detemir has been recommended only for patients with type 1 diabetes. Insulin Glargine 0-8 insulin Homo sapiens 51-58 17296465-3 2006 Insulin glargine is a long-acting (up to 24-hour duration of effect), parenteral blood glucose-lowering agent. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17296465-5 2006 OBJECTIVE: The aim of this study was to assess whether the SC injection of insulin glargine is more painful than neutral insulin in a clinical setting. Insulin Glargine 83-91 insulin Homo sapiens 75-82 17122525-0 2006 Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program. Insulin Glargine 30-38 insulin Homo sapiens 22-29 17122525-7 2006 Mean adjusted HbA1c in the glargine group was 8.80 at baseline, 7.89 before initiation of insulin glargine (P < 0.001 vs baseline), and 7.34 after adding insulin glargine (P < 0.001 vs pre-glargine). Insulin Glargine 27-35 insulin Homo sapiens 90-97 17122525-10 2006 Adding long-acting basal insulin therapy with insulin glargine produced significant incremental improvement in HbA1c. Insulin Glargine 54-62 insulin Homo sapiens 25-32 17122525-10 2006 Adding long-acting basal insulin therapy with insulin glargine produced significant incremental improvement in HbA1c. Insulin Glargine 54-62 insulin Homo sapiens 46-53 17109592-10 2006 CONCLUSIONS: Once-daily glargine insulin provides good glycemic control in hyperglycemic patients after cardiovascular surgery. Insulin Glargine 24-32 insulin Homo sapiens 33-40 17122525-1 2006 OBJECTIVE: To evaluate the contribution of long-acting basal insulin therapy (insulin glargine) to glycemic control in a predominantly Hispanic population participating in a community-based diabetes management program, Project Dulce. Insulin Glargine 86-94 insulin Homo sapiens 61-68 17228850-0 2006 Insulin glargine in patients with severe hepato-gastroenterology diseases and hyperglycemia receiving parenteral nutrition. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17228850-8 2006 CONCLUSIONS: This study confirms the possibility of using insulin glargine in patients receiving parenteral nutrition with hyperglycemia diagnosed diabetics or not diabetics. Insulin Glargine 66-74 insulin Homo sapiens 58-65 17228850-1 2006 OBJECTIVE: The aim of this nonrandomized observational study is to verify and confirm whether it is possible to use insulin glargine (Lantus) subcutaneously in patients receiving parenteral nutrition (PN) and whether the analogue is capable of obtaining and maintaining good glycemic control without inducing hypoglycemia. Insulin Glargine 124-132 insulin Homo sapiens 116-123 17228850-1 2006 OBJECTIVE: The aim of this nonrandomized observational study is to verify and confirm whether it is possible to use insulin glargine (Lantus) subcutaneously in patients receiving parenteral nutrition (PN) and whether the analogue is capable of obtaining and maintaining good glycemic control without inducing hypoglycemia. Insulin Glargine 134-140 insulin Homo sapiens 116-123 17047914-0 2006 From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a "routine" diabetes clinic? Insulin Glargine 24-32 insulin Homo sapiens 33-40 17026485-6 2006 For example, questions have emerged about the relationship between the use of insulin lispro and insulin glargine and the progression of diabetic retinopathy. Insulin Glargine 105-113 insulin Homo sapiens 78-85 17026485-6 2006 For example, questions have emerged about the relationship between the use of insulin lispro and insulin glargine and the progression of diabetic retinopathy. Insulin Glargine 105-113 insulin Homo sapiens 97-104 16990633-0 2006 Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine. Insulin Glargine 116-124 insulin Homo sapiens 108-115 17229660-0 2006 Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Insulin Glargine 83-91 insulin Homo sapiens 26-33 17229660-0 2006 Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Insulin Glargine 83-91 insulin Homo sapiens 75-82 17229660-1 2006 OBJECTIVE: To determine the optimal dose of insulin glargine needed to maintain glycemic control in patients undergoing conversion from intravenous regular insulin infusions to a subcutaneous insulin regimen. Insulin Glargine 52-60 insulin Homo sapiens 44-51 17229660-1 2006 OBJECTIVE: To determine the optimal dose of insulin glargine needed to maintain glycemic control in patients undergoing conversion from intravenous regular insulin infusions to a subcutaneous insulin regimen. Insulin Glargine 52-60 insulin Homo sapiens 156-163 17229660-1 2006 OBJECTIVE: To determine the optimal dose of insulin glargine needed to maintain glycemic control in patients undergoing conversion from intravenous regular insulin infusions to a subcutaneous insulin regimen. Insulin Glargine 52-60 insulin Homo sapiens 156-163 17229660-10 2006 CONCLUSION: Conversion from continuous insulin infusion to subcutaneously administered insulin glargine at a dose equal to 80% of the total daily insulin requirements resulted in the highest percentage of CBGM values in the glycemic target range of 80 to 150 mg/dL within the first 24 hours after regimen conversion in comparison with conversion at 40% and 60%, albeit the difference between the 40% and 80% groups was not statistically significant. Insulin Glargine 95-103 insulin Homo sapiens 39-46 17229660-10 2006 CONCLUSION: Conversion from continuous insulin infusion to subcutaneously administered insulin glargine at a dose equal to 80% of the total daily insulin requirements resulted in the highest percentage of CBGM values in the glycemic target range of 80 to 150 mg/dL within the first 24 hours after regimen conversion in comparison with conversion at 40% and 60%, albeit the difference between the 40% and 80% groups was not statistically significant. Insulin Glargine 95-103 insulin Homo sapiens 87-94 17229660-10 2006 CONCLUSION: Conversion from continuous insulin infusion to subcutaneously administered insulin glargine at a dose equal to 80% of the total daily insulin requirements resulted in the highest percentage of CBGM values in the glycemic target range of 80 to 150 mg/dL within the first 24 hours after regimen conversion in comparison with conversion at 40% and 60%, albeit the difference between the 40% and 80% groups was not statistically significant. Insulin Glargine 95-103 insulin Homo sapiens 87-94 17633894-7 2006 Insulin glargine led to solubility at pH 4 and to slow absorption in neutral pH environment. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17034640-0 2006 Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Insulin Glargine 62-70 insulin Homo sapiens 54-61 17034640-2 2006 Although exenatide and insulin glargine appear to have similar efficacy for treatment of type 2 diabetes, there are several differences between the two treatments that could influence outcomes from the patient"s perspective. Insulin Glargine 31-39 insulin Homo sapiens 23-30 17034640-12 2006 CONCLUSION: This analysis found that both exenatide and insulin glargine were associated with significant improvements in patient-reported outcomes when added to oral medications among patients with type 2 diabetes. Insulin Glargine 64-72 insulin Homo sapiens 56-63 17065670-4 2006 RESULTS: A1C and FPG decreased similarly in the glargine insulin (9.1 +/- 0.4 to 7.6 +/- 0.3% and 212 +/- 14 to 139 +/- 5 mg/dl, respectively, both P < 0.0001) and rosiglitazone (9.4 +/- 0.3 to 7.6 +/- 0.4% and 223 +/- 14 to 160 +/- 19 mg/dl, respectively, both P < 0.005) groups. Insulin Glargine 48-56 insulin Homo sapiens 57-64 17065670-15 2006 At 4 months, glargine insulin (3.6 +/- 0.5 to 4.2 +/- 0.4 mg . Insulin Glargine 13-21 insulin Homo sapiens 22-29 17065670-21 2006 CONCLUSIONS: Triple therapy with glargine insulin or rosiglitazone similarly reduced A1C, primarily by suppressing basal EGP (hepatic). Insulin Glargine 33-41 insulin Homo sapiens 42-49 17065670-22 2006 Glargine insulin reduced basal EGP by increasing plasma insulin levels, while rosiglitazone decreased basal hepatic glucose production by improving hepatic insulin sensitivity. Insulin Glargine 0-8 insulin Homo sapiens 9-16 17065670-22 2006 Glargine insulin reduced basal EGP by increasing plasma insulin levels, while rosiglitazone decreased basal hepatic glucose production by improving hepatic insulin sensitivity. Insulin Glargine 0-8 insulin Homo sapiens 56-63 16990633-1 2006 PURPOSE: The purpose of this observational study was to determine if switching from isophane insulin human (NPH) to insulin glargine would improve glycemic control in a medically vulnerable population with uncontrolled diabetes. Insulin Glargine 124-132 insulin Homo sapiens 116-123 16990633-8 2006 Patients experienced significantly fewer diabetes-associated visits over six months while on insulin glargine. Insulin Glargine 101-109 insulin Homo sapiens 93-100 16990633-12 2006 CONCLUSION: The results of our study indicate that both NPH- and glargine-based basal insulin regimens result in similar levels of glycemic control in a medically vulnerable population with diabetes, without significant differences in the number or severity of hypoglycemic episodes or in refill frequency. Insulin Glargine 65-73 insulin Homo sapiens 86-93 17121210-3 2006 (2) Insulin detemir is the second long-acting human insulin analogue to be marketed in Europe (after insulin glargine) for the treatment of diabetes in adults and children over 6 years of age. Insulin Glargine 109-117 insulin Homo sapiens 4-11 17003324-0 2006 Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients: response to Rosenstock et al. Insulin Glargine 43-51 insulin Homo sapiens 35-42 17115351-11 2006 CONCLUSIONS: Starting insulin in Type 2 diabetes patients with twice-daily BIAsp 30 plus met can reduce HbA (1c) and mean prandial plasma glucose increment to a greater extent than once-daily glarg plus glim. Insulin Glargine 192-197 insulin Homo sapiens 22-29 16621116-1 2006 OBJECTIVE: The purpose of this study was to evaluate the effect of administration time of insulin glargine (IG) on glycemic control in children and adolescents with Type 1 diabetes. Insulin Glargine 98-106 insulin Homo sapiens 90-97 17079829-5 2006 Various types of insulin are available in the market, including newer analogs (Iispro, aspart, glargine). Insulin Glargine 95-103 insulin Homo sapiens 17-24 17121210-7 2006 (4) About 10 trials, involving more than 3000 patients, showed that insulin detemir, insulin isophane and insulin glargine have similar efficacy in treating both type 1 and type 2 diabetes. Insulin Glargine 114-122 insulin Homo sapiens 68-113 17136338-0 2006 The insulin analog glargine during an unplanned pregnancy. Insulin Glargine 19-27 insulin Homo sapiens 4-11 16867163-0 2006 An update on the long-acting insulin analogue glargine. Insulin Glargine 46-54 insulin Homo sapiens 29-36 16865331-0 2006 Effectiveness and safety of insulin glargine in the therapy of complicated or secondary diabetes: clinical audit. Insulin Glargine 36-44 insulin Homo sapiens 28-35 16865331-6 2006 Mean daily insulin dosage was 12.0+/-4.8 UI for glargine alone and 37.4+/-22.6 UI for basal-bolus scheme. Insulin Glargine 48-56 insulin Homo sapiens 11-18 16865331-10 2006 Mean daily insulin dosage was 12.5+/-6.1 UI for glargine alone and 27.2+/-9.1 UI for basal-bolus scheme. Insulin Glargine 48-56 insulin Homo sapiens 11-18 16911626-0 2006 Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Insulin Glargine 45-53 insulin Homo sapiens 37-44 16911626-0 2006 Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Insulin Glargine 45-53 insulin Homo sapiens 101-108 16911626-8 2006 Plasma free insulin concentration was higher in the afternoon with twice-daily glargine (21.9 +/- 1.4 vs. 16.1 +/- 1.3 mU/l, P = 0.009), but lower overnight (12.1 +/- 1.7 vs. 17.8 +/- 1.7 mU/l, P = 0.030), compared with once-daily injection. Insulin Glargine 79-87 insulin Homo sapiens 12-19 16969428-7 2006 Two new basal insulin analogues have come to the market: insulin glargine, which has been widely used for some years now, and detemir. Insulin Glargine 65-73 insulin Homo sapiens 14-21 16969428-7 2006 Two new basal insulin analogues have come to the market: insulin glargine, which has been widely used for some years now, and detemir. Insulin Glargine 65-73 insulin Homo sapiens 57-64 16911626-10 2006 CONCLUSIONS: Blood glucose concentration rises in the late afternoon in association with falling plasma insulin levels towards the end of the 24-h period after insulin glargine injection in some people with Type 1 diabetes using once-daily glargine at dinner-time plus a rapid-acting insulin analogue at meal-times. Insulin Glargine 168-176 insulin Homo sapiens 160-167 16911626-10 2006 CONCLUSIONS: Blood glucose concentration rises in the late afternoon in association with falling plasma insulin levels towards the end of the 24-h period after insulin glargine injection in some people with Type 1 diabetes using once-daily glargine at dinner-time plus a rapid-acting insulin analogue at meal-times. Insulin Glargine 168-176 insulin Homo sapiens 160-167 16911626-10 2006 CONCLUSIONS: Blood glucose concentration rises in the late afternoon in association with falling plasma insulin levels towards the end of the 24-h period after insulin glargine injection in some people with Type 1 diabetes using once-daily glargine at dinner-time plus a rapid-acting insulin analogue at meal-times. Insulin Glargine 240-248 insulin Homo sapiens 104-111 16911626-11 2006 This is prevented by twice-daily injection of insulin glargine. Insulin Glargine 54-62 insulin Homo sapiens 46-53 16867163-3 2006 Glargine is a new long-acting insulin analogue with an action profile designed to overcome this and has now been in clinical use for a number of years. Insulin Glargine 0-8 insulin Homo sapiens 30-37 16842477-9 2006 CONCLUSIONS: Adding insulin glargine is more likely to achieve a lower HbA(1c) level than conventional therapy with oral agents. Insulin Glargine 28-36 insulin Homo sapiens 20-27 16776752-8 2006 Forty-four per cent of patients receiving IMT and 31% of patients receiving insulin glargine achieved HbA1c < or = 7%. Insulin Glargine 84-92 insulin Homo sapiens 76-83 16776752-9 2006 Two-hour postprandial glucose values (for all three meals) and predinner glucose values were significantly less with IMT than with insulin glargine (p = 0.0034, 0.0001, 0.0066 and 0.0205). Insulin Glargine 139-147 insulin Homo sapiens 131-138 16776752-12 2006 The mean insulin dose at the end of therapy was greater for IMT than for once-daily insulin glargine (0.353 +/- 0.256 vs. 0.276 +/- 0.207 IU/kg, p = 0.0107). Insulin Glargine 92-100 insulin Homo sapiens 9-16 16776752-12 2006 The mean insulin dose at the end of therapy was greater for IMT than for once-daily insulin glargine (0.353 +/- 0.256 vs. 0.276 +/- 0.207 IU/kg, p = 0.0107). Insulin Glargine 92-100 insulin Homo sapiens 84-91 16801571-1 2006 OBJECTIVE: This randomized controlled trial assesses the effect on glycemic control of continuous glucose monitoring system (CGMS)-guided insulin therapy adjustment in young people with type 1 diabetes on intensive diabetes treatment regimens with continuous subcutaneous insulin infusion (CSII) or glargine. Insulin Glargine 299-307 insulin Homo sapiens 138-145 16513202-2 2006 We investigated whether increasing the dose of insulin glargine up to half of the total insulin requirement could lead to better glycemic control in type 2 diabetic patients who were treated on basal-prandial insulin therapy. Insulin Glargine 55-63 insulin Homo sapiens 47-54 16513202-2 2006 We investigated whether increasing the dose of insulin glargine up to half of the total insulin requirement could lead to better glycemic control in type 2 diabetic patients who were treated on basal-prandial insulin therapy. Insulin Glargine 55-63 insulin Homo sapiens 88-95 16513202-2 2006 We investigated whether increasing the dose of insulin glargine up to half of the total insulin requirement could lead to better glycemic control in type 2 diabetic patients who were treated on basal-prandial insulin therapy. Insulin Glargine 55-63 insulin Homo sapiens 88-95 16513202-5 2006 The dose of insulin glargine was increased by 2-4 units to meet the target fasting blood glucose, whereas the dose of NPH was principally unchanged as a control group. Insulin Glargine 20-28 insulin Homo sapiens 12-19 16513202-10 2006 Increasing the dose of glargine without changing the total daily insulin dose resulted in significantly better glycemic control in type 2 diabetic patients on basal-prandial insulin therapy. Insulin Glargine 23-31 insulin Homo sapiens 174-181 16842489-0 2006 Treatment with insulin glargine does not suppress serum IGF-1. Insulin Glargine 23-31 insulin Homo sapiens 15-22 16842489-1 2006 AIMS: A 6-8-fold higher insulin-like growth factor 1 (IGF-1) receptor binding affinity in vitro is reported for the insulin analogue glargine compared with human insulin. Insulin Glargine 133-141 insulin Homo sapiens 24-31 16842489-1 2006 AIMS: A 6-8-fold higher insulin-like growth factor 1 (IGF-1) receptor binding affinity in vitro is reported for the insulin analogue glargine compared with human insulin. Insulin Glargine 133-141 insulin Homo sapiens 116-123 16842489-3 2006 Assuming a higher binding affinity of insulin glargine to pituitary IGF-1 receptors, serum IGF-1 concentrations should decrease via negative feedback. Insulin Glargine 46-54 insulin Homo sapiens 38-45 16842478-6 2006 Mean doses were 23 U before the morning and 37 U before the evening meal for Mix 25/75 and 44 U for insulin glargine. Insulin Glargine 108-116 insulin Homo sapiens 100-107 16842489-6 2006 In contrast to the hypothesis, serum IGF-1 concentrations were higher during insulin glargine treatment compared with NPH insulin in patients with Type 1 diabetes (177 +/- 18 vs. 159 +/- 18 microg/l, P < 0.02, n = 17, age 28 +/- 2 years). Insulin Glargine 85-93 insulin Homo sapiens 77-84 16805721-0 2006 Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16805721-5 2006 Insulin glargine (glargine) was the first DNA-recombinant long-acting insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16805721-5 2006 Insulin glargine (glargine) was the first DNA-recombinant long-acting insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 70-77 16805721-5 2006 Insulin glargine (glargine) was the first DNA-recombinant long-acting insulin analogue. Insulin Glargine 18-26 insulin Homo sapiens 0-7 16805721-5 2006 Insulin glargine (glargine) was the first DNA-recombinant long-acting insulin analogue. Insulin Glargine 18-26 insulin Homo sapiens 70-77 16805721-8 2006 Since its launch, the use of glargine in Type 1 and Type 2 diabetes has been extensively reviewed to determine its place in the current insulin market. Insulin Glargine 29-37 insulin Homo sapiens 136-143 16805721-11 2006 In Type 2 diabetes, it has been advised that glargine only be considered for: those who require assistance to administer insulin injections; those whose lifestyle is restricted significantly by recurrent symptomatic hypoglycaemic episodes; or those who would otherwise need twice-daily basal insulin injections in combination with oral glucose-lowering drugs. Insulin Glargine 45-53 insulin Homo sapiens 121-128 16805721-11 2006 In Type 2 diabetes, it has been advised that glargine only be considered for: those who require assistance to administer insulin injections; those whose lifestyle is restricted significantly by recurrent symptomatic hypoglycaemic episodes; or those who would otherwise need twice-daily basal insulin injections in combination with oral glucose-lowering drugs. Insulin Glargine 45-53 insulin Homo sapiens 292-299 16807582-0 2006 More from PHARMAC on long-acting insulin analogues: insulin glargine now funded. Insulin Glargine 60-68 insulin Homo sapiens 33-40 17088864-1 2006 Insulin glargine or rosiglitazone as add-on therapies. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16807582-0 2006 More from PHARMAC on long-acting insulin analogues: insulin glargine now funded. Insulin Glargine 60-68 insulin Homo sapiens 52-59 16715577-6 2006 RESULTS: Insulin glargine and NPH insulin achieved similar HbA1c reductions (adjusted mean difference -0.047; 90% CI -0.232, 0.138; per-protocol analysis). Insulin Glargine 17-25 insulin Homo sapiens 9-16 16715577-7 2006 Confirmed nocturnal hypoglycemia was significantly lower with insulin glargine vs. NPH insulin (16.9 vs. 30.0%; p <0.01; safety analysis). Insulin Glargine 70-78 insulin Homo sapiens 62-69 16715577-8 2006 Patients receiving insulin glargine were significantly more likely to achieve HbA1c levels < 7.0% without hypoglycemia (27 vs. 17%; p = 0.014; per-protocol analysis). Insulin Glargine 27-35 insulin Homo sapiens 19-26 16715577-9 2006 There was a more pronounced treatment satisfaction improvement with insulin glargine vs. NPH insulin (p <0.02; full analysis). Insulin Glargine 76-84 insulin Homo sapiens 68-75 16715577-10 2006 The proportion of patients who lost time from work or normal activities due to diabetes was lower with insulin glargine vs. NPH (1.8 vs. 3.3%; full analysis). Insulin Glargine 111-119 insulin Homo sapiens 103-110 16715577-11 2006 CONCLUSIONS: In patients with T2DM, inadequately controlled on OADs, once-daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin. Insulin Glargine 88-96 insulin Homo sapiens 80-87 16552747-0 2006 Study of the aggregation of insulin glargine by light scattering. Insulin Glargine 36-44 insulin Homo sapiens 28-35 16552747-1 2006 Insulin glargine (Lantus, Aventis Pharma, Deutschland, GmbH) is a new long-acting human insulin analog. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16552747-1 2006 Insulin glargine (Lantus, Aventis Pharma, Deutschland, GmbH) is a new long-acting human insulin analog. Insulin Glargine 8-16 insulin Homo sapiens 88-95 16552747-2 2006 Structural modification of the insulin molecule at two sites alters its pH, causing insulin glargine to precipitate in the neutral environment of subcutaneous tissue and to form a depot that is slowly absorbed into the bloodstream. Insulin Glargine 92-100 insulin Homo sapiens 31-38 16552747-2 2006 Structural modification of the insulin molecule at two sites alters its pH, causing insulin glargine to precipitate in the neutral environment of subcutaneous tissue and to form a depot that is slowly absorbed into the bloodstream. Insulin Glargine 92-100 insulin Homo sapiens 84-91 16552747-5 2006 The aggregation of insulin glargine can be responsible for its slow in situ absorption allowing for a more controlled release. Insulin Glargine 27-35 insulin Homo sapiens 19-26 16505505-3 2006 Insulin glargine was forced-titrated to target fasting plasma glucose (FPG) < or =5.5-6.7 mmol/l (< or =100-120 mg/dl), and rosiglitazone was increased to 8 mg/day any time after 6 weeks if FPG was >5.5 mmol/l. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16856705-7 2006 Both the mother and the newborn resulted in perfect health conditions confirming that the possibility of using glargine insulin profiles during pregnancy in selected cases with close monitoring may exist. Insulin Glargine 111-119 insulin Homo sapiens 120-127 17682263-11 2006 A relatively simple titration regimen using once-daily bedtime basal insulin glargine has demonstrated efficacy for improving glycemic control in many patients with type 2 diabetes and is a strategy that may also be useful for Latinos as an introduction to insulin therapy and as the foundation of a more comprehensive insulin regimen in the future. Insulin Glargine 77-85 insulin Homo sapiens 69-76 17682263-11 2006 A relatively simple titration regimen using once-daily bedtime basal insulin glargine has demonstrated efficacy for improving glycemic control in many patients with type 2 diabetes and is a strategy that may also be useful for Latinos as an introduction to insulin therapy and as the foundation of a more comprehensive insulin regimen in the future. Insulin Glargine 77-85 insulin Homo sapiens 257-264 17682263-11 2006 A relatively simple titration regimen using once-daily bedtime basal insulin glargine has demonstrated efficacy for improving glycemic control in many patients with type 2 diabetes and is a strategy that may also be useful for Latinos as an introduction to insulin therapy and as the foundation of a more comprehensive insulin regimen in the future. Insulin Glargine 77-85 insulin Homo sapiens 257-264 16647408-0 2006 Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus. Insulin Glargine 51-59 insulin Homo sapiens 20-27 16647408-0 2006 Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus. Insulin Glargine 51-59 insulin Homo sapiens 43-50 16456680-0 2006 Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16734552-7 2006 CONCLUSIONS: Glargine provided less diurnal fluctuation in serum insulin levels than NPH and ultralente in healthy volunteers and patients with DMT1. Insulin Glargine 13-21 insulin Homo sapiens 65-72 16734552-8 2006 This lower fluctuation of glargine over NPH or ultralente can help to reduce hyper- or hypoglycemia risks associated with insulin therapy and accordingly encourage achievement of better blood glucose control. Insulin Glargine 26-34 insulin Homo sapiens 122-129 16598316-0 2006 Pregnant women with type 1 diabetes mellitus treated by glargine insulin. Insulin Glargine 56-64 insulin Homo sapiens 65-72 16758949-5 2006 His history data showed that the patient had been suffering from type 2 diabetes mellitus for 10 years and taking Glargin (insulin), 12 U/kg, once daily and Glucophage (metformin), 850 mg thrice daily. Insulin Glargine 114-121 insulin Homo sapiens 123-130 16505505-1 2006 OBJECTIVE: To evaluate the efficacy and safety of add-on insulin glargine versus rosiglitazone in insulin-naive patients with type 2 diabetes inadequately controlled on dual oral therapy with sulfonylurea plus metformin. Insulin Glargine 65-73 insulin Homo sapiens 57-64 16505505-4 2006 RESULTS: A1C improvements from baseline were similar in both groups (-1.7 vs. -1.5% for insulin glargine vs. rosiglitazone, respectively); however, when baseline A1C was >9.5%, the reduction of A1C with insulin glargine was greater than with rosiglitazone (P < 0.05). Insulin Glargine 96-104 insulin Homo sapiens 88-95 16505505-5 2006 Insulin glargine yielded better FPG values than rosiglitazone (-3.6 +/- 0.23 vs. -2.6 +/- 0.22 mmol/l; P = 0.001). Insulin Glargine 8-16 insulin Homo sapiens 0-7 16505505-6 2006 Insulin glargine final dose per day was 38 +/- 26 IU vs. 7.1 +/- 2 mg for rosiglitazone. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16505505-7 2006 Confirmed hypoglycemic events at plasma glucose <3.9 mmol/l (<70 mg/dl) were slightly greater for the insulin glargine group (n = 57) than for the rosiglitazone group (n = 47) (P = 0.0528). Insulin Glargine 116-124 insulin Homo sapiens 108-115 16505505-9 2006 More patients in the insulin glargine group had confirmed nocturnal hypoglycemia of <3.9 mmol/l (P = 0.02) and <2.8 mmol/l (P < 0.05) than in the rosiglitazone group. Insulin Glargine 29-37 insulin Homo sapiens 21-28 16505505-10 2006 Effects on total cholesterol, LDL cholesterol, and triglyceride levels from baseline to end point with insulin glargine (-4.4, -1.4, and -19.0%, respectively) contrasted with those of rosiglitazone (+10.1, +13.1, and +4.6%, respectively; P < 0.002). Insulin Glargine 111-119 insulin Homo sapiens 103-110 16505505-12 2006 Insulin glargine had less weight gain than rosiglitazone (1.6 +/- 0.4 vs. 3.0 +/- 0.4 kg; P = 0.02), fewer adverse events (7 vs. 29%; P = 0.0001), and no peripheral edema (0 vs. 12.5%). Insulin Glargine 8-16 insulin Homo sapiens 0-7 16505505-13 2006 Insulin glargine saved $235/patient over 24 weeks compared with rosiglitazone. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16505505-14 2006 CONCLUSIONS: Low-dose insulin glargine combined with a sulfonylurea and metformin resulted in similar A1C improvements except for greater reductions in A1C when baseline was > or =9.5% compared with add-on maximum-dose rosiglitazone. Insulin Glargine 30-38 insulin Homo sapiens 22-29 16505505-15 2006 Further, insulin glargine was associated with more hypoglycemia but less weight gain, no edema, and salutary lipid changes at a lower cost of therapy. Insulin Glargine 17-25 insulin Homo sapiens 9-16 16673208-0 2006 Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Insulin Glargine 19-27 insulin Homo sapiens 11-18 16112241-1 2006 OBJECTIVE: This study examined the long-term glycaemic control and safety of insulin glargine (LANTUS) in patients with Type 2 diabetes. Insulin Glargine 85-93 insulin Homo sapiens 77-84 16682829-7 2006 Insulin glargine was administered at the median dosage of 0.3 U/kg/day (range 0.2-0.5). Insulin Glargine 8-16 insulin Homo sapiens 0-7 16466605-1 2006 OBJECTIVE: This retrospective analysis was performed to establish the effect of initiating insulin glargine (LANTUS; sanofi-aventis, Paris, France), a once-daily basal insulin analogue, in combination with an educational programme on glycaemic control and body weight in sub-optimally controlled patients with Type 2 diabetes in clinical practice. Insulin Glargine 99-107 insulin Homo sapiens 91-98 16466605-3 2006 These patients had previously been treated with oral antidiabetic agents (OADs; n = 18) or insulin only (n = 28) and had then received insulin glargine in combination with OADs or prandial insulin, for 30 months. Insulin Glargine 143-151 insulin Homo sapiens 135-142 16466605-3 2006 These patients had previously been treated with oral antidiabetic agents (OADs; n = 18) or insulin only (n = 28) and had then received insulin glargine in combination with OADs or prandial insulin, for 30 months. Insulin Glargine 143-151 insulin Homo sapiens 135-142 16466605-10 2006 CONCLUSIONS: Insulin glargine in combination with educational support and close clinical supervision significantly improved metabolic control without significant weight change in patients with Type 2 diabetes in clinical practice over 30 months. Insulin Glargine 21-29 insulin Homo sapiens 13-20 16112241-1 2006 OBJECTIVE: This study examined the long-term glycaemic control and safety of insulin glargine (LANTUS) in patients with Type 2 diabetes. Insulin Glargine 95-101 insulin Homo sapiens 77-84 16112241-2 2006 STUDY DESIGN AND METHODS: This <or=28-month, long-term extension of a multinational, multicentre, open-label 52-week study enrolled patients from the original study to continue taking insulin glargine at bedtime plus previous oral hypoglycaemic agents (OHAs). Insulin Glargine 195-203 insulin Homo sapiens 187-194 16112241-9 2006 CONCLUSION: Long-term insulin glargine treatment plus OHAs provides continued glycaemic control and is well tolerated in patients with Type 2 diabetes. Insulin Glargine 30-38 insulin Homo sapiens 22-29 16112241-10 2006 Therefore, insulin glargine appears to be suitable for the long-term management of Type 2 diabetes. Insulin Glargine 19-27 insulin Homo sapiens 11-18 16543674-0 2006 Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Insulin Glargine 69-77 insulin Homo sapiens 61-68 16523182-3 2006 Simplicity is synonymous with the regimen of once-daily basal insulin glargine given at any time of the day (at the same time each day). Insulin Glargine 70-78 insulin Homo sapiens 62-69 16543674-3 2006 We investigated the efficacy of mitiglinide combined with insulin glargine, the first soluble insulin analog that has a flat and prolonged effect. Insulin Glargine 66-74 insulin Homo sapiens 94-101 16554934-4 2006 In addition, two long acting insulin analogues have been developed: glargine and detemir. Insulin Glargine 68-76 insulin Homo sapiens 29-36 16932261-0 2006 Does a patient-administered titration algorithm of insulin glargine improve glycemic control? Insulin Glargine 59-67 insulin Homo sapiens 51-58 16501691-0 2006 Multiple daily insulin regimen using insulin glargine in type 1 diabetic Saudi children. Insulin Glargine 45-53 insulin Homo sapiens 15-22 16501691-0 2006 Multiple daily insulin regimen using insulin glargine in type 1 diabetic Saudi children. Insulin Glargine 45-53 insulin Homo sapiens 37-44 16627386-6 2006 It also confirmed that a long-acting insulin analogue, glargine, causes less hypoglycemia than human NPH insulin when used in this way. Insulin Glargine 55-63 insulin Homo sapiens 37-44 16669545-4 2006 Insulin glargine may contribute to improving the glycemic values in patients receiving artificial nutrition with hyperglycemia. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16409565-0 2006 Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Insulin Glargine 50-58 insulin Homo sapiens 42-49 16409565-0 2006 Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Insulin Glargine 50-58 insulin Homo sapiens 96-103 16409565-1 2006 AIMS: To compare blood glucose control when insulin glargine is given at lunch-time, dinner-time, and bed-time in people with Type 1 diabetes using insulin lispro at meal-times. Insulin Glargine 52-60 insulin Homo sapiens 148-155 16409565-8 2006 Plasma free insulin concentration was lower at the end of the afternoon with dinner-time glargine than other injection times (D: 11.5 +/- 1.4 vs. L: 20.2 +/- 1.3 or B: 16.5 +/- 1.3 mU/l, P < 0.001). Insulin Glargine 89-97 insulin Homo sapiens 12-19 16409565-10 2006 CONCLUSIONS: Blood glucose levels rise around the time of injection of insulin glargine whether given at lunch-time, dinner-time or bed-time. Insulin Glargine 79-87 insulin Homo sapiens 71-78 16409565-11 2006 Bed-time injection leads to hyperglycaemia in the early part of the night which is improved by giving insulin glargine at lunch-time or dinner-time. Insulin Glargine 110-118 insulin Homo sapiens 102-109 16373887-9 2006 CONCLUSIONS: In a predominantly primary care setting, addition of insulin glargine using a simple algorithm achieved significant improvements in glycemic control in patients with type 2 diabetes in all four study arms. Insulin Glargine 74-82 insulin Homo sapiens 66-73 16627387-7 2006 The most physiologic regimen of insulin available is continuous subcutaneous insulin infusion with an insulin pump; however, insulin glargine is a useful alternative to pump therapy. Insulin Glargine 133-141 insulin Homo sapiens 32-39 16021649-0 2005 A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Insulin Glargine 42-50 insulin Homo sapiens 34-41 16450317-0 2006 Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17319470-0 2006 Insulin glargine in the treatment of type 1 and type 2 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17319470-1 2006 Insulin glargine is an analogue of human insulin that is modified to provide a consistent level of plasma insulin over a long duration. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17319470-1 2006 Insulin glargine is an analogue of human insulin that is modified to provide a consistent level of plasma insulin over a long duration. Insulin Glargine 8-16 insulin Homo sapiens 41-48 17319470-1 2006 Insulin glargine is an analogue of human insulin that is modified to provide a consistent level of plasma insulin over a long duration. Insulin Glargine 8-16 insulin Homo sapiens 106-113 17319470-2 2006 Pharmacokinetic and pharmacodynamic studies show that a single injection of insulin glargine leads to a smooth 24-hour time-action profile with no undesirable pronounced peaks of activity. Insulin Glargine 84-92 insulin Homo sapiens 76-83 17319470-4 2006 The convenience of a once-daily injection, a lack of need for resuspension (insulin glargine is a clear solution when injected), and lower rates of hypoglycemia should translate into improvements in patient treatment satisfaction. Insulin Glargine 84-92 insulin Homo sapiens 76-83 17319470-5 2006 This review appraises the evidence for the view that insulin glargine represents an advance in basal insulin therapy for both type 1 and type 2 diabetes patients. Insulin Glargine 61-69 insulin Homo sapiens 53-60 17319470-5 2006 This review appraises the evidence for the view that insulin glargine represents an advance in basal insulin therapy for both type 1 and type 2 diabetes patients. Insulin Glargine 61-69 insulin Homo sapiens 101-108 16382306-0 2005 Use of insulin glargine in patients with hyperglycaemia receiving artificial nutrition. Insulin Glargine 15-23 insulin Homo sapiens 7-14 16382306-1 2005 The purpose of this study was to verify whether it is possible to use insulin glargine (Lantus) subcutaneously in patients receiving artificial nutrition (AN) and if the analogue is capable of obtaining and maintaining good glycaemic control without inducing hypoglycaemia. Insulin Glargine 78-86 insulin Homo sapiens 70-77 16382306-1 2005 The purpose of this study was to verify whether it is possible to use insulin glargine (Lantus) subcutaneously in patients receiving artificial nutrition (AN) and if the analogue is capable of obtaining and maintaining good glycaemic control without inducing hypoglycaemia. Insulin Glargine 88-94 insulin Homo sapiens 70-77 16382306-8 2005 This study confirms the possibility of using insulin glargine in patients receiving AN with hyperglycaemia regardless of the type of nutrition and whether or not the patient is diabetic. Insulin Glargine 53-61 insulin Homo sapiens 45-52 17107224-7 2006 Insulin glargine, with its flat time-action profile, near 24-hour duration of action, reduced risk of hypoglycemia, and improved glycemic control compared with insulin suspension isophane (neutral protamine hagedorn [NPH] insulin), may help to overcome some of these barriers.Initial results from a small study have indicated the feasibility of treating individuals with pre-diabetes to near-normoglycemia using a regimen of low-dose insulin glargine plus caloric restriction. Insulin Glargine 8-16 insulin Homo sapiens 0-7 17107224-8 2006 This is being followed up in the ongoing ORIGIN (Outcomes Reduction with Initial Glargine INtervention) study, which will investigate whether treatment to near-normoglycemia with insulin glargine in individuals with IGT, IFG, or new-onset type 2 diabetes can reduce cardiovascular morbidity and mortality compared with conventional management of these conditions, and whether the rate of progression to type 2 diabetes can be similarly reduced.Further studies are needed to investigate the potential benefits of insulin therapy in individuals with pre-diabetes. Insulin Glargine 81-89 insulin Homo sapiens 179-186 17107224-8 2006 This is being followed up in the ongoing ORIGIN (Outcomes Reduction with Initial Glargine INtervention) study, which will investigate whether treatment to near-normoglycemia with insulin glargine in individuals with IGT, IFG, or new-onset type 2 diabetes can reduce cardiovascular morbidity and mortality compared with conventional management of these conditions, and whether the rate of progression to type 2 diabetes can be similarly reduced.Further studies are needed to investigate the potential benefits of insulin therapy in individuals with pre-diabetes. Insulin Glargine 187-195 insulin Homo sapiens 179-186 16306570-0 2005 A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication. Insulin Glargine 35-43 insulin Homo sapiens 27-34 16306570-0 2005 A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication. Insulin Glargine 35-43 insulin Homo sapiens 57-64 16021649-8 2005 Insulin glargine was well tolerated, with a similar rate of local injection and systemic adverse events versus NPH insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16021649-9 2005 CONCLUSIONS: A single, bedtime, subcutaneous dose of insulin glargine provided a level of glycaemic control at least as effective as NPH insulin, without an increased risk of hypoglycaemia. Insulin Glargine 61-69 insulin Homo sapiens 53-60 16230722-6 2005 INTERVENTION: Exenatide, 10 microg twice daily, or insulin glargine, 1 daily dose titrated to maintain fasting blood glucose levels of less than 5.6 mmol/L (<100 mg/dL). Insulin Glargine 59-67 insulin Homo sapiens 51-58 16856426-1 2005 UNLABELLED: Insulin glargine is a new long-acting insulin analog with a duration of action of 24 hours and can be given once a day as the only basal insulin combined with short or rapid-acting insulin as bolus insulin for each meal. Insulin Glargine 20-28 insulin Homo sapiens 149-156 16856426-1 2005 UNLABELLED: Insulin glargine is a new long-acting insulin analog with a duration of action of 24 hours and can be given once a day as the only basal insulin combined with short or rapid-acting insulin as bolus insulin for each meal. Insulin Glargine 20-28 insulin Homo sapiens 149-156 16856426-1 2005 UNLABELLED: Insulin glargine is a new long-acting insulin analog with a duration of action of 24 hours and can be given once a day as the only basal insulin combined with short or rapid-acting insulin as bolus insulin for each meal. Insulin Glargine 20-28 insulin Homo sapiens 149-156 16856426-2 2005 The goals of this study were to evaluate short term result of treatment with insulin glargine compared to NPH and to determine the initial dosage of insulin glargine in Thai adolescents with type 1 diabetes. Insulin Glargine 85-93 insulin Homo sapiens 77-84 16856426-2 2005 The goals of this study were to evaluate short term result of treatment with insulin glargine compared to NPH and to determine the initial dosage of insulin glargine in Thai adolescents with type 1 diabetes. Insulin Glargine 157-165 insulin Homo sapiens 149-156 16856426-3 2005 We reviewed charts of 10 adolescents (median age 20.8 years, range 12.3-22.7 years) with type 1 diabetes who had received insulin glargine for > or = 4 months (median 16.5 months, range 4-25 months). Insulin Glargine 130-138 insulin Homo sapiens 122-129 16856426-8 2005 CONCLUSION: Insulin glargine is another promising therapy for adolescents with type 1 diabetes. Insulin Glargine 20-28 insulin Homo sapiens 12-19 16856426-10 2005 Insulin glargine should be started at 50% of the new total daily insulin dosage. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16856426-10 2005 Insulin glargine should be started at 50% of the new total daily insulin dosage. Insulin Glargine 8-16 insulin Homo sapiens 65-72 16856426-0 2005 Preliminary data of insulin glargine use among Thai adolescents and young adults with type 1 diabetes mellitus treated at Siriraj Hospital. Insulin Glargine 28-36 insulin Homo sapiens 20-27 16856426-1 2005 UNLABELLED: Insulin glargine is a new long-acting insulin analog with a duration of action of 24 hours and can be given once a day as the only basal insulin combined with short or rapid-acting insulin as bolus insulin for each meal. Insulin Glargine 20-28 insulin Homo sapiens 12-19 16856426-1 2005 UNLABELLED: Insulin glargine is a new long-acting insulin analog with a duration of action of 24 hours and can be given once a day as the only basal insulin combined with short or rapid-acting insulin as bolus insulin for each meal. Insulin Glargine 20-28 insulin Homo sapiens 50-57 16459456-5 2005 We report the successful use of Glargine insulin in the treatment of three infants with NDM, review the recent discoveries, and discuss guidelines for the care of newborns with NDM. Insulin Glargine 32-40 insulin Homo sapiens 41-48 16230722-11 2005 Body weight decreased 2.3 kg with exenatide and increased 1.8 kg with insulin glargine (difference, -4.1 kg [CI, -4.6 to -3.5 kg]). Insulin Glargine 78-86 insulin Homo sapiens 70-77 16230722-15 2005 Of the 551 participants, 19.4% of those receiving exenatide and 9.7% of those receiving insulin glargine withdrew from the study. Insulin Glargine 96-104 insulin Homo sapiens 88-95 16230722-17 2005 CONCLUSIONS: Exenatide and insulin glargine achieved similar improvements in overall glycemic control in patients with type 2 diabetes that was suboptimally controlled with oral combination therapy. Insulin Glargine 35-43 insulin Homo sapiens 27-34 16230722-8 2005 RESULTS: Baseline mean hemoglobin A1c level was 8.2% for patients receiving exenatide and 8.3% for those receiving insulin glargine. Insulin Glargine 123-131 insulin Homo sapiens 115-122 16230722-9 2005 At week 26, both exenatide and insulin glargine reduced hemoglobin A1c levels by 1.11% (difference, 0.017 percentage point [95% CI, -0.123 to 0.157 percentage point]). Insulin Glargine 39-47 insulin Homo sapiens 31-38 16230722-10 2005 Exenatide reduced postprandial glucose excursions more than insulin glargine, while insulin glargine reduced fasting glucose concentrations more than exenatide. Insulin Glargine 92-100 insulin Homo sapiens 84-91 16126116-0 2005 Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Insulin Glargine 21-29 insulin Homo sapiens 13-20 16126116-0 2005 Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Insulin Glargine 31-37 insulin Homo sapiens 13-20 16126116-1 2005 OBJECTIVE: To determine the efficacy and safety of insulin glargine (IG) in children and adolescents with type 1 diabetes. Insulin Glargine 59-67 insulin Homo sapiens 51-58 16126116-10 2005 CONCLUSIONS: Insulin glargine is an efficacious treatment to improve metabolic control in children and adolescents with type 1 diabetes. Insulin Glargine 21-29 insulin Homo sapiens 13-20 16160867-5 2005 Within-subject variability (ANOVA) for insulin exposure over 24 h was 15% for glargine and 19% for NPH, compared with 67% for ultralente (p<0.05, glargine and NPH vs ultralente). Insulin Glargine 78-86 insulin Homo sapiens 39-46 16334621-1 2005 BACKGROUND: Newer insulin analogues viz., premix insulin analogue (biphasic insulin aspart) and insulin glargine are now available in India. Insulin Glargine 104-112 insulin Homo sapiens 18-25 16186314-0 2005 Use of insulin glargine during pregnancy in seven type 1 diabetic women. Insulin Glargine 15-23 insulin Homo sapiens 7-14 16176210-0 2005 Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Insulin Glargine 72-80 insulin Homo sapiens 64-71 16176210-1 2005 AIM: Insulin glargine is a long-acting insulin analogue with favourable clinical characteristics. Insulin Glargine 13-21 insulin Homo sapiens 5-12 16176210-1 2005 AIM: Insulin glargine is a long-acting insulin analogue with favourable clinical characteristics. Insulin Glargine 13-21 insulin Homo sapiens 39-46 16176210-6 2005 CONCLUSIONS: The long-acting kinetics of insulin glargine require precipitation in the subcutaneous tissue. Insulin Glargine 49-57 insulin Homo sapiens 41-48 16176210-7 2005 Therefore, each patient"s injection technique should be carefully checked when treatment with insulin glargine is initiated, particularly in young and lean individuals. Insulin Glargine 102-110 insulin Homo sapiens 94-101 16285076-15 2005 In comparative trials, when combined with an oral antidiabetic, insulin glargine was no more effective than insulin isophane in terms of HbA1c levels or weight gain. Insulin Glargine 72-80 insulin Homo sapiens 64-71 16285076-16 2005 Insulin glargine seems to provoke less hypoglycaemia but, in the absence of adequate follow-up, its long-term adverse effects are not known. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16389894-7 2005 Availability of new short-acting (lispro, aspart and glulisine) and long-acting analogs (glargine, detemir) of human insulin, with improved pharmacokinetic characteristics, and a lesser variability and better reproducibility, should facilitate a tight glucose control in insulin-treated patients. Insulin Glargine 89-97 insulin Homo sapiens 117-124 16141481-0 2005 Concomitant use of insulin glargine and NPH in type I diabetes. Insulin Glargine 27-35 insulin Homo sapiens 19-26 16395988-0 2005 Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16395988-1 2005 BACKGROUND AND RATIONALE: Recent data suggest that insulin glargine might be a cost-effective alternative to conventional insulin therapy in patients with type 2 diabetes mellitus (T2DM). Insulin Glargine 59-67 insulin Homo sapiens 51-58 16395988-2 2005 The aim of this observational study was to evaluate the treatment costs of insulin glargine in combination with oral antidiabetic drugs (OADs) compared with conventional insulin therapy in T2DM in everyday clinical practice. Insulin Glargine 83-91 insulin Homo sapiens 75-82 16395988-12 2005 These results were achieved with significantly lower insulin doses and fewer blood glucose test strips in the insulin glargine group, which therefore led to cost equivalence when compared with conventional insulin therapy. Insulin Glargine 118-126 insulin Homo sapiens 53-60 16395988-12 2005 These results were achieved with significantly lower insulin doses and fewer blood glucose test strips in the insulin glargine group, which therefore led to cost equivalence when compared with conventional insulin therapy. Insulin Glargine 118-126 insulin Homo sapiens 110-117 16395988-12 2005 These results were achieved with significantly lower insulin doses and fewer blood glucose test strips in the insulin glargine group, which therefore led to cost equivalence when compared with conventional insulin therapy. Insulin Glargine 118-126 insulin Homo sapiens 110-117 16138636-0 2005 [American Diabetes Association"s Annual Meeting: new data on insulin glargine: early combination promises more success]. Insulin Glargine 69-77 insulin Homo sapiens 61-68 16109071-0 2005 Use of insulin glargine in children under age 6 with type 1 diabetes. Insulin Glargine 15-23 insulin Homo sapiens 7-14 16109071-2 2005 The purpose of this study is to evaluate the use of insulin glargine (Lantus in children under age 6 with type 1 diabetes (T1D). Insulin Glargine 60-68 insulin Homo sapiens 52-59 16109071-2 2005 The purpose of this study is to evaluate the use of insulin glargine (Lantus in children under age 6 with type 1 diabetes (T1D). Insulin Glargine 70-76 insulin Homo sapiens 52-59 16109071-9 2005 The average daily insulin dose in the glargine group was higher than that in the NPH group (0.8+/- 0.2 vs. 0.7+/- 0.2 U/kg/day; p=0.03). Insulin Glargine 38-46 insulin Homo sapiens 18-25 16138177-1 2005 Insulin glargine is a long-acting insulin analogue providing a more predictable and reproducible circulating insulin profile than other available basal insulin products. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16138177-1 2005 Insulin glargine is a long-acting insulin analogue providing a more predictable and reproducible circulating insulin profile than other available basal insulin products. Insulin Glargine 8-16 insulin Homo sapiens 34-41 16138177-1 2005 Insulin glargine is a long-acting insulin analogue providing a more predictable and reproducible circulating insulin profile than other available basal insulin products. Insulin Glargine 8-16 insulin Homo sapiens 109-116 16138177-1 2005 Insulin glargine is a long-acting insulin analogue providing a more predictable and reproducible circulating insulin profile than other available basal insulin products. Insulin Glargine 8-16 insulin Homo sapiens 109-116 16138177-3 2005 Evidence from randomised controlled clinical trials demonstrates reduced rates of hypoglycaemia in patients with type 1 and type 2 diabetes using insulin glargine compared with other basal insulin. Insulin Glargine 154-162 insulin Homo sapiens 146-153 16138177-4 2005 Insulin glargine has been registered for use in New Zealand since June 2001, but currently remains unsubsidised by PHARMAC. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16138177-5 2005 Reducing the incidence and impact of diabetes is one of the stated aims in the New Zealand Health Strategy and the complete lack of funding for pharmaceutical agents such as insulin glargine severely limits its accessibility to patients with diabetes and would seem in contradiction to this aim. Insulin Glargine 182-190 insulin Homo sapiens 174-181 16043769-0 2005 Use of glargine insulin before and during pregnancy in a woman with type 1 diabetes and Addison"s Disease. Insulin Glargine 7-15 insulin Homo sapiens 16-23 15867042-0 2005 Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Insulin Glargine 30-38 insulin Homo sapiens 9-16 16041197-7 2005 Baseline treatment costs were 2.7-fold higher in the insulin glargine group. Insulin Glargine 61-69 insulin Homo sapiens 53-60 16041197-8 2005 Absolute cost reductions in the insulin glargine and reference groups were 185 dollars and 72 dollars per patient, respectively. Insulin Glargine 40-48 insulin Homo sapiens 32-39 16041197-9 2005 Incremental cost savings were 69 dollars per insulin glargine user, including more than 200 dollars in incremental savings for inpatient claims. Insulin Glargine 53-61 insulin Homo sapiens 45-52 16041197-10 2005 Hypoglycemia decreased from 9.5% to 3.8% of inpatient claims in the insulin glargine group but remained 1.1% throughout in the reference group. Insulin Glargine 76-84 insulin Homo sapiens 68-75 16041197-11 2005 Insulin glargine use was associated with reduced inpatient hypoglycemia-related claims paid and short-term reductions in the inpatient and total costs of diabetes-related care. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15619291-0 2005 An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. Insulin Glargine 93-101 insulin Homo sapiens 85-92 15619291-1 2005 OBJECTIVE: The advantages of continuous subcutaneous insulin infusion (CSII) or insulin glargine have been demonstrated both in adult and paediatric diabetic patients; however, as no data comparing these two approaches during childhood are available, we have examined the efficacy of these two intensive approaches. Insulin Glargine 88-96 insulin Homo sapiens 80-87 15619291-3 2005 Twenty patients underwent CSII, while the other 16 (significantly younger for age) started insulin glargine at bedtime. Insulin Glargine 99-107 insulin Homo sapiens 91-98 15818714-8 2005 For the moment, the use of insulin glargine during pregnancy is not recommended owing to the lack of data on maternal and fetal effects. Insulin Glargine 35-43 insulin Homo sapiens 27-34 16239201-10 2005 The recommended dose of insulin glargine after the switch in treatment is equal to the total daily basal dose on CSII. Insulin Glargine 32-40 insulin Homo sapiens 24-31 15879567-7 2005 Newer long-acting agents such as insulin glargine provide a steadier and more reliable level of basal insulin coverage and may have significant advantages over traditional long-acting insulins as part of a basal-bolus treatment strategy. Insulin Glargine 41-49 insulin Homo sapiens 33-40 15879567-7 2005 Newer long-acting agents such as insulin glargine provide a steadier and more reliable level of basal insulin coverage and may have significant advantages over traditional long-acting insulins as part of a basal-bolus treatment strategy. Insulin Glargine 41-49 insulin Homo sapiens 102-109 15867042-0 2005 Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Insulin Glargine 30-38 insulin Homo sapiens 39-46 15867042-2 2005 A flexible multiple daily insulin (FMDI) regimen (premeal lispro plus bedtime glargine) results in lower hemoglobin A1c (HbA1c) levels and fewer hypoglycemic episodes than does a multiple daily insulin (MDI) regimen among school-aged children and adolescents with type 1 diabetes mellitus (DM). Insulin Glargine 78-86 insulin Homo sapiens 26-33 15844050-0 2005 [Does insulin glargin (lantus) lead to a progression in diabetic retinopathy? Insulin Glargine 14-21 insulin Homo sapiens 6-13 15787660-1 2005 AIMS: To compare the effects on glycaemic control after using continuous subcutaneous insulin infusion (CSII) or insulin glargine. Insulin Glargine 121-129 insulin Homo sapiens 113-120 15787660-7 2005 An additional 0.1% lower HbA1c would be expected if glargine had been optimized with basal insulin 40-60% of the daily dose. Insulin Glargine 52-60 insulin Homo sapiens 91-98 15787660-10 2005 CONCLUSION: Both regimes improved metabolic control, but CSII resulted in significantly higher reduction in HbA1c than after insulin glargine treatment, particularly in those individuals who had higher levels of HbA1c at baseline. Insulin Glargine 133-141 insulin Homo sapiens 125-132 16035288-3 2005 Insulin analogues, with ultrashort activity (insulin lispro or aspart) or with a basal activity (insulin glargine or detemir), offer some pharmacokinetic advantages when compared to conventional insulins. Insulin Glargine 105-113 insulin Homo sapiens 0-7 16035288-3 2005 Insulin analogues, with ultrashort activity (insulin lispro or aspart) or with a basal activity (insulin glargine or detemir), offer some pharmacokinetic advantages when compared to conventional insulins. Insulin Glargine 105-113 insulin Homo sapiens 97-104 15793205-0 2005 Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Insulin Glargine 39-47 insulin Homo sapiens 31-38 15793205-0 2005 Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Insulin Glargine 39-47 insulin Homo sapiens 75-82 15793205-0 2005 Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Insulin Glargine 83-91 insulin Homo sapiens 31-38 15793205-1 2005 OBJECTIVE: Insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides effective glycemic control with reduced hypoglycemia risk (particularly nocturnal) compared with NPH insulin in patients with type 2 diabetes. Insulin Glargine 19-27 insulin Homo sapiens 11-18 15793205-1 2005 OBJECTIVE: Insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides effective glycemic control with reduced hypoglycemia risk (particularly nocturnal) compared with NPH insulin in patients with type 2 diabetes. Insulin Glargine 19-27 insulin Homo sapiens 59-66 15793205-1 2005 OBJECTIVE: Insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides effective glycemic control with reduced hypoglycemia risk (particularly nocturnal) compared with NPH insulin in patients with type 2 diabetes. Insulin Glargine 29-35 insulin Homo sapiens 11-18 15793205-1 2005 OBJECTIVE: Insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides effective glycemic control with reduced hypoglycemia risk (particularly nocturnal) compared with NPH insulin in patients with type 2 diabetes. Insulin Glargine 29-35 insulin Homo sapiens 59-66 15793205-2 2005 A recent "treat-to-target" study has shown that more patients on insulin glargine reached HbA(1c) levels < or =7.0% without confirmed nocturnal hypoglycemia compared with NPH insulin. Insulin Glargine 73-81 insulin Homo sapiens 65-72 15793205-3 2005 We further assessed the risk for hypoglycemia in a meta-analysis of controlled trials of a similar design for insulin glargine versus once- or twice-daily NPH insulin in adults with type 2 diabetes. Insulin Glargine 118-126 insulin Homo sapiens 110-117 15793205-7 2005 There was a consistent significant reduction of hypoglycemia risk associated with insulin glargine, compared with NPH insulin, in terms of overall symptomatic (11%; P = 0.0006) and nocturnal (26%; P < 0.0001) hypoglycemia. Insulin Glargine 90-98 insulin Homo sapiens 82-89 15793205-8 2005 Most notably, the risk of severe hypoglycemia and severe nocturnal hypoglycemia were reduced with insulin glargine by 46% (P = 0.0442) and 59% (P = 0.0231), respectively. Insulin Glargine 106-114 insulin Homo sapiens 98-105 15793205-9 2005 CONCLUSIONS: These results confirmed that insulin glargine given once daily reduces the risk of hypoglycemia compared with NPH insulin, which can facilitate more aggressive insulin treatment to a HbA(1c) target of < or =7.0% in patients with type 2 diabetes. Insulin Glargine 50-58 insulin Homo sapiens 42-49 15793214-0 2005 Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Insulin Glargine 15-23 insulin Homo sapiens 7-14 15793215-0 2005 Successful treatment of insulin allergy in a 1-year-old infant with neonatal diabetes by lispro and glargine insulin. Insulin Glargine 100-108 insulin Homo sapiens 24-31 15844050-0 2005 [Does insulin glargin (lantus) lead to a progression in diabetic retinopathy? Insulin Glargine 23-29 insulin Homo sapiens 6-13 15677775-7 2005 CONCLUSIONS: Initiating insulin treatment by adding basal insulin glargine once daily to glimepiride plus metformin treatment was safer and more effective than beginning twice-daily injections of 70/30 and discontinuing OADs in type 2 diabetic patients inadequately controlled with OADs. Insulin Glargine 66-74 insulin Homo sapiens 24-31 15813164-5 2005 The pharmacokinetic properties of the new insulin analogs (eg, insulin lispro, insulin aspart, insulin glargine) offer significant advantages, such as improved control of nocturnal hypoglycemia with basal insulin glargine, and improved postprandial glucose control, with insulin lispro or insulin aspart. Insulin Glargine 103-111 insulin Homo sapiens 42-49 15735188-0 2005 Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Insulin Glargine 49-57 insulin Homo sapiens 41-48 15735188-1 2005 OBJECTIVE: To study the effects of exercise on the absorption of the basal long-acting insulin analog insulin glargine (Lantus), administered subcutaneously in individuals with type 1 diabetes. Insulin Glargine 110-118 insulin Homo sapiens 87-94 15735188-1 2005 OBJECTIVE: To study the effects of exercise on the absorption of the basal long-acting insulin analog insulin glargine (Lantus), administered subcutaneously in individuals with type 1 diabetes. Insulin Glargine 110-118 insulin Homo sapiens 102-109 15735188-1 2005 OBJECTIVE: To study the effects of exercise on the absorption of the basal long-acting insulin analog insulin glargine (Lantus), administered subcutaneously in individuals with type 1 diabetes. Insulin Glargine 120-126 insulin Homo sapiens 87-94 15735188-1 2005 OBJECTIVE: To study the effects of exercise on the absorption of the basal long-acting insulin analog insulin glargine (Lantus), administered subcutaneously in individuals with type 1 diabetes. Insulin Glargine 120-126 insulin Homo sapiens 102-109 15735188-3 2005 (125)I-labeled insulin glargine at the usual basal insulin dose was injected subcutaneously into the thigh on the evening (2100) before the study day on two occasions 1 week apart. Insulin Glargine 23-31 insulin Homo sapiens 15-22 15677775-7 2005 CONCLUSIONS: Initiating insulin treatment by adding basal insulin glargine once daily to glimepiride plus metformin treatment was safer and more effective than beginning twice-daily injections of 70/30 and discontinuing OADs in type 2 diabetic patients inadequately controlled with OADs. Insulin Glargine 66-74 insulin Homo sapiens 58-65 15616226-3 2005 RESEARCH DESIGN AND METHODS: To determine whether the use of glargine insulin as a basal insulin would result in a comparable HbA1c and less glycemic variation and hypoglycemia than ultralente insulin, 22 individuals (aged 44 +/- 14 years [+/-SD], 55% men) with type 1 diabetes who were experienced with multiple daily insulin injections and had an HbA1c of <7.8% were randomized in a crossover design to receive either glargine or ultralente as the basal insulin for 4 months. Insulin Glargine 61-69 insulin Homo sapiens 70-77 15693442-3 2005 Insulin glargine is a new extended-action recombinant insulin analog, which is absorbed slowly into the bloodstream, reaching peak action in about 4 h and maintaining this concentration profil for 24-30 h. Some studies demonstrated that insulin glargine reduces the incidence of hypoglycemia and is at least as effective as NPH insulin given once or twice daily. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15693442-3 2005 Insulin glargine is a new extended-action recombinant insulin analog, which is absorbed slowly into the bloodstream, reaching peak action in about 4 h and maintaining this concentration profil for 24-30 h. Some studies demonstrated that insulin glargine reduces the incidence of hypoglycemia and is at least as effective as NPH insulin given once or twice daily. Insulin Glargine 8-16 insulin Homo sapiens 54-61 15693442-3 2005 Insulin glargine is a new extended-action recombinant insulin analog, which is absorbed slowly into the bloodstream, reaching peak action in about 4 h and maintaining this concentration profil for 24-30 h. Some studies demonstrated that insulin glargine reduces the incidence of hypoglycemia and is at least as effective as NPH insulin given once or twice daily. Insulin Glargine 8-16 insulin Homo sapiens 237-244 15693442-3 2005 Insulin glargine is a new extended-action recombinant insulin analog, which is absorbed slowly into the bloodstream, reaching peak action in about 4 h and maintaining this concentration profil for 24-30 h. Some studies demonstrated that insulin glargine reduces the incidence of hypoglycemia and is at least as effective as NPH insulin given once or twice daily. Insulin Glargine 245-253 insulin Homo sapiens 0-7 15693442-3 2005 Insulin glargine is a new extended-action recombinant insulin analog, which is absorbed slowly into the bloodstream, reaching peak action in about 4 h and maintaining this concentration profil for 24-30 h. Some studies demonstrated that insulin glargine reduces the incidence of hypoglycemia and is at least as effective as NPH insulin given once or twice daily. Insulin Glargine 245-253 insulin Homo sapiens 54-61 15693442-3 2005 Insulin glargine is a new extended-action recombinant insulin analog, which is absorbed slowly into the bloodstream, reaching peak action in about 4 h and maintaining this concentration profil for 24-30 h. Some studies demonstrated that insulin glargine reduces the incidence of hypoglycemia and is at least as effective as NPH insulin given once or twice daily. Insulin Glargine 245-253 insulin Homo sapiens 237-244 15902802-0 2005 Poisoning with insulin glargine. Insulin Glargine 23-31 insulin Homo sapiens 15-22 15616226-8 2005 CONCLUSIONS: We conclude that while use of either ultralente or glargine as a basal insulin can result in excellent glycemic control, treatment with glargine is associated with slightly but significantly lower HbA1c and less nocturnal glycemic variability and hypoglycemia. Insulin Glargine 64-72 insulin Homo sapiens 84-91 15701210-7 2004 Indeed, newer insulin analogs, both short-acting (insulin lispro, insulin aspart) and long-acting (insulin glargine), are an important part of a treatment strategy to circumvent diabetes complications and overcome the shortcomings of conventional insulin preparations. Insulin Glargine 107-115 insulin Homo sapiens 14-21 15793346-0 2005 Insulin glargine: a long acting insulin analog. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15793346-0 2005 Insulin glargine: a long acting insulin analog. Insulin Glargine 8-16 insulin Homo sapiens 32-39 15793346-4 2005 Insulin glargine is newer, long acting insulin analog with duration of action of 24 hr. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15793346-4 2005 Insulin glargine is newer, long acting insulin analog with duration of action of 24 hr. Insulin Glargine 8-16 insulin Homo sapiens 39-46 15793346-7 2005 In the current scenario, though it is difficult to achieve an ideal replacement therapy, insulin glargine is definitely a positive step in that direction. Insulin Glargine 97-105 insulin Homo sapiens 89-96 15823767-11 2004 Gain in mean (SD) body weight was greater with Mix 75/25 than insulin glargine (2.3 [4.0] kg vs 1.6 [4.0] kg; P = 0.006). Insulin Glargine 70-78 insulin Homo sapiens 62-69 15823767-12 2004 For all randomized patients, mean (SD) hypoglycemia rates were lower with insulin glargine (0.68 [1.38] vs 0.39 [1.24] episodes/patient per 30 days; P = 0.041), although nocturnal hypoglycemia was similar. Insulin Glargine 82-90 insulin Homo sapiens 74-81 15823767-13 2004 CONCLUSION: In this study population, Mix 75/25 plus metformin was associated with lower HbA(1c) than insulin glargine plus metformin, smaller rise in ppBG after breakfast and dinner, and higher proportion of patients achieving HbA(1c) < or =7.0%, with a slight increase in overall (but not nocturnal) hypoglycemia. Insulin Glargine 110-118 insulin Homo sapiens 102-109 15498088-0 2004 Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Insulin Glargine 58-66 insulin Homo sapiens 50-57 15545844-5 2004 RESULTS: Patients treated with insulin glargine (n = 52) and NPH insulin (n = 48) achieved similar reductions from baseline in glycohemoglobin (-0.41% versus -0.46%) and fasting blood glucose (-22 mg/dL versus -22 mg/dL) at week 28. Insulin Glargine 39-47 insulin Homo sapiens 31-38 15545844-10 2004 Significantly fewer patients also reported one or more symptomatic episodes confirmed by blood glucose less than 50 mg/dL with insulin glargine (17.3%) versus NPH insulin (31.3%; P < 0.005). Insulin Glargine 135-143 insulin Homo sapiens 127-134 15545844-11 2004 CONCLUSION: Bedtime insulin glargine is as effective as bedtime NPH insulin in improving glycemic control, with significantly less hypoglycemia. Insulin Glargine 28-36 insulin Homo sapiens 20-27 15537471-2 2004 Insulin glargine, a long-acting insulin, has shown benefits of decreased nocturnal hypoglycemia without significant weight gain, while providing good glycemic control in clinical trials. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15537471-2 2004 Insulin glargine, a long-acting insulin, has shown benefits of decreased nocturnal hypoglycemia without significant weight gain, while providing good glycemic control in clinical trials. Insulin Glargine 8-16 insulin Homo sapiens 32-39 15537471-4 2004 The objective of this study was to evaluate the effectiveness of insulin glargine over a 12-month period in a clinical practice setting, and measure its effects on HRQOL in a subset of patients. Insulin Glargine 73-81 insulin Homo sapiens 65-72 15537471-5 2004 DESIGN AND METHODS: Patients with diabetes in a large private endocrinology practice were initiated on insulin glargine. Insulin Glargine 111-119 insulin Homo sapiens 103-110 15537471-10 2004 In the year following insulin glargine therapy, there were significantly fewer hypoglycemic events per patient than in the year prior to insulin glargine therapy (group T1D: -0.33, P = 0.002; group T2D: -0.20, P = 0.004). Insulin Glargine 30-38 insulin Homo sapiens 22-29 15537471-11 2004 HRQOL subset analysis also revealed a significant decrease in A1C (P < 0.0001) after 16 weeks of therapy with insulin glargine. Insulin Glargine 121-129 insulin Homo sapiens 113-120 15537471-14 2004 CONCLUSIONS: Insulin glargine use over a 12-month period in a clinical practice setting was shown to significantly improve A1C without adversely impacting weight or the occurrence of hypoglycemia. Insulin Glargine 21-29 insulin Homo sapiens 13-20 15551297-12 2004 CONCLUSIONS: In order to best prevent hypoglycaemia, insulin should preferably be given as continuous subcutaneous infusion via a minipump (the "golden standard") or multiple daily insulin administrations with insulin analogues (basal insulin glargine, meal insulin rapid-acting insulin analogues) in T1 DM. Insulin Glargine 243-251 insulin Homo sapiens 53-60 15498088-1 2004 BACKGROUND: Glargine is a long-acting insulin analogue potentially more suitable than NPH insulin in intensive treatment of Type 1 diabetes mellitus (T1 DM), but no study has proven superiority. Insulin Glargine 12-20 insulin Homo sapiens 38-45 15525480-0 2004 Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Insulin Glargine 85-93 insulin Homo sapiens 59-66 15525480-17 2004 The cost-effectiveness of insulin glargine in both type 1 and type 2 diabetes is highly sensitive to the amount of utility associated with reducing the fear of hypoglycaemia. Insulin Glargine 34-42 insulin Homo sapiens 26-33 15525480-0 2004 Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Insulin Glargine 85-93 insulin Homo sapiens 77-84 15525480-20 2004 Further research into insulin glargine is needed that addresses the quality of life issues associated with fear of hypoglycaemia and also the economic impact of balance of HbA1c control and incidence of hypoglycaemia achieved in practice. Insulin Glargine 30-38 insulin Homo sapiens 22-29 15525480-21 2004 Studies examining the economic evidence on insulin glargine should be published. Insulin Glargine 51-59 insulin Homo sapiens 43-50 15525480-1 2004 OBJECTIVES: To evaluate the use of insulin glargine in its licensed basal-bolus indication in terms of both clinical and cost-effectiveness. Insulin Glargine 43-51 insulin Homo sapiens 35-42 15525480-3 2004 REVIEW METHODS: A systematic review of the literature, involving a range of databases, was performed to identify all papers relating to insulin glargine. Insulin Glargine 144-152 insulin Homo sapiens 136-143 15525480-5 2004 For type 1 diabetes patients, insulin glargine appears to be more effective than neutral protamine Hagedorn (NPH) in reducing fasting blood glucose (FBG) but not in reducing glycosylated haemoglobin (HbA1c) and there is some evidence that both insulins are as effective as each other in both FBG and HbA1c control. Insulin Glargine 38-46 insulin Homo sapiens 30-37 15525480-8 2004 In studies where insulin glargine is demonstrated to be superior to NPH in controlling nocturnal hypoglycaemia, this may be only apparent when compared with once-daily NPH and not twice-daily NPH. Insulin Glargine 25-33 insulin Homo sapiens 17-24 15525480-9 2004 Further, this superiority of glargine over NPH in the control of nocturnal hypoglycaemia may relate to one formulation of insulin glargine (HOE901[80]) and not another (HOE901[30]). Insulin Glargine 29-37 insulin Homo sapiens 122-129 15525480-9 2004 Further, this superiority of glargine over NPH in the control of nocturnal hypoglycaemia may relate to one formulation of insulin glargine (HOE901[80]) and not another (HOE901[30]). Insulin Glargine 130-138 insulin Homo sapiens 122-129 15314935-0 2004 [Insulin glargine--a systematic review of clinical studies. Insulin Glargine 9-17 insulin Homo sapiens 1-8 15487981-2 2004 New insulin analogues, such as insulin lispro, aspart and glargine, allow more physiological insulin replacement and greater freedom in the timing and content of meals, compared with regular insulin preparations. Insulin Glargine 58-66 insulin Homo sapiens 4-11 15453117-4 2004 Insulin glargine has a long duration of action and has demonstrated its usefulness in diabetes type 2, specifically a lower incidence of (nocturnal) hypoglycaemia compared to isophane insulin, in clinical practice. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15281015-0 2004 Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism. Insulin Glargine 26-34 insulin Homo sapiens 18-25 15281015-2 2004 Glargine is used to provide basal insulin levels. Insulin Glargine 0-8 insulin Homo sapiens 34-41 19667675-7 2004 Although such a profile may be achieved with a continuous subcutaneous insulin infusion, new basal insulin analogues, such as once daily, 24-hour insulin glargine, combined with mealtime lispro or aspart, offer comparable glycemic control without the drawbacks of insulin pump use in type 1 diabetes. Insulin Glargine 154-162 insulin Homo sapiens 99-106 19667675-7 2004 Although such a profile may be achieved with a continuous subcutaneous insulin infusion, new basal insulin analogues, such as once daily, 24-hour insulin glargine, combined with mealtime lispro or aspart, offer comparable glycemic control without the drawbacks of insulin pump use in type 1 diabetes. Insulin Glargine 154-162 insulin Homo sapiens 99-106 19667675-7 2004 Although such a profile may be achieved with a continuous subcutaneous insulin infusion, new basal insulin analogues, such as once daily, 24-hour insulin glargine, combined with mealtime lispro or aspart, offer comparable glycemic control without the drawbacks of insulin pump use in type 1 diabetes. Insulin Glargine 154-162 insulin Homo sapiens 99-106 19667675-8 2004 Insulin glargine reduces the frequency of nocturnal hypoglycemia compared with NPH when used with rapid-acting analogues and thus facilitates optimal insulin replacement therapy. Insulin Glargine 8-16 insulin Homo sapiens 0-7 19667675-8 2004 Insulin glargine reduces the frequency of nocturnal hypoglycemia compared with NPH when used with rapid-acting analogues and thus facilitates optimal insulin replacement therapy. Insulin Glargine 8-16 insulin Homo sapiens 150-157 19667676-5 2004 In the meantime, the tools for translating this concept to clinical practice can be extrapolated from the Treat-to-Target Trial, which showed that the addition of once-daily basal insulin glargine to oral agents, using a structured titration algorithm based on fasting plasma glucose monitoring, can achieve stringent glycemic control with less risk of nocturnal hypoglycemia than NPH insulin. Insulin Glargine 188-196 insulin Homo sapiens 180-187 15364161-0 2004 Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Insulin Glargine 181-189 insulin Homo sapiens 173-180 15364161-1 2004 OBJECTIVE: To see if insulin glargine improves glycemic control in a clinical setting. Insulin Glargine 29-37 insulin Homo sapiens 21-28 15628812-10 2004 CONCLUSIONS: Transfer to glargine treatment from NPH in MDI regimens significantly reduces severe hypoglycemic episodes despite a decline in long-acting basal insulin without significant weight gain. Insulin Glargine 25-33 insulin Homo sapiens 159-166 15317436-13 2004 Basal therapy with glargine insulin provides similar to lower A1C levels with less hypoglycemia than NPH insulin. Insulin Glargine 19-27 insulin Homo sapiens 28-35 15311441-0 2004 Insulin glargine for type 2 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15311441-1 2004 Insulin glargine is a biosynthetic human insulin analogue that controls blood glucose levels over 24 hours without a pronounced peak. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15311441-1 2004 Insulin glargine is a biosynthetic human insulin analogue that controls blood glucose levels over 24 hours without a pronounced peak. Insulin Glargine 8-16 insulin Homo sapiens 41-48 15281015-9 2004 While binding of glargine to the insulin receptor was identical to insulin, degradation of glargine was reduced compared to insulin (16.3% +/- 0.3% v 21.6% +/- 0.4% degraded/h, P < .01). Insulin Glargine 17-25 insulin Homo sapiens 33-40 15314935-2 2004 The prescription of insulin glargine has increased in Sweden and during 2003 the cost in the county of Skane equalled all intermediate-acting insulins (ATC-code A10AC01). Insulin Glargine 28-36 insulin Homo sapiens 20-27 15336483-0 2004 Insulin glargine clinical trials. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15200492-0 2004 Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Insulin Glargine 68-76 insulin Homo sapiens 0-7 15231979-0 2004 Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Insulin Glargine 121-129 insulin Homo sapiens 91-98 15231979-0 2004 Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Insulin Glargine 121-129 insulin Homo sapiens 91-98 14722023-10 2004 Insulin and the new, long-acting insulin analog glargine interacted with the IGF-IR with thousand- and hundred-fold less potency than IGF-I itself. Insulin Glargine 48-56 insulin Homo sapiens 33-40 15200492-0 2004 Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Insulin Glargine 68-76 insulin Homo sapiens 60-67 15200492-1 2004 Insulin glargine is a long-acting insulin analogue, with a longer duration of action and a flatter time-action profile compared with NPH insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15200492-1 2004 Insulin glargine is a long-acting insulin analogue, with a longer duration of action and a flatter time-action profile compared with NPH insulin. Insulin Glargine 8-16 insulin Homo sapiens 34-41 15200492-2 2004 These properties can be predicted to result in higher glucose levels during the night and lower glucose levels after dinner following bedtime injection of insulin glargine compared with an equal dose of NPH insulin injected at bedtime. Insulin Glargine 163-171 insulin Homo sapiens 155-162 15200492-5 2004 The "treat-to-target study" (756 insulin-naive patients treated for 24 weeks) showed that good glycaemic control can be achieved with aggressive titration of the insulin dose with either once-daily insulin glargine or NPH insulin combined with oral agents (mean endpoint HbA(1c) was 6.96% with insulin glargine and 6.97% with NPH insulin); however, this was achieved with less variability and nocturnal hypoglycaemia with insulin glargine. Insulin Glargine 302-310 insulin Homo sapiens 162-169 15200492-5 2004 The "treat-to-target study" (756 insulin-naive patients treated for 24 weeks) showed that good glycaemic control can be achieved with aggressive titration of the insulin dose with either once-daily insulin glargine or NPH insulin combined with oral agents (mean endpoint HbA(1c) was 6.96% with insulin glargine and 6.97% with NPH insulin); however, this was achieved with less variability and nocturnal hypoglycaemia with insulin glargine. Insulin Glargine 302-310 insulin Homo sapiens 162-169 15200492-6 2004 These data support use of insulin glargine instead of NPH insulin for basal insulin replacement in patients with type 2 diabetes. Insulin Glargine 34-42 insulin Homo sapiens 26-33 15189493-0 2004 Initiation of insulin glargine in children and adolescents with type 1 diabetes. Insulin Glargine 22-30 insulin Homo sapiens 14-21 15189493-1 2004 BACKGROUND: Glargine (Lantus) is a recently approved, long-acting insulin analog that is increasingly being used in children with diabetes. Insulin Glargine 12-20 insulin Homo sapiens 66-73 15189493-1 2004 BACKGROUND: Glargine (Lantus) is a recently approved, long-acting insulin analog that is increasingly being used in children with diabetes. Insulin Glargine 22-28 insulin Homo sapiens 66-73 15189493-7 2004 The total daily long-acting insulin dose decreased by about 20% after initiating glargine therapy. Insulin Glargine 81-89 insulin Homo sapiens 28-35 15222663-0 2004 The utility of insulin glargine in the treatment of diabetes mellitus. Insulin Glargine 23-31 insulin Homo sapiens 15-22 15013454-7 2004 Of currently available insulins, glargine has the activity profile best suited to basal insulin therapy, with no prominent activity peak and a long duration of action, allowing a single daily injection in most cases. Insulin Glargine 33-41 insulin Homo sapiens 23-30 15222663-10 2004 CONCLUSION: Compared with baseline, insulin glargine therapy at 1 year was associated with an overall significant reduction in A1C of 0.53 +/- 1.4%. Insulin Glargine 44-52 insulin Homo sapiens 36-43 15176145-2 2004 This article discusses such regimens and whether the risk of hypoglycaemia can be reduced by using the new basal insulin analogue, insulin glargine. Insulin Glargine 139-147 insulin Homo sapiens 113-120 15176145-2 2004 This article discusses such regimens and whether the risk of hypoglycaemia can be reduced by using the new basal insulin analogue, insulin glargine. Insulin Glargine 139-147 insulin Homo sapiens 131-138 15013455-3 2004 Further, 2 recent randomized, controlled trials support the clinical utility of supplementing oral pharmacotherapy with once-daily insulin glargine to achieve and maintain target glycosylated hemoglobin levels < or =7%. Insulin Glargine 139-147 insulin Homo sapiens 131-138 15013455-4 2004 This simple treat-to-target strategy may be readily adopted in general practice through a widely translatable algorithm moving from oral pharmacotherapy to early addition of basal insulin glargine if glycemic targets are not met. Insulin Glargine 188-196 insulin Homo sapiens 180-187 15013455-5 2004 The once-daily flexible dosing of insulin glargine and its smooth, flat profile, associated with fewer episodes of nocturnal hypoglycemia, make it among the safest and most practical tools to date for transforming the paradigm of type 2 diabetes management. Insulin Glargine 42-50 insulin Homo sapiens 34-41 14656737-2 2004 Structural changes in a long-acting insulin analog, insulin glargine, may change its binding properties to insulin receptor and structurally homologous receptors, such as the insulin-like growth factor-1 receptor, and thereby alter its vascular effects. Insulin Glargine 60-68 insulin Homo sapiens 36-43 15013456-2 2004 The recently introduced rapid-acting insulin analogues lispro and aspart and the long-acting analogue glargine are further refinements of insulin therapy. Insulin Glargine 102-110 insulin Homo sapiens 138-145 15013456-5 2004 Truly effective control of basal insulin has been achieved by the introduction of the insulin pump in the 1980s and insulin glargine in 2001. Insulin Glargine 124-132 insulin Homo sapiens 33-40 15013456-6 2004 Insulin glargine is the first insulin analogue to provide, in a majority of patients, a continuous level of insulin without a pronounced peak after a single daily injection, closely mimicking the normal pancreatic release of basal insulin in healthy individuals. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15013456-6 2004 Insulin glargine is the first insulin analogue to provide, in a majority of patients, a continuous level of insulin without a pronounced peak after a single daily injection, closely mimicking the normal pancreatic release of basal insulin in healthy individuals. Insulin Glargine 8-16 insulin Homo sapiens 30-37 15013456-6 2004 Insulin glargine is the first insulin analogue to provide, in a majority of patients, a continuous level of insulin without a pronounced peak after a single daily injection, closely mimicking the normal pancreatic release of basal insulin in healthy individuals. Insulin Glargine 8-16 insulin Homo sapiens 108-115 15013456-6 2004 Insulin glargine is the first insulin analogue to provide, in a majority of patients, a continuous level of insulin without a pronounced peak after a single daily injection, closely mimicking the normal pancreatic release of basal insulin in healthy individuals. Insulin Glargine 8-16 insulin Homo sapiens 108-115 15013456-9 2004 More importantly, the greatest benefit of insulin glargine has been to change positively the way physicians and patients think about insulin therapy. Insulin Glargine 50-58 insulin Homo sapiens 42-49 15013456-9 2004 More importantly, the greatest benefit of insulin glargine has been to change positively the way physicians and patients think about insulin therapy. Insulin Glargine 50-58 insulin Homo sapiens 133-140 14684428-0 2004 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Insulin Glargine 42-50 insulin Homo sapiens 13-20 14684428-0 2004 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Insulin Glargine 42-50 insulin Homo sapiens 34-41 14684428-3 2004 The tests in the type 2 diabetic patients were performed before and after 6 months and 3.5 years of combination therapy with insulin glargine and metformin. Insulin Glargine 133-141 insulin Homo sapiens 125-132 14684428-9 2004 CONCLUSIONS: We conclude that insulin glargine therapy improves endothelium-dependent and endothelium-independent vasodilatation. Insulin Glargine 38-46 insulin Homo sapiens 30-37 14656737-2 2004 Structural changes in a long-acting insulin analog, insulin glargine, may change its binding properties to insulin receptor and structurally homologous receptors, such as the insulin-like growth factor-1 receptor, and thereby alter its vascular effects. Insulin Glargine 60-68 insulin Homo sapiens 52-59 14656737-6 2004 Hyperinsulinemia (120 minutes; infusion rate: 1 mU/kg per minute) was created by infusing either insulin glargine or human regular insulin. Insulin Glargine 105-113 insulin Homo sapiens 5-12 14656737-10 2004 CONCLUSIONS: Insulin glargine and regular human insulin have similar acute stimulatory effects on endothelium-dependent vasodilation in humans. Insulin Glargine 21-29 insulin Homo sapiens 13-20 15000764-3 2004 An insulin pump was used by 216 patients, and 299 patients were taking insulin glargine for at least 6 months. Insulin Glargine 79-87 insulin Homo sapiens 71-78 15000764-6 2004 The insulin glargine group significantly reduced basal insulin intake at follow-up. Insulin Glargine 12-20 insulin Homo sapiens 4-11 15000764-6 2004 The insulin glargine group significantly reduced basal insulin intake at follow-up. Insulin Glargine 12-20 insulin Homo sapiens 55-62 15000764-9 2004 Patients with type 1 diabetes can achieve similar glycemic control using insulin glargine with premeal insulin lispro or by using an external infusion pump with insulin lispro or insulin aspart. Insulin Glargine 81-89 insulin Homo sapiens 73-80 15112902-1 2004 Insulin glargine (Lantus)]. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15112902-1 2004 Insulin glargine (Lantus)]. Insulin Glargine 18-24 insulin Homo sapiens 0-7 15112902-2 2004 Insulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15112902-2 2004 Insulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. Insulin Glargine 8-16 insulin Homo sapiens 37-44 15112902-2 2004 Insulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. Insulin Glargine 18-24 insulin Homo sapiens 0-7 15112902-2 2004 Insulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. Insulin Glargine 18-24 insulin Homo sapiens 37-44 15112902-3 2004 Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue (pH > 7,4) from which small amounts of insulin glargine are gradually released. Insulin Glargine 280-288 insulin Homo sapiens 26-33 15112902-4 2004 The plasma concentration versus time profile of insulin glargine is therefore relatively constant over 24 hours as compared to conventional human insulins, especially NPH. Insulin Glargine 56-64 insulin Homo sapiens 48-55 15112902-6 2004 Reproducibility of plasma insulin levels is also improved with insulin glargine as compared to human NPH insulin. Insulin Glargine 71-79 insulin Homo sapiens 26-33 15112902-6 2004 Reproducibility of plasma insulin levels is also improved with insulin glargine as compared to human NPH insulin. Insulin Glargine 71-79 insulin Homo sapiens 63-70 15112902-7 2004 Insulin glargine administration should be combined to rapid insulin injections, before each meal in order to control postprandial hyperglycaemia, or with oral antidiabetic agents in type 2 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15112902-8 2004 The pharmacokinetic properties of insulin glargine allow an easier titration of basal insulin dose, which should facilitate adequate blood glucose control while decreasing the risk of hypoglycaemia, especially during night time. Insulin Glargine 42-50 insulin Homo sapiens 34-41 15112902-8 2004 The pharmacokinetic properties of insulin glargine allow an easier titration of basal insulin dose, which should facilitate adequate blood glucose control while decreasing the risk of hypoglycaemia, especially during night time. Insulin Glargine 42-50 insulin Homo sapiens 86-93 15112902-9 2004 Insulin glargine use is safe with no increased antigenicity, immunogenicity or mitogenicity reactions as compared to human insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15646368-2 2004 The single injection of a long-acting zinc insulin (CAS 8049-62-5) suspension or insulin glargine (CAS 160337-95-1) in both species induced a steep to moderate fall in blood glucose concentration. Insulin Glargine 89-97 insulin Homo sapiens 81-88 14976467-7 2003 These insulin forms, obtained by genetic engineering, allow for a 4 daily dose administration, ultrarapid at meal times and glargine once daily, which mimic a more physiological insulin secretion and as such probably render them more efficacious. Insulin Glargine 124-132 insulin Homo sapiens 6-13 14741069-0 2004 Insulin glargine: long-acting basal insulin analog for improved metabolic control. Insulin Glargine 8-16 insulin Homo sapiens 0-7 14741069-0 2004 Insulin glargine: long-acting basal insulin analog for improved metabolic control. Insulin Glargine 8-16 insulin Homo sapiens 36-43 14680430-0 2004 Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 14741069-3 2004 Clinical trial data indicate that insulin glargine may satisfy basal insulin requirements, with an improved safety profile relative to other available insulins used for basal supplementation. Insulin Glargine 42-50 insulin Homo sapiens 34-41 14741069-3 2004 Clinical trial data indicate that insulin glargine may satisfy basal insulin requirements, with an improved safety profile relative to other available insulins used for basal supplementation. Insulin Glargine 42-50 insulin Homo sapiens 69-76 14741069-4 2004 This review describes the unique pharmacokinetic properties and clinical efficacy of insulin glargine. Insulin Glargine 93-101 insulin Homo sapiens 85-92 15251616-0 2004 Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Insulin Glargine 19-27 insulin Homo sapiens 11-18 15251616-4 2004 RESULTS: A greater mean decrease in fasting blood glucose (FBG) was achieved at endpoint with insulin glargine than with NPH insulin (-21 mg/dL versus -10 mg/dL [-1.17 mmol/L versus -0.56 mmol/L]; P = 0.015), and a greater percentage of patients treated with insulin glargine reached the target FBG (32.6% versus 21.3%; P = 0.015). Insulin Glargine 102-110 insulin Homo sapiens 94-101 15251616-4 2004 RESULTS: A greater mean decrease in fasting blood glucose (FBG) was achieved at endpoint with insulin glargine than with NPH insulin (-21 mg/dL versus -10 mg/dL [-1.17 mmol/L versus -0.56 mmol/L]; P = 0.015), and a greater percentage of patients treated with insulin glargine reached the target FBG (32.6% versus 21.3%; P = 0.015). Insulin Glargine 267-275 insulin Homo sapiens 94-101 15251616-6 2004 After the 1-month titration phase, the percentage of patients who reported at least one symptomatic hypoglycemic event confirmed by a blood glucose value of less than 50 mg/dL (2.8 mmol/L) was significantly lower with insulin glargine than with NPH insulin (73.3% versus 81.7%; P = 0.021). Insulin Glargine 226-234 insulin Homo sapiens 218-225 15251616-7 2004 Furthermore, the percentage of patients who reported at least one symptomatic hypoglycemic event confirmed by a blood glucose value of less than 36 mg/dL (2.0 mmol/L) was significantly lower with insulin glargine than with NPH insulin (36.6% versus 46.2%; P = 0.033). Insulin Glargine 204-212 insulin Homo sapiens 196-203 15251616-8 2004 CONCLUSION: Once-daily insulin glargine was at least as effective as twice-daily NPH insulin in improving fasting glycemic control and resulted in fewer reported symptomatic hypoglycemic events. Insulin Glargine 31-39 insulin Homo sapiens 23-30 14740274-4 2003 Both the time to maximum GIR and the suppression of serum C-peptide were similar with insulin glargine and human insulin. Insulin Glargine 94-102 insulin Homo sapiens 86-93 14740274-6 2003 The observed differences in the Cmax (the mean value for insulin glargine was about 25% lower than that of human insulin) could be explained by lower cross-reactivity of insulin glargine in the human insulin radioimmunoassay. Insulin Glargine 65-73 insulin Homo sapiens 57-64 14740274-6 2003 The observed differences in the Cmax (the mean value for insulin glargine was about 25% lower than that of human insulin) could be explained by lower cross-reactivity of insulin glargine in the human insulin radioimmunoassay. Insulin Glargine 178-186 insulin Homo sapiens 57-64 14740274-6 2003 The observed differences in the Cmax (the mean value for insulin glargine was about 25% lower than that of human insulin) could be explained by lower cross-reactivity of insulin glargine in the human insulin radioimmunoassay. Insulin Glargine 178-186 insulin Homo sapiens 113-120 14740274-6 2003 The observed differences in the Cmax (the mean value for insulin glargine was about 25% lower than that of human insulin) could be explained by lower cross-reactivity of insulin glargine in the human insulin radioimmunoassay. Insulin Glargine 178-186 insulin Homo sapiens 113-120 14740274-6 2003 The observed differences in the Cmax (the mean value for insulin glargine was about 25% lower than that of human insulin) could be explained by lower cross-reactivity of insulin glargine in the human insulin radioimmunoassay. Insulin Glargine 178-186 insulin Homo sapiens 113-120 14740274-7 2003 The employed intravenous route, though definitely not the intended clinical use of insulin glargine, provided the clinical evidence in healthy subjects that on a molar basis insulin glargine is equipotent to regular human insulin regarding glucose disposal. Insulin Glargine 182-190 insulin Homo sapiens 174-181 14740274-7 2003 The employed intravenous route, though definitely not the intended clinical use of insulin glargine, provided the clinical evidence in healthy subjects that on a molar basis insulin glargine is equipotent to regular human insulin regarding glucose disposal. Insulin Glargine 182-190 insulin Homo sapiens 174-181 14657818-0 2003 Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. Insulin Glargine 107-115 insulin Homo sapiens 99-106 14657818-9 2003 CONCLUSION: Insulin glargine therapy can reduce hypoglycemic episodes in children and adolescents with suboptimal glucose control without jeopardizing glycemic control. Insulin Glargine 20-28 insulin Homo sapiens 12-19 14626260-0 2003 Insulin glargine: a long-acting insulin for diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 14578243-9 2003 In doing this, glargine causes significantly less nocturnal hypoglycemia than NPH, thus reducing a leading barrier to initiating insulin. Insulin Glargine 15-23 insulin Homo sapiens 129-136 14626260-0 2003 Insulin glargine: a long-acting insulin for diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 32-39 14626260-1 2003 Insulin glargine is a once-daily, biosynthetic, human insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 0-7 14626260-1 2003 Insulin glargine is a once-daily, biosynthetic, human insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 54-61 14626260-2 2003 Some trials show that in patients with type 1 diabetes mellitus, insulin glargine offers an advantage in blood glucose control compared with NPH insulin. Insulin Glargine 73-81 insulin Homo sapiens 65-72 14626260-3 2003 There is some evidence of decreased nocturnal and symptomatic hypoglycemia in patients receiving insulin glargine compared with those receiving NPH insulin, but there are no significant differences in the incidence of severe hypoglycemia. Insulin Glargine 105-113 insulin Homo sapiens 97-104 14626260-4 2003 Insulin glargine is approved for use in Canada, but it has not yet been marketed. Insulin Glargine 8-16 insulin Homo sapiens 0-7 14521170-0 2003 Computerized generation of circadian sensor modal days with continuous glucose monitoring for comparison of various insulin regimens based on insulin glargine in type 1 diabetes. Insulin Glargine 150-158 insulin Homo sapiens 116-123 12925063-0 2003 Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes. Insulin Glargine 15-23 insulin Homo sapiens 7-14 14526272-0 2003 Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. Insulin Glargine 64-72 insulin Homo sapiens 39-46 14526272-0 2003 Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. Insulin Glargine 64-72 insulin Homo sapiens 56-63 16437009-6 2003 Either continuous subcutaneous insulin infusion (CSII), or once day injection of the long-acting insulin analogue glargine is required to optimally replace basal insulin. Insulin Glargine 114-122 insulin Homo sapiens 97-104 16437009-6 2003 Either continuous subcutaneous insulin infusion (CSII), or once day injection of the long-acting insulin analogue glargine is required to optimally replace basal insulin. Insulin Glargine 114-122 insulin Homo sapiens 97-104 12823235-0 2003 Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Insulin Glargine 31-39 insulin Homo sapiens 23-30 12823235-5 2003 RESULTS: No differences between treatment groups were observed in adjusted mean fasting plasma glucose; significant decreases of 3.4 mmol/l, 3.5 mmol/l and 3.1 mmol/l were observed within the insulin glargine (30), insulin glargine (80) and NPH insulin groups, respectively (P<0.0001 in each case). Insulin Glargine 200-208 insulin Homo sapiens 192-199 12823235-5 2003 RESULTS: No differences between treatment groups were observed in adjusted mean fasting plasma glucose; significant decreases of 3.4 mmol/l, 3.5 mmol/l and 3.1 mmol/l were observed within the insulin glargine (30), insulin glargine (80) and NPH insulin groups, respectively (P<0.0001 in each case). Insulin Glargine 200-208 insulin Homo sapiens 215-222 12823235-9 2003 CONCLUSIONS: Insulin glargine is as safe and effective as NPH insulin given once daily and in this study caused fewer episodes of nocturnal hypoglycaemia. Insulin Glargine 21-29 insulin Homo sapiens 13-20 12931275-1 2003 The aim of this study was to compare the subcutaneous absorption characteristics of insulin glargine with NPH insulin in patients with Type 2 diabetes. Insulin Glargine 92-100 insulin Homo sapiens 84-91 12931275-4 2003 The median time for 25%, 50% and 75% of the radioactivity to disappear from the injection site was significantly longer for insulin glargine compared with NPH insulin (T75% 15.0 and 6.5 h, p=0.009; T50% 26.3 and 13.4 h, p=0.009; T25% 42.4 and 26.6 h, p=0.019, respectively). Insulin Glargine 132-140 insulin Homo sapiens 124-131 12931275-7 2003 The subcutaneous absorption of insulin glargine in fasting Type 2 diabetes patients was significantly (2-3 times) slower compared with NPH insulin in patients with Type 2 diabetes. Insulin Glargine 39-47 insulin Homo sapiens 31-38 12931275-8 2003 The slower absorption of insulin glargine correlated with the fall in plasma glucose levels over a 24 h period compared with the faster insulin absorption and more rapid decrease in plasma glucose levels observed in response to NPH insulin. Insulin Glargine 33-41 insulin Homo sapiens 25-32 12734137-12 2003 Bedtime use of insulin glargine results in fewer episodes of nighttime hypoglycemia than neutral protamine Hagedorn regimens. Insulin Glargine 23-31 insulin Homo sapiens 15-22 12766103-1 2003 OBJECTIVE: Insulin glargine (Lantus), a long-acting human insulin analog, provides effective glycemic control when administered at bedtime. Insulin Glargine 19-27 insulin Homo sapiens 11-18 12766103-1 2003 OBJECTIVE: Insulin glargine (Lantus), a long-acting human insulin analog, provides effective glycemic control when administered at bedtime. Insulin Glargine 19-27 insulin Homo sapiens 58-65 12766103-1 2003 OBJECTIVE: Insulin glargine (Lantus), a long-acting human insulin analog, provides effective glycemic control when administered at bedtime. Insulin Glargine 29-35 insulin Homo sapiens 11-18 12766103-1 2003 OBJECTIVE: Insulin glargine (Lantus), a long-acting human insulin analog, provides effective glycemic control when administered at bedtime. Insulin Glargine 29-35 insulin Homo sapiens 58-65 12766103-5 2003 Median total daily insulin dose was similar at baseline (0.65, 0.65, and 0.66 IU/kg for breakfast, dinner, and bedtime, respectively) and remained relatively constant over the study period; however, the insulin glargine-to-total insulin dose ratio increased more in the breakfast group than in the dinner and bedtime groups. Insulin Glargine 211-219 insulin Homo sapiens 203-210 12766103-5 2003 Median total daily insulin dose was similar at baseline (0.65, 0.65, and 0.66 IU/kg for breakfast, dinner, and bedtime, respectively) and remained relatively constant over the study period; however, the insulin glargine-to-total insulin dose ratio increased more in the breakfast group than in the dinner and bedtime groups. Insulin Glargine 211-219 insulin Homo sapiens 203-210 12766103-9 2003 CONCLUSIONS: These data suggest that insulin glargine, in combination with insulin lispro, is safe and effective when administered before breakfast, before dinner, or at bedtime. Insulin Glargine 45-53 insulin Homo sapiens 37-44 12809451-10 2003 RESULTS: Hemoglobin A(1c) levels improved by -1.24% (two-sided 90% CI, -1.10% to -1.38%) with morning insulin glargine, by -0.96% (CI, -0.81% to -1.10%) with bedtime insulin glargine, and by -0.84% (CI, -0.69% to -0.98%) with bedtime NPH insulin. Insulin Glargine 110-118 insulin Homo sapiens 102-109 12809451-11 2003 Hemoglobin A(1c) improvement was more pronounced with morning insulin glargine than with NPH insulin (0.40% [CI, 0.23% to 0.58%]; P = 0.001) or bedtime insulin glargine (0.28% [CI, 0.11% to 0.46%]; P = 0.008). Insulin Glargine 70-78 insulin Homo sapiens 62-69 12809451-13 2003 Nocturnal hypoglycemia was less frequent with morning (39 of 236 patients [17%]) and bedtime insulin glargine (52 of 227 patients [23%]) than with bedtime NPH insulin (89 of 232 patients [38%]) (P < 0.001). Insulin Glargine 101-109 insulin Homo sapiens 93-100 12809451-14 2003 CONCLUSION: The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine than with glimepiride in combination with bedtime NPH insulin in patients with type 2 diabetes. Insulin Glargine 123-131 insulin Homo sapiens 115-122 12809451-15 2003 Morning insulin glargine provided better glycemic control than did bedtime insulin glargine or bedtime NPH insulin. Insulin Glargine 16-24 insulin Homo sapiens 8-15 12860485-0 2003 Insulin glargine: a systematic review of a long-acting insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12860485-0 2003 Insulin glargine: a systematic review of a long-acting insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 55-62 12860485-1 2003 BACKGROUND: Insulin glargine is the first long-acting basal insulin analogue indicated for subcutaneous administration once daily at bedtime in adults with type 1 or type 2 diabetes mellitus and pediatric patients aged > or = 6 years with type 1 diabetes. Insulin Glargine 20-28 insulin Homo sapiens 12-19 12860485-1 2003 BACKGROUND: Insulin glargine is the first long-acting basal insulin analogue indicated for subcutaneous administration once daily at bedtime in adults with type 1 or type 2 diabetes mellitus and pediatric patients aged > or = 6 years with type 1 diabetes. Insulin Glargine 20-28 insulin Homo sapiens 60-67 12860485-3 2003 OBJECTIVE: The goal of this article was to help determine the current place in therapy of insulin glargine by reviewing all available efficacy and tolerability data published since its introduction onto the market. Insulin Glargine 98-106 insulin Homo sapiens 90-97 12860485-8 2003 All large clinical trials (> or = 100 patients) evaluating the efficacy and tolerability of insulin glargine in patients with type 1 or type 2 diabetes were included in the review. Insulin Glargine 103-111 insulin Homo sapiens 95-102 12860485-16 2003 Given these limitations, the available data suggest that insulin glargine treatment produces statistically significant reductions in FPG or FBG levels at end point both compared with baseline and compared with NPH insulin (P < 0.001) without achieving overall significant improvements in HbA(1c) values. Insulin Glargine 65-73 insulin Homo sapiens 57-64 12860485-17 2003 However, a recent abstract of a small 52-week trial in patients with type 1 diabetes reported a 0.4% additional decrease in HbA(1c) with insulin glargine treatment compared with NPH insulin. Insulin Glargine 145-153 insulin Homo sapiens 137-144 12860485-18 2003 Patients have reported greater treatment satisfaction with insulin glargine compared with NPH insulin. Insulin Glargine 67-75 insulin Homo sapiens 59-66 12860485-20 2003 Currently, the cost of insulin glargine is twice that of NPH insulin on a per-unit basis. Insulin Glargine 31-39 insulin Homo sapiens 23-30 12860485-21 2003 CONCLUSIONS: As a basal insulin replacement, insulin glargine administered once daily demonstrates a steady time-action profile over 24 hours without a pronounced peak. Insulin Glargine 53-61 insulin Homo sapiens 24-31 12860485-21 2003 CONCLUSIONS: As a basal insulin replacement, insulin glargine administered once daily demonstrates a steady time-action profile over 24 hours without a pronounced peak. Insulin Glargine 53-61 insulin Homo sapiens 45-52 12860485-22 2003 Based on the evidence from published clinical trials, insulin glargine appears to have equal clinical efficacy to NPH insulin, produces similar reductions in HbA(1c), and is associated with lower FPG and FBG levels and a consistent and significant reduction in the incidence of nocturnal hypoglycemia in patients with type 2 diabetes. Insulin Glargine 62-70 insulin Homo sapiens 54-61 16563061-12 2003 CONCLUSION: Insulin glargine and insulin aspart are two of the newest insulin products approved for managing diabetes mellitus. Insulin Glargine 20-28 insulin Homo sapiens 12-19 16563061-12 2003 CONCLUSION: Insulin glargine and insulin aspart are two of the newest insulin products approved for managing diabetes mellitus. Insulin Glargine 20-28 insulin Homo sapiens 70-77 12663625-0 2003 Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Insulin Glargine 98-106 insulin Homo sapiens 67-74 12716810-8 2003 Total daily insulin doses were similar with the three treatments, but with glargine there was an increase in basal and a decrease in mealtime insulin requirements (P < 0.05). Insulin Glargine 75-83 insulin Homo sapiens 12-19 12716810-8 2003 Total daily insulin doses were similar with the three treatments, but with glargine there was an increase in basal and a decrease in mealtime insulin requirements (P < 0.05). Insulin Glargine 75-83 insulin Homo sapiens 142-149 12716810-10 2003 In-hospital profiles confirmed outpatient blood glucose data and indicated more steady plasma insulin concentrations at night and before meals with glargine versus NPH (P < 0.05). Insulin Glargine 148-156 insulin Homo sapiens 94-101 12716810-12 2003 CONCLUSIONS: Regimens of basal insulin with either NPH four times/day or glargine once/day in type 1 diabetic patients both result in good glycemic control. Insulin Glargine 73-81 insulin Homo sapiens 31-38 12716810-14 2003 In contrast to NPH, which should be given at bedtime, insulin glargine can be administered at dinnertime without deteriorating blood glucose control. Insulin Glargine 62-70 insulin Homo sapiens 54-61 12783637-0 2003 Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12783637-0 2003 Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 41-48 12783637-2 2003 Insulin glargine is a novel, long-acting human insulin analog that is indicated in type 1 diabetic patients aged >or=6, or in type 2 diabetic patients who require basal insulin for glycemic control. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12783637-2 2003 Insulin glargine is a novel, long-acting human insulin analog that is indicated in type 1 diabetic patients aged >or=6, or in type 2 diabetic patients who require basal insulin for glycemic control. Insulin Glargine 8-16 insulin Homo sapiens 47-54 12783637-2 2003 Insulin glargine is a novel, long-acting human insulin analog that is indicated in type 1 diabetic patients aged >or=6, or in type 2 diabetic patients who require basal insulin for glycemic control. Insulin Glargine 8-16 insulin Homo sapiens 172-179 12783637-3 2003 Insulin glargine is a recombinant insulin with a modified structure that allows it to dissolve in an acidic solution, but to precipitate in the physiological subcutaneous tissue forming a depot effect. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12783637-3 2003 Insulin glargine is a recombinant insulin with a modified structure that allows it to dissolve in an acidic solution, but to precipitate in the physiological subcutaneous tissue forming a depot effect. Insulin Glargine 8-16 insulin Homo sapiens 34-41 12783637-4 2003 In contrast to Neutral Protamine Hagedorn (NPH) insulin, insulin glargine has a slower onset, a longer duration of action, and no peak in metabolic activity. Insulin Glargine 65-73 insulin Homo sapiens 57-64 12783637-5 2003 Once-daily subcutaneous administration of insulin glargine at bedtime has comparable efficacy to that of NPH insulin once or twice daily when used in combination with bolus insulin in type 1 diabetic patients, or in conjunction with oral antidiabetic drugs in type 2 diabetic patients. Insulin Glargine 50-58 insulin Homo sapiens 42-49 12783637-6 2003 Overall, insulin glargine has similar adverse effects when compared with NPH insulin. Insulin Glargine 17-25 insulin Homo sapiens 9-16 12783637-7 2003 Insulin glargine has been associated with less nocturnal hypoglycemia and improved treatment satisfaction in several clinical trials with durations of < 52 weeks. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12783637-9 2003 In summary, insulin glargine offers a promising alternative as a once-daily basal insulin therapy in patients with type 1 and type 2 diabetes. Insulin Glargine 20-28 insulin Homo sapiens 12-19 12783637-9 2003 In summary, insulin glargine offers a promising alternative as a once-daily basal insulin therapy in patients with type 1 and type 2 diabetes. Insulin Glargine 20-28 insulin Homo sapiens 82-89 12663625-0 2003 Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Insulin Glargine 98-106 insulin Homo sapiens 67-74 12734781-9 2003 CONCLUSIONS: This study demonstrated that insulin glargine is as effective as NPH insulin in achieving glycaemic control in patients with Type 2 diabetes, and is associated with fewer episodes of symptomatic hypoglycaemia, particularly nocturnal episodes. Insulin Glargine 50-58 insulin Homo sapiens 42-49 12610040-9 2003 CONCLUSIONS: Combination therapy with insulin glargine plus lispro reduced the incidence of nocturnal hypoglycemia and was at least as effective as R/NPH insulin therapy in maintaining glycemic control in adolescents on multiple injection regimens. Insulin Glargine 46-54 insulin Homo sapiens 38-45 12705692-3 2003 Besides human insulin, insulin analogues (lispro, aspart and glargine) have been introduced to therapeutic use. Insulin Glargine 61-69 insulin Homo sapiens 23-30 12537172-4 2003 Oral agents and long-acting insulin are usually discontinued before surgery, although the newer long-acting insulin analog glargine may be appropriately administered for basal insulin coverage throughout the surgical period. Insulin Glargine 123-131 insulin Homo sapiens 108-115 12537172-4 2003 Oral agents and long-acting insulin are usually discontinued before surgery, although the newer long-acting insulin analog glargine may be appropriately administered for basal insulin coverage throughout the surgical period. Insulin Glargine 123-131 insulin Homo sapiens 108-115 12904090-0 2003 Insulin glargine: an updated review of its use in the management of diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12661778-0 2003 Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Insulin Glargine 29-37 insulin Homo sapiens 21-28 12661778-2 2003 This study examined the primary metabolic degradation products of insulin glargine (LANTUS) in humans. Insulin Glargine 74-82 insulin Homo sapiens 66-73 12661778-2 2003 This study examined the primary metabolic degradation products of insulin glargine (LANTUS) in humans. Insulin Glargine 84-90 insulin Homo sapiens 66-73 12828834-0 2003 Optimizing glycemic control with insulin glargine. Insulin Glargine 41-49 insulin Homo sapiens 33-40 12661778-3 2003 DESIGN: In this single dose, open-label study, insulin glargine was administered subcutaneously at a dose of 0.6 IU/kg; placebo was administered to one control subject. Insulin Glargine 55-63 insulin Homo sapiens 47-54 12661778-10 2003 RESULTS: Metabolic profiling revealed a clear pattern: insulin glargine is metabolised by sequential cleavage at the carboxy terminus of the B chain, to yield products M1 and M2, which are both structurally similar to human insulin. Insulin Glargine 63-71 insulin Homo sapiens 55-62 12661778-10 2003 RESULTS: Metabolic profiling revealed a clear pattern: insulin glargine is metabolised by sequential cleavage at the carboxy terminus of the B chain, to yield products M1 and M2, which are both structurally similar to human insulin. Insulin Glargine 63-71 insulin Homo sapiens 224-231 12661778-12 2003 CONCLUSION: Thus, during treatment with a subcutaneous injection of insulin glargine, metabolic degradation is likely to be initiated at the injection site and continued within the circulatory system. Insulin Glargine 76-84 insulin Homo sapiens 68-75 12904090-1 2003 Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12904090-1 2003 Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Insulin Glargine 8-16 insulin Homo sapiens 28-35 12904090-2 2003 Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from which small amounts of insulin glargine are gradually released. Insulin Glargine 266-274 insulin Homo sapiens 26-33 12904090-3 2003 The plasma concentration versus time profile of insulin glargine is therefore relatively constant in relation to conventional human insulins, with no pronounced peak over 24 hours. Insulin Glargine 56-64 insulin Homo sapiens 48-55 12904090-5 2003 Early randomised trials with insulin glargine generally showed greater reductions in fasting blood or plasma glucose levels and a reduced frequency of nocturnal hypoglycaemia relative to neutral protamine Hagedorn (NPH) insulin in patients with type 1 diabetes mellitus. Insulin Glargine 37-45 insulin Homo sapiens 29-36 12904090-7 2003 More recent data with insulin glargine have included evidence of improved glycaemic control, with improvements in satisfaction with treatment over NPH insulin. Insulin Glargine 30-38 insulin Homo sapiens 22-29 12904090-10 2003 Results from comparative studies and meta-analyses in individuals with type 2 diabetes show lower incidences of nocturnal hypoglycaemia with insulin glargine than with NPH insulin, with two studies showing a significantly greater improvement in glycosylated haemoglobin levels with insulin glargine than with NPH. Insulin Glargine 149-157 insulin Homo sapiens 141-148 12904090-10 2003 Results from comparative studies and meta-analyses in individuals with type 2 diabetes show lower incidences of nocturnal hypoglycaemia with insulin glargine than with NPH insulin, with two studies showing a significantly greater improvement in glycosylated haemoglobin levels with insulin glargine than with NPH. Insulin Glargine 290-298 insulin Homo sapiens 141-148 12904090-12 2003 Long-term data show maintenance of glycaemic control with insulin glargine for up to 39 months in adults and children with type 1 and adults with type 2 diabetes. Insulin Glargine 66-74 insulin Homo sapiens 58-65 12904090-13 2003 In conclusion, insulin glargine is an effective and well tolerated basal insulin therapy when given as a single daily subcutaneous injection to patients with diabetes, with benefits in terms of glycaemic control and reduced frequency of hypoglycaemia over regimens based on conventional basal insulins. Insulin Glargine 23-31 insulin Homo sapiens 15-22 12904090-13 2003 In conclusion, insulin glargine is an effective and well tolerated basal insulin therapy when given as a single daily subcutaneous injection to patients with diabetes, with benefits in terms of glycaemic control and reduced frequency of hypoglycaemia over regimens based on conventional basal insulins. Insulin Glargine 23-31 insulin Homo sapiens 73-80 12904090-14 2003 Accumulating data and official recommendations show the suitability of insulin glargine for first-line use in selected patients with type 2 diabetes who require insulin treatment, as well as in patients with type 1 disease, and confirm its use in children and adolescents. Insulin Glargine 79-87 insulin Homo sapiens 71-78 12904090-14 2003 Accumulating data and official recommendations show the suitability of insulin glargine for first-line use in selected patients with type 2 diabetes who require insulin treatment, as well as in patients with type 1 disease, and confirm its use in children and adolescents. Insulin Glargine 79-87 insulin Homo sapiens 161-168 12166545-0 2002 Insulin glargine (Lantus). Insulin Glargine 8-16 insulin Homo sapiens 0-7 12391389-0 2002 Insulin glargine: a new basal insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12391389-0 2002 Insulin glargine: a new basal insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 30-37 12351503-0 2002 Insulin glargine in continuous enteric tube feeding. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12324986-5 2002 These include increased use of intensive insulin therapy in patients with type 1 diabetes; the development of new insulin analogs, including insulin glargine for injection therapy and short-acting agents that are particularly suitable for use in pumps and the establishment of comprehensive and standardized treatment goals and guidelines. Insulin Glargine 149-157 insulin Homo sapiens 114-121 12324986-5 2002 These include increased use of intensive insulin therapy in patients with type 1 diabetes; the development of new insulin analogs, including insulin glargine for injection therapy and short-acting agents that are particularly suitable for use in pumps and the establishment of comprehensive and standardized treatment goals and guidelines. Insulin Glargine 149-157 insulin Homo sapiens 114-121 12324987-0 2002 An overview of insulin glargine. Insulin Glargine 23-31 insulin Homo sapiens 15-22 12324987-1 2002 Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12324987-1 2002 Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Insulin Glargine 8-16 insulin Homo sapiens 53-60 12324987-3 2002 As would be expected for a more satisfactory basal insulin, clinical trials comparing insulin glargine with NPH insulin show less nocturnal hypoglycaemia, improved pre-breakfast blood glucose levels, or both. Insulin Glargine 94-102 insulin Homo sapiens 51-58 12324987-3 2002 As would be expected for a more satisfactory basal insulin, clinical trials comparing insulin glargine with NPH insulin show less nocturnal hypoglycaemia, improved pre-breakfast blood glucose levels, or both. Insulin Glargine 94-102 insulin Homo sapiens 86-93 12324987-5 2002 Thus, insulin glargine represents the first major advance in the provision of basal insulin injection therapy for people with type 1 and type 2 diabetes for over 50 years. Insulin Glargine 14-22 insulin Homo sapiens 6-13 12324987-5 2002 Thus, insulin glargine represents the first major advance in the provision of basal insulin injection therapy for people with type 1 and type 2 diabetes for over 50 years. Insulin Glargine 14-22 insulin Homo sapiens 84-91 12324990-7 2002 Insulin glargine, a new insulin analogue developed using recombinant DNA technology, has a flat pharmacodynamic profile and a 24-h duration of action. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12324990-7 2002 Insulin glargine, a new insulin analogue developed using recombinant DNA technology, has a flat pharmacodynamic profile and a 24-h duration of action. Insulin Glargine 8-16 insulin Homo sapiens 24-31 12324990-8 2002 Results from a recent comparative study indicate that insulin glargine plus oral therapy may provide better post-dinner glucose control as well as less symptomatic and nocturnal hypoglycemia than oral therapy combined with NPH insulin. Insulin Glargine 62-70 insulin Homo sapiens 54-61 12324990-9 2002 The studies reviewed in the present article support the conclusion that combination therapy with insulin glargine combined with one or more oral antidiabetic agents may be the treatment of choice for achieving glycemic control in patients with type 2 diabetes. Insulin Glargine 105-113 insulin Homo sapiens 97-104 12145255-0 2002 Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: a case report. Insulin Glargine 35-43 insulin Homo sapiens 27-34 12166545-0 2002 Insulin glargine (Lantus). Insulin Glargine 18-24 insulin Homo sapiens 0-7 12166545-1 2002 Insulin glargine (Lantus) is a long-acting, human insulin analogue that has been specifically designed to overcome the deficiencies of traditionally available "intermediate-acting" insulins that are currently used for basal insulin supplementation. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12150359-10 2002 Insulin glargine provides a nearly constant, peakless release of insulin when injected subcutaneously once daily. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12150359-10 2002 Insulin glargine provides a nearly constant, peakless release of insulin when injected subcutaneously once daily. Insulin Glargine 8-16 insulin Homo sapiens 65-72 12166545-1 2002 Insulin glargine (Lantus) is a long-acting, human insulin analogue that has been specifically designed to overcome the deficiencies of traditionally available "intermediate-acting" insulins that are currently used for basal insulin supplementation. Insulin Glargine 8-16 insulin Homo sapiens 50-57 12166545-1 2002 Insulin glargine (Lantus) is a long-acting, human insulin analogue that has been specifically designed to overcome the deficiencies of traditionally available "intermediate-acting" insulins that are currently used for basal insulin supplementation. Insulin Glargine 8-16 insulin Homo sapiens 181-188 12166545-1 2002 Insulin glargine (Lantus) is a long-acting, human insulin analogue that has been specifically designed to overcome the deficiencies of traditionally available "intermediate-acting" insulins that are currently used for basal insulin supplementation. Insulin Glargine 18-24 insulin Homo sapiens 0-7 12166545-1 2002 Insulin glargine (Lantus) is a long-acting, human insulin analogue that has been specifically designed to overcome the deficiencies of traditionally available "intermediate-acting" insulins that are currently used for basal insulin supplementation. Insulin Glargine 18-24 insulin Homo sapiens 50-57 12166545-1 2002 Insulin glargine (Lantus) is a long-acting, human insulin analogue that has been specifically designed to overcome the deficiencies of traditionally available "intermediate-acting" insulins that are currently used for basal insulin supplementation. Insulin Glargine 18-24 insulin Homo sapiens 181-188 12166545-2 2002 In contrast to NPH insulin, subcutaneous insulin glargine injected once daily provides a relatively constant basal level of circulating insulin with no pronounced peak. Insulin Glargine 49-57 insulin Homo sapiens 41-48 12166545-3 2002 In patients with type 1 and type 2 diabetes, once-daily insulin glargine achieves equivalent glycaemic control to NPH insulin given once or twice daily In patients with type 1 diabetes, it is associated with significantly lower fasting blood glucose (FBG) levels, especially in those patients previously on twice-daily NPH insulin. Insulin Glargine 64-72 insulin Homo sapiens 56-63 12166545-4 2002 Insulin glargine is well tolerated and elicits less hypoglycaemia, especially nocturnal episodes, than NPH insulin, with similar levels of glycaemic control. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12166545-6 2002 Patients with type 1 and type 2 diabetes have also reported higher levels of treatment satisfaction when treated with insulin glargine. Insulin Glargine 126-134 insulin Homo sapiens 118-125 12166545-7 2002 Insulin glargine provides the opportunity to achieve target blood glucose levels more effectively and safely compared with NPH insulin, due to the reduced risk of hypoglycaemia, especially nocturnal hypoglycaemia. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12166545-8 2002 Insulin treatment needs to be individualised, with the dose of insulin glargine adjusted according to the blood glucose level as part of an aggressive regimen in an attempt to achieve near normoglycaemia without incurring episodes of hypoglycaemia. Insulin Glargine 71-79 insulin Homo sapiens 0-7 12166545-8 2002 Insulin treatment needs to be individualised, with the dose of insulin glargine adjusted according to the blood glucose level as part of an aggressive regimen in an attempt to achieve near normoglycaemia without incurring episodes of hypoglycaemia. Insulin Glargine 71-79 insulin Homo sapiens 63-70 12166545-9 2002 Insulin glargine should be used in combination with short-acting insulin analogues in patients with type 1 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12166545-10 2002 In patients where oral hypoglycaemic agents are failing, insulin glargine can be added. Insulin Glargine 65-73 insulin Homo sapiens 57-64 12166610-11 2002 Insulin glargine has a peakless action profile and lasts approximately 24 hours. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12166610-15 2002 Insulin glargine reproduces closely the pharmacokinetics and pharmacodynamics of CSII and should be considered for substitution of basal insulin, especially in type 1 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12166610-15 2002 Insulin glargine reproduces closely the pharmacokinetics and pharmacodynamics of CSII and should be considered for substitution of basal insulin, especially in type 1 diabetes. Insulin Glargine 8-16 insulin Homo sapiens 137-144 12060061-11 2002 These results indicate that the predetermined dose of insulin glargine will not need to be reduced after commencing treatment because of a risk of accumulation. Insulin Glargine 62-70 insulin Homo sapiens 54-61 12032121-0 2002 Use of insulin glargine during pregnancy in a type 1 diabetic woman. Insulin Glargine 15-23 insulin Homo sapiens 7-14 12022906-0 2002 Insulin glargine: a new basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12022906-0 2002 Insulin glargine: a new basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 30-37 12022906-1 2002 OBJECTIVE: To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of insulin glargine. Insulin Glargine 145-153 insulin Homo sapiens 137-144 12022906-2 2002 DATA SOURCES: Primary and review articles regarding insulin glargine were identified by MEDLINE search (1966-July 2001); abstracts were identified through Institute for Scientific Information Web of Science (1995-July 2001) and the American Diabetes Association. Insulin Glargine 60-68 insulin Homo sapiens 52-59 12022906-6 2002 DATA SYNTHESIS: Insulin glargine is a long-acting, recombinant human insulin analog that is given once daily as a basal source of insulin in patients with type 1 or type 2 diabetes mellitus. Insulin Glargine 24-32 insulin Homo sapiens 16-23 12022906-6 2002 DATA SYNTHESIS: Insulin glargine is a long-acting, recombinant human insulin analog that is given once daily as a basal source of insulin in patients with type 1 or type 2 diabetes mellitus. Insulin Glargine 24-32 insulin Homo sapiens 69-76 12022906-6 2002 DATA SYNTHESIS: Insulin glargine is a long-acting, recombinant human insulin analog that is given once daily as a basal source of insulin in patients with type 1 or type 2 diabetes mellitus. Insulin Glargine 24-32 insulin Homo sapiens 130-137 12022906-8 2002 Insulin glargine has a slower onset of action than NPH insulin and a longer duration of action with no peak activity. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12022906-9 2002 Once-daily administration of insulin glargine has comparable efficacy to that of NPH insulin administered once or twice daily in basal-bolus regimens when used in combination with intermittent doses of regular insulin or insulin lispro in patients with type 1 and type 2 diabetes, and in conjunction with oral antidiabetic agents in patients with type 2 diabetes. Insulin Glargine 37-45 insulin Homo sapiens 29-36 12022906-10 2002 Overall, insulin glargine has an incidence of hypoglycemia comparable to or less than that of NPH insulin, with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin seen in some studies. Insulin Glargine 17-25 insulin Homo sapiens 9-16 12022906-11 2002 CONCLUSIONS: Insulin glargine is a long-acting insulin analog capable of providing 24-hour basal insulin coverage when administered once daily at bedtime. Insulin Glargine 21-29 insulin Homo sapiens 13-20 12022906-11 2002 CONCLUSIONS: Insulin glargine is a long-acting insulin analog capable of providing 24-hour basal insulin coverage when administered once daily at bedtime. Insulin Glargine 21-29 insulin Homo sapiens 47-54 12022906-11 2002 CONCLUSIONS: Insulin glargine is a long-acting insulin analog capable of providing 24-hour basal insulin coverage when administered once daily at bedtime. Insulin Glargine 21-29 insulin Homo sapiens 97-104 12022906-13 2002 Insulin glargine physiologically provides basal insulin but, for most patients, the addition of a rapid-acting insulin, like insulin lispro, before or with meals will need to be included in the treatment regimen to achieve optimal management of blood glucose concentrations. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12022906-13 2002 Insulin glargine physiologically provides basal insulin but, for most patients, the addition of a rapid-acting insulin, like insulin lispro, before or with meals will need to be included in the treatment regimen to achieve optimal management of blood glucose concentrations. Insulin Glargine 8-16 insulin Homo sapiens 48-55 12060061-1 2002 AIMS: Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. We investigated the multiple-dose pharmacokinetic properties of insulin glargine to determine whether daily injections lead to the accumulation of circulating insulin levels and a corresponding decrease in blood glucose levels in patients with Type 1 diabetes. Insulin Glargine 14-22 insulin Homo sapiens 6-13 12060061-1 2002 AIMS: Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. We investigated the multiple-dose pharmacokinetic properties of insulin glargine to determine whether daily injections lead to the accumulation of circulating insulin levels and a corresponding decrease in blood glucose levels in patients with Type 1 diabetes. Insulin Glargine 14-22 insulin Homo sapiens 40-47 12060061-1 2002 AIMS: Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. We investigated the multiple-dose pharmacokinetic properties of insulin glargine to determine whether daily injections lead to the accumulation of circulating insulin levels and a corresponding decrease in blood glucose levels in patients with Type 1 diabetes. Insulin Glargine 14-22 insulin Homo sapiens 169-176 12060061-1 2002 AIMS: Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. We investigated the multiple-dose pharmacokinetic properties of insulin glargine to determine whether daily injections lead to the accumulation of circulating insulin levels and a corresponding decrease in blood glucose levels in patients with Type 1 diabetes. Insulin Glargine 14-22 insulin Homo sapiens 169-176 12060061-3 2002 Each patient"s optimal insulin glargine dose was determined during a dose-finding phase. Insulin Glargine 31-39 insulin Homo sapiens 23-30 12060061-4 2002 After a washout period, patients were treated over 12 days with a constant daily dose of insulin glargine injected in the abdominal subcutaneous adipose tissue at 22:00 h, and with preprandial insulin lispro. Insulin Glargine 97-105 insulin Homo sapiens 89-96 11944602-0 2002 Insulin glargine: basal insulin of choice? Insulin Glargine 8-16 insulin Homo sapiens 0-7 11944604-5 2002 Hypoglycemia is the most commonly reported adverse effect, especially within the first four weeks after a switch to insulin glargine. Insulin Glargine 124-132 insulin Homo sapiens 116-123 11944602-0 2002 Insulin glargine: basal insulin of choice? Insulin Glargine 8-16 insulin Homo sapiens 24-31 11944604-6 2002 Insulin glargine should not be mixed with any other insulin product and should be administered with a syringe that has not been used for other insulin products or other medications. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11944604-6 2002 Insulin glargine should not be mixed with any other insulin product and should be administered with a syringe that has not been used for other insulin products or other medications. Insulin Glargine 8-16 insulin Homo sapiens 143-150 11944604-7 2002 Insulin glargine is administered once daily at bedtime. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11944604-8 2002 Patients previously receiving twice-daily isophane insulin (NPH) should receive an insulin glargine dosage 20% less than the total daily dose of NPH insulin. Insulin Glargine 91-99 insulin Homo sapiens 51-58 11944604-8 2002 Patients previously receiving twice-daily isophane insulin (NPH) should receive an insulin glargine dosage 20% less than the total daily dose of NPH insulin. Insulin Glargine 91-99 insulin Homo sapiens 83-90 11944604-0 2002 Insulin glargine: a new long-acting insulin product. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11944604-10 2002 Insulin glargine should be considered for patients who continue to have elevated morning blood glucose levels and problems with nocturnal hypoglycemia despite receiving NPH insulin at bedtime. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11944604-11 2002 In patients with type 2 diabetes mellitus, insulin glargine significantly improved glycemic control compared with once-daily NPH insulin, but not when it was compared with combined treatment with once- or twice-daily NPH insulin. Insulin Glargine 51-59 insulin Homo sapiens 43-50 11944604-0 2002 Insulin glargine: a new long-acting insulin product. Insulin Glargine 8-16 insulin Homo sapiens 36-43 11944604-13 2002 Insulin glargine is a new long-acting formulation that can provide prolonged basal glucose control in patients with diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11944604-1 2002 The pharmacodynamics, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of insulin glargine are reviewed. Insulin Glargine 117-125 insulin Homo sapiens 109-116 11944604-3 2002 Insulin glargine precipitates after subcutaneous injection, slowing absorption. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11944604-4 2002 Insulin glargine is used as a basal insulin and exhibits a flat pharmacokinetic profile, with a duration of action of at least 24 hours. Insulin Glargine 8-16 insulin Homo sapiens 0-7 12008682-1 2002 The objective of this study was to compare the efficacy and safety of insulin glargine, a long-acting insulin analog, with NPH insulin in children and adolescents with type 1 diabetes mellitus (T1DM). Insulin Glargine 78-86 insulin Homo sapiens 70-77 12008682-1 2002 The objective of this study was to compare the efficacy and safety of insulin glargine, a long-acting insulin analog, with NPH insulin in children and adolescents with type 1 diabetes mellitus (T1DM). Insulin Glargine 78-86 insulin Homo sapiens 102-109 12008682-4 2002 The percentage of symptomatic hypoglycemic events was similar between groups; however, fewer patients in the insulin glargine group reported severe hypoglycemia (23% vs 29%) and severe nocturnal hypoglycemia (13% vs 18%), although these differences were not statistically significant (p = 0.22 and p = 0.19, respectively). Insulin Glargine 117-125 insulin Homo sapiens 109-116 12008682-5 2002 Fewer serious adverse events occurred in the insulin glargine group than in the NPH insulin group (p < 0.02). Insulin Glargine 53-61 insulin Homo sapiens 45-52 12008682-6 2002 A once-daily subcutaneous dose of insulin glargine provides effective glycemic control and is well tolerated in children and adolescents with T1DM. Insulin Glargine 42-50 insulin Homo sapiens 34-41 11813930-0 2001 Insulin glargine. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11921426-9 2002 Insulin glargine is a new long-acting insulin which is soluble and precipitates after injection, resulting in a long half-life with a residual activity of about 50% 24 h after injection. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11921426-9 2002 Insulin glargine is a new long-acting insulin which is soluble and precipitates after injection, resulting in a long half-life with a residual activity of about 50% 24 h after injection. Insulin Glargine 8-16 insulin Homo sapiens 38-45 11921426-10 2002 Insulin glargine is a peakless insulin and studies in both type 1 and type 2 diabetic patients indicate that glargine improves fasting blood glucose control and reduces the incidence of nocturnal hypoglycaemia. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11921426-10 2002 Insulin glargine is a peakless insulin and studies in both type 1 and type 2 diabetic patients indicate that glargine improves fasting blood glucose control and reduces the incidence of nocturnal hypoglycaemia. Insulin Glargine 8-16 insulin Homo sapiens 31-38 11921426-10 2002 Insulin glargine is a peakless insulin and studies in both type 1 and type 2 diabetic patients indicate that glargine improves fasting blood glucose control and reduces the incidence of nocturnal hypoglycaemia. Insulin Glargine 109-117 insulin Homo sapiens 0-7 11921426-10 2002 Insulin glargine is a peakless insulin and studies in both type 1 and type 2 diabetic patients indicate that glargine improves fasting blood glucose control and reduces the incidence of nocturnal hypoglycaemia. Insulin Glargine 109-117 insulin Homo sapiens 31-38 15765621-0 2002 Spotlight on insulin glargine in type 1 and 2 diabetes mellitus. Insulin Glargine 21-29 insulin Homo sapiens 13-20 15765621-1 2002 Insulin glargine is a recombinant human insulin analog produced by DNA technology using a nonpathogenic strain of Escherichia coli. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15765621-1 2002 Insulin glargine is a recombinant human insulin analog produced by DNA technology using a nonpathogenic strain of Escherichia coli. Insulin Glargine 8-16 insulin Homo sapiens 40-47 15765621-3 2002 Because of these properties, absorption of insulin glargine is delayed and the analog provides a fairly constant, basal insulin supply without peaks in plasma insulin levels for approximately 24 hours, similar to that achieved by a continuous subcutaneous insulin infusion. Insulin Glargine 51-59 insulin Homo sapiens 43-50 15765621-4 2002 Insulin glargine is indicated as a once daily subcutaneous injection to provide basal glycemic control in adults and children aged >6 years with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15765621-5 2002 Fasting plasma glucose and fasting blood glucose levels generally improved to a greater extent in patients with type 1 diabetes mellitus receiving insulin glargine than patients who administered Neutral Protamine Hagedorn (NPH) insulin. Insulin Glargine 155-163 insulin Homo sapiens 147-154 15765621-8 2002 One of the most common adverse events with insulin glargine treatment was injection site pain which, in some studies, occurred more frequently than in patients receiving NPH insulin. Insulin Glargine 51-59 insulin Homo sapiens 43-50 15765621-11 2002 In conclusion, insulin glargine once a day provides basal control of glycemia for approximately 24 hours without inducing peaks in plasma insulin levels in patients with type 1 or 2 diabetes mellitus. Insulin Glargine 23-31 insulin Homo sapiens 15-22 15765621-12 2002 In long-term, well designed trials insulin glargine once daily improved glycemic control at least as effectively as NPH insulin given once or twice daily. Insulin Glargine 43-51 insulin Homo sapiens 35-42 15765621-13 2002 The drug was well tolerated and in most studies the incidence of nocturnal hypoglycemia was significantly less in patients treated with insulin glargine compared with patients receiving NPH insulin. Insulin Glargine 144-152 insulin Homo sapiens 136-143 15765621-14 2002 Therefore, insulin glargine is likely to be a useful addition to the armamentarium of insulin therapy by establishing basal glycemic control with once daily administration and a reduced risk of nocturnal hypoglycemia. Insulin Glargine 19-27 insulin Homo sapiens 11-18 15765621-14 2002 Therefore, insulin glargine is likely to be a useful addition to the armamentarium of insulin therapy by establishing basal glycemic control with once daily administration and a reduced risk of nocturnal hypoglycemia. Insulin Glargine 19-27 insulin Homo sapiens 86-93 11813930-3 2001 OBJECTIVE: This article reviews the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, and potential drug interactions of insulin glargine, a new long-acting recombinant human insulin analogue. Insulin Glargine 147-155 insulin Homo sapiens 139-146 11813930-3 2001 OBJECTIVE: This article reviews the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, and potential drug interactions of insulin glargine, a new long-acting recombinant human insulin analogue. Insulin Glargine 147-155 insulin Homo sapiens 193-200 11727406-17 2001 Newer insulin analogues such as the rapidly acting Lispro insulin and the peakless, long-acting glargine insulin are increasingly being used because of their unique physiologic pharmacokinetics. Insulin Glargine 96-104 insulin Homo sapiens 6-13 11813930-5 2001 METHODS: Primary research and review articles on insulin glargine were identified through a search of MEDLINE from 1966 to July 2001. Insulin Glargine 57-65 insulin Homo sapiens 49-56 11813930-10 2001 RESULTS: Insulin glargine has a slower onset of action than human neutral protamine Hagedorn (NPH) insulin, a longer duration of action (up to 24 hours), and no pronounced peak. Insulin Glargine 17-25 insulin Homo sapiens 9-16 11813930-12 2001 A decreased incidence of hypoglycemia, particularly at night, has been reported with insulin glargine compared with human NPH insulin. Insulin Glargine 93-101 insulin Homo sapiens 85-92 11813930-13 2001 Insulin glargine appears to be comparable to human NPH insulin in terms of toxicity, adverse effects, immunogenicity, and potential for drug interactions. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11813930-14 2001 Results of clinical trials of insulin glargine in both type 1 and type 2 diabetes support its use in combination with a short-acting insulin, insulin lispro, or oral antidiabetic medications. Insulin Glargine 38-46 insulin Homo sapiens 30-37 11813930-15 2001 Although insulin glargine cannot be mixed with other insulin preparations, it has the potential convenience of providing basal insulin with once-daily bedtime dosing. Insulin Glargine 17-25 insulin Homo sapiens 9-16 11813930-16 2001 CONCLUSIONS: Based on the as yet small amount of data from full clinical study reports in peer-reviewed publications, insulin glargine appears to be a well-tolerated and effective basal insulin preparation for patients with type 1 or type 2 diabetes (including pediatric patients). Insulin Glargine 126-134 insulin Homo sapiens 118-125 11813930-16 2001 CONCLUSIONS: Based on the as yet small amount of data from full clinical study reports in peer-reviewed publications, insulin glargine appears to be a well-tolerated and effective basal insulin preparation for patients with type 1 or type 2 diabetes (including pediatric patients). Insulin Glargine 126-134 insulin Homo sapiens 186-193 11813930-18 2001 Insulin glargine may be a useful new option for meeting overnight insulin requirements, although most patients will require a rapid-acting insulin such as insulin lispro with or before meals for optimal management of blood glucose levels. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11813930-18 2001 Insulin glargine may be a useful new option for meeting overnight insulin requirements, although most patients will require a rapid-acting insulin such as insulin lispro with or before meals for optimal management of blood glucose levels. Insulin Glargine 8-16 insulin Homo sapiens 66-73 11739448-8 2001 We conclude that in human skeletal muscle cells, insulin glargine is equivalent to human insulin for metabolic responses and does not display augmented mitogenic effects. Insulin Glargine 57-65 insulin Homo sapiens 49-56 11910975-5 2001 Insulin glargin could be an interesting alternative to bedtime NPH but needs further data in type 2 diabetes. Insulin Glargine 8-15 insulin Homo sapiens 0-7 11703429-6 2001 Glargine insulin, a soluble and essentially peakless long-acting insulin analogue, may provide a better basal insulin for MDI regimens, but there are limited published data with this agent in children with T1DM. Insulin Glargine 0-8 insulin Homo sapiens 9-16 11703429-6 2001 Glargine insulin, a soluble and essentially peakless long-acting insulin analogue, may provide a better basal insulin for MDI regimens, but there are limited published data with this agent in children with T1DM. Insulin Glargine 0-8 insulin Homo sapiens 65-72 11703429-6 2001 Glargine insulin, a soluble and essentially peakless long-acting insulin analogue, may provide a better basal insulin for MDI regimens, but there are limited published data with this agent in children with T1DM. Insulin Glargine 0-8 insulin Homo sapiens 65-72 11739448-1 2001 The aim of this study was to determine whether the long-acting insulin analog, insulin glargine, behaves like human insulin for metabolic and mitogenic responses in differentiated cultured human skeletal muscle cells from nondiabetic and diabetic subjects. Insulin Glargine 87-95 insulin Homo sapiens 63-70 11739448-1 2001 The aim of this study was to determine whether the long-acting insulin analog, insulin glargine, behaves like human insulin for metabolic and mitogenic responses in differentiated cultured human skeletal muscle cells from nondiabetic and diabetic subjects. Insulin Glargine 87-95 insulin Homo sapiens 79-86 11739448-1 2001 The aim of this study was to determine whether the long-acting insulin analog, insulin glargine, behaves like human insulin for metabolic and mitogenic responses in differentiated cultured human skeletal muscle cells from nondiabetic and diabetic subjects. Insulin Glargine 87-95 insulin Homo sapiens 79-86 11739448-3 2001 Insulin glargine displaced [(125)I]IGF-I from the IGF-I-binding site with approximately 0.5% the potency of IGF-I. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11490321-0 2001 Insulin glargine (Lantus), a new long-acting insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11712396-5 2001 Insulin glargine and SoLongln, long-acting insulin analogues, could preserve the stable basic insulin profiles during a day as compared with NPH insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11712396-5 2001 Insulin glargine and SoLongln, long-acting insulin analogues, could preserve the stable basic insulin profiles during a day as compared with NPH insulin. Insulin Glargine 8-16 insulin Homo sapiens 43-50 11712396-5 2001 Insulin glargine and SoLongln, long-acting insulin analogues, could preserve the stable basic insulin profiles during a day as compared with NPH insulin. Insulin Glargine 8-16 insulin Homo sapiens 94-101 11472271-1 2001 This review summarizes the results of clinical trials with the currently available insulin analogues (i.e., insulin lispro, insulin aspart, and insulin glargine) and evaluates their clinical benefit applying the standards of evidence-based medicine. Insulin Glargine 152-160 insulin Homo sapiens 83-90 11825324-0 2001 Insulin glargine: the first clinically useful extended-action insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11825324-0 2001 Insulin glargine: the first clinically useful extended-action insulin analogue. Insulin Glargine 8-16 insulin Homo sapiens 62-69 11825324-1 2001 Insulin glargine is a new extended-action insulin analogue, created by recombinant DNA modification of human insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11825324-1 2001 Insulin glargine is a new extended-action insulin analogue, created by recombinant DNA modification of human insulin. Insulin Glargine 8-16 insulin Homo sapiens 42-49 11825324-1 2001 Insulin glargine is a new extended-action insulin analogue, created by recombinant DNA modification of human insulin. Insulin Glargine 8-16 insulin Homo sapiens 109-116 11825324-3 2001 Pharmacodynamic studies have demonstrated a prolonged metabolic profile without a pronounced peak and with a duration of action of 20 - 30 h. In clinical studies in people with Type 1 and Type 2 diabetes, insulin glargine has demonstrated improved pre-breakfast blood glucose control and a reduction in the frequency of hypoglycaemia, especially nocturnal hypoglycaemia, in comparison with neutral protamine hagedorn (NPH) insulin. Insulin Glargine 213-221 insulin Homo sapiens 205-212 11825324-3 2001 Pharmacodynamic studies have demonstrated a prolonged metabolic profile without a pronounced peak and with a duration of action of 20 - 30 h. In clinical studies in people with Type 1 and Type 2 diabetes, insulin glargine has demonstrated improved pre-breakfast blood glucose control and a reduction in the frequency of hypoglycaemia, especially nocturnal hypoglycaemia, in comparison with neutral protamine hagedorn (NPH) insulin. Insulin Glargine 213-221 insulin Homo sapiens 423-430 11825324-5 2001 However, whilst appearing achievable, insulin glargine has not yet demonstrated the ability to improve HbA(1c), though this may relate to inexperience in the use of the new compound. Insulin Glargine 46-54 insulin Homo sapiens 38-45 11825324-6 2001 In order to fully exploit its metabolic advantages, it appears vital that the dose of insulin glargine should be titrated to achieve aggressive pre-breakfast blood glucose targets beyond those achievable with NPH in the absence of nocturnal hypoglycaemia. Insulin Glargine 94-102 insulin Homo sapiens 86-93 11825324-7 2001 Insulin glargine appears to be a promising new addition to the insulin family and with increased experience in its use, especially in combination with rapid-acting insulin analogues, its full benefits may be realised. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11825324-7 2001 Insulin glargine appears to be a promising new addition to the insulin family and with increased experience in its use, especially in combination with rapid-acting insulin analogues, its full benefits may be realised. Insulin Glargine 8-16 insulin Homo sapiens 63-70 11825324-8 2001 The use of insulin glargine with a rapid-acting insulin analogue brings us the closest we have ever been to providing the physiological insulin replacement that has long been awaited. Insulin Glargine 19-27 insulin Homo sapiens 11-18 11825324-8 2001 The use of insulin glargine with a rapid-acting insulin analogue brings us the closest we have ever been to providing the physiological insulin replacement that has long been awaited. Insulin Glargine 19-27 insulin Homo sapiens 48-55 11825324-8 2001 The use of insulin glargine with a rapid-acting insulin analogue brings us the closest we have ever been to providing the physiological insulin replacement that has long been awaited. Insulin Glargine 19-27 insulin Homo sapiens 48-55 12643106-3 2001 With the introduction of faster-acting insulin analogues, lispro and aspart, and a peakless long-acting insulin analogue, glargine, the goal of safe and effective tight glycemic control may now be within reach for many patients. Insulin Glargine 122-130 insulin Homo sapiens 104-111 11490321-0 2001 Insulin glargine (Lantus), a new long-acting insulin. Insulin Glargine 8-16 insulin Homo sapiens 45-52 11490321-0 2001 Insulin glargine (Lantus), a new long-acting insulin. Insulin Glargine 18-24 insulin Homo sapiens 0-7 11490321-0 2001 Insulin glargine (Lantus), a new long-acting insulin. Insulin Glargine 18-24 insulin Homo sapiens 45-52 11553198-0 2001 Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Insulin Glargine 65-73 insulin Homo sapiens 57-64 11553198-2 2001 Insulin glargine, a new long-acting insulin analogue, provides constant, peakless insulin release following once-daily administration and is associated with fewer hypoglycaemic episodes, despite metabolic control equivalent to that achieved with NPH human basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 36-43 11553198-2 2001 Insulin glargine, a new long-acting insulin analogue, provides constant, peakless insulin release following once-daily administration and is associated with fewer hypoglycaemic episodes, despite metabolic control equivalent to that achieved with NPH human basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 82-89 11553198-2 2001 Insulin glargine, a new long-acting insulin analogue, provides constant, peakless insulin release following once-daily administration and is associated with fewer hypoglycaemic episodes, despite metabolic control equivalent to that achieved with NPH human basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11553198-2 2001 Insulin glargine, a new long-acting insulin analogue, provides constant, peakless insulin release following once-daily administration and is associated with fewer hypoglycaemic episodes, despite metabolic control equivalent to that achieved with NPH human basal insulin. Insulin Glargine 8-16 insulin Homo sapiens 82-89 11402927-0 2001 [Clinical effects and pharmacodynamics of insulin analogs lispro, aspart and glargin]. Insulin Glargine 77-84 insulin Homo sapiens 42-49 11553198-5 2001 RESULTS: Treatment satisfaction improved with insulin glargine at all time points, including endpoint, but deteriorated slightly with NPH. Insulin Glargine 54-62 insulin Homo sapiens 46-53 11553198-7 2001 Outcomes were better with insulin glargine for the DTSQ items, Perceived Frequency of Hyperglycaemia and Hypoglycaemia, with statistically significant differences at week 28 and endpoint for hyperglycaemia (P = 0.0373 and 0.0379) and at week 20 for hypoglycaemia (P = 0.0024). Insulin Glargine 34-42 insulin Homo sapiens 26-33 11577797-0 2001 Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11367996-1 2001 What is the value of insulin glargine in general practice? Insulin Glargine 29-37 insulin Homo sapiens 21-28 11213905-0 2001 Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. Insulin Glargine 61-69 insulin Homo sapiens 53-60 11213905-0 2001 Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. Insulin Glargine 71-77 insulin Homo sapiens 53-60 11315821-1 2001 OBJECTIVE: To determine the safety and efficacy of the long-acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone. Insulin Glargine 82-90 insulin Homo sapiens 74-81 11315821-9 2001 Subjects in the insulin glargine group experienced less weight gain than those in the NPH group (0.4 vs. 1.4 kg, P < 0.0007). Insulin Glargine 24-32 insulin Homo sapiens 16-23 11315821-10 2001 CONCLUSIONS: In patients with type 2 diabetes, once-daily bedtime insulin glargine is as effective as once- or twice-daily NPH in improving and maintaining glycemic control. Insulin Glargine 74-82 insulin Homo sapiens 66-73 11315821-11 2001 In addition, insulin glargine deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin. Insulin Glargine 21-29 insulin Homo sapiens 13-20 11577797-5 2001 Fasting plasma glucose and fasting blood glucose levels generally improved to a greater extent in patients with type 1 diabetes mellitus receiving insulin glargine than patients who administered Neutral Protamine Hagedorn (NPH) insulin. Insulin Glargine 155-163 insulin Homo sapiens 147-154 11577797-8 2001 One of the most common adverse events with insulin glargine treatment was injection site pain which, in some studies, occurred more frequently than in patients receiving NPH insulin. Insulin Glargine 51-59 insulin Homo sapiens 43-50 11577797-11 2001 CONCLUSIONS: Insulin glargine once a day provides basal control of glycaemia for approximately 24 hours without inducing peaks in plasma insulin levels in patients with type 1 or 2 diabetes mellitus. Insulin Glargine 21-29 insulin Homo sapiens 13-20 11577797-12 2001 In long term, well designed trials insulin glargine once daily improved glycaemic control at least as effectively as NPH insulin given once or twice daily. Insulin Glargine 43-51 insulin Homo sapiens 35-42 11577797-13 2001 The drug was well tolerated and in most studies the incidence of nocturnal hypoglycaemia was significantly less in patients treated with insulin glargine compared with patients receiving NPH insulin. Insulin Glargine 145-153 insulin Homo sapiens 137-144 11577797-1 2001 UNLABELLED: Insulin glargine is a recombinant human insulin analogue produced by DNA technology using a nonpathogenic strain of Escherichia coli. Insulin Glargine 20-28 insulin Homo sapiens 12-19 11577797-1 2001 UNLABELLED: Insulin glargine is a recombinant human insulin analogue produced by DNA technology using a nonpathogenic strain of Escherichia coli. Insulin Glargine 20-28 insulin Homo sapiens 52-59 11577797-3 2001 Because of these properties, absorption of insulin glargine is delayed and the analogue provides a fairly constant, basal insulin supply without peaks in plasma insulin levels for approximately 24 hours, similar to that achieved by a continuous subcutaneous insulin infusion. Insulin Glargine 51-59 insulin Homo sapiens 43-50 11577797-14 2001 Therefore, insulin glargine is likely to be a useful addition to the armamentarium of insulin therapy by establishing basal glycaemic control with once daily administration and a reduced risk of nocturnal hypoglycaemia. Insulin Glargine 19-27 insulin Homo sapiens 11-18 11577797-4 2001 Insulin glargine is indicated as a once daily subcutaneous injection to provide basal glycaemic control in adults and children aged >6 years with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11577797-14 2001 Therefore, insulin glargine is likely to be a useful addition to the armamentarium of insulin therapy by establishing basal glycaemic control with once daily administration and a reduced risk of nocturnal hypoglycaemia. Insulin Glargine 19-27 insulin Homo sapiens 86-93 11460580-11 2001 At present, the long-acting insulin analogue glargine is the retarded insulin preparation of choice because its action profile is flat, peakless and long-lasting (approximately 24 hours). Insulin Glargine 45-53 insulin Homo sapiens 28-35 11460580-14 2001 Insulin glargine reproduces closely the pharmacokinetics and pharmacodynamics of continuous s.c. insulin infusion, and should always be preferred to NPH in all insulin-requiring diabetic patients, both type 1 and type 2. Insulin Glargine 8-16 insulin Homo sapiens 0-7 11460580-14 2001 Insulin glargine reproduces closely the pharmacokinetics and pharmacodynamics of continuous s.c. insulin infusion, and should always be preferred to NPH in all insulin-requiring diabetic patients, both type 1 and type 2. Insulin Glargine 8-16 insulin Homo sapiens 97-104 11130552-0 2000 Safety of insulin glargine. Insulin Glargine 18-26 insulin Homo sapiens 10-17 11225967-0 2000 Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine. Insulin Glargine 113-121 insulin Homo sapiens 105-112 11118018-0 2000 Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Insulin Glargine 100-108 insulin Homo sapiens 85-92 11118018-7 2000 Interindividual variability (calculated as differences in SD of plasma insulin concentrations and glucose infusion rates in different treatments) was lower with glargine than with NPH and ultralente (P < 0.05) but was similar with glargine and CSII (NS). Insulin Glargine 161-169 insulin Homo sapiens 71-78 11118018-10 2000 Glargine is a peakless insulin, it lasts nearly 24 h, it has lower intersubject variability than NPH and ultralente, and it closely mimics CSII, the gold standard of basal insulin replacement. Insulin Glargine 0-8 insulin Homo sapiens 23-30 11118018-10 2000 Glargine is a peakless insulin, it lasts nearly 24 h, it has lower intersubject variability than NPH and ultralente, and it closely mimics CSII, the gold standard of basal insulin replacement. Insulin Glargine 0-8 insulin Homo sapiens 172-179 11225967-11 2000 CONCLUSIONS: We conclude that insulin glargine and regular human insulin elicit comparable symptomatic and counter-regulatory hormonal responses during hypoglycaemia in healthy or diabetic subjects, and induce similar rates of glucose disposal. Insulin Glargine 38-46 insulin Homo sapiens 30-37 11094649-0 2000 Insulin glargine. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16049868-0 2000 Insulin glargine (Aventis Pharma). Insulin Glargine 8-16 insulin Homo sapiens 0-7 11092290-1 2000 OBJECTIVE: To determine the safety and efficacy of the long-acting insulin analog, insulin glargine, as a component of basal bolus therapy in patients with type 1 diabetes. Insulin Glargine 91-99 insulin Homo sapiens 67-74 11092290-1 2000 OBJECTIVE: To determine the safety and efficacy of the long-acting insulin analog, insulin glargine, as a component of basal bolus therapy in patients with type 1 diabetes. Insulin Glargine 91-99 insulin Homo sapiens 83-90 11092290-4 2000 These differences were evident early and persisted throughout the study More patients in the insulin glargine group (29.6%) than in the NPH group (16.8%) reached a target fasting blood glucose of 119 mg/dl (< 6.6 mmol/l). Insulin Glargine 101-109 insulin Homo sapiens 93-100 11092290-6 2000 Insulin glargine treatment was also associated with a significant decrease in the variability of fasting blood glucose values (P = 0.0124). Insulin Glargine 8-16 insulin Homo sapiens 0-7 11092290-8 2000 Overall, adverse events were similar in the two treatment groups with the exception of injection site pain, which was more common in the insulin glargine group (6.1%) than in the NPH group (0.3%). Insulin Glargine 145-153 insulin Homo sapiens 137-144 11092290-10 2000 CONCLUSIONS: Basal insulin therapy with insulin glargine once a day appears to be as safe and at least as effective as using NPH insulin once or twice a day in maintaining glycemic control in patients with type 1 diabetes receiving basal-bolus insulin treatment with insulin lispro. Insulin Glargine 48-56 insulin Homo sapiens 19-26 11092290-10 2000 CONCLUSIONS: Basal insulin therapy with insulin glargine once a day appears to be as safe and at least as effective as using NPH insulin once or twice a day in maintaining glycemic control in patients with type 1 diabetes receiving basal-bolus insulin treatment with insulin lispro. Insulin Glargine 48-56 insulin Homo sapiens 40-47 11092290-10 2000 CONCLUSIONS: Basal insulin therapy with insulin glargine once a day appears to be as safe and at least as effective as using NPH insulin once or twice a day in maintaining glycemic control in patients with type 1 diabetes receiving basal-bolus insulin treatment with insulin lispro. Insulin Glargine 48-56 insulin Homo sapiens 40-47 11092290-10 2000 CONCLUSIONS: Basal insulin therapy with insulin glargine once a day appears to be as safe and at least as effective as using NPH insulin once or twice a day in maintaining glycemic control in patients with type 1 diabetes receiving basal-bolus insulin treatment with insulin lispro. Insulin Glargine 48-56 insulin Homo sapiens 40-47 16049868-1 2000 Insulin glargine is a biosynthetic human insulin analog which has been developed by Aventis Pharma (formerly Hoechst Marion Roussel, HMR), for the treatment of types I and II diabetes. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16049868-1 2000 Insulin glargine is a biosynthetic human insulin analog which has been developed by Aventis Pharma (formerly Hoechst Marion Roussel, HMR), for the treatment of types I and II diabetes. Insulin Glargine 8-16 insulin Homo sapiens 41-48 16049868-2 2000 In April 1999, HMR filed insulin glargine for approval in both Europe and the US [322507]. Insulin Glargine 33-41 insulin Homo sapiens 25-32 16049868-3 2000 In April 2000, the FDA approved insulin glargine (as Lantus) for the treatment of adult patients with type II diabetes mellitus, who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients with type I diabetes mellitus [363836]. Insulin Glargine 40-48 insulin Homo sapiens 32-39 16049868-3 2000 In April 2000, the FDA approved insulin glargine (as Lantus) for the treatment of adult patients with type II diabetes mellitus, who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients with type I diabetes mellitus [363836]. Insulin Glargine 40-48 insulin Homo sapiens 147-154 16049868-3 2000 In April 2000, the FDA approved insulin glargine (as Lantus) for the treatment of adult patients with type II diabetes mellitus, who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients with type I diabetes mellitus [363836]. Insulin Glargine 53-59 insulin Homo sapiens 32-39 16049868-3 2000 In April 2000, the FDA approved insulin glargine (as Lantus) for the treatment of adult patients with type II diabetes mellitus, who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients with type I diabetes mellitus [363836]. Insulin Glargine 53-59 insulin Homo sapiens 147-154 16049868-5 2000 In June 2000, the EMEA approved insulin glargine for the treatment of both type I and II diabetes [370984]. Insulin Glargine 40-48 insulin Homo sapiens 32-39 16049868-8 2000 Insulin glargine is in phase III trials in Japan as a substitute for basal insulin in the treatment of Type I diabetes [216445]. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16049868-9 2000 Two formulations of insulin glargine with zinc have also been tested in phase I trials. Insulin Glargine 28-36 insulin Homo sapiens 20-27 16049868-13 2000 Insulin glargine was designated as a medium priority project by HMR, which means the project had been set tight deadlines which if not achieved, would have resulted in discontinuation [221118]. Insulin Glargine 8-16 insulin Homo sapiens 0-7 16049868-14 2000 In April 2000, Novo Nordisk filed a complaint in Germany against Aventis claiming that the production and sale of insulin glargine infringes two German patents held by Novo Nordisk [364362]. Insulin Glargine 122-130 insulin Homo sapiens 114-121 16049868-15 2000 In July 2000, Credit Lyonnais Securities Europe predicted that insulin glargine was likely to enjoy a strong competitive position for several years in Europe and the US, following launch in these territories during 2000, while it was predicted that a registration dossier would be submitted in Japn in 2002. Insulin Glargine 71-79 insulin Homo sapiens 63-70 10981882-0 2000 Insulin glargine. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10937510-0 2000 Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Insulin Glargine 88-96 insulin Homo sapiens 80-87 10937511-6 2000 Insulin glargine was given subcutaneously once daily at bedtime. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10937510-3 2000 We compared the efficacy and safety of glargine (a long-acting insulin analog) and NPH insulins in insulin-naive type 2 diabetic patients treated with oral antidiabetic agents. Insulin Glargine 39-47 insulin Homo sapiens 63-70 10937511-9 2000 RESULTS: At study end point, insulin glargine-pooled groups had significantly lower fasting plasma glucose (FPG) levels than the NPH insulin group, with adjusted mean FPG levels reduced by 2.2 mmol/l (P = 0.0001). Insulin Glargine 37-45 insulin Homo sapiens 29-36 10937510-11 2000 CONCLUSIONS: Use of insulin glargine compared with NPH is associated with less nocturnal hypoglycemia and lower post-dinner glucose levels. Insulin Glargine 28-36 insulin Homo sapiens 20-27 10937511-10 2000 Insulin glargine was superior to NPH insulin in reducing FPG levels in patients who had previously received NPH insulin twice daily but not in patients who had previously received NPH once daily. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10937511-11 2000 FPG levels were more stable in patients using insulin glargine than in patients using NPH insulin. Insulin Glargine 54-62 insulin Homo sapiens 46-53 10937510-12 2000 These data are consistent with peakless and longer duration of action of insulin glargine compared with NPH. Insulin Glargine 81-89 insulin Homo sapiens 73-80 10937511-13 2000 Insulin glargine patients exhibited lower FPG levels after 5:00 A.M.; the difference was significant by 8:00 A.M. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10937511-14 2000 The adjusted mean FPG for insulin glargine[30] was 7.8 mmol/l; for insulin glargine[80], 7.3 mmol/l; and for NPH, 10.7 mmol/l. Insulin Glargine 34-42 insulin Homo sapiens 26-33 10937510-14 2000 These data support use of insulin glargine instead of NPH in insulin combination regimens in type 2 diabetes. Insulin Glargine 34-42 insulin Homo sapiens 26-33 10937511-1 2000 U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Insulin Glargine 13-21 insulin Homo sapiens 5-12 10937511-2 2000 OBJECTIVE: Insulin glargine (HOE 901, 21(A)-Gly-30(B)a-L-Arg-30(B)b-L-Arg human insulin) is a novel recombinant analog of human insulin with a shift in the isoelectric point producing a retarded absorption rate and an increased duration of action that closely mimics normal basal insulin secretion. Insulin Glargine 19-27 insulin Homo sapiens 11-18 10937511-2 2000 OBJECTIVE: Insulin glargine (HOE 901, 21(A)-Gly-30(B)a-L-Arg-30(B)b-L-Arg human insulin) is a novel recombinant analog of human insulin with a shift in the isoelectric point producing a retarded absorption rate and an increased duration of action that closely mimics normal basal insulin secretion. Insulin Glargine 19-27 insulin Homo sapiens 80-87 10937511-2 2000 OBJECTIVE: Insulin glargine (HOE 901, 21(A)-Gly-30(B)a-L-Arg-30(B)b-L-Arg human insulin) is a novel recombinant analog of human insulin with a shift in the isoelectric point producing a retarded absorption rate and an increased duration of action that closely mimics normal basal insulin secretion. Insulin Glargine 19-27 insulin Homo sapiens 128-135 10937511-2 2000 OBJECTIVE: Insulin glargine (HOE 901, 21(A)-Gly-30(B)a-L-Arg-30(B)b-L-Arg human insulin) is a novel recombinant analog of human insulin with a shift in the isoelectric point producing a retarded absorption rate and an increased duration of action that closely mimics normal basal insulin secretion. Insulin Glargine 19-27 insulin Homo sapiens 128-135 10937511-4 2000 The aim of this study was to evaluate 2 formulations of insulin glargine for safety and efficacy in the treatment of patients with type 1 diabetes. Insulin Glargine 64-72 insulin Homo sapiens 56-63 10841002-0 2000 Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Insulin Glargine 41-49 insulin Homo sapiens 33-40 10841002-1 2000 OBJECTIVE: To determine the subcutaneous absorption rates and the appearance in plasma of 3 formulations of the long-acting human insulin analog insulin glargine (HOE 901) differing only in zinc content (15, 30, and 80 microg/ml). Insulin Glargine 153-161 insulin Homo sapiens 130-137 10841002-1 2000 OBJECTIVE: To determine the subcutaneous absorption rates and the appearance in plasma of 3 formulations of the long-acting human insulin analog insulin glargine (HOE 901) differing only in zinc content (15, 30, and 80 microg/ml). Insulin Glargine 153-161 insulin Homo sapiens 145-152 10866053-8 2000 In contrast, the 2 long-acting insulin analogs, glargine and detemir, differed significantly from human insulin. Insulin Glargine 48-56 insulin Homo sapiens 31-38 10866053-8 2000 In contrast, the 2 long-acting insulin analogs, glargine and detemir, differed significantly from human insulin. Insulin Glargine 48-56 insulin Homo sapiens 104-111 10841002-3 2000 Study 1 compared the subcutaneous abdominal injection of 0.15 U/kg of 125I-labeled insulin glargine[15], insulin glargine[80], NPH insulin, and placebo. Insulin Glargine 91-99 insulin Homo sapiens 83-90 10866053-9 2000 The combination of the B31B32diArg and A21Gly substitutions provided insulin glargine with a 6- to 8-fold increased IGF-I receptor affinity and mitogenic potency compared with human insulin. Insulin Glargine 77-85 insulin Homo sapiens 69-76 10841002-4 2000 In study 2, 0.2 U/kg of insulin glargine[30] was injected into the arm, leg, and abdominal regions. Insulin Glargine 32-40 insulin Homo sapiens 24-31 10841002-9 2000 Insulin glargine, however, did not exhibit a distinct peak. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10841002-10 2000 Weighted average plasma glucose concentration between 0 and 6 h was significantly lower after NPH compared with insulin glargine (P < 0.001). Insulin Glargine 120-128 insulin Homo sapiens 112-119 10834424-1 2000 OBJECTIVE: To study the pharmacodynamic properties of the subcutaneously injected long-acting insulin analog HOE901 (30 microg/ml zinc) in comparison with those of NPH insulin and placebo. Insulin Glargine 109-115 insulin Homo sapiens 94-101 10932964-6 2000 The turn of the millennium is now witnessing the development of long acting insulin analogues like insulin glargine, which can provide continuous low-level basal insulin concentrations similar to natural settings. Insulin Glargine 107-115 insulin Homo sapiens 76-83 10932964-6 2000 The turn of the millennium is now witnessing the development of long acting insulin analogues like insulin glargine, which can provide continuous low-level basal insulin concentrations similar to natural settings. Insulin Glargine 107-115 insulin Homo sapiens 99-106 10834424-7 2000 CONCLUSIONS: This study shows that the soluble long-acting insulin analog HOE901 induces a smoother metabolic effect than NPH insulin, from which a better substitution of basal insulin requirements may follow. Insulin Glargine 74-80 insulin Homo sapiens 59-66 10834411-0 2000 Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10834411-0 2000 Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety. Insulin Glargine 18-24 insulin Homo sapiens 0-7 15992080-0 1999 Insulin glargine: the first clinically useful extended-acting insulin in half a century? Insulin Glargine 8-16 insulin Homo sapiens 0-7 10834423-0 2000 Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Insulin Glargine 31-39 insulin Homo sapiens 23-30 10834423-0 2000 Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Insulin Glargine 31-39 insulin Homo sapiens 53-60 10834423-1 2000 U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Insulin Glargine 28-36 insulin Homo sapiens 20-27 10834423-2 2000 OBJECTIVE: Insulin glargine (21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin) is a biosynthetic insulin analog with a prolonged duration of action compared with NPH human insulin. Insulin Glargine 19-27 insulin Homo sapiens 11-18 10834423-2 2000 OBJECTIVE: Insulin glargine (21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin) is a biosynthetic insulin analog with a prolonged duration of action compared with NPH human insulin. Insulin Glargine 19-27 insulin Homo sapiens 65-72 10834423-2 2000 OBJECTIVE: Insulin glargine (21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin) is a biosynthetic insulin analog with a prolonged duration of action compared with NPH human insulin. Insulin Glargine 19-27 insulin Homo sapiens 92-99 10834423-2 2000 OBJECTIVE: Insulin glargine (21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin) is a biosynthetic insulin analog with a prolonged duration of action compared with NPH human insulin. Insulin Glargine 19-27 insulin Homo sapiens 92-99 10834423-9 2000 After the 1-month titration phase, significantly fewer subjects receiving insulin glargine experienced symptomatic hypoglycemia (39.9 vs. 49.2%, P = 0.0219) or nocturnal hypoglycemia (18.2 vs. 27.1%, P = 0.0116) with a blood glucose level <2.0 mmol/l compared with subjects receiving NPH insulin. Insulin Glargine 82-90 insulin Homo sapiens 74-81 10834423-10 2000 CONCLUSIONS: Lower FPG levels with fewer episodes of hypoglycemia were achieved with insulin glargine compared with once- or twice-daily NPH insulin as part of a basal-bolus regimen in patients with type 1 diabetes. Insulin Glargine 93-101 insulin Homo sapiens 85-92 10834424-0 2000 Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Insulin Glargine 62-70 insulin Homo sapiens 39-46 10834424-0 2000 Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Insulin Glargine 62-70 insulin Homo sapiens 54-61 10730548-0 2000 Insulin glargine. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10730548-1 2000 Insulin glargine is an extended-action biosynthetic human insulin. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10730548-1 2000 Insulin glargine is an extended-action biosynthetic human insulin. Insulin Glargine 8-16 insulin Homo sapiens 58-65 10730548-4 2000 In small euglycaemic clamp studies, the onset of action of insulin glargine was shown to be later, the duration of action longer and the time-action profile flatter than that of Neutral Protamine Hagedorn (NPH) insulin in patients with type 1 diabetes mellitus and healthy volunteers. Insulin Glargine 67-75 insulin Homo sapiens 59-66 10730548-5 2000 Four large clinical trials of up to 28 weeks" duration have shown that a single bedtime dose of insulin glargine, in combination with preprandial short-acting insulin, is as effective or more effective than once or twice daily NPH plus short-acting insulin in improving glycaemic control in patients with type 1 diabetes mellitus. Insulin Glargine 104-112 insulin Homo sapiens 96-103 10730548-6 2000 In 3 large comparative trials, insulin glargine decreased glycosylated haemoglobin and/or fasting blood glucose levels to a similar extent to that seen with NPH insulin in patients with insulin-dependent or non-insulin-dependent type 2 diabetes mellitus, either as monotherapy or in combination with oral hypoglycaemic agents. Insulin Glargine 39-47 insulin Homo sapiens 31-38 10730548-7 2000 Insulin glargine appears to be well tolerated. Insulin Glargine 8-16 insulin Homo sapiens 0-7 10730548-8 2000 A lower incidence of hypoglycaemia, especially at night, was reported in most trials with insulin glargine when compared with NPH insulin. Insulin Glargine 98-106 insulin Homo sapiens 90-97 10820651-0 1999 Insulin glargine. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15992080-11 1999 It thus appears that insulin glargine is a genuinely new addition to the insulin family, and with further clinical experience it may well be possible to achieve better basal blood glucose control (without enhanced risk of hypoglycaemia), particularly at night or in conjunction with rapid-acting insulin analogues. Insulin Glargine 29-37 insulin Homo sapiens 21-28 15992080-11 1999 It thus appears that insulin glargine is a genuinely new addition to the insulin family, and with further clinical experience it may well be possible to achieve better basal blood glucose control (without enhanced risk of hypoglycaemia), particularly at night or in conjunction with rapid-acting insulin analogues. Insulin Glargine 29-37 insulin Homo sapiens 73-80 15992080-11 1999 It thus appears that insulin glargine is a genuinely new addition to the insulin family, and with further clinical experience it may well be possible to achieve better basal blood glucose control (without enhanced risk of hypoglycaemia), particularly at night or in conjunction with rapid-acting insulin analogues. Insulin Glargine 29-37 insulin Homo sapiens 73-80 15992080-0 1999 Insulin glargine: the first clinically useful extended-acting insulin in half a century? Insulin Glargine 8-16 insulin Homo sapiens 62-69 15992080-1 1999 Insulin glargine (HOE 901) appears to be the first clinically useful extended-acting insulin preparation for 50 years. Insulin Glargine 8-16 insulin Homo sapiens 0-7 15992080-1 1999 Insulin glargine (HOE 901) appears to be the first clinically useful extended-acting insulin preparation for 50 years. Insulin Glargine 8-16 insulin Homo sapiens 85-92 15992080-7 1999 disappearance studies confirm that insulin glargine has a much slower onset of effect than NPH (Neutral Protamine Hagedorn) insulin, and a much more protracted profile of action. Insulin Glargine 43-51 insulin Homo sapiens 35-42 15992080-9 1999 Patient studies in Type 1 and Type 2 diabetes published to date are inconclusive, but appear to confirm differences in pharmacokinetics between insulin glargine and NPH, with significantly lower fasting plasma glucose levels or reduction in night hypoglycaemia. Insulin Glargine 152-160 insulin Homo sapiens 144-151